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The Office for Drug Control and Crime Prevention (UNODCCP) became the Office on
Drugs and Crime (UNODC) on 1 October 2002. The Office on Drugs and Crime
includes the United Nations International Drug Control Programme (UNDCP).
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CHAPTER 7: Methodology
Drugs are everywhere, say alarmed parents. The drug problem is out of control, cries the media.  Legalize drugs to
reduce crime, say some commentators.
Such exasperation is understandable in the many communities where illicit drugs cause crime, illness, violence
and death. Yet, worldwide statistical evidence points to a different reality: drug control is working and the
world drug problem is being contained.
This is true whether we look over the long term or even just over the past few years. Humanity has entered
the 21st century with much lower levels of drug cultivation and drug addiction than 100 years earlier.  Even
more importantly, in the past few years, worldwide efforts to reduce the threat posed by illicit drugs have
effectively reversed a quarter-century-long rise in drug abuse that, if left unchecked, could have become a
global pandemic.  
The illicit drug problem has three main elements: cultivation and production; trafficking and retailing; and
consumption and abuse.  We do not know as much as we would like about the middle link of this chain as
the drug trade is notoriously hard to monitor.  But, as this report shows, we do know a lot about the beginning
and the end of the chain and can confidently make two points: (1) There is less land under coca and opium
cultivation today than a few years ago, and significantly less than a century ago; (2) The severity of drug
addiction has been contained. The number of addicts, especially those dependent on cocaine and heroin, has
declined massively over the last century and, worldwide, has remained stable in the past few years. 
Of course, the world drug control system is the sum of its parts and progress in one area can be offset by
opposite trends elsewhere. Greater global success will depend on the commitment of all our societies to turn
containment of the drug problem into a sustained reduction - everywhere. We are not there yet.
This World Drug Report demonstrates progress made in 2005, but also highlights some weak elements in the
global drug control system - most notably heroin supply in Afghanistan, cocaine demand in Europe, and
cannabis supply/demand everywhere. The main trends can be summarized as follows. 
The world’s supply of opium has shrunk, but in an unbalanced way. Within a few years, Asia’s notorious Golden
Triangle, once the world’s narcotics epicentre, could become opium-free. But in Afghanistan, while the area
under opium cultivation decreased in 2005, the country’s drug situation remains vulnerable to reversal. This
could happen as early as 2006. 
In the past five years, the area under coca cultivation in the Andean countries has fallen by more than a quarter.
In order for this trend to be sustainable, richer countries – the consumers of cocaine – need to invest more in
helping Andean farmers to switch to licit crops. As this report points out, demand for cocaine is rising in
Europe to alarming levels. I urge European Union governments not to ignore this peril. Too many professional,
educated Europeans use cocaine, often denying their addiction, and drug abuse by celebrities is often presented
uncritically by the media, leaving young people confused and vulnerable.
Trends in cocaine trafficking are hard to assess.  Cocaine seizures have increased dramatically.  Markets have
been thrown into turmoil due to intensified coca eradication in the Andean countries and better law
1
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enforcement worldwide.  As crime cartels look for new trafficking routes, especially towards the European
Union, countries in the Caribbean, West Africa and Central Africa are under attack.  They need to be assisted,
not least in their efforts to tackle corrupt and ineffective law enforcement. 
Cannabis, which gets special attention in this report, is the world’s most abused illicit drug.   Global oversight
of supply is impractical as it is a weed that grows under the most varied conditions, at many different latitudes
and in many countries. National policies on cannabis vary and sometimes change from one year to the next.
With supply virtually unlimited and demand subject to the vagaries of government policy, traffickers have
invested heavily in increasing the potency – and therefore the market attractiveness — of cannabis.  The result
has been devastating: today, the characteristics of cannabis are no longer that different from those of other
plant-based drugs such as cocaine and heroin. 
With cannabis-related health damage increasing, it is fundamentally wrong for countries to make cannabis
control dependent on which party is in government. Policy swings or reversals leave young people confused as
to just how dangerous cannabis is.  The cannabis pandemic, like other challenges to public health, requires
consensus, and a stable and consistent engagement across society at large so countries can take appropriate and
long-term remedial action.
After years of rapid increases, the market for amphetamine-type stimulants (ATS) is stabilizing.  In some parts
of the world, such as the United States, methamphetamine is considered drug public enemy number one.  In
other regions, notably Europe, synthetic psychoactive substances have lost some of their earlier appeal and been
replaced by cocaine.  Seizures have skyrocketed, demonstrating once again that the popularity of drugs in some
countries tends to offset their decline elsewhere, causing the market to reorganize itself.  It is encouraging to
see law enforcement taking advantage of the disarray among traffickers. 
The World Drug Report is a repository of statistics and not the place to formulate policy.  But the data prompt
a few inescapable conclusions. First, countries need to do more to reduce drug demand in general and to target
ATS and cannabis in particular. The profile of the users of these drugs differs from that of those who use
cocaine and heroin, and treatment appropriate to their needs is still not widely available.  Second, there is an
urgent need to prevent the spread of HIV/AIDS among injecting drug users, whether they are street addicts,
sex slaves, or prison inmates. 
Third, while drug market trends are moving in the right direction, more work is needed to ensure that these
trends will be sustained.  After so many years of drug control experience, we now know that a coherent, long-
term strategy can reduce drug supply, demand and trafficking.  If this does not happen, it will be because some
nations fail to take the drug issue sufficiently seriously and pursue inadequate policies. In other words, each
society faces the drug problem it deserves.  
Antonio Maria Costa
Executive Director
United Nations Office on Drugs and Crime
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3The work of the United Nations Office on Drugs and Crime (UNODC) is supported by three pillars:  
• Research and analytical work to increase knowledge and understanding of drugs and crime issues and
expand the evidence-base for policy and operational decisions; 
• Normative work to assist States in the ratification and implementation of the international treaties, the
development of domestic legislation on drugs, crime and terrorism, and the provision of secretariat and
substantive services to the treaty-based and governing bodies; and 
• Field-based technical cooperation projects to enhance the capacity of Member States to counteract illicit
drugs, crime and terrorism. 
Recognizing the importance of comprehensive, factual and objective information in the field of international
drug control, the General Assembly entrusted UNODC with the mandate to publish "comprehensive and
balanced information about the world drug problem" in 1998. 
UNODC has published such assessments annually since 1999.  The year 2004 saw the consolidation of the
former Global Illicit Drug Trends publication and the World Drug Report, published in a two-volume edition.
The first volume provides an analysis of the global situation and of the four main drug markets, the second
volume compiles detailed statistics. Together they provide the most complete picture of the world drug
problem. 
As in previous years, the present report is based on data obtained primarily from the annual reports
questionnaire (ARQ) sent by Governments to UNODC in 2005, supplemented by other sources when
necessary and where available. Two of the main limitations herein are: (i) that ARQ reporting is not systematic
enough, both in terms of number of countries responding and of content, and (ii) that most countries lack the
adequate monitoring systems required to produce reliable, comprehensive and internationally comparable
data. National monitoring systems are, however, improving and UNODC has contributed to this process.
As part of the ongoing effort to increase our knowledge base on the world drug problem, UNODC has been
working towards the creation of an Illicit Drug Index. The Illicit Drug Index is meant to provide a single
standard measure of the drug problem that would enable comparisons across regions and countries and over
time. The basic concept and methodology of the Illicit Drug Index was highlighted in the 2005 edition of the
World Drug Report. Work on the Illicit Drug Index continues with a view to providing Member States with a
comparable measure of the extent and evolution of the drug problem and further developments will be
presented in future editions of the World Drug Report. 
Electronic copies of the report can be accessed via the UNODC website at www.unodc.org. Comments and
feedback on the report can be sent to: worlddrugreport@unodc.org.
Introduction
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The designations employed and the presentation of the material in this publication do not imply the expression of
any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any
country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.   
Countries and areas are referred to by the names that were in official use at the time the relevant data were collected.
In various sections, this report refers to a number of regional designations. These are not official designations. They
are defined as follows: West and Central Europe: EU 25 plus EFTA plus San Marino and Andorra; East Europe:
European CIS countries; Southeast Europe: Turkey and the non-EU Balkan countries; North America: Canada,
Mexico and United States of America.
The following abbreviations have been used in this report:
ARQ         Annual reports questionnaire
ATS         Amphetamine-type stimulants
CICAD       Inter-American Drug Abuse Control Commission
CIS        Commonwealth of Independent States
DEA         United States of America, Drug Enforcement Administration
DELTA Database on Estimates and Long Term Trend Analysis
DUMA Drug Use Monitoring in Australia
EMCDDA     European Monitoring Centre for Drugs and Drug Addiction
ESPAD European School Survey Project on Alcohol and other Drugs
F.O. UNODC Field Office
Govt. Government
ICMP UNODC Global Illicit Crop Monitoring Programme
INCB        International Narcotics Control Board
INCSR United States of America, International Narcotics Control Strategy Report
Interpol   International Criminal Police Organization
LSD         lysergic acid diethylamide
NAPOL National Police
PCP         phencyclidine
THC tetrahydrocannabinol
UNAIDS  Joint and Co-sponsored United Nations Programme on Human   
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
UNODC         United Nations Office on Drugs and Crime
WCO World Customs Organization 
WHO         World Health Organization
Weights and measurements
u. Unit
lt. Litre
kg Kilogram
ha Hectare
mt Metric ton
u. Unit
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The World Drug Report tries to provide a comprehensive
and up-to-date picture of the world drug situation. This
is essential to assess the performance of drug control
interventions and to guide policy-making. While data in
this report is, in many cases, provided for at least the last
ten years, its analysis emphasizes the most recent and
most topical developments. Monitoring current devel-
opments is essential, however, it is also important to
take a longer-term view to assess the performance of the
multilateral drug control system.  
International drug control is one of the oldest forms of
multilateralism, older than the United Nations and even
predating its predecessor body, the League of Nations.
While the use of psychoactive plants has been with us
for a long time, it was at the beginning of the 20th cen-
tury when a series of national or local drug problems
turned into an international problem. The International
Opium Commission was convened in Shanghai, China,
in 1909 and spawned the first instrument of interna-
tional law to deal with psychoactive substances: the
Hague Opium Convention of 1912.  
From these origins began a process that has evolved into
the multilateral drug control system.  The scope of con-
trol over drugs has broadened and deepened over the
years, from opium to cocaine to cannabis to psy-
chotropic substances, and from the regulation of pro-
duction and trade of medical drugs to the goal of
international cooperation against the multi-faceted
problems associated with illicit drugs. The legal frame-
work for this whole multilateral control system is now
provided by three international drug conventions
(1961, 1971 and 1988) which enjoy quasi-universal
adherence. 
Evidence of long-term containment
With regard to the performance of that multilateral
system, there is evidence that, over the last hundred
years, it has reduced and contained the drug problem at
the global level. While tracking a trend over a century is
difficult because there are few facts, some baselines can
be found. The best is for the opium problem, because it
was investigated at the Shanghai Commission in 1909.  
Shortly before the Shanghai Commission was convened,
world opium production was estimated to have been at
least 30,000 metric tons. Nearly a hundred years later,
world opium production is down to about 5,000 metric
tons, which includes some 400 metric tons of licit med-
ical opium and 4,620 metric tons of illicit opium. The
world’s population has grown from about 1.65 million
in 1900 to 6.4 billion. Opium production is thus 80
percent less in a world that is more than three times
larger. 
In China, which had, at the time, a population of about
450 million, there were close to 25 million opium users.
Today, the estimated number of opiate users in Asia is
some 8.5 million. There are of course, many other drugs
today. But the trend is still a powerful illustration of the
containment of illicit drug production over a century.
The picture is more bleak for licit psychoactive sub-
stances. Tobacco, a particularly addictive substance, is a
case in point. About 28 per cent of the world’s adult
population is estimated to use tobacco, which exceeds,
by far, the number of people using illicit drugs (4 per
cent for cannabis and 1 per cent for ATS, cocaine and
opiates combined). 
Executive Summary
Chapter 1: Trends in World Drug Markets
The multilateral drug control system has, in fact, con-
tained the problem to 5 per cent of the world popula-
tion (age 15-64). This is an achievement that should not
be underrated and provides a useful perspective when
analysing more recent developments.
Of these 5 per cent of the population (age 15-64), who
use illicit drugs at least once a year (annual prevalence),
only about half of them (2.7 per cent of the population
age 15-64) use drugs regularly, that is, at least once per
month. The number of what are commonly understood
to be drug addicts or problem drug users is some 25 mil-
lion persons worldwide, equivalent to 0.6 per cent of
the population age 15-64.  This estimate does not seem
to have changed much in recent years at the global level
as increases in some countries were offset by declines in
others.  
Encouraging signs of mid-term containment 
A review of the problem over the more recent past also
brings to light some positive developments. Throughout
the 1990s, the global area under coca cultivation was
around 200,000 hectares. Since 2000, there has been a
reduction by more than a quarter. Last year global
opium poppy cultivation was also 36 per cent below the
levels recorded in 1998 (237,819 hectares) and 46 per
cent lower than in 1991 (281,560 hectares), despite the
resurgence of opium poppy production in Afghanistan
over the past years. 
Even with drug abuse, where data is often not available
or comparable, there have been some positive trends. At
the global level, use of ATS, cocaine and opiates has
remained largely stable for the past three years. So, while
the number of drug users is still unacceptably high,
there is hope that the use of at least some illicit drugs
can be contained. 
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Use of illicit drugs compared to use of tobacco
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tobacco estimates: derived from WHO,  World Health Statistics
2006.  
Illegal drug use at the global level (2004)
Current world situation: Further signs of stabilization,
except for cannabis
The extent of drug use is one important indicator of the
magnitude of the global drug problem. UNODC estab-
lishes annual prevalence estimates based on data pro-
vided by Governments in their annual reports
questionnaire.
The total number of drug users in the world is now esti-
mated at some 200 million people, equivalent to about
5 per cent of the global population age 15-64. Cannabis
remains by far the most widely used drug (some 162
million people), followed by amphetamine-type stimu-
lants (some 35 million people), which include amphet-
amines (used by 25 million people) and ecstasy (almost
10 million people). The number of opiate abusers is
estimated at some 16 million people, of which 11 mil-
lion are heroin abusers. Some 13 million people are
cocaine users. 
The paucity of the data on which the annual prevalence
estimates are based does not allow for the identification
of clear global trends in the short term. As an imperfect
complement, UNODC relies on the perception of the
trends in their countries by national experts. A global
analysis of these perceptions suggest that the strongest
increase over the last decade was for cannabis use and
ATS, and at lower levels for opiates and cocaine. After
some stabilization in 2003, ATS drug use was perceived
as having increased again, reflecting the prevailing view
in East and South-East Asia that methamphetamine use
has started rising again. 
Opiate abuse trends flattened in recent years. However,
by 2004, opiate abuse perceptions again went upwards,
as many countries around Afghanistan experienced a
renewed supply-push following Afghanistan’s good
opium harvests of 2003 and 2004. In other parts of the
world, including North America and Western Europe,
abuse levels remained constant for opiates. After years of
increases, cocaine use is perceived as declining slightly,
notably in the Americas. In Europe, by contrast, cocaine
use continues to expand.   
Treatment demand provides some insight into the
world drug problem, in terms of the impact of drugs on
health. In Africa, most treatment is required for
cannabis use  whereas for Asia and Europe treatment
demand is highest for opiates. Treatment demand for
cocaine use is highest in South America, followed by
North America. For abuse of ATS, treatment demand is
highest in Asia, followed by Oceania, North America,
Europe and Africa. The level of treatment demand tends
to mirror the abuse situation, with cannabis being the
big exception. Only a relatively small proportion of the
9
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Main problem drugs (as reflected in treatment demand) in 2004 (or latest year available)
Source: UNODC, Annual Reports Questionnaire Data/DELTA and National Government Reports.
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millions of cannabis users require treatment services. It
should be noted, however, that treatment demand for
cannabis has continuously increased over the past years,
particularly in Europe and North America. Treatment
demand for heroin abuse has shown an upward trend in
Africa, notably East Africa. Treatment demand for ATS
has been rising in North America, Asia and Europe and
treatment demand for cocaine has moved upwards in
Europe. 
Governments have collected information on drug
seizures since the time of the League of Nations. If
seizure data are collected by a large number of countries
over a longer period of time, they are usually a good
indicator of underlying changes in illicit drug traffick-
ing patterns.
Existing data show a continuous increase in the level of
world seizures, with increases for both cannabis herb
and cannabis resin (+6 per cent), opiates (+ 9 per cent),
and cocaine (+18 per cent) in 2004. Seizures of amphet-
amines declined by 25 per cent in 2004 whereas ecstasy
seizures increased significantly, albeit from a much lower
level. The reasons for the increases in the different drug
groups are manifold but most increases can be explained
by a combination of wider availability of the drug and
strengthened law enforcement efforts. This is particu-
larly true for cocaine seizures where efforts of law
enforcement authorities on rapid intelligence sharing
appear to have paid off. The decline of seizures of
amphetamines should be seen in a larger perspective.
For the past ten years, seizures in this drug category have
increased on average by 12 per cent per year. 
Global drug seizures, excluding cannabis (in weight equivalents), 2002-2004
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Several positive developments were observed: the total
area under opium poppy cultivation declined in 2005,
as did global opium production. Global seizures of opi-
ates (heroin, morphine and opium) increased, particu-
larly in South-East Europe, and global abuse of opiates
appears to be stable. 
Decline in global opium poppy cultivation
In 2005, the estimated area under illicit opium poppy
cultivation in the world decreased by 22 per cent (from
195,940 hectares to 151,500 hectares) due to lower cul-
tivation in the three main source countries of illicit
opium in the world: Afghanistan, Myanmar and Lao
People’s Democratic Republic (Lao PDR). Global
opium production was estimated at 4,620 metric tons of
which 4,100 metric  tons (89 per cent) were produced
in Afghanistan. 
Afghanistan: first fall in opium poppy 
cultivation since 2001
In Afghanistan, in 2005, opium poppy cultivation
decreased for the first time since 2001. The area under
opium poppy cultivation decreased by 21 per cent from
about 131,000 hectares in 2004 to 104,000 hectares in
2005. The national trend, however, masked consider-
able provincial differences. While sharp declines could
be seen in some provinces (e.g. Nangarhar, from 28,213
hectares to 1,093 hectares), cultivation increased in
others (e.g. Kandahar, from 4,959 hectares to 12,989
hectares).
Early indications are, however, that planting of opium
poppy  increased during 2006, particularly in the south-
ern provinces. 
An overlooked success story: 
South–East Asia
Sustained progress has been made by the Governments
of Myanmar and Lao PDR in addressing  illicit opium
poppy cultivation. In 2005, Myanmar achieved a fur-
ther reduction of the total area under cultivation, by
26 per cent to 32,800 hectares. In Lao PDR, cultivation
dropped by an impressive 72 per cent, to 1,800 hectares.
With an estimated opium production of only 14 metric
tons, the country is on the verge of becoming opium
poppy free. Since 1998, the year of the General Assem-
bly Special Session on the World Drug Problem, opium
poppy cultivation in these two South-East Asian coun-
tries has been reduced by 78 per cent.
Global opium poppy cultivation, 1990-2005
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Sustaining these remarkable achievements may, how-
ever, largely depend on the availability of socio-eco-
nomic alternatives for the farmers who have given up a
traditional source of their livelihood. This makes the
provision of development assistance to these communi-
ties both a humanitarian and a strategic necessity.
Significant reductions in Latin America
In the Americas, opium poppy continues to be culti-
vated for use in the illicit markets in North America.
Estimates by the Government of Colombia put the area
under opium poppy cultivation at about 2,000 hectares,
a reduction of 50 per cent compared to the 4,000
hectares recorded in 2004. The Government of Mexico
did not provide any cultivation data to UNODC at the
time of producing the present report but the United
States estimates that, in 2005, 3,300 hectares were
devoted to opium poppy cultivation in Mexico, equiva-
lent to a decline of 32 per cent since 2003. The situa-
tion as regards opium poppy cultivation in Peru is diffi-
cult to quantify as the UNODC supported national
illicit crop monitoring system has not yet established a
reliable methodology for the detection of opium poppy
in that country.  Colombia, Mexico and Peru all con-
tinue to eradicate opium poppy cultivation. 
Global opium production declines by 5 per cent
Despite the 18 per cent decrease in the area under
opium poppy cultivation, global opium production
decreased by only 5 per cent, to 4,620 metric tons in
2005. In Afghanistan, potential opium production was
estimated at around 4,100 metric tons, representing a
2 per cent decrease compared to 2004. The clear dis-
crepancy between the large reduction in cultivation and
the relatively small reduction in production was prima-
rily due to more favourable weather conditions during
the 2005 growing season in Afghanistan. In 2005,
Afghanistan was therefore the source of 89 per cent of
global opium production, followed by Myanmar (7 per
cent).
Opiates are trafficked along three main trafficking
routes 
While it is extremely difficult to measure actual drug
trafficking flows, seizures provide a useful indicator.
Thus, three major trafficking routes for opiates (heroin,
morphine and opium) can be identified: 
• from Afghanistan to neighbouring countries, the
Middle East and Europe;
Golden Triangle area under cultivation (in hectares)    
1998 2005
Myanmar 130,300 32,800
Lao PDR 26,837 1,800
Thailand 716 insignificant
Viet Nam 442 insignificant
Total 158,295 34,600
Estimated global opium production, 1990-2005
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Seizures of opium in Asia in 2004 (only highest ranking countries represented)
Heroin and morphine seizures 2003-2004: extent and trends (only highest ranking countries represented)
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• from Myanmar/Lao PDR to neighbouring coun-
tries in South-East Asia, (notably China) and to
Oceania (mainly Australia);
• from Latin America (Mexico, Colombia and Peru)
to North America (notably USA)  
The proportion of opiate seizures, expressed in heroin
equivalents, along the Afghanistan–Europe trafficking
route increased from 78 per cent to 85 per cent between
2002 and 2004, reflecting rising levels of opium pro-
duction in Afghanistan and rising levels of opiate traf-
ficking from that country. The volume of opiate seizures
along the other two main routes showed a downward
trend (from 7 per cent to 4 per cent in the Americas,
and from 15 to 11 per cent for the South-East
Asia/Oceania route).  
Global seizures of opiates increase, by 9 percent, to
120 metric tons 
Global seizures of opiates reached 120 metric tons in
2004 (+ 9 per cent compared to 2003). Increases were
particularly strong in South-East Europe (+109 per
cent) reflecting the resumption of large-scale trafficking
along the Balkan route. Highest seizures were reported
by Iran, followed by Pakistan and China. The largest
heroin seizures were reported from China (10.8 metric
tons). The estimated global interception rate for opiates
was 24 per cent of global production, a clear increase
from the 10 percent recorded 10 years earlier. 
Changes in opium production centres affect trafficking
patterns in Afghanistan 
The shift in opium production centres in Afghanistan
affected the way opium and heroin was trafficked to
neighbouring countries in 2005. Decreasing opium pro-
duction in north-eastern Afghanistan reduced the level
of trafficking to countries in Central Asia. Declining
opium production in eastern Afghanistan also reduced
the amounts of opiates trafficked towards Pakistan. On
the other hand, opiate trafficking towards the Islamic
Republic of Iran continued to increase (close to 60 per
cent, up from 40 per cent of the opiates leaving
Afghanistan in 2004).  Ongoing production increases of
opium in southern Afghanistan in 2006 are likely to put
an additional burden on to law enforcement authorities
of Iran in their efforts to prevent the trafficking of
Afghan opiates to their country.   
Increases in opiate seizures in South-East Europe
Europe’s opiate seizure rose by 49 per cent in 2004 and
reached almost 29 metric tons (in heroin equivalents),
the highest such figure ever recorded.  The increase in
European seizures was primarily due to the doubling of
opiate seizures in South-East Europe where more than
15 metric tons were seized, exceeding the total seizures
made in West & Central Europe and Eastern Europe.  
Turkey reported, once again, most opiate seizures in
Europe, a position the country has held without inter-
ruption since 1987. The second largest opiate seizures in
Europe, for the second year in a row, were reported by
the Russian Federation (4 metric tons or 14 per cent of
European opiate seizures). The largest seizures among
West European countries were made in the United
Kingdom, Italy, Netherlands, Germany and France. The
United Kingdom is Europe’s main opiate market and a
final destination country. 
Opiate seizures rise by 60 per cent in Africa 
Opiate seizures in Africa also showed a strong increase
in 2004 (+60 per cent). The bulk of this increase is due
to seizures made in West and Central Africa which more
than doubled between 2003 and 2004. Heroin is traf-
ficked through African countries for markets in Europe
and, to a lesser extent, North America.  Sources of the
opiates are both countries in South-West Asia and
South-East Asia. The overall amounts of opiates seized
in Africa are, however, still very modest (0.3 per cent of
global opiate seizures), but may not properly reflect the
actual level of trafficking flows as many countries lack
adequate law enforcement capabilities. 
Global opiate seizures, expressed in heroin
equivalents, by substance, 1980-2004
Source: UNODC, Annual Reports questionnaire Data/DELTA.
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Global abuse of opiates appears to be stable
Almost 16 million people in the world, or 0.4 per cent
of the world’s population aged between 15 and 64 years,
are abusers of opiates. The prevalence estimate is simi-
lar compared to the one published in the 2005 World
Drug Report. 
More than half of the world’s opiate abusing population
lives in Asia and the highest levels of opiate abuse are
along the main drug trafficking routes originating from
Afghanistan. 
At the global level, of the world’s 16 million opiates
abusers, some 70 per cent (11 million) are abusers of
heroin. However, the proportions vary by region. In
Africa, all opiates abusers reportedly abuse heroin. In
Asia, around 64 per cent of opiate users abuse heroin as
use of opium is still widespread.
Along with increasing opiate production in
Afghanistan, some neighbouring countries of
Afghanistan and opiate transit countries in Eastern
Africa as well as some of the countries along the Balkan
route in South-East Europe reported rising levels of
opiate abuse in 2004. These increases were, however,
again largely offset by falling levels of opiate abuse
reported from countries in East and South-East Asia
and Oceania, reflecting ongoing declines of opiate pro-
duction in the Golden Triangle (notably in Myanmar
and Lao PDR). Trends in North America and in most
of Western Europe were largely stable. The net result
was a small increase in expert perception of the global
use of drugs. 
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Sources: UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC's Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
HONLEA reports and local studies.
Changes in abuse of heroin and other opiates, 2004 (or latest year available)  
Sources: UNODC, Annual Reports Questionnaire Data,  Government reports, UNODC Field Offices,  UNODC’s Drug Abuse Information Net-
work for Asia and the Pacific (DAINAP), EMCDDA, HONLEA reports and local studies.
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Some encouraging trends were noted on the
coca/cocaine market. The area under coca cultivation
remained essentially stable and well below levels
recorded in 2000. Global production of cocaine stayed
largely at the same level and seizures of cocaine rose to
new  highs. Global cocaine use declined slightly. 
Global cultivation of coca remains stable in 2005
Preliminary figures suggest that the total area under coca
cultivation remained stable in 2005. Thus the area
under coca cultivation (159,600 hectares) was 28 per
cent below the peak levels recorded in 2000 (221,300
hectares). Most coca continues to be cultivated in
Colombia (54 per cent), followed by Peru (30 per cent)
and Bolivia (16 per cent). 
After four consecutive years of decline, over which coca
cultivation decreased in Colombia, the total area under
coca cultivation in that country increased by 8 percent
to 86,000 hectares. The increase came about despite sus-
tained eradication efforts of the Government of Colom-
bia. Some coca is cultivated in national parks which
causes environmental damage, primarily deforestation.
Nonetheless, the area under coca cultivation in Colom-
bia is still 47 per cent less than in 2000.
Coca cultivation declined in Bolivia (-8 per cent) and in
Peru (-4 per cent) in 2005. However, the areas under
coca cultivation are 74 per cent higher in Bolivia and 11
per cent in Peru as compared to the levels in 2000.
Estimated production of cocaine stays largely at the
same level
The potential production of cocaine reached 910 metric
tons in 2005. Potential cocaine production in Peru
amounted to 180 metric tons in 2005 and to 90 metric
tons in Bolivia. The overall level of cocaine production
remained essentially stable in 2005 and is practically
unchanged from the levels of a decade ago. 
Global cocaine seizures rose to another record high in
2004 
There are two main trafficking routes for cocaine: 
• from the Andean region, notably Colombia, to the
United States (often via Mexico), and 
• from the Andean region to Europe (via the
Caribbean and, increasingly, via Africa).  
Cocaine seizures increased to 588 metric tons in 2004,
an 18 per cent increase and the highest figure ever
recorded. This followed an increase in global cocaine
seizures of 34 per cent in 2003. The increase has been
– to a large extent - the result of better cooperation
among law enforcement services and improved sharing
of intelligence information. Indications are that this
trend continued in 2005 and will probably continue in
2006.
Coca/Cocaine market
1998 1999 2000 2001 2002 2003 2004 2005
Bolivia 38,000 21,800 14,600 19,900 21,600 23,600 27,700 25,400
Peru 51,000 38,700 43,400 46,200 46,700 44,200 50,300 48,200
Colombia 101,800 160,100 163,300 144,800 102,000 86,000 80,000 86,000
Total 190,800 220,600 221,300 210,900 170,300 153,800 158,000 159,600
Coca cultivation in the Andean region, 1998-2005 (hectares)
Global cocaine seizures, regional breakdown, 
1980-2004
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Colombia seizes the most cocaine
For the third year in a row, Colombia seized most
cocaine in the world (almost 188 metric tons), 32 per
cent of the world total and an increase of 29 per cent
compared to 2003.  The second largest seizures were
reported from the United States (166 metric tons,
28 per cent of the world total). In Ecuador, there has
been a 9-fold increase in seizures (5 metric tons in 2004,
44 metric tons in 2005). 
European cocaine seizures were close to 80 metric tons
in 2004 and about 100 metric tons in 2005. Over the
1994-2004 period they increased by, on average, 10 per
cent per year. Spain remains Europe’s main entry point
for cocaine. Large increases in cocaine seizures have also
been reported from Portugal which has become another
major gateway for cocaine destined for European mar-
kets. Portugal reported the third largest cocaine seizures
among European countries in 2004, after Spain and the
Netherlands.   
One of the main cocaine trafficking routes to Europe
continues to go via the Caribbean region. The Nether-
lands Antilles are of special importance in this regard.
The Dutch authorities made more than 40 per cent of
their total seizures in the waters around the Netherlands
Antilles in 2004. There are also important cocaine ship-
ments to metropolitan France transiting the Caribbean
region, including the French overseas departments in
the Caribbean.
Cocaine seizures in West and Central Africa show six-
fold increase
The rising importance of Africa, and notably of West
Africa, as a transit point for cocaine shipments destined
for European markets is becoming more evident.
Seizures made in Africa increased more than three-fold
in 2004 with seizures in West and Central Africa
increasing more than six-fold. Most of this cocaine is
destined for Spain and Portugal for onward shipment to
other European countries. Largest seizures over the
2000-2004 period in Africa were made in Cape Verde,
followed by South Africa, Kenya, Ghana and Nigeria.
Despite this increase, African seizures still account for
less than 1 per cent of global cocaine seizures but there
are indications that only a very small proportion of
cocaine transiting the African continent is actually
seized. If it is sustained, this shift in trafficking patterns
is likely to have an impact on abuse in Africa. 
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Cocaine seizures in 2004 (only highest ranking countries represented)
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Overall level of cocaine use declines slightly 
Cocaine use is estimated to affect 13.4 million people or
0.3 percent of the population age 15-64. Drug use per-
ception trends show - for the first time in years- a mod-
erate decline in 2004. Most cocaine continues to be
used in the Americas, particularly North America,
which accounts, with 6.5 million users, for almost half
the global cocaine market. In the United States, recently
released prevalence studies for high school students
showed that, for both cocaine and crack cocaine, annual
prevalence declined in 2005. Cocaine prevalence rates
are some 20 per cent lower than in 1998. Declines in
student surveys have been also reported from Canada
and in studies conducted in a number of South Ameri-
can countries. 
The opposite trend is observed in Europe, where
cocaine use is still rising. The 3.5 million cocaine users
in Europe account for 26 per cent of global cocaine use.
Almost 25 per cent of the world’s cocaine users are in
West and Central Europe. Cocaine use in West and
Central Europe (1.1 per cent of the population age 15-
64) is still lower than in North America (2.3 per cent)
but the trend in Europe is pointing upwards. Annual
prevalence rates of more than 2 per cent have been
reported from Spain and the United Kingdom. 
In Oceania, the level of cocaine use is 0.9 per cent of the
population age 15-64 and was perceived as falling.
Cocaine use in Africa showed an upward trend in 2004,
partly reflecting the increased use of Africa as a tran-
shipment location for trafficking of cocaine to Europe.
Cocaine use in Asia is still very limited. 
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experts: cocaine
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC’s Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Changes in abuse of cocaine, 2004 (or latest year available)  
Sources: UNODC, Annual Reports Questionnaire Data,  Government reports, UNODC Field Offices,  UNODC’s Drug Abuse Information
Network for Asia and the Pacific (DAINAP), EMCDDA, CICAD,  HONLEA reports and local studies.
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The group of amphetamine-type stimulants (ATS)
encompasses amphetamines (amphetamine, metham-
phetamine), ecstasy (MDMA and related substances)
and other synthetic stimulants (methcathinone, phen-
termine, fenetylline etc.).
Signs of stabilization
After years of massive increases in the 1990s, the mar-
kets for amphetamine type stimulants seem to be stabi-
lizing, reflecting improved international law
enforcement cooperation and improvements in precur-
sor control. The quantities of precursors and the
number of illicit laboratories seized increased, as
enforcement efforts intensified, but end-product
seizures declined and the number of ATS users remained
roughly stable.   
UNDOC’s global production estimate for ATS is at 480
metric tons, slightly higher than a year earlier, but still
lower than the estimate for 2000. The broad error mar-
gins for the 2004 estimate, however, do not allow for a
statistically valid statement whether production has
increased. Methamphetamine manufacture and traffick-
ing has spread beyond the traditional markets of Asia
and North America (e.g. to South Africa), though in
Europe it is still limited.  
An even stronger geographical spread has been observed
with regard to ecstasy production and trafficking.
While there seem to have been some declines in the ‘tra-
ditional’ manufacturing locations of Western Europe
(notably the Netherlands), ecstasy production is spread-
ing to other parts of the world, including North Amer-
ica, Oceania and South-East Asia.  Amphetamine
production continues to be concentrated in Europe, but
some shifts from the traditional centre (Netherlands)
towards the new EU member states and the EU candi-
date countries have been noticed.   
Seizures of amphetamines fall sharply 
In 2004, seizures of amphetamines declined to 21
metric tons (-26 per cent). Since 2000, they have
declined by 53 per cent, mainly reflecting lower seizures
in East & South-East Asia. The highest seizures of
amphetamines were reported from the United States,
followed by China, Belgium, Thailand and the United
Kingdom. 
Ecstasy seizures skyrocket
Global seizures of ecstasy passed the 8 metric ton mark
in 2004, up from less than 5 metric tons in 2003. Most
ecstasy continues to be manufactured in Europe which
also accounts for the majority of seizures made of that
substance (53 per cent). More than 20 per cent of all
ecstasy seizures are made in North America, reflecting
decisive action by enforcement authorities to counteract
illicit trafficking. The highest seizures of ecstasy were
reported from Canada, Belgium, Australia, Netherlands
and the United Kingdom.
Use of methamphetamine increasing again in parts of
Asia and southern Africa
Some 25 million people used amphetamines in 2004,
while some 10 million people used ecstasy. More than
60 per cent of the world’s amphetamines users live in
Asia while more than 50 per cent of the world’s ecstasy
users live in Western Europe and North America.
Annual prevalence of amphetamines use is highest in
Oceania, followed by North America and East and
South-East Asia. In Europe, which is home to an esti-
mated 2.7 million users of amphetamines, ampheta-
mine use is far more widespread than the use of
methamphetamine which is limited to the Czech
Republic and some Baltic States. 
Following some decline in 2003, use of methampheta-
mine was perceived to increase again in several parts of
Asia. Exceptions were Japan and Thailand which
reported a falling methamphetamine trend. Declining
trends in the Asia/Pacific region were also observed in
Australia. Strong increases in methamphetamine use
were reported from South Africa, reflecting the emer-
gence of local production.  
Mixed signals from North America and Europe
Trends for North America are stable to increasing.
Methamphetamine use data for Mexico show an upward
trend. In the United States, household survey data
showed a stable level of methamphetamine use between
2003 and 2004 and surveys on adolescent use of
methamphetamine have shown declining rates. How-
ever, treatment data continue to move clearly upwards,
growing more strongly for methamphetamine than for
any other substance. 
Amphetamine-Type Stimulants market
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Seizures of amphetamines (excluding ‘ecstasy’) in 2004 (only highest ranking countries represented)
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The European amphetamine market also provides a
mixed picture. Amphetamine use was reported to have
been stable in the United Kingdom, France and most
Nordic countries and declining in Spain. Rising levels of
use were reported from Germany, Italy and most central
and East European countries.   
The net result of all these trends was a small increase in
the global drug use trend, as perceived by experts in
2004.
Global level of ecstasy use shows signs of stabilization
following years of strong growth
Use of ecstasy shows divergent trends. Massive declines
in ecstasy use have been reported from countries in
North America over the last few years, notably the
United States, as reflected in student surveys. These sur-
veys also show that availability has declined and that the
perceived health risks have increased. The situation is
different in Europe. Following years of increase, result-
ing in ever higher ecstasy prevalence data, exceeding
those of amphetamine in a number of countries, ecstasy
use has started to stabilize in several West European
countries. In several South-East European countries,
however, ecstasy use continues expanding. Increases
have been also reported from countries in East & South-
East Asia and Oceania.   
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Twelve-year drug use trend, as perceived by
experts: amphetamine-type stimulants
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC’s Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Changes in the use of ATS (methamphetamine and amphetamine), 2004 (or latest year available)  
Sources:  UNODC, Annual Reports Questionnaire Data,  Government reports, UNODC Field Offices,  UNODC’s Drug Abuse Information
Network for Asia and the Pacific (DAINAP), EMCDDA, CICAD, HONLEA reports and local studies.
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Changes in the use of Ecstasy (MDMA, MDA, MDEA), 2004 (or latest year available)  
Sources:  UNODC, Annual Reports Questionnaire Data,  Government reports, UNODC Field Offices,  UNODC’s Drug Abuse Information
Network for Asia and the Pacific (DAINAP), EMCDDA, CICAD, HONLEA reports and local studies.
Cannabis market 
Two types of cannabis dominate world cannabis mar-
kets
Two types of cannabis are produced in the world drug
market. Production of cannabis herb (marijuana) is
widely dispersed. Cannabis resin (hashish) is produced in
about 40 countries in the world, with main sources
being Morocco, Afghanistan and Pakistan. 
Sharp drop in cannabis production in Morocco
Cannabis resin from Morocco primarily supplies
Europe, the world’s largest market for that substance. In
cooperation with UNODC, the Government of
Morocco carries out cannabis cultivation surveys. The
area under cannabis cultivation dropped sharply in
2005, from 120,500 hectares in 2004 to an area of
72,500 hectares in 2005. The reduced availability of
cannabis resin will affect the cannabis resin market in
Europe. Cannabis users in that region may increasingly
turn to herbal cannabis which has become more widely
available in that region over the years. Cannabis resin
production in Morocco declined from 3,070 metric tons
in 2003 to 2,760 metric tons in 2004 and 1,070 metric
tons in 2005, which is equivalent to a decline of 61 per
cent in 2005.
Cannabis resin is also produced in Afghanistan, where
the cultivated area could be 30,000 hectares, and Pa-
kistan.
Increase in cannabis seizures
Cannabis herb and resin remain the most widely traf-
ficked drugs worldwide, accounting for the majority of
all seizures. For the first time, cannabis herb seizures sur-
passed 6,000 metric tons (+6 per cent) in 2004. Most
cannabis herb seizures were reported from Mexico, fol-
lowed by the United States, South Africa, Nigeria and
Morocco. In 2004, seizures of cannabis resin also
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increased by 6 per cent to 1,470 metric tons. Most
seizures of cannabis resin were made by Spain, followed
by Pakistan, France, Morocco and Iran.  
Cannabis remains the most widely used drug – and
consumption continues to increase at the global level
Cannabis remains by far the most commonly used drug
in the world. An estimated 162 million people used
cannabis in 2004, equivalent to some 4 per cent of the
global population age 15-64. In relative terms, cannabis
use is most prevalent in Oceania, followed by North
America and Africa. While Asia has the lowest preva-
lence expressed as part of the population, in absolute
terms it is the region that is home to some 52 million
cannabis users, more than a third of the estimated total.
The next largest markets, in absolute terms, are Africa
and North America. 
Trend data from the Americas show mixed results and
are best described as stable to slightly declining, though
in some countries cannabis use is also increasing. In the
United States, the annual prevalence of cannabis use
among the general population remained essentially
stable in 2004. Cannabis use among secondary school
students in the United States, however, continued to
decline.  Between 1997 and 2005 cannabis use among
Seizures of cannabis resin in % of world total and kg-
highest ranking countries – 2004
* data refer to 2003 
794,437
135,639
103,705
86,800
86,500
69,030
41,146
39,921
28,994
16,101
Spain
Pakistan
France
Morocco
Iran
United Kingdom
Afghanistan
Belgium
Portugal
Netherlands
54%
9%
7%
6%
6%
* 5%
Cannabis herb seizures 2003-2004: extent and trends (countries reporting seizures of more than 10kg.)
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high school students fell by some 20 percent.  Declin-
ing use rates of cannabis were reported from Oceania. 
All these declines were, however, not sufficient to offset
the increases reported from Africa, Asia and some coun-
tries in Europe. Perceptions by experts continued to
point upwards, suggesting that the expansion of global
cannabis use continued in 2004. Since the late 1990s,
cannabis use increased by more than 10 per cent at the
global level, as shown by the UNODC annual preva-
lence estimates.  All available indicators suggest that the
expansion of cannabis use over the last decade was
stronger than increases for opiates or cocaine, similar to
the one observed for the amphetamine-type stimulants.
While ATS use however, has declined, cannabis use is
still increasing.  
Cannabis resin seizures 2003-2004: extent and trends (countries reporting seizures of more than 10kg.)
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Though an estimated 162 million people use cannabis
annually and it is produced in some 176 countries
around the world, many basic facts about the supply
and demand for this drug remain obscure. As the risks
posed by cannabis consumption become clearer, our
ignorance of this health issue begins to look particularly
alarming. Of particular concern is the recent growth in
potency and market share of re-engineered forms of the
drug in the developed world. Coming to terms with
cannabis will require a greater understanding of the
dynamics of the market.
The world’s biggest drug market is growing and
uncharted
All available indicators suggest that global cannabis pro-
duction, after having fallen in the late 1980s (mainly
due to large-scale eradications in Latin America), rose
again in the 1990s and continues rising in the new mil-
lennium. The volumes of cannabis seized internationally
have been increasing since the early 1990s, and surveys
show that global demand has also increased.
It is often assumed that since cannabis has been studied
for decades, the nature of the drug must be well under-
stood. But it is exceedingly difficult to document where
some 4 per cent of the world’s adult population are
securing their supplies. Cannabis can be grown in vir-
tually any country, and is increasingly grown indoors in
the developed nations. Unlike other illicit drugs, users
can, and do, cultivate their own supply, and so produc-
tion is diffuse. Very few Governments can give an accu-
rate estimate of the area of cultivation in their own
countries, and the amount of drug product these fields
would yield is subject to a range of variables, including
the type of cannabis desired and the number of crops
possible in the year.
The circumstances around cannabis consumption are
no better understood. In most markets, cannabis is
Changes in the use of cannabis, 2004 (or latest year available) 
Sources: UNODC, Annual Reports Questionnaire Data,  Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
Information
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cheap. Consequently, the precise amounts bought and
consumed remain vague to all parties concerned. Sur-
veys indicate that most users get their drug for free or
buy it through social networks. Casual users generally
consume cannabis in groups, and only a small amount
of the drug is necessary to produce the desired effect.
The standard consumption unit (a joint) is larger than
the standard dose unit (a few inhalations) for most
users. In the end, most users would find it difficult to
say how much cannabis they smoke in any given con-
sumption session.
Cannabis is everywhere
There is no region in the world where cannabis is not
the dominant illicit drug, and few regions where
cannabis use is not growing. It is everywhere, and
spreading. While not every cannabis market is trans-
national (in the sense that production occurs in a dif-
ferent country than consumption), the problem is truly
international.
North America is the largest cannabis consuming region
in economic terms. Mexico alone is responsible for some
35 per cent of global herbal cannabis seizures, and con-
ducts an ongoing intensive eradication campaign.
Despite eradicating upwards of 80 per cent of the
cannabis cultivated in the country, it is still able to
supply a large share of the massive United States market
with the residual 20 per cent. High-potency indoor
cannabis has come to dominate the Canadian market,
another source of significant imports to the US.
Africa comes second in the world in terms of herbal
cannabis seizures, remarkable given limited law enforce-
ment capacity. Africa is home to the world’s leading pro-
ducer of cannabis resin – Morocco, the site of the largest
known cannabis cultivation area.  Southern, Western,
and Eastern Africa all contain large cannabis producing
countries, but there are few specifics about the scale of
cultivation.
Central and South America pose something of a puzzle.
Large seizures are regularly made in several countries,
but surveys indicate small user populations and, with
the exception of Colombia, no country is known to be
a major cannabis exporter beyond the region. Paraguay
is said to be the major source of the cannabis consumed
in the Southern Cone and Brazil, and, according to
Government estimates, may be the single largest pro-
ducer of herbal cannabis in the world. 
Oceania has the world’s highest annual use levels,
including those of Papua New Guinea, where an esti-
mated 30 per cent of the adult population consumes the
drug annually. Most countries appear to be self-suffi-
cient in their cannabis supply. For example, Australia
used to import cannabis, but growing law enforcement
and growing domestic indoor production have greatly
reduced the flows into the country.
Much of Europe users prefers cannabis resin to herbal
cannabis, but this appears to be changing in many
important markets. The Netherlands has been at the
vanguard of the indoor cannabis revolution, and is cur-
rently named as an important source for at least 20
other countries. In Eastern Europe, Albania plays a sim-
ilar role, said to be supplying another dozen countries
with both herbal cannabis and resin. Most of the
cannabis resin in Europe, however, continues to be traf-
ficked from Morocco.
While use levels are low in Asia, the size of the popula-
tion means that the continent is home to the largest
group of cannabis users, an estimated third of the global
total. Central Asia is said to be the original birthplace of
cannabis and is home to the world’s largest feral
cannabis fields, which could easily supply world
demand if they were actively cultivated. Afghanistan is
the world’s second largest producer of resin from
cannabis, grown alongside opium poppy fields.
Lebanon was once the world’s leading resin supplier,
and might be still if it were not for continual eradication
efforts. South Asia is the home of hand-rubbed cannabis
resin, and recent research indicates 2.3 million Indians
are dependent on cannabis.
A global market that defies efforts to size it up
Given this wide geographic spread, the variety of ways
that cannabis is cultivated and the general paucity of
data, it is difficult to estimate the size of the global
market.  Looking at the available information from the
top six producer countries, which together are responsi-
ble for three quarters of global seizures, a rough estimate
of 231,000 hectares can be derived, providing some
30,000 metric tons of herbal cannabis and 7,000 metric
tons of resin. Of this, less than a fifth (17 per cent) is
seized.
Looking at demand side estimates, it appears that up to
95 per cent of global cannabis is consumed by the 14
per cent of the annual cannabis-using population who
use the drug every day. Of this, more than two-thirds
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(69 per cent) is consumed by the 4 per cent who are
chronically intoxicated. As is often the case, demand-
side estimates are less than those found on the supply
side – about 19,000 metric tons.
Reconciling these estimates is a challenge, and under-
scores how little is known about the global cannabis
markets. With the exception of Morocco, no country in
the world publishes scientific estimates of the scale and
nature of cannabis cultivation within its borders. Devel-
oped countries cannot say with any precision how much
of the cannabis consumed by their populations is
imported and how much is produced domestically, in
high-tech,  indoor operations aimed at producing a
high-potency drug. This information may be lacking
due to a perception that cannabis consumption is not a
very important issue. Given the scale of consumption
and an emerging understanding of the risks involved,
this attitude may be misplaced.
The emergence of ‘new cannabis’ and the reassessment
of health risks
There are two sets of developments that should cause
policymakers to re-think their positions on cannabis.
One is a doubling of potency in sinsemilla cannabis
(consisting of the unfertilised buds of the female plant)
and a growing market share for this drug.  The second
is recent research indicating that the health risks associ-
ated with cannabis consumption may have been under-
estimated in the past. The two trends may be related: as
high-potency cannabis grows in popularity, the risks of
consumption may have been thrown into high relief.
The re-engineering of cannabis
Since the 1970s, cannabis breeders in North America
and Europe have been working to create more potent
cannabis, and the market for high-potency, indoor-pro-
duced sinsemilla appears to be growing in many key
consumption countries. Sinsemilla potency has
increased dramatically in the last decade in the United
States, Canada, and Netherlands – the three countries at
the vanguard of cannabis breeding and production tech-
nology – and there are indications that its market share
is growing in many others. 
Impact on public health: Three reasons to worry
While more research is required to determine the
impact of this ‘new’ cannabis, there has been an increase
of acute health episodes, with the number of people
complaining of ‘unexpected effects’ of consuming
cannabis in emergency rooms increasing in the United
States. Similarly, in parallel, there has been a growth of
rehabilitation demand by those seeking help with
cannabis problems in the United States and Europe.
In addition, the most recent research indicates that the
health risks of using cannabis have been underestimated
in the past. About 9 per cent of those who try cannabis
find themselves unable to stop using the drug. Cannabis
has been linked to precipitating psychosis in vulnerable
individuals, and aggravating its symptoms in diagnosed
schizophrenics. Cannabis can also produce negative
acute effects, including panic attacks, paranoia, and psy-
chotic symptoms.
Despite the popular perception that the risks of
cannabis are widely understood, new research indicates
that there is still much to be learned about the drug. At
the same time, cannabis itself is changing, and more
potent forms of the drug are growing in popularity.  As
cannabis is consumed by a significant share of the global
population, monitoring these developments is essential. 
Progress in coming to terms with cannabis is impeded
by the lack of an international consensus on the topic,
the drug conventions notwithstanding. National prac-
tices on cannabis have begun to diverge, and this frag-
mentation is impeding a coordinated and effective
approach. It is high time the topic is revisited at the
international level, so that what is truly a global issue
can be tackled within the multilateral framework that
was constructed for just such a purpose.
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The world drug situation in perspective 
The World Drug Report tries to provide a comprehensive
and up-to-date picture of the world drug situation. This
is essential to assess the performance of drug control
interventions and to guide policy-making. While data in
this report is, in many cases, provided for at least the last
ten years, most of its analysis emphasizes the most
recent and most topical developments. Monitoring cur-
rent developments is essential but it is also important to
take a longer-term view to assess the performance of the
multilateral drug control system.  
The only real basis for an assessment has to be an answer
to the question whether the drug problem is getting
better or worse, and whether illicit drug production,
trafficking and consumption are increasing or decreas-
ing.  Unfortunately, there is no definitive answer.  Hard
evidence – both qualitative and quantitative – is thin on
the ground.  The evidence becomes more and more
patchy as one changes the time-span of the enquiry
from a year, to a decade, to a century.  Tracking a trend
– changes between two points in time, usually the pres-
ent and some point in the past – is difficult at the best
of times, particularly when it concerns an illicit activity
which is usually concealed.  It is not enough to know
the situation as it is now.  Answering the question of
whether the present situation is better or worse neces-
sarily implies knowing what the situation was at the
moment in the past with which one is comparing.  This
is usually called a baseline.  It is obviously easier if the
baseline and the present situation can be captured in
some kind of quantitative measure.  The trend can then
be expressed in simple arithmetic:  not just better or
worse, but better or worse by a certain percentage.  If
there is no arithmetic, the trend can only be expressed
by perception:  when one is inclined to see the glass as
half empty then the trend is worse; when one is inclined
to see the glass as half full, then the trend is better. 
There are thus at least three time-spans on which one
can focus an assessment of trends in how the drug prob-
lem is evolving:  changes from one year to the next, over
a decade, and over a century.  The first is appropriate,
and possible, because the present Report is part of an
on-going series of publications which are designed to
show an annual trend.  Indeed, the rest of this Report
details the year-on-year trend in production, trafficking
and consumption of illicit drugs.  The second temporal
focus, on a decade, is appropriate because of the mile-
stone of the twentieth special session of the United
Nations General Assembly devoted to countering the
world drug problem  together (UNGASS) in 1998, and
the assessment of its goals and targets in 2008. This is
not dealt with here because it will doubtless be exam-
ined, in some detail, in subsequent issues of the World
Drug Report.  The third temporal focus, on a century,
is examined in the following paragraphs.
The drug control system is one of the oldest forms of
multilateralism, spanning nearly a century.  The use of
psychoactive plants may have been with us for millen-
nia, but a series of local or national drug problems only
turned into an international problem in the beginning
of the 20th century.  The Shanghai Opium Commission
of 1909 was convened in recognition of the fact that the
causes and consequences of the problem went well
beyond China.  This is why the histories of drug con-
trol and of multilateral regulatory regimes are so closely
inter-linked.  The Shanghai Commission spawned the
first instrument of international law to deal with psy-
choactive drugs:  the Hague Opium Convention of
1912. It required each signatory to enact domestic leg-
islation controlling narcotic drugs so they could be
restricted to medical use.  From these origins came a still
continuing process of expanding domestic legislation in
countries.  It illustrates a unique dimension of all mul-
tilateral regimes.  They have a mandatory nature.  When
countries become signatories to an international con-
vention, they incur an obligation to enact complemen-
tary legislation and thus have to measure their own
policies against international standards.  The Shanghai
Commission and Hague Convention also began a
process that has evolved into the multilateral drug con-
trol system.  The scope of control over drugs has broad-
ened and deepened over the years, from opium to
cocaine to cannabis to psychotropic substances, and
from the regulation of production and trade of medical
drugs to the goal of international cooperation against
the multi-faceted problems associated with illicit drugs.
1.1 The evolution of the world drug problem
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The legal framework for this whole multilateral control
system is provided by the three international drug con-
ventions.1
In the long-term, the drug problem has been con-
tained
With regard to the performance of that multilateral
system, there is evidence that, over the last hundred
years, it has reduced and contained the drug problem at
the global level. Tracking a long-term trend over a cen-
tury is difficult because the evidence is in short supply.
Some baselines can, however, be found.  The best, in
terms of detail, is for opium, because it was the opium
problem which was investigated at the Shanghai Com-
mission in 1909.  Comparing the size of the opium
problem in one country – China – at the beginning of
the 20th century with the size of the opium problem in
the world at large today, gives one some idea of how the
problem has evolved over a century.  Such a comparison
has been made in a previous issue of this Report.2 It is
useful to recapitulate because it carries considerable
explanatory power.
Just before the convening of the Shanghai Opium Com-
mission, in 1907/1908, world opium production was
estimated to have been at least 30,000 metric tons.
Almost three quarters of this was produced in China,
one-sixth in India and the rest in Indochina, Persia and
Turkey.3 Nearly a hundred years later, world opium
production declined by more than 80% to around
5,000 tons in 2005, including 4,620 tons of illegal
opium and some 400 tons of licit medical opium4. Over
the same period, the population of the world grew three
fold, from less than 2 billion to over 6 billion.  Opium
production is thus eighty per cent smaller in a world
which is three times larger. There are of course, many
other drugs today.  But the trend is a powerful illustra-
tion of the containment of illicit drug production over
a century, notably for the opiates which,  despite this
decline, are still the main problem drugs in the world,
responsible for most drug related morbidity and mor-
tality.
Another illustration of containment in the long-term
can be derived from comparing the consumption of
opium over a century.  At the beginning of the 20th cen-
tury, China alone is said to have had about 25 million
opium users5 .  
Today, at the beginning of the 21st century, there are less
than 16 million opiate users in the world (of which
some 11 million use heroin). Again, there are many
other psychoactive drugs available, and heroin is more
dangerous than opium, but containment of the problem
over a century still appears to be a sustainable argument. 
A third argument in support of long-term containment
is to compare illicit drugs with other licit, legitimately
available, psychoactive drugs.  The most instructive
comparison would be between illicit drugs and tobacco.
Though it is both psychoactive and addictive, nicotine
was never put under the drug control regime.  The
recent World Health Organization Framework Conven-
tion on Tobacco Control does control tobacco products,
but the approach is fundamentally different.  Compared
to illicit drugs, tobacco markets are relatively unregu-
lated, relying on taxation, advertising and age-related
controls of consumption.  Comparing these markets
with the much more strictly regulated markets for illicit
drugs is, as noted above, instructive.  The annual preva-
lence of tobacco use in the world is about one quarter
(age 15+) of the world population – some 1.7 billion
people.  The annual prevalence of illicit drug use –
taking all illicit drugs – is only 5 per cent of the world
population (age 15-64) – some  200 million people.
Tobacco consumption is thus eight-fold more than
illicit drug consumption.  Even more telling, tobacco
claims 25 times as many lives as illicit drug abuse.6 Had
there been no drug control system, the size of the drug
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1  The Single Convention on Narcotic Drugs of 1961 (United Nations Treaty Series, vol. 520, No.7515), the Convention on Psychotropic Substances
of 1971 (Ibid, vol.1019, No. 14956) and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (Ibid,
vol. 1582, No. 27627).
2 United Nations Office on Drugs and Crime, World Drug Report 2004, (United Nations publication, Sales No. E.04.XI.16) pp. 26- 27
3 International Opium Commission, Shanghai, China, 1-26 February 1909.
4 Licit opium estimate from the International Narcotics Control Board, as published in Narcotic Drugs: Estimated World Requirements for 2006,
Statistics for 2004 (United Nations publication, Sales No.E. 06.XI.3), p. 175. The estimate of licit opium production for the 2005 amounts to 374.3
tons, but may change. Illicit opium estimates are detailed in this Report in the chapter 'Opium/heroin market'. 
5 International Opium Commission, Shanghai, China, 1-26 February 1909; Vol. 1, Report of the Proceadings, p.68.
6 The World Health Organization estimates that some 200,000 people died from drug abuse in the year 2000, equivalent to 0.4 per cent of all deaths
worldwide. Tobacco, on the other hand, is said to claim about 5 million annually.  United Nations Office on Drugs and Crime, World Drug Report
2004, (United Nations publication, Sales No. E.04.XI.16),  Vol. 1, pp. 25-26.
using population, as well as the burden of disease asso-
ciated with it, would have been much greater – perhaps
even at levels close to tobacco.  The multilateral drug
control system therefore helped to contain the problem
at 5 per cent of the world population (age 15-64) or less
than one per cent if only problem drug use is consid-
ered.  This is an achievement that should not be under-
rated and provides a useful perspective within which
more recent developments can be analysed.
Estimated overall level of drug use in the world
remains stable 
Some 200 million people or 5 per cent of the world’s
population aged between 15 and 64 years have used
drugs at least once in the previous 12 months.  The
global estimate of drug users thus remains the same as
the estimate published in the 2005 World Drug Report.
Increases in some drug categories (cannabis and ecstasy)
were offset by some declines in others and by an
observed tendency towards poly-drug abuse. However,
changes in the estimates must be interpreted with cau-
tion because they not only reflect actual changes in the
number of drug users but, to an unknown and probably
large extent, changes in data collection and reporting
methods as well. 
Of all illicit drugs, cannabis remains by far the most
widely used illicit drug. The number of cannabis users
in the world surpassed the 160 million mark in 2005
and is now estimated at some 162 million people, or 4
per cent of the world’s population in the 15-64 age
group.
With some 35 million users, amphetamine-type stimu-
lants (ATS)7 are the second most widely used group of
drugs in the world. Estimates for the 2006 World Drug
Report are slightly higher than those presented in the
previous year, reflecting an increase in the estimate of
ecstasy users (22 per cent), due to increased reporting of
ecstasy use in developing countries. The increase was
particularly pronounced in Asia.  The number of ecstasy
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Fig. 1a: Use of all illicit drugs compared to use of
tobacco 
(in % of world population age 15-64)
7 The group of amphetamine-type stimulants (ATS) encompasses amphetamines (amphetamine, methamphetamine), ecstasy (MDMA and related
substances) and other synthetic substances (such as methcathinone, phentermine, fenetylline etc.). 
28%
4% 1%
0
5
10
15
20
25
30
Tobacco Cannabis ATS, cocaine,
opiates
Fig. 1b: Illegal drug use at the global level
users in North America, on the other hand, is now
clearly lower than a few years ago, reflecting successes in
curbing supply and raising the awareness of the risks
related to ecstasy consumption. Ecstasy use in Europe
remained largely stable. 
The global estimates of amphetamines users are now
slightly lower, reflecting lower estimates for Asia, where
more than 60 per cent of the world’s amphetamines
users are found.  The lower overall estimate masks, how-
ever, ongoing increases of methamphetamine use in a
number of Asian countries and in some African coun-
tries. Amphetamines use in Europe and in the Americas
remained largely stable.  
The number of opiate users in the world remains stable
at around 16 million people (of which 11 million
people abuse heroin). This mainly reflects increasing
levels of opiate abuse in some parts of Asia (countries
surrounding or close to Afghanistan) and Eastern
Europe (C.I.S. states) which exceeded the declines
reported from a number of countries in East and South-
East Asia and from Australia. In Africa, the estimated
number of heroin users now approaches the one million
mark, reflecting spillover effects from increased heroin
trafficking through that region. 
Estimates of the number of cocaine users – some 13 mil-
lion people – are slightly lower than last year,  though
almost unchanged from those made for the late 1990s.
The estimates suggest that at the global level, at least,
the upward trend in cocaine consumption has come to
a halt, notably in the Americas. This positive trend,
however, goes hand in hand with the observation that in
a number of other countries cocaine consumption con-
tinues rising.   
Trends in annual prevalence estimates show moderate
increases
UNODC global prevalence estimates suggest that over-
all drug use has been rising, over the last few years,
mainly due to increased levels of cannabis and ecstasy
use.  
No significant changes were observed for most other
drugs. Use of amphetamines is more widespread than in
the late 1990s but seems to have declined as compared
to the early years of the new century. 
These results are indicative of underlying drug use
trends but, due to frequent lack of data availability, they
should not be mistaken as scientific proof of such
trends8. 
Drug Use Trends move upwards
In addition to estimates of the total number of drug
users, UNODC collects Government experts’ percep-
tion of national drug use trends as part of the Annual
Reports Questionnaire (ARQ). Based on this informa-
tion, UNODC establishes  drug trend indicators for the
four main drug categories:  opiates, cocaine, cannabis,
amphetamine-type stimulants.
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Table 1: Extent of drug use (annual prevalence*) estimates 2004/05(or latest year available)
Amphetamines Ecstasy
All illicit 
drugs 
Cannabis
Amphetamine-type 
stimulants Opiates
of which 
heroin
Cocaine
(million people) 200 162.4 25 9.7 15.9 11.3 13.4
in % of global 
population age 15-64
4.9% 3.9% 0.5% 0.2% 0.4% 0.3% 0.30%
Annual prevalence is a measure of the number/percentage of people who have used an illicit drug at least once in the 12 month-
period preceding the assessment.  The annual prevalence estimate is derived from national survey results and extrapolations 
from partial information on the drug situation in the various countries. 
Note: As drug users frequently take more than one substance (poly-drug use), the world total for all illicit drugs together is not 
equal to the sum of the estimates for each individual drug group.
Sources: UNODC, Annual Reports Questionnaire data, National Reports, UNODC estimates. 
8  Scientifically valid prevalence studies - even 8 years after UNGASS where Governments pledged to undertake such studies in regular intervals -  are
still very limited and lacking in many countries or must be considered outdated (in some countries the most 'recent' studies date back to the mid
1990s) . Thus, changes in the underlying data material could also reflect availability of new studies or better estimates rather than changes in drug
consumption. 
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Drug use trends are reported by Government experts for
the following categories: ‘large increase’, ‘some increase’,
‘no great change’, ‘ some decrease’, ‘large decrease’.
These reported trends are then weighted by the size of
the countries’ drug using populations, in order to more
accurately reflect the overall trend at the global level9. 
The main advantage of this method is that far more
countries are in a position to provide perceptions of
drug use trends rather than actual estimates of the
number of drug users in their countries. The underlying
problem remains, however, that without proper drug
monitoring systems in place, perception is not necessar-
ily a very reliable measure of actual drug use trends.
These caveats must be kept in mind in interpreting the
following results.  
Compared to the estimates published in 2005 World
Drug Report, the drug use perception trends were as fol-
lows: 
• Cannabis use is perceived to be increasing further;
• For the first time in years, cocaine use was per-
ceived as declining slightly;
• Upward trends are perceived for both opiate use
and ATS use, including ecstasy.
Over the last twelve years, the strongest increases in
drug use were perceived for cannabis and amphetamine-
type stimulants. Increases in opiates and cocaine were
less pronounced.
In addition to respective individual drug trends, an
overall drug use perception trend indicator was estab-
lished, based on the results of the main drug categories
and weighted by their importance for overall drug con-
sumption. This composite index (figure 3) suggests that
cannabis was responsible for most of the increase in
global drug use over the last decade, followed by the
amphetamine-type stimulants. 
The perceived increase in drug use over the last decade
must be also seen in a wider context. If all Governments
had reported  ‘some  increase’ in each year, the trend
data would have shown a value of 112 after 12 years (1
point per year); and if all countries had report ‘strong
increases’  the value would have amounted to 124 (2
points per year).  The actual composite index, based on
the drug trend data reported by Member States, shows
a value of 104.5 after 12 years, reflecting the fact that
drug use did not increase in all countries, but remained
stable or declined in some countries. The actual drug
use perception trend after 12 years lies in between ‘not
much change’  and ‘some increase’  and is actually closer
Fig. 2: UNODC estimates of illicit drug use, late 1990s to 2004/2005 
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2005. 
9  A detailed explanation on the establishment of the drug use perception trends is shown in the section on methodology in Volume 2 of the present
report.  
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Fig. 3: Drug use trends - all drugs (based on expert opinion, weighted by the estimated number ofusers)
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Sources: UNODC, Annual Reports Questionnaire Data (for trends) and UNODC drug use estimates (World Drug Report). 
Fig. 4: Twelve year trends (as perceived by expert, weighted by the estimated number of users)
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Sources: Annual Reports Questionnaire Data for trends and UNODC, WDR 2005 estimates of the number of drug users. 
to a stable (100) trend than to a rising trend (‘some
increase’: 112).     
Treatment demand is highest in North America, Ocea-
nia and Western Europe
The demand for drug abuse treatment is an important
indicator for assessing the world drug situation and pro-
vides an idea of the type of drugs that cause the biggest
burden on national health systems. Member States
reported a total of 3.7 million people under treatment
for drug abuse to UNODC. The actual world total is
likely to be larger as many countries do not have com-
prehensive treatment registry systems.   For comparison,
UNODC estimates that some 25 million (0.6 per cent
of the world’s population age 15-64) are drug depend-
ent.
Based on reported data,  some 580 persons per one mil-
lion inhabitants were treated for drug abuse in 2004.
The highest numbers of drug treatment per million
inhabitants are found in North America (5,200), fol-
lowed by Oceania (2,700) and Western Europe (1,300).
All other regions show values below the global average.
The lowest numbers have been reported from Asia (132)
and from Africa (19), reflecting the lack of appropriate
treatment structures in many of the countries of these
regions.  
Treatment demand for opiate abuse continues to be
highest in Asia and Europe  
In Asia and Europe - home to more than 70 per cent of
the world’s total population -   opiates account for the
bulk of drug-related treatment demand (65 per cent and
59 per cent respectively in 200410). The proportion of
opiate-related treatment demand has been on the
decline, in both Europe and Asia since the late 1990s11.
This reflects increasing abuse of other drugs (cannabis,
cocaine and ATS in Europe and ATS and cannabis in
Asia) as well the decline of opium production in South-
East Asia and, in 2001, in Afghanistan. It should be
noted, however, that since the resumption of opium
production in Afghanistan, opiate-related treatment
demand in Asia has grown slightly (from 63 per cent in
2002/03  to 65 per cent in 2004).  
In Oceania, opiates used to be the primary drug result-
ing in treatment demand (66 per cent in the mid
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Fig. 5: Twelve year drug use, as perceived by experts
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Fig. 6: Drug treatment per million inhabitants in
2004
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Source: UNODC, Annual Reports Questionnaire data / DELTA. 
10  Difficulties faced here are that some countries only have data available from a few clinics whereas others have country-wide monitoring systems in
place. Simply adding up the number of people treated for the various drugs would give a strong bias in favour of the countries which have nationwide
monitoring systems in place while disregarding the information provided by others. In order to overcome this problem, the proportions at the
country level were first calculated and, based on these results, the (unweighted) averages for the respective region were derived. The data shown are
those reported for 2004; in case no data for a specific country were reported for 2004, data obtained from previous years were used or, if available,
data for 2005.  
11 The subsequent comparisons are based on treatment data statistics compiled and published in the  2000 World Drug Report.  
1990s). This proportion declined in the wake of the
Australian heroin shortage of 2001. In 2004, demand
for opiate related treatment was thus considerably lower
(34 per cent). Interestingly, treatment demand for
opiate use was even lower than that for cannabis-related
treatment (36 per cent).
Treatment for cocaine abuse is highest in the Americas
but the strongest increase is recorded in Europe
For South America, cocaine continues to account for
most of the drug abuse related treatment demand (54
per cent) though the proportion has declined since the
late 1990s (down from 65 per cent). High proportions
of cocaine related treatment demand are also encoun-
tered in North America (41 per cent). The strongest
increase in cocaine related treatment demand was
observed in Europe (rising from 3 per cent to 7 per
cent). Cocaine is still mainly a problem of Western
Europe, where it accounts for more than 10 per cent of
treatment demand; in Eastern Europe the proportion is
at less than 2 per cent. 
Cannabis-related treatment demand remains highest
in Africa 
For Africa, most of the demand for drug use treatment
is linked to cannabis (63 per cent 2004), but demand
for opiates related treatment (12 per cent) has increased
in recent years, notably in Eastern Africa.  Spill-overs
from trafficking of opiates via these countries to South-
ern Africa, Western Africa and Europe seem to have
been responsible for higher heroin abuse levels. Para-
doxically as heroin production in Latin America
(Colombia and Mexico) is declining, heroin transit traf-
ficking from South-West Asia via Africa to markets in
North America might lead to further increases of heroin
abuse in Africa in the future. 
Treatment demand for cannabis has increased in most
parts of the world since the late 1990s.  It increased in
North America (from 23 per cent to 43 per cent) and is
now at levels similar to cocaine-related treatment
demand.  Increases in cannabis-related treatment
demand were also reported from South America (from
15 per cent to 24 per cent), Europe (from 10 per cent
to 16 per cent), Oceania (from 13 per cent to 36 per
cent) and Asia (from 9 per cent to 12 per cent). 
Treatment demand for ATS is highest in East &
South-East Asia, Oceania,  North America and Europe 
The proportions of ATS abuse-related treatment
demand are highest in Oceania (19 per cent) and in Asia
(17 per cent), followed by North America (12 per cent)
and Europe (10 per cent).  In most regions, ATS-related
treatment demand is now higher than in the late 1990s.
Treatment demand for ATS rose in Oceania from 12 per
cent to 19 per cent; in Asia from 12 per cent to 17 per
cent; in North America from 5 per cent to 12 per cent,
in Europe from 8 per cent to 10 per cent and in Africa
from 3 per cent to 6 per cent of all drug related treat-
ment demand between the late 1990s and 2004.   
The highest proportion of ATS related treatment
demand are found in East & South-East Asia
(unweighted average 32 per cent in 2004). In a number
of countries,  including the Philippines, Japan, Repub-
lic of Korea and Thailand, more than half of all drug-
related treatment is related to methamphetamine abuse.  
In North America, methamphetamine treatment
demand is highest in the United States and in some
areas of Mexico and Canada bordering the United
States. In 2004, about 18 per cent of overall treatment
demand was linked to the abuse of amphetamine-type
stimulants in the United States. Traditionally a phe-
nomenon of the western and south-western states of the
United States, methamphetamine abuse and related
treatment demand, have spread eastwards over the last
decade and already affect many of the Midwestern
states. Treatment demand for methamphetamine abuse
is still low in the Northeast but it seems to be only a
question of time until those states will also suffer the
consequences of large-scale methamphetamine abuse
and will require related treatment.     
In Africa, rising levels of methamphetamine abuse have
been felt most acutely in South Africa where ATS-
related treatment accounted for 14 per cent of overall
treatment demand in that country. Most other ATS-
related treatment demand in Africa is linked to licit
pharmaceutical products diverted to illicit drug markets.
In Europe, only the Czech Republic reports metham-
phetamine to be a major problem (54 per cent of all
treatment demand in 2004). This substance is also being
used in a few other European countries such as Slovakia
(24 per cent of treatment demand), Estonia, Latvia and,
albeit at very low levels, United Kingdom. Demand for
treatment for other ATS, notably amphetamine, is, rel-
atively high in several of the Nordic countries (Iceland,
Finland and Sweden). 
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Treatment demand for cannabis and ATS abuse on the
rise
By drug, the picture for treatment demand can be sum-
marized as follows: 
• Cannabis is increasingly requiring treatment in
North America, Oceania, Europe, Africa, South
America and Asia; 
• Cocaine has declined in overall drug treatment in
the Americas, but continues rising in Europe;
• Opiates have declined in overall treatment in sev-
eral regions; 
• ATS in treatment has increased in Asia, North
America,  Europe and Africa.
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Fig. 7: Proportion of people in drug treatment for specific substances - 1997/98 and 2004
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Seizures remain an important indicator of the world
drug problem  
Seizure statistics are a further source of information on
the evolution of the world drug situation. Their main
advantage is that they are systematically and compre-
hensively  recorded and reported by most Member
States. As they have been reported since the times of the
League of Nations, seizure statistics are in fact the
largest time-series drug data, thus allowing for long-
term analysis of the evolution of drug markets. 
It is, however, clear that the capacity to make seizures
varies considerably among nations. This has to be taken
into account in making comparisons among countries.
There are also some basic problems related to the
recording of seizures. One such problem is non-report-
ing which, although it has declined over the years, can
still be a problem for some regions.
Secondly, if more than one law enforcement body is
involved in making drug seizures - and this seems to be
increasingly the case - there is a potential danger of
double counting. This can be the case both within
countries as well as between countries12.
Another problem is that it may take a long time to dis-
mantle major drug trafficking networks. Once a drug
ring is dismantled and  seizures are made in a specific
year, it would be wrong to interpret such seizures as
proof of rising drug trafficking activities in that specific
year. Finally, seizures and the related dismantling of
drug trafficking networks could lead to a reduction of
drug trafficking operations in the subsequent period;
but it is equally possible that seizures made are just the
tip of the iceberg, and more seizures are an indication of
intensified drug trafficking operations. 
All of these shortcomings have cast doubt as to the
validity and usefulness of collecting seizure data.
Nonetheless, experience has shown that seizure data, in
combination with other indicators (such as purity data,
price data and, if available,  drug production estimates,
treatment data, arrest data, drug use survey data etc.) are
a very powerful tool for investigating major trafficking
flows and their trends. In particular, when larger geo-
graphical units are investigated (subregions or regions)
and seizures are looked at over longer periods of time,
they have proven to be rather good reflections of under-
lying trafficking trends.  Drug seizures have, in general,
been in line with drug production trends (though grad-
ually showing higher interception rates) and, in the
main consumer markets,  with drug consumption
trends. 
Seizure data can be examined from three different
angles: 
• the number of seizures cases  
• the quantities of drugs seized and 
• the number of drug units seized. 
Number of seizure cases increases slightly in 2004
A total of 1.3 million seizure cases were reported to
UNODC from 93 countries in 2004 (+1 per cent).
However, a number of countries (19 in total) had
reported seizure cases to UNODC in 2003, but not in
2004 (Instead, another 19 countries had reported
seizure cases to UNODC in 2004, but not in 2003).
Assuming that the overall number of seizure cases of the
non-reporting countries was not zero but the same as in
2003, the total number of seizure cases would have
increased to 1.36 million (+8 per cent on a year earlier),
i.e. marginally higher than the seizure cases reported in
2000 and 2001. Comparing the seizure cases of the
countries reporting in both 2003 and 2004, the increase
would have amounted to 6 per cent - which is still less
than the long-term rate of increase. As compared to
1985, seizure cases increased by 8 per cent on average
per year, or 4 ½ fold in total. Most of the increase took
place in the 1990s (+16 per cent per year over the 1990-
2000 period).  
12  A seizure case made by customs and then handed over to the police, may, in some countries, enter the police registry as well. This could result in
double counting once the police seizure statistics and the customs seizure statistics are aggregated at the national level. There could be also potential
problems of double counting once seizures are done in cooperation between local police and the national (federal) authorities. Similarly, it cannot
be excluded that a seizure made, for instance, on a ship,  in close cooperation between drug law enforcement agencies from two countries, are
recorded in both countries as a seizure, thus leading to double counting once the consolidated country reports, sent to international bodies, are
aggregated. The likelihood of double counting may also have increased in recent years following the introduction of seizures as one of the
performance  indicators of police forces.  A possible solution to this problem would be to extension of the existing performance indicators to a
category of 'seizures made in cooperation with other law enforcement bodies', which could still allow enforcement bodies to take credit for their
work while avoiding double counting.       
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Cannabis accounted for 53 per cent, opiates for 15 per
cent, amphetamine-type stimulants (including ecstasy)
for 10 per cent and cocaine for 9 per cent of total drug
seizure cases reported in 2004. These four drug groups
thus accounted for 88 per cent of all drug seizures made
in 2004. 
The most striking trend over the last few years has been
the increase in cannabis seizures. After having declined
in relative terms between 1990 and 2000, the propor-
tion of cannabis in overall drug seizure cases increased
from 45 per cent in 2000 to 53 per cent in 2004. The
proportions of most other drugs declined accordingly.
The only exception was cocaine. Its share in global
seizure cases rose from 5 per cent in 2000 to 9 per cent
in 2004. 
Fig. 8: Number of seizure cases, 1985-2004
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Fig. 9: Proportion of seizure cases according to drug category, 1990-2004
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Largest quantities of seized drugs are cannabis, cocaine
and opiates 
Turning from the number of seizure cases to the quan-
tities seized, a total of 119 countries reported such infor-
mation to UNODC in 2004. Including information
obtained from other sources13, seizure information from
152 countries and territories is included in UNODC’s
database (DELTA) which forms the basis for the subse-
quent analysis. Quantities of drugs seized are thus the
most comprehensive drug data set available. 
… with significant increases observed for ecstasy, opium,
cannabis herb, and cocaine  
For the various drug groups changes in 2004 as com-
pared to a year earlier were as follows: 
The strongest increases in seizures for individual drugs
in 2004 as compared to a year earlier were for:
Drug No. of countries
Cannabis herb 135
Cocaine 119
Heroin 114
Cannabis resin 83
Ecstasy 69
Opium 60
Amphetamine 47
Methamphetamine 42
LSD 40
Depressants 40
Morphine 34
Crack-cocaine 32
Khat* 19
Cannabis oil 19
Methadone 11
GHB 9
Methaqualone 8
Ketamine*  6
* Not under international control
Table 2: Number of countries reporting drug seizures
in 2004
Drug
Cannabis herb 6,200
Cannabis resin 1,500
Coca leaf 1,200
Cocaine 590
Opium 210
Heroin & morphine 100
Khat 97
Amphetamines 20
Ecstasy 8
Methaqualone  5
Other depressants 2
Quantity in tons
Table 3: The largest quantities of drugs seized in 2004
(rounded) concerned 
Ecstasy: +87 per cent
Opium: +57 per cent
Khat: +40 per cent
Coca leaf: +29 per cent
Cocaine: +18 per cent
Heroin:  +13 per cent
Cannabis herb:  + 6 per cent
Cannabis resin: + 6 per cent
Amphetamine: + 5 per cent
Cocaine: +18 per cent
Opiates (in heroin equivalents): +9 per cent
Cannabis: +6 per cent
ATS: -11per cent
13  Government reports, UNODC Field Offices, Drug Abuse Information Network for Asia and the Pacific (DAINAP), Interpol, World Customs
Organization (WCO), International Narcotics Control Board (INCB),  EUROPOL,  Comisión Interamericana para el Control del Abuso de Drogas
(CICAD),  United States State Department International Narcotics Control Strategy Report etc.     
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The increase in ecstasy seizures was particularly high as
the base year for comparison (2003) was rather low.
Nonetheless, as compared to the year 2002 ecstasy
seizures were still 20 per cent higher, and they were the
highest ever reported. 
The increase in opium seizures reflected the re-emer-
gence of large-scale opium production in Afghanistan.
As compared to 2001 (the year of the Afghan opium
ban) and 2002, global opium seizures doubled.  Global
opium seizures were, however, still slightly lower than in
1999/2000 (Afghanistan’s peak harvest of 1999) and
1994 (reflecting the previous peak in Afghanistan’s
opium production). While heroin seizures increased,
morphine seizures declined in 2004. Heroin and mor-
phine seizures, taken together, remained roughly stable.  
Seizures of khat –  which is under control in a number
of countries though not under international control –
increased strongly in 2004 but were still 80 per cent
lower than in 2002.  
Both seizures of coca leaf and of cocaine turned out to
be the highest ever reported.  At first sight, this may
seem surprising since the area under coca cultivation has
declined since the year 2000 and remained largely stable
in 2004. However, reductions in the area under cultiva-
tion seem to have been largely offset by higher yields
and improved cocaine processing capabilities.  Still more
important, greater enforcement effort and improved
cooperation among enforcement agencies helped to
increase seizures. 
Strongest declines reported for GHB, LSD, metham-
phetamine and morphine
The strongest declines in global drug seizures in 2004
were observed for GHB (-85 per cent), LSD (-51 per
cent), methamphetamine (–50 per cent) and morphine
(-10 per cent).
Long-term trends show increases primarily for syn-
thetic drugs and cannabis 
The analysis of seizure data over longer periods is more
relevant for the identification of underlying trafficking
Fig. 10: Global cannabis seizures (in weight
equivalents), 2002-2004
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Fig. 11: Global drug seizures, excluding cannabis (in weight equivalents), 2002-2004
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trends. The strongest increases in seizures over the 1994-
2004 period were reported for: 
• depressants (mainly diverted pharmaceuticals such
as benzodiazepines and barbiturates)  which have,
on average, increased by 21 per cent every year,
and
• ecstasy (21 per cent per year)  
The second largest increases over the ten-year period
were observed for the amphetamines (amphetamine and
methamphetamine). Seizures of amphetamines
increased, on average, by 12 per cent per year. Even the
strong decline of amphetamines seizures in 2004 (-26
per cent) has not changed this trend. 
Seizures of cannabis herb have shown larger increases
(10 per cent per year) than seizures of cannabis resin,
which grew only at a rate of 5 per cent per year. This
reflects the stronger expansion of the market for
cannabis herb in many countries. 
Growth in heroin and morphine seizures together
amounted to 9 per cent per year, reflecting the trend
towards further processing of opium into morphine and
heroin in the producer countries. As a consequence, the
proportion of morphine and heroin in the trafficking of
all opiates has risen over the last decade. 
Seizures of coca leaf and of cocaine (5½  per cent per
year) were below the average for all drugs (7 per cent per
year).14 This is probably due to the fact that cocaine
production has remained largely stable over the last
decade. Increases in seizures were mainly the conse-
quence of improved enforcement activities. 
The strongest declines in seizures over a long term
period were observed for methaqualone, which is pri-
marily seized in countries of southern Africa, and for
LSD. This is in line with other indicators showing a
decline in production and abuse of these substances over
the last decade.    
Seizures in unit terms continue to climb in 2004 
The analysis of quantities of drugs seized allows for the
identification of growth rates of the seizures of various
drugs. However, as the quantities of drugs seized are not
directly comparable, it is difficult to draw conclusions
on overall drug trafficking patterns. Since the ratio of
Fig. 12: Average annual change in seizures, 1994-2004
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14  This average for all drugs was calculated on the basis of unit equivalents.    
46
World Drug Report 2006 Volume I. Analysis
OPIUM
0
50
100
150
200
250
300
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
m
et
ric
 t
on
s
HEROIN AND MORPHINE
0
20
40
60
80
100
120
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
m
et
ric
 t
on
s
COCAINE
0
100
200
300
400
500
600
700
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
m
et
ric
 t
on
s
CANNABIS HERB
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
m
et
ric
 t
on
s
CANNABIS RESIN
0
200
400
600
800
1,000
1,200
1,400
1,600
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
m
et
ric
 t
on
s
AMPHETAMINES
0
5
10
15
20
25
30
35
40
45
50
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
m
et
ric
 t
on
s
Fig. 13: Trends in world seizures, 1994-2004 (in metric tons)
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weight-to-psychoactive effects varies greatly from one
drug to another, the indicator weight of seizures assumes
more utility if it is converted into a typical unit of con-
sumption, or the dose taken by drug users to experience
a high.15 Expressing drug seizures in such typical
units/doses enables a more meaningful comparison of
the quantities of different drugs seized. 
Typical doses tend to vary across countries (and some-
times across regions within a country), across the vari-
ous substances aggregated under one drug category (e.g.
commercial cannabis herb and high-grade cannabis
herb), across user groups and across time. Unfortu-
nately, such detailed conversion ratios are not available.
Comparisons made here are based on global conversion
rates of grams/milligrams per dose. The results should
be thus interpreted as indications of overall patterns
rather than  precise estimates. 
Based on such calculations, global seizures reported in
2004 were equivalent to some 34 billion drug units
(doses).  This is  equivalent to an increase of 7.6 per cent
as compared to a year earlier. The increase in 2004 was
thus stronger than the average annual growth rate over
the 1994-2004 period (6.8 per cent). Global drug
seizures almost doubled over this period. 
The increase in seizures took place across all regions.  In
2004, most seizures were made in the Americas (39 pe
cent), followed by Europe (31 per cent), Asia (15 per
cent), Africa (14 per cent) and Oceania (0.2 per cent). 
While most seizures continue to be made in the Amer-
icas, the strongest increases have been reported from
Europe. The proportion of Europe in total seizures rose
from 17 per cent in 1990 to 26 per cent in 2000 and 31
per cent in 2004, suggesting that drug trafficking has
also increased in this part of the world. The proportions
of  seizures made in North America, in contrast,
remained largely stable (25 per cent in 1990, 25 per cent
in 2000 and 26 per cent in 2004). The proportion of
seizures made in other parts of the world fluctuated
strongly year on year, so that it is difficult to identify any
clear trends. The proportion of seizures made in South
America ranged from 11 per cent to 27 per cent over the
1990-2004 period,  in Asia from 15 per cent to 26 per
cent, in Africa from 7 per cent to 24 per cent and in the
Oceania region from 0.2 per cent to 0.7 per cent.
On a per capita basis, data suggest that drug trafficking
is most widespread in North America, followed by
Europe. Most drugs in 2004 were seized in North
America (21 doses per inhabitant per year), followed by
Europe (15 doses) and South America (10 doses per
inhabitants). The global average was 5 doses per inhab-
itant. Per capita seizures in Africa were close to the
Fig. 14: Regional breakdown of drug seizures in unit equivalents, 1985-2004
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15 For the purpose of this calculation, the following typical consumption units/doses (at street purity) were assumed: cannabis herb 0.5 grams; cannabis
resin 0.135 grams; cocaine and ecstasy 0.1 grams; heroin and amphetamines, 0.03 grams; LSD 0.00005 grams (50 micrograms).
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global average, mainly reflecting high levels of cannabis
seizures. The lowest per capita levels were reported from
Asia (1 dose per inhabitant). However, the Near &
Middle East /South-West Asia region had a rate that was
twice the global average (10 doses per inhabitant),
reflecting large-scale trafficking of drugs originating in
Afghanistan.   
Seizure in unit terms can also shed some slight as to the
relative importance of various drugs in trafficking. The
most important drugs in terms of seizures, expressed in
unit equivalents, at the global level are cannabis (69 per
cent), followed by cocaine (18 per cent), opiates (10 per
cent) and ATS (2 per cent). 
Though cannabis seizures increased in absolute terms,
their proportion in all seizures declined over the 1985-
2000 period,  from 90 per cent to 60 per cent. However,
since 2000, the proportion of cannabis in all seizures has
been rising again and reached 69 per cent in 2004,
reflecting rising levels of cannabis production and
cannabis use and also rising levels of cannabis traffick-
ing. The only other drug which showed rising propor-
tions in recent years was cocaine (from 12 per cent in
2000 to 18 per cent in 2004, though the proportion of
cocaine in total seizures is lower than in 1998 (20 per
cent) or in 1994 (20 per cent)). 
Comparing seizures expressed in doses and the reported
drug seizure cases,  it becomes apparent that – except for
cannabis – the ranking of the most trafficked drugs dif-
fers. While opiates and ATS are the second and third
most widely seized substance in terms of seizure cases,
followed by cocaine; in terms of drug dosages seized,
cocaine ranks second, ahead of opiates and ATS. This
reflects the fact that at the global level far larger drug
quantities are seized, on average, per cocaine seizure (4.3
kg in 2004) – often found on ships or containers -  than
per heroin (0.3 kg) or ATS (0.2 kg) seizure.16
Containment of opium and cocaine production: inFig. 16: Global drug seizures in unit equivalents,
1985-2004
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Fig. 17: Proportion of drug categories in seizures, in
unit equivalents
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Fig. 15: Drug doses seized per inhabitant in 2004
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16  This calculation was based on information from countries providing both seizures in weight terms and the number of seizure cases for various drugs
for the year 2004. 
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2005, opium declined and cocaine remained stable
For coca and opium, the two substances for which
UNODC, in collaboration with the Governments con-
cerned, has been undertaking detailed surveys, the situ-
ation looked quite positive for 2005. While for 2004
opium/heroin production and cocaine production had
still increased, global opium production declined in
2005 by 5 per cent and cocaine production decreased by
3 per cent. The global area under opium cultivation was
151,500 hectares and the global area under coca culti-
vation was 159,600 hectares in 2005. It is thus compa-
rable to the size of some of the smaller countries17. 
Global heroin production was estimated at 462 tons in
2005, and global cocaine production at 932 tons. 
The decline in global opium production of 5 per cent
in 2005 was due to lower levels of opium production in
Afghanistan (-2 per cent), lower levels of opium pro-
duction in Myanmar (-16 per cent), in Laos (-67 per
cent) as well as in Latin America (-25 per cent). The
declines in the area under poppy cultivation were even
more impressive: twenty-three per cent in total, reflect-
ing a decline of 21 per cent in the area under cultivation
in Afghanistan, -26 per cent in Myanmar,  -73 per cent
in Laos and -30 per cent in Latin America.  Seen in per-
spective, the 2005 area under global poppy cultivation
(151,500 hectares) was - with the exception of 2001 -
the lowest since 1987. 
The overall decline in global opium production could
have been far more pronounced, if yields in Afghanistan
had not recovered in 2005 from their low levels a year
earlier. Opium production in Afghanistan (4,100 tons)
accounted for 89 per cent of global opium production
in 2005.  The next largest producers were Myanmar
with 312 tons (6.8 per cent). Mexico and Colombia
accounted for 2 per cent, Pakistan for 1.3 per cent and
Laos for 0.3 per cent of global opium production.
The global area under coca cultivation amounted to
159,600 hectares by the end of 2005 and was thus
largely stable as compared to a year earlier (+1 per cent).
Though higher than in 2003 and 2004, the area under
coca cultivation was still lower than in all years of the
1990s and lower than in the late 1980s. The area
increased in Colombia in 2005 by 7.5 per cent to
86,000 hectares, but declined in Peru to 48,200 hectares
(-4.2 per cent) and Bolivia to 25,400 hectares(-8.3 per
cent), reversing the trends in 2004 when coca declined
in Colombia and increased in Peru and Bolivia. As com-
pared to the year 2000, the area under coca cultivation
is still 47 per cent lower in Colombia, though 11 per
cent higher in Peru and 74 per cent higher in Bolivia.
The net result is an area under cultivation in 2005 that
is still 28 per cent lower than in 2000. 
Improved yields and laboratory efficiency have, how-
ever, prevented these gains from being translated into
any significant decline in cocaine production. Cocaine
production in 2005 was 3 per cent lower than a year ear-
lier but was still slightly higher than in 2000 (6 per
cent), though marginally lower than in 1996 (-2 per
cent) and about the same as a decade earlier.     
Cannabis herb production continues to increase…
There are strong indications that cannabis herb produc-
tion continued increasing in 2004/05. UNODC’s
cannabis herb production estimates show a value of
45,000 tons in 2004/05, up from the estimate of 42,100
tons published in the 2005 World Drug Report. As com-
pared to the early 1990s, cannabis herb production
appears to have doubled.  In contrast, to the estimates
on heroin and cocaine,  the estimates collected from
Member States are – in most cases – not based on strict
scientific criteria and must thus be treated with caution.
…while cannabis resin production appears to have
declined in 2005
UNDOC’s cannabis resin estimates for 2004 were
7,500 metric tons, slightly higher than those for
2002/03 (6,300 metric tons). However, there are indi-
cations that global production fell in 2005, following
the massive reduction of cannabis resin production in
Morocco, the world’s largest cannabis resin producer.
Cannabis resin production, derived from remote sensing
studies and ground surveys in Morocco, declined from
3,070 metric tons in 2003 and 2,760 metric tons in
2004 to 1,070 metric tons in 2005, a decline of more
17 The global area under opium or coca cultivation is larger than the size of  countries or areas such as Saint Kitts and Nevis (26,900 ha),  Maldives
(29,800 ha), Malta (31,560 ha), Grenada (34,450 ha), Saint Vincent and the Grenadines (38,930 ha), Barbados  (43,000 ha).
than 60 per cent in 2005.  There are not, as yet, suffi-
cient data available for UNODC to provide an overall
production estimate for 2005, but the strong decline in
Morocco should have been sufficient to reduce global
cannabis resin production in 2005.  
ATS production has been contained in recent years,
but is still higher than in the late 1990s 
UNODC has estimated volumes of ATS production for
the years 1997-99,  2000-2001 and  2003 and 2004.
The estimates, showed a rapidly rising production for
the late 1990s (from 246 to 410 metric tons for the
amphetamines and 49 to 113 tons for ecstasy).  In sub-
sequent years, however, production declined to 332
metric tons of amphetamines and 90 metric tons of
ecstasy.  For 2004 amphetamines production was esti-
mated at 354 metric tons and ecstasy production at 126
metric tons. Given large margins of error in these esti-
mates, the conclusion is likely to be that overall ATS
production remained more or less stable in 2004,
though production was higher than in the late 1990s.
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Opium/heroin market 
Developments in Afghanistan will shape the situation
on the opium/heroin market
For the first time since 2002, global opium poppy pro-
duction decreased, largely due to a significant drop in
the area under opium poppy cultivation in Afghanistan.
Nevertheless, with Afghanistan holding the overwhelm-
ing share of global opium production (89 per ent in
2005), developments in that country will continue to
shape the situation on the world opium/heroin market.
Unfortunately, early indications are that the achieve-
ments of 2005 will not be repeated in 2006. Findings
from the UNODC Afghanistan Opium Rapid Assess-
ment Survey show that planting of opium poppy has
risen. Strong increases are foreseen for seven provinces.
This includes the province of Helmand, which already
had the highest levels of opium poppy cultivation in the
country. In 2005, a quarter of the area under opium
poppy cultivation was located in Helmand alone. If
counted separately, Helmand province would be the
third largest opium poppy cultivator in the world, after
Myanmar. The strong increases in the levels of cultiva-
tion in Helmand province are said to be induced by
drug traffickers who  encourage villagers to grow opium
poppy. Helmand is also the most significant province in
terms of heroin manufacture and trafficking. There is a
clear threat that drug trafficking will continue to per-
meate the province and that this could potentially
endanger the stability of Afghanistan.
Declines in opium production have been achieved in
the two major opium producing countries of South-East
Asia: Myanmar and Lao People’s Democratic Republic
(Lao PDR). Achievements are even more impressive
when the long-term trend is examined: Since 1998, the
area under opium poppy cultivation in both countries
has been reduced from 157,100 hectares to 34,600
hectares, a decline of 78 per cent. In 2005, both coun-
tries only accounted for seven per cent of global opium
production, compared to one-third of global opium
production in 1998. At the beginning of the 1990s,
Myanmar rivalled Afghanistan as leading opium pro-
ducer in the world. If these declines can be sustained,
and this appears to be the case, South-East Asia could
disappear from the global illicit opium production map
in the not too distant future. Heroin of South-East
Asian origin has already become very rare in European
drug markets and has lost its once dominant position in
North America. 
A reduction in opium poppy production was also
observed in Latin America. In Colombia, the area under
opium poppy cultivation was cut in half, from 4,000 in
2004 to 2,000 hectares in 2005. This will affect the
availability of heroin in the illicit markets of North
America. There is, of course, a danger that some of the
possible shortfall of heroin will be compensated with
heroin from Afghanistan.
Increasing amounts of heroin will be trafficked
through West and Central Asia, stretching law enforce-
ment authorities to the limits
Increasing availability of opium and heroin will increase
trafficking from Afghanistan to opiates markets in West
and Central Asia and Europe. Shifts in the production
centres in Afghanistan have already altered trafficking
routes, with more opiates leaving Afghanistan towards
Iran and less being trafficked towards Pakistan and Cen-
tral Asian countries. However, as cultivation and pro-
duction levels in Badakshan, the north-eastern province
in Afghanistan, and the starting point of the Central
Asian opiate trafficking route, are expected to increase,
this trend could change again. 
Opiate abuse could rise in the countries along the
main trafficking route 
While the annual prevalence estimate for opiates shows
a globally stable level of opiate abuse, strong increases
are shown in some countries that lie along the main traf-
ficking routes of opiates. The number of opiate users in
Iran, already estimated to be above one million, could
further increase. Similarly, this may affect abuse levels in
the Russian Federation and other CIS countries, which
already seem to have high levels of opiate abuse.
1.2 The outlook for world drug markets
52
World Drug Report 2006 Volume I. Analysis
Coca/cocaine market
Containment of the cocaine market defined by stable
production levels and increasing interception rates
The area under coca cultivation and production of
cocaine remained essentially stable in 2005. The area
under cultivation is 28 per cent less than in 2000 and
26 per cent less than a decade ago. Cocaine production,
however, has failed to decline due to better yields and
improved know-how in cocaine processing. Production
remained practically unchanged from the levels a decade
ago. The past years have also seen record levels of
cocaine interception. Global seizures of cocaine rose to
a record high in 2004 and indications are that this trend
continued in 2005 and possibly 2006. 
In 2004, 84 per cent of all cocaine seizures were made
in the Americas. The world’s highest seizures were made
by Colombia. Strong increases were also reported from
North America where the level of seizures increased by
41 per cent from 2003 to 2004. Possibly as a result of
the interdiction, cocaine purity levels have declined. 
A continuous rise in cocaine seizures made in Europe
over the past five years also indicates that trafficking
organizations increasingly target the European market.
In some cases, however, cocaine is already stopped in the
Western Hemisphere, as indicated by the fact that 42
per cent of Dutch cocaine seizures are made in the
waters off the cost of Netherlands Antilles. 
Cocaine for Europe is increasingly transshipped
through Africa
For some time, cocaine has transited Africa en route to
Europe. In its report for 2005, the International Nar-
cotics Control Board notes that drug trafficking organ-
izations are increasingly using West African countries
for cocaine trafficking. Seizure levels have confirmed
this trend. Cocaine seizures in Africa increased to more
than 3 tons in 2004 and far higher levels are regularly
seized by European law enforcement agencies off the
coasts of Cape Verde, Senegal and Mauritania. In con-
trast to 1997 and 2001, when cocaine seizures in Africa
were at an even higher level and dropped sharply in sub-
sequent years, the current development is likely to
become more permanent as there is some anecdotal evi-
dence that some cocaine trafficking organizations have
shifted their operations to African countries to run their
trade from there. Cocaine trafficking in that region will
therefore, in all likelihood, increase.
Global prevalence of cocaine expected to be stable but
situation in largest markets varies
No major changes were noted in the global cocaine
market, with prevalence levels remaining at almost the
same levels. The United States market appears stable or
declining. European countries report a general upward
trend of cocaine use and this may well continue for
some time as cocaine use levels are still lower in Europe
than in North America and its image among the general
population is still not very negative in Europe. The tran-
shipment of cocaine is also likely to have spillover effects
in the African countries affected by this sort of traffick-
ing. 
Cannabis
Cannabis continues to be the largest drug market in
the world; production increases foreseen for cannabis
herb
The cannabis market consists of two different markets:
the market for cannabis herb, which is the largest drug
market in the world, and the market for cannabis resin.
The number of countries in which cannabis is cultivated
continued to increase. UNODC estimates that cannabis
herb is cultivated in some 176 countries in the world.
Unlike opium and coca, for which relatively reliable
production data can be obtained, estimates on cannabis
production are often based on perception and scientifi-
cally valid monitoring systems are the exception.
Nevertheless, there are indications that the level of
cannabis herb production will continue to increase.
Cultivation of cannabis is traditionally easy as the plant
can grow in virtually every inhabited region in the
world. Furthermore, over the years, special strains have
been cultivated which can be grown indoors and hydro-
ponically. With cannabis seeds and growing parapher-
nalia available in grow shops in several developed
countries and also on the Internet, it has been easier to
procure cannabis and there is no indication that
cannabis users have not utilized these opportunities. 
… whereas global production for cannabis resin is
expected to decline, due to lower production in
Morocco
Cannabis resin production on the other hand, appears
to be in decline, at least for 2005. The Government of
Morocco has been carrying out cannabis cultivation sur-
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veys, in cooperation with UNODC, and results from
the 2005 survey show that cannabis resin production
fell for the second consecutive year in 2005, to about
1,070 metric tons (-61 per cent). As Morocco is a major
source of cannabis resin seized in Europe, the largest
cannabis resin market in the world, the lower availabil-
ity of cannabis resin is expected to be felt in the cannabis
resin market in Europe. Cannabis users in that region
may increasingly turn to herbal cannabis the availability
of which has been increasing over the years. 
Cannabis use will continue to increase as will the
demand for treatment in cannabis use
Cannabis use has continued growing. The annual preva-
lence estimate published in the 2004 World Drug
Report (referring to 2001) was 146 million of cannabis
users who have used the drug at least once during the
past 12 months. This figure was raised to 162 million
for 2004/05. While direct comparisons of these esti-
mates must be treated with caution as they also reflect
improved data availability, the magnitude and other
indicators suggest that cannabis use continues to
expand. As treatment demand for cannabis use has
risen, there are also indications that the effects of the
drug are more harmful than believed so far, possibly
reflecting, inter alia, the emergence of higher potency
cannabis on the markets. 
Amphetamine-type stimulants (ATS)
Global production of amphetamine-type stimulants
may well increase
Traditionally, methamphetamine has been the largest of
the ATS markets with production centres in Asia and
North America. The latest developments are that man-
ufacturing and trafficking of methamphetamine has
spread beyond these two traditional regions. Increases
have been reported, inter alia, from South Africa. Use of
methamphetamine has increased in some parts of Asia
and this trend is likely to continue. In the United States,
use of methamphetamine has shown a westward expan-
sion over the last decade, and it is expected that this
trend will continue. General population surveys have
not, as yet, shown an increase but this may change in the
future.  Treatment episode data from the United States
continue to show an upward trend. The European
methamphetamine problem has been very limited in
scope and has, so far, only affected a few countries.
While itt is too early to identify a general upward trend
of methamphetamine abuse in Europe, past experience
has shown that drug trends observed in the United
States (cannabis, cocaine) have also affected the Euro-
pean drug markets with some delay.  
Amphetamine is rising again in Europe
More amphetamine-producing laboratories were
detected in 2004 than in 2003, most of them in Europe.
Use of amphetamine appears to be stable in  the United
Kingdom, where annual prevalence of amphetamine has
fallen steadily over the past five years. Increased pro-
duction and use levels, however, have been reported
from Germany and some Central European countries.
There is a likelihood that this upward trend will con-
tinue. 
At the global level, ecstasy will gain in importance in
developing countries
After considerable increases, ecstasy appears to have lost
momentum in some parts of the world. This can be
attributed to the decisive action that some countries
have taken against the drug. In the United States,
ecstasy use among young people has shown a steadily
downward trend in recent years. In Europe, the main
production centre of ecstasy, use has surpassed that of
amphetamines and in some countries, prevalence of
ecstasy among young adults is higher than in the United
States. There are signs that in countries where ecstasy
use is already high, the market is stagnating while it is
still going to increase in countries with lower levels of
ecstasy prevalence. This also applies to developing coun-
tries, notably in East and South-East Asia where there
seems to be the largest potential of expansion of the
ecstasy market. Increases in treatment demand have
already been reported. There is no sign that this trend
will abate in the near future. Ecstasy use, in the devel-
oped countries as a whole, can be expected to remain
stable.
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Estimated area under illicit opium poppy cultivation
decreases by 22  per cent
In 2005, the estimated area under illicit opium poppy
cultivation in the world decreased by 22 per cent, due
to less cultivation in the three main source countries of
illicit opium in the world: Afghanistan, Myanmar and
Lao People's Democratic Republic (Lao PDR).
This was particularly noteworthy, as in Afghanistan, in
2005, opium poppy cultivation decreased for the first
time after three consecutive years of increases. The area
under opium poppy cultivation in Afghanistan
decreased by 21 per cent from about 131,000 hectares
in 2004 to a level of 104,000 hectares in 2005. Opium
poppy cultivation decreased in 19 provinces in 2005.
The largest declines - in absolute terms - were found in
Nangarhar (27,120 hectares), Badakshan (8,237
hectares) and in Uruzgan (6,475 hectares). There is con-
siderable diversity in opium poppy cultivation in
Afghanistan. While opium poppy cultivation in Central
Afghanistan almost disappeared in 2005, declining from
4,600 hectares in 2004 to a mere 106 hectares in 2005,
increases of more than 10 per cent were seen in 10
provinces. Altogether, five provinces (in order of mag-
nitude: Helmand, Kandahar, Balkh, Farah and Badak-
shan) accounted for 65 per cent of the total area under
opium poppy cultivation in 2005. 
Sustained progress has been made by the Governments
of Myanmar and Lao PDR in addressing the issue of
illicit opium poppy cultivation. In 2005, Myanmar
achieved a further reduction of the total area under
opium poppy cultivation, by 26 per cent to 32,800
hectares. In Lao PDR, cultivation even dropped by a
staggering 72 per cent, to 1,800 hectares. Since 1998,
the year of the Twentieth Special Session of the General
Assembly on countering the World Drug Problem
together, opium poppy cultivation in these two South-
East Asia countries has been reduced by 78 per cent.
In the Americas, opium poppy continues to be culti-
vated for use in the illicit markets in North America. In
Colombia, opium poppy cultivation was introduced in
the 1980s when coffee prices declined. Estimates by the
Government of Colombia put the area under opium
poppy cultivation at about 2,000 hectares, a reduction
of 50 per cent compared to the 4,000 hectares recorded
in 2004. The Government of the United States esti-
mates that, in 2005, 3,300 hectares were devoted to
opium poppy cultivation in Mexico. (The Government
of Mexico did not provide any cultivation data to
UNODC at the time of producing the present report.)
The situation as regards opium poppy cultivation in
Peru is difficult to quantify as the UNODC supported
national illicit crop monitoring system has not yet estab-
lished a reliable methodology for the detection of opium
poppy in Peru.  Colombia, Mexico and Peru all con-
tinue to eradicate opium poppy cultivation. 
Low levels of opium poppy cultivation continue to exist
in many regions and countries such as the Caucasus
region, Russian Federation, Thailand, Ukraine and Viet
Nam. 
… but global opium production declines by only 5 per
cent
Despite the decrease in the area under opium poppy
cultivation, global opium production decreased by only
5 per cent to 4,620 metric tons in 2005. In Afghanistan,
potential opium production was estimated at around
4,100 metric tons, representing a 2.4 per cent decrease
compared to 2004. The clear discrepancy between the
large decrease in cultivation and the relatively small
decrease in production was primarily due to more
favourable weather conditions during the growing
season. In Afghanistan, the opium yield in 2005 was
estimated at 39 kg/ha, an increase of 22 per cent com-
pared to the 2004 yield figure of 32 kg/ha. 
1.3 Opium / Heroin market
1.3.1 Production
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Higher yields were also reported from Myanmar. In
Shan State, where ninety per cent of the total opium
poppy cultivation in Myanmar takes place, yields
ranged from 5.4 kg in East Shan State to 13.4 kg in
South Shan State, where additional rain and improved
cultivation practices resulted in significantly higher
yields. 
Opium prices mirror the supply situation
In Afghanistan, overall prices for fresh  opium at harvest
time remained essentially stable at around US$100/kg
in 2005. However, regional price differences are pro-
nounced and mirror the supply situation throughout
the country. While low prices in northern Afghanistan
reflect strong production increases in that area, the high-
est prices can be found in central Afghanistan where cul-
tivation practically ceased in 2005. In Myanmar, the
average farm gate price of opium at harvest time was
estimated at US$ 187/kg which represents an increase of
22 per cent compared to 2004. In Lao PDR, the aver-
age farm gate price of opium increased by 139 per cent
to US$ 521, reflecting the scarcity of opium produced
in a country that is on the verge of becoming opium
poppy free. 
Most opium processing laboratories dismantled in
Russia, Moldova and Afghanistan
In 2004, 11 countries reported the destruction of
opium processing laboratories involved in the illicit
manufacture of products of the opium/heroin group in
2004 with a total of 787 sites destroyed. Most laborato-
ries were reported destroyed by the Russian Federation
(57 per cent), followed by Republic of Moldova (24 per
cent), and Afghanistan (16 per cent). Laboratories in the
Republic of Moldova mostly produced acetylated
opium, whereas laboratories destroyed in Afghanistan
and the Russian Federation mainly produced heroin and
opium, respectively. Smaller numbers of destroyed lab-
oratories were reported by Colombia (9), Australia (5),
India (3), Myanmar (2), Belarus, Hong Kong Special
Administrative Region of China, Mexico and Turkey (all
1 each). 
Continuous decline of reported heroin processing labo-
ratories in Turkey
Over the last couple of years, the number of destroyed
laboratories belonging to the opium/heroin group has
shown strong fluctuations without indicating a clear
trend.  Comparisons over several years, however, show
the declining number of heroin processing laboratories
dismantled in Turkey, which was once considered one of
the main heroin processing locations. Only one heroin
processing laboratory was reported dismantled in 2004,
down from 10 in 2002 and 14 in 1997. This appears to
support information that opium is increasingly being
processed into morphine and heroin in Afghanistan.
While in 1992/93, 56 per cent of the morphine and
heroin seizures of Turkey consisted of morphine, this
proportion fell to 35 per cent over the 2000-2004
period and to just 2 per cent in 2005, also suggesting
that there has been a downward trend in heroin manu-
facture in Turkey, while heroin manufacture in
Afghanistan has increased.  
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(a) Opium poppy harvestable after eradication.
(b) Due to small production, cultivation and production were included in the category " Other countries", for Viet Nam as of  2000 and for Thailand
as of 2003.
(c) According to the Government of Colombia, cultivation covered 7,350 hectares and 6,500 hectares and production amounted to 73 mt and 65 mt
in 1998 and 1999 respectively. 
(d) As its survey system is under development, the Government of Mexico indicates that it can neither provide cultivation estimates nor endorse those
published by UNODC, which are derived from US Government surveys. 
(e) Includes countries such as Russia, Ukraine, Central Asia, Caucasus region, other C.I.S. countries, Baltic countries, Guatemala, Peru, Viet Nam (as
of 2000), Thailand (as of 2003), India, Egypt and Lebanon.
(f ) All figures refer to dry opium.
(g) Heroin estimates are based on the Afghanistan Opium Survey (430 mt in 2004 and 420 mt in 2005). For other countries, a 10:1 ratio is used for
conversion from opium to heroin.
OPIUM
Table 4. GLOBAL ILLICIT CULTIVATION OF OPIUM POPPY AND PRODUCTION 
OF OPIUM, 1990-2005
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
SOUTH-WEST ASIA
  Afghanistan 41,300 50,800 49,300 58,300 71,470 53,759 56,824 58,416 63,674 90,583    82,171 7,606 74,100 80,000 131,000 104,000
  Pakistan 7,488 7,962 9,493 7,329 5,759 5,091 873 874 950 284 260 213 622 2,500 1,500 2,400
  Subtotal 48,788 58,762 58,793 65,629 77,229 58,850 57,697 59,290 64,624 90,867 82,431 7,819 74,722 82,500 132,500 106,400
SOUTH-EAST ASIA
  Lao PDR 30,580 29,625 19,190 26,040 18,520 19,650 21,601 24,082 26,837 22,543 19,052 17,255 14,000 12,000 6,600 1,800
  Myanmar 150,100 160,000 153,700 165,800 146,600 154,070 163,000 155,150 130,300 89,500 108,700 105,000 81,400 62,200 44,200 32,800
  Thailand (b) 1,782 3,727 3,016 998 478 168 368 352 716 702 890 820 750
  Viet Nam (b) 18,000 17,000 12,199 4,268 3,066 1,880 1,743 340 442 442
  Subtotal 200,462 210,352 188,105 197,106 168,664 175,768 186,712 179,924 158,295 113,187 128,642 123,075 96,150 74,200 50,800 34,600
LATIN AMERICA
  Colombia (c) 1,160 6,578 5,008 15,091 5,226 4,916 6,584 7,350 6,500 6,500 4,300 4,100 4,100 3,950 2,000
  Mexico (d) 5,450 3,765 3,310 3,960 5,795 5,050 5,100 4,000 5,500 3,600 1,900 4,400 2,700 4,800 3,500 3,300
  Subtotal 5,450 4,925 9,888 8,968 20,886 10,276 10,016 10,584 12,850 10,100 8,400 8,700 6,800 8,900 7,450 5,300
OTHER
  Combined (e) 8,054 7,521 2,900 5,704 5,700 5,025 3,190 2,050 2,050 2,050 2,479 2,500 2,500 3,000 5,190 5,200
GRAND TOTAL 262,754 281,560 259,686 277,407 272,479 249,919 257,615 251,848 237,819 216,204 221,952 142,094 180,172 168,600 195,940 151,500
SOUTH-WEST ASIA
  Afghanistan 1,570    1,980    1,970    2,330    3,416    2,335    2,248    2,804    2,693    4,565    3,276    185       3,400    3,600    4,200 4,100
  Pakistan 150       160       181       161       128       112       24          24          26          9            8            5            5            52          40 61
  Subtotal 1,720 2,140 2,151 2,491 3,544 2,447 2,272 2,828 2,719 4,574 3,284 190 3,405 3,652 4,240 4,161
SOUTH-EAST ASIA
  Lao PDR 202       196       127       169       120       128       140       147       124       124       167       134       112       120       43 14
  Myanmar 1,621    1,728    1,660    1,791    1,583    1,664    1,760    1,676    1,303    895       1,087    1,097    828       810       370 312
  Thailand (b) 20          23          14          17          3            2            5            4            8            8            6            6            9            
  Viet Nam (b) 90          85          61          21          15          9            9            2            2            2            
  Subtotal 1,933    2,032    1,862    1,998    1,721    1,803    1,914    1,829    1,437    1,029    1,260    1,237    949       930 413 326
LATIN AMERICA
  Colombia (c) 16          90          68          205       71          67          90          100       88          88          80          76          76          56           28
  Mexico (d) 62          41          40          49          60          53          54          46          60          43          21          71          47          -        73           69
  Subtotal 62          57          130       117       265       124       121       136       160       131       109       151       123       76 129 97
OTHER
  Combined (e) 45          45          -        4            90          78          48          30          30          30          38          18 14 4            68 36
GRAND TOTAL 3,760     4,274     4,143     4,610     5,620     4,452     4,355     4,823     4,346     5,764     4,691     1,596     4,491     4,662     4,850 4,620
Potential HEROIN 376        427        414        461        562        445        436        482        435        576        469        160        449        466        495(g) 472(g)
POTENTIAL PRODUCTION IN METRIC TONS
OPIUM(f)
CULTIVATION(a) IN HECTARES
HEROIN
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Fig. 18: Global opium poppy cultivation 1990-2005 (ha)
Fig. 19: Global opium production 1990-2005 (metric tons)
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Map 2. Opium poppy cultivation (2003 - 2005)
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Map 3. Opium production (2003 - 2005)
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Fig. 20: 
Annual opium poppy cultivation and opium production in main producing countries, 1990 - 2005
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Fig. 21: Opium poppy cultivation 
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Differences in opium yield between Afghanistan and Myanmar are due to differences in opium
poppy varieties and growing conditions. Variations of yields from year to year in the same country
are mostly caused by changes in weather conditions and/or, as in the case of Afghanistan in 2001,
by a shift in the relative distribution of cultivation from irrigated to rain-fed land.
Fig. 22: Opium yields in Afghanistan and Myanmar (kg/ha), 1999-2005
Fig. 23: Opium production
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Table 5. Significant opium poppy eradication reported (ha), 1995-2005
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Afghanistan 400         121      21,430 5,103      
Colombia 5,074    7,412    7,333   3,077   8,434      9,279   2,583   3,371   2,994   3,865   2,108      
Egypt 65        
Lao PDR 4,134   3,556   2,575      
Mexico 15,389  14,671  17,732 17,449 15,461    15,717 15,350 19,157 20,034 15,926 20,803    
Myanmar 3,310    1,938    3,093   3,172   9,824      1,643   9,317   7,469   638      2,820   3,907      
Pakistan 867       654      2,194   1,197      1,704   1,484   4,185   5,200   707         
Peru 4          18           26        155      14        57        98        92           
Thailand 580       886       1,053   716      808         757      832      507      767      122      110         
Venezuela 87        154         
Vietnam 477       1,142    340      439      426      32        
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Opiates are trafficked along three major routes … 
There are currently three distinct production centres for
opiates which supply three distinct markets. Trafficking
flows are as follows:
• from Afghanistan to neighbouring countries, the
Middle East and Europe;
• from Myanmar/Laos to neighbouring countries
of South-East Asia, (notably China) and to the
Oceania region (mainly Australia);
• from Latin America (Mexico, Colombia and Peru)
to North America (notably USA)  
The bulk of global opiate seizures (heroin, morphine
and opium, expressed in heroin equivalents18) takes
place in the countries surrounding Afghanistan (South-
West Asia, South and Central Asia: 60 per cent of global
seizures in 2004). Including Europe, such seizures
amounted to almost 85 per cent of the global total.
Remaining opiate seizures are made in East & South-
East Asia and Oceania, accounting for 11 per cent of the
global total; the Americas (4 per cent of the global
total)and Africa (0.3 per cent). Africa is supplied from
both South-West Asia and South-East Asia.
… with most seizures being made along the
Afghanistan-Europe trafficking route.
Between 2002 and 2004, the proportion of opiate
seizures along the Afghanistan–Europe trafficking route
increased from 78 per cent to 85 per cent, reflecting
rising levels of opium production in Afghanistan and
thus rising levels of opiate trafficking from Afghanistan.
The volume of opiate seizures along the other two main
routes showed a downward trend (from 7 per cent to 4
per cent in the Americas, and from 15 to 11 per cent for
the South-East Asia/Oceania route). These declines in
the proportions in total opiate seizures in the latter two
markets are in line with reports of actual declines of pro-
duction in South-East Asia and in Latin America. 
While there is some opiate trafficking from South-East
Asia to North America and to Europe and from South-
West Asia to South-East Asia (notably China) and to
North America, the amounts trafficked across the vari-
ous markets tend to be rather small.
Global seizures of opiates continue to increase …
Global seizures of opiates (heroin, morphine and
opium, expressed in heroin equivalents) reached 120
metric tons in 2004, an increase of 9 per cent as com-
pared to the previous year. Following a decline of opium
and morphine seizures in 2001, the year of the opium
poppy cultivation ban in Afghanistan, and of heroin in
2002 (mainly reflecting a delay of about a year in the
production of opium in Afghanistan and the arrival of
heroin in the West European markets), opiate seizures
grew again strongly in subsequent years. Global opiate
seizures in 2004 were 21 per cent higher than in 2000.
Over the 1994-2004 period opiate seizures grew, on
average, by 8 per cent per year. 
1.3.2 Trafficking 
18 Opium, morphine and heroin, expressed in heroin equivalents using a 10 : 1 ratio for opium to heroin (i.e. 10 kg opium for the manufacture of 1
kg of heroin) and a 1:1 conversion rate for morphine to heroin. 
Fig. 24: Distribution of opiate seizures (expressed in
heroin equivalents18), 2002-2004 
Source: UNODC, Annual Reports questionnaire Data/DELTA.
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The increases in opiate seizures in 2003 had been par-
ticularly pronounced in South-West Asia (+75 per cent)
and Central Asia (+33 per cent), i.e. in the countries
surrounding Afghanistan, reflecting the large scale
resumption of opium production in Afghanistan in
2002 and 2003. In 2004, increases in opiate seizures
were particularly strong in South-East Europe (Turkey
and the Balkan countries: +109 per cent) reflecting the
resumption of large-scale trafficking along the Balkan
route. 
… and exceed the rise in global opium  production
If opium, heroin and morphine seizures for 2004 are
transformed into opium equivalents, opiate interception
ratios for Afghanistan are equivalent to 1.1 per cent of
domestic opium production. They rise to 15.5 per cent
if seizures of South-West Asia are considered  and  to 17
per cent if seizures of Central Asia are included as well.
At the global level, an estimated  25 per cent of globally
produced opiates were seized in 2004, up from 23 per
cent in 2003 and just 10 per cent in 1994, indicating
that global enforcement efforts improved over the last
decade.  
Significant increase of global  opium seizures in 2004 …
Opium seizures increased by 57 per cent to 210 metric
tons in 2004 and are thus approaching the peak levels
of  1999 and 2000 (the years prior to the 2001 opium
ban in Afghanistan), reflecting – inter alia – increases
of opium production in Afghanistan. 
The large majority of opium (94 per cent) continues to
be seized  in South-West Asia. Seizures in this subregion
increased by 77 per cent in 2004. The increase in opium
seizures outpaced the increase in opium production in
Afghanistan, which amounted to 17 per cent in 2004. 
Most opium continues to be seized in the Islamic
Republic of Iran, which in 2004, with seizures of 35
metric tons, accounted for 83 per cent of all opium
seizures in the world. Compared to 2003, opium
seizures in Iran increased by 34 per cent in 2004. The
level of opium seizures in Afghanistan also increased
strongly, from 8.4 metric tons in 2003 to 21.5 metric
tons in 2004, thus approaching the seizures reported
from Pakistan (25 metric tons). 
... and seizures of heroin and morphine reaching a new
record high
Global heroin seizures rose by 13 per cent in 2004 while
morphine seizures declined by 10 per cent, reflecting a
trend towards trafficking the end-product rather than
the intermediary product.  Heroin and morphine
seizures together rose by 3 per cent to close to 100
metric tons in 2004, a new record high.    
Seizures of heroin and morphine more than doubled in
Afghanistan, from 0.9 metric tons in 2003 to 2.5 metric
tons in 2004, reflecting strengthened law enforcement
capacity. For South-West Asia as a whole, heroin and
Fig. 25: Global opiate seizures, expressed in heroin
equivalents, regional breakdown, 1980-2004
Source: UNODC, Annual Reports questionnaire Data/DELTA.
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Fig. 26: Global opiate seizures, expressed in heroin
equivalents, by substance, 1980-2004
Source: UNODC, Annual Reports questionnaire Data/DELTA.
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morphine seizures amounted to 45 tons, with the bulk
seized in Pakistan (25 tons) and in Iran (18 tons).
Seizures in Central Asia amounted to 6 metric tons in
2004.  
The shift in opium production centres in Afghanistan
affected the way opium and heroin was trafficked to
neighbouring countries. Already in 2004, it was
observed that seizures in Pakistan and in the Central
Asian countries bordering Afghanistan fell, while
seizures in Iran rose, indicating a possible shift in long-
established trafficking patterns. This development con-
tinued and became even more pronounced in 2005.  
Decreasing opium production in Badakshan (north-
eastern Afghanistan) affected the level of trafficking to
countries in Central Asia (19 per cent, down from 24
per cent of the opiates leaving Afghanistan in 2004).
Most of the opiates trafficked via Central Asia are des-
tined for the Russian Federation, with only some 15 per
cent being trafficked onwards to other illicit drug mar-
kets in Europe. 
Declining opium production in eastern Afghanistan
also reduced the amounts of opiates trafficked towards
Pakistan. In 2004, about 20 per cent of all opiates are
estimated to have left Afghanistan via Pakistan, down
from 37 per cent a year earlier. Strengthened controls
along the Afghanistan/Pakistan border also appear to
have contributed to the decline. On the other hand,
opiate trafficking towards Iran continued to increase
(close to 60 per cent, up from 40 per cent of the opiates
leaving Afghanistan in 2004).  While these results for
2005 may have been exceptional, ongoing production
increases of opium in southern Afghanistan in 200623
are likely to put an additional burden on law enforce-
ment authorities of Iran in their efforts to prevent the
trafficking of Afghan opiates to and through their coun-
try.   
Strong increases of opiate seizures in Europe… 
Europe’s opiate seizure rose by 49 per cent in 2004 and
reached almost 29 metric tons (in heroin equivalents),
the highest such figure ever recorded.  
While most of the opiates for the C.I.S. countries and
some of the opiates for the Nordic countries are traf-
ficked via Central Asia, most of the opiates for Western
Europe are trafficked from Afghanistan to Turkey and
then along various branches of the Balkan route. More
than 90 per cent of opiates in Europe originate in
Afghanistan.
The largest amounts of opiates over the last decade were
trafficked from Turkey via Bulgaria, Romania and Hun-
gary to Slovakia, the Czech Republic, Germany and the
Netherlands, or via Hungary and/or Slovakia to Austria
and then to Germany and the Netherlands. In addition,
a southern branch developed as of 1999/2000, with
heroin smuggled from Turkey via Bulgaria and the
former Yugoslav Republic of Macedonia (FYROM) to
Albania, Italy, Austria and Germany. Since 2003/04, the
traditional Balkan route from Turkey via Bulgaria,
FYROM, Serbia & Montenegro, Bosnia Herzegovina,
Croatia, Slovenia, Austria, Germany and the Nether-
lands has re-emerged and gained in importance, while
trafficking via the more eastern Balkan route (Hungary)
has lost in importance. In addition, trucks transported
on ferries from Turkey to Albania, Croatia, Slovenia and
northern Italy (Trieste) are frequently used to traffic opi-
ates to Western Europe, often transiting Austria and
Germany. The German Federal Criminal Police Office
reports that in 2004, 45 per cent of all German heroin
seizures took place close to the Austrian border. There
have been also reports of shipments from Iran via the
Caucasus region to the Ukraine and then to Romania
for final destinations in Western Europe.
The increase in European seizures was primarily due to
the doubling of opiate seizures in South-East Europe
(Balkan route countries). The largest increases in South-
East Europe were reported by Turkey, Serbia & Mon-
tenegro, Croatia and Albania. More than 15 metric tons
were seized in South East Europe, exceeding the total
seizures made in West & Central Europe (9  metric
tons) and Eastern Europe (4 metric tons in European
C.I.S. countries).  
Turkey more than doubled its seizures and accounted
with more than 13 metric tons for 47 per cent of all
European opiate seizures in 2004. Thus, the Turkish
authorities reported, once again, most opiate seizures in
Europe, a position the country has held without inter-
ruption since 1987. The use of improved risk assessment
tools also appears to have contributed to this increase.
The second largest opiate seizures in Europe, for the
second year in a row, were reported by the Russian Fed-
eration (4 metric tons or 14 per cent of European opiate
seizures). 
The largest seizures among West European countries
were made by the authorities in United Kingdom19,
Italy, Netherlands, Germany and France. United King-
dom, Italy and Netherlands accounted for close to 70
per cent of all opiate seizures in West & Central Europe
in 2004. If Germany and France are included, that pro-
portion rises to close to 85 per cent.  
The United Kingdom is Europe’s main opiate market
and a final destination country. Usually, opiates are traf-
ficked to the United Kingdom via the Balkan route.
However, for 2004, it has been reported that heroin has
also been trafficked by air from Pakistan. An estimated
25 per cent of total trafficked opiates is estimated to
enter the United Kingdom that way.  Further reports
received in 2005/2006 indicate that heroin shipments
are trafficked from Bangladesh to Pakistan for onward
trafficking to the United Kingdom. The increased traf-
ficking of heroin towards the United Kingdom has
already become apparent in the increases in heroin
purity for England & Wales, an indicator for improved
supply.   
Italy is Europe’s second largest market for opiates as well
as an important transit country. In 2004, an estimated
71 per cent of all seizures were destined for domestic
use, with the remaining portion destined for transit to
other countries, mainly Germany (26 per cent). Fifty
eight per cent of the identified heroin deliveries entered
Italy via Albania and 21 per cent were brought to Italy
directly via Turkey.  Eighty five per cent of all opiates
enter Italy by sea.  Seizures in Italy – in contrast to many
other countries -  remained unchanged in 2004.  
The Netherlands is primarily an important tranship-
ment location of opiates to other countries in West
Europe, primarily France, Belgium, United Kingdom
and Germany. The involvement of Dutch groups in this
trade is, however, limited.  Seizures in the Netherlands
tripled in 2004, like seizures in neighbouring Belgium. 
Increases in opiate seizures in 2004 were also reported
from several countries in West and Central Europe, e. g.
Poland (6-fold), Austria (5-fold), Czech Republic (4-
fold), the Nordic countries: Denmark, Norway and
Sweden (2-fold); Luxembourg (+70 per cent), Germany
(+20 per cent), Spain (+12 per cent) and France (+5 per
cent). 
These seizures – in combination with hardly any notice-
able heroin price changes -  indicate a rising supply and
thus higher availability of opiates in Europe. However,
this has not – as yet – entailed an increase in the demand
for opiates in Western Europe.  
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Fig. 27: Average purity* of heroin in the England & Wales: 1997 to 4th quarter of 2005 
*unweighted results of police and customs
Source: UK Forensic Science Service. 
19  Latest data available for the UK refer to the year 2003.  
Opiate seizures in Africa increase by 60 per cent
Opiate seizures in Africa also showed a strong increase
in 2004 (+60 per cent). The bulk of this increase is due
to seizures made in West and Central Africa which more
than doubled between 2003 and 2004. West and Cen-
tral Africa accounted for 63 per cent of all African
heroin seizures in 2004. Increases were also reported and
from Eastern Africa (+18 per cent), which accounts for
20 per cent of  African seizures and from Northern
Africa (+30 per cent), which accounts for 12 per cent of
African opiate seizures. Heroin is trafficked through
African states for markets in Europe and, to a lesser
extent, North America.  Sources of the opiates are both
countries in South-West Asia (mainly Pakistan) and
South-East Asia (mainly Thailand). The overall
amounts of opiates seized in Africa are, however, still
very modest (0.3 per cent of global opiate seizures),
mainly reflecting inadequate law enforcement capabili-
ties. 
In South-East Asia, opiate seizures remain stable…  
Opiates seizures in East and South-East Asia remained
essentially stable in 2004 at 13 metric tons.  China
accounted for 82 per cent of these seizures, followed by
Myanmar (8 per cent) and Thailand (6 per cent). With
a seizure level of 11 metric tons, China reported the
third largest opiate seizures worldwide after Iran and
Pakistan. If only heroin is considered, China had with
10.8 metric tons – for the fourth year in a row – the
world’s largest heroin seizures. 
…Sharp fall in Oceania …  
A sharp drop in opiate seizures was recorded for Ocea-
nia. Opiate seizures in Australia in 2003-2004 dropped
by 86 per cent and were the lowest since 1986. Most of
the heroin seized in Australia continues to originate in
South-East Asia. 
… Decline in the Americas. 
Opiates seizures declined in the Americas in 2004 (-29
per cent), primarily reflecting lower levels of opiate
seizures in Mexico (-80 per cent) and in the United
States (-22 per cent). The main trafficking routes for
heroin are from Mexico and from Colombia to the
United States.  The largest seizures of opiates in the
Americas in 2004 were made by the United States, fol-
lowed by Colombia. At the global level, the USA ranked
10th in terms of opiate seizures in 2004. 
In line with declining levels of supply, heroin prices
started rising in the USA in 2004. Retail purity of
Colombian heroin in the USA showed a clear down-
ward trend over the 2001-2004 period.  Availability of
heroin, as perceived among US high-school students,
has even shown a downward trend over the last decade. 
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Fig. 28: Retail purity of Colombian heroin in the USA
2001-2004
Source: ONDCP, National Drug Control Strategy 2006.
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Fig. 29: Perceived availability of heroin among US
high-school students (unweighted average of
8th, 10th and 12th graders seeing it 'fairly
easy'  or ' very easy'  to get heroin) 
Source: NIDA, Monitoring the Future.
26.9
19.9
24.1
15
20
25
30
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
20
05
p
e
rc
e
iv
e
d
 a
v
a
il
a
b
il
it
y
 i
n
 %
68
World Drug Report 2006 Volume I. Analysis
Fig. 30: USA: Heroin retail and wholesale prices
(US$/gram), 1990-2004 
Fig. 31: Europe: Heroin retail and wholesale
prices (US$/gram), 1990-2005 
Note: Retail and wholesale prices are not directly comparable because purity levels differ.
Fig. 32: Wholesale heroin prices in Europe and the USA (US$/gram, 1990-2005, at street purity)
* 2005 data not available
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Year 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Metric tons 145      247      174      196     179     239     213     106     97        133      210       
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Fig. 35: Global seizures of heroin and morphine*, 1994 - 2004
Year 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Metric tons 42        44       40        54         56         60        78         66         73         97        99        
 * data refer to 2003
 * metric ton equivalents. 1 kilogram of morphine is assumed to be 1 kilogram of heroin. 
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Global abuse of opiates remains essentially stable
Almost 16 million people in the world, or 0.4 per cent
of the world's population age 15-64, are abusers of opi-
ates. The prevalence estimate has remained essentially
stable compared to the one published in the 2005
World Drug Report. 
Opiates continue to be the main problem drug world-
wide, accounting for almost two thirds of all treatment
demand in Asia and close to 60 per cent of treatment
demand in Europe. 
Highest level of opiates abuse along the main opiate
trafficking route 
More than half of the world's opiates abusing popula-
tion live in Asia and the highest levels of opiates abuse
are along the main drug trafficking routes originating
from Afghanistan. Annual prevalence of opiates, includ-
ing heroin, is high, for example, in the Islamic Repub-
lic of Iran where the number of drug abusers is said to
exceed 1.2 million (2.8 per cent of the general popula-
tion age 15-64). It is also high in Kyrgyzstan ( 2.3 per
cent of the population age 15-64) and Kazakhstan (1.3
per cent), and the number of registered drug users has
continued to rise. The number of opiate users in Pak-
istan is estimated at around 0.7 million, including half
a million using heroin (based on study results of
2000/2001). A study published in India in 2004
revealed prevalence rates of around 0.7 per cent for
males20 , which is equivalent to an annual prevalence of
around 0.4 per cent of the general population age 15-64
or slightly less than 3 million people.  While abuse esti-
mates for China show a rather low prevalence rate of less
than 0.2 per cent, this is still equivalent to 1.7 million
people. 
The West and Central European opiates market is esti-
mated to encompass some 1.6 million people.  Major
opiates markets in Western Europe are the United King-
dom (some 340,000), Italy (300,000), Spain (190,000),
Germany and France (about 170,000 persons each) and
Portugal (50,000). 
In the Americas, the largest opiates market is the United
States with less than 1.2 million heroin users. According
to national household survey results, Brazil is the largest
opiates market in South America, with an estimated
700,000 users. It should be noted that most opiates
users in Brazil use synthetic opiates and heroin abuse
levels are very low.  
Heroin abusers make up about 71 percent of opiate
abusers 
Globally about 71 per cent of the world's 16 million
opiates abusers are abuse heroin, an estimated 11 mil-
lion people. However, the proportions vary by region.
Whereas almost all opiate consumers in Africa are
reportedly abusing heroin, about two thirds of opiate
1.3.3 Abuse
Fig. 36: Regional breakdown of opiates abusers
Sources: UNODC, Annual Reports Questionnaire Data, Govt.
reports, reports of regional bodies, UNODC estimates.
Africa
6%
Americas
14%
Asia
54%
Europe
25%
Oceania
1%
20  UNODC and Ministry of Social Justice and Empowerment, Government of India, The Extent, Pattern and Trends of Drug Abuse in India, National
Survey, 2004. 
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abuses abusers consume heroin in Asia where use of
opium is still widespread in a number of countries. Asia
and Europe together account for 80 per cent of the
world's heroin abusers.
The number of heroin abusers in West and Central
Europe has been stable over the past few years and is
estimated at around 1½ million. The number of  heroin
abusers in East Europe is estimated to be already higher
than the corresponding number for West & Central
Europe. Estimates of heroin abuse in Europe as a whole
(3.3 million people) are higher than the corresponding
estimates for the Americas as a whole (1 ½ million
people).  The largest numbers of heroin abusers are,
however, found in Asia, accounting with 5.4 million for
almost half of all heroin users worldwide. 
Heroin abuse, by injection, exposes drug users to
HIV/AIDS. Injecting drug use has propelled HIV/epi-
demics, inter alia,  in India, Indonesia, Iran (Islamic
Republic of ), Libyan Arab Jamahiriya, Pakistan, Spain,
Ukraine, Uruguay and Viet Nam, according to the Joint
United Nations Programme on HIV/AIDS. In China,
Central Asia and several countries of East Europe inject-
ing drug use has been the most frequently cited mode of
transmission for HIV among HIV/AIDS cases in recent
years.  
Countries in East Africa, particularly Kenya, Mozam-
bique and United Republic of Tanzania, have reported
large increases in heroin abuse. A large increase of opiate
abuse has been also reported by some countries in West
Africa, including Côte d'Ivoire and Senegal. These
increases are possibly a spillover effect due to increased
availability of heroin which is trafficked through the
region destined towards markets in Europe and North
America.
Opiate abuse continues rising in Asia, mainly among
countries close to Afghanistan - though falling in East
and South-East Asia  
UNODC's drug use perception trend, based on expert
opinion gathered from Member States, suggests that
opiate use continued growing in Asia in 2004, mainly
reflecting increases in opiate abuse reported from neigh-
bouring countries of Afghanistan, including the central
Asian countries and most countries in South and South-
West Asia.  
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
Table 6. Annual prevalence of opiate abuse, 2003-2005
Number of in % of  population Number of in % of  population
abusers  age 15-64 abusers  age 15-64
EUROPE 4,030,000 0.7 3,340,000 0.6
West & Central Europe 1,565,000 0.5 1,445,000 0.5
South-East Europe 180,000 0.2 175,000 0.2
Eastern Europe 2,285,000 1.6 1,720,000 1.2
AMERICAS 2,280,000 0.4 1,540,000 0.3
 North America 1,300,000 0.5 1,240,000 0.4
South America 980,000 0.3 300,000 0.1
ASIA 8,530,000 0.3 5,430,000 0.2
OCEANIA 90,000 0.4 30,000 0.2
AFRICA 910,000 0.2 910,000 0.2
GLOBAL 15,840,000 0.4 11,250,000 0.3
of which abuse of heroin
            Above global average
            Around global average
            Below global average
Abuse of opiates
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In contrast, most countries of East and South-East Asia
reported declines in opiate abuse in 2004, apparently
reflecting the strong declines of opium production in
Myanmar and Lao PDR.  These declines were, however,
not sufficient to offset the increases in opiate use among
neighbouring countries of Afghanistan.        
Over a 12-year period (1992-2004) the drug use trend
for Asia followed the global trend line, except for the last
few years in which the increase was far more important
in Asia than at the global level. Thus, by 2004, the drug
use perception indicator for  Africa was already clearly
above the global average and above the threshold line of
a 'significant increase. 
Stable to declining use levels in West and Central
Europe but rising abuse levels in East Europe  
Opiate abuse remained largely stable or declined in
West and Central Europe in 2004 according to reports
received from Member States. A number of indirect
indicators (treatment demand, arrest figures, drug-
related deaths etc.) seem to confirm this assessment.
This ongoing positive trend was, however, offset by
rising levels of opiate abuse reported from East Europe
(C.I.S. countries) as well as some countries of south-
eastern Europe along the Balkan route, which are
already suffering from a supply push of Afghan opiates.
The net result was a small increase in UNODC's drug
use perception trend for opiates in Europe. Nonetheless,
the drug use perception trend for Europe is still mar-
ginally below the global average and basically at the
same levels as in 2000 suggesting that consumption of
opiates - overall - has stabilized in recent years, follow-
ing years of strong increase in the 1990s.   
Stable to declining trend of opiate abuse in the Amer-
icas 
UNODC's drug use perception trend shows essentially
stable results for opiate abuse in the Americas for 2004
and some decline since 2001/02.  This trend is reflected
Fig. 37: Twelve-year opiate use trends as perceived by
experts : Asia 
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC's Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Fig. 38: Twelve-year opiate use trends as perceived by
experts: Europe
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC's Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Fig. 39: Annual prevalence of heroin use among 12th
graders in US high-schools, 1980-2005 
Source: NIDA, Monitoring the Future, Overview of Key Findings
2005. 
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in school survey results from the United States and
Canada which show that after increases in the 1990s,
heroin use is declining again. In the United States,
heroin remained essentially stable, at the lower levels,
over the 2003-2005 period. Falling opium production
levels in Latin America as well as in South-East Asia -
the two main traditional supply lines for the North
American market - may have contributed to this.  
Opiate use in Oceania continues to remain below
levels recorded in 2000
The most striking shifts in UNODC opiate drug use
perception trend were reported from Oceania. Follow-
ing strong increases in the 1990s, expert perception on
the trends declined after 2000. 
Oceania, and notably Australia, used to have some of
the highest opiate prevalence rates worldwide. This
changed after a major heroin shortage in 2001,
prompted by the dismantling of some major heroin traf-
ficking networks which had supplied the Australian
market with heroin from South-East Asia. The 'heroin
drought' prompted a fall in the purity levels while
heroin prices rose strongly, thus squeezing large sections
of heroin users out of the market. The number of drug-
related deaths declined substantially. Fears that higher
prices for heroin would result in higher crime did not
materialize. Contrary to some concerns, the changes
were not short-lived but the reduced availability of
heroin lasted until well into 2005. 
The 2004 National Drug Strategy Household Survey
showed that annual prevalence of heroin use - after
having fallen drastically in 2001 - remained stable at the
lower levels in 2004. In addition, first results of the
ongoing Drug Use Monitoring in Australia project
(DUMA), where arrested people at selected police sta-
tions across the country are regularly tested for drug
abuse, suggest that this positive trend also continued in
2005. 
Fig. 40: Twelve-year opiate use trends as perceived by
experts: Americas
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC's Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Fig. 41: Australia: heroin use among the general 
population (age 14 and above), 1993-2004
Source: Australian Institute of Health and Welfare, 2004 National
Drug Strategy - Household Survey. 
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Fig. 42: Testing of arrestees for heroin abuse in 
Australia*  
* unweighted average of results from Western Australia (East
Perth), South Australia (Adelaide), New South Wales (Sydney) and
Queensland (Brisbane and Southport). 
Source: Australia Institute of Criminology, Drug Use Monitoring in
Australia (DUMA). 
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Opiate use in Africa starts rising 
Drug use trends reported from Africa suggest that opiate
abuse has started rising, notably in countries of Eastern
and Southern Africa and some countries in West Africa,
apparently linked to trafficking activities and resulting
spill-over effects. The upward trend is particularly noted
in South Africa where heroin used to account for less
than 1 per cent of treatment demand (including alco-
hol). By the first two quarters of 2005, this proportion
had increased to 7 per cent. 
For the 1992-2004 period as a whole, opiate use trends,
as reported by African  States to UNODC, show a mar-
ginally  higher level of increase than at the global level.
The increase in 2004 was the strongest over the last few
years. 
Composite opiate use perception trends increase
reflecting higher use in Asia 
If the composite indicator is broken down by regions,
data show that the increase over the last decade was pri-
marily due to higher use of opiates in Asia.  In contrast,
for the other regions, notably for Europe, and the Amer-
icas, the markets appear to have been rather stable since
2000.  
Fig. 43:Twelve-year opiate use trends as perceived by
experts: Oceania 
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC's Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Fig. 44: South Africa - heroin as primary drug in treat-
ment demand*
* unweighted average of treatment (incl. alcohol) in 6 provinces.
Source: SACENDU, Research Brief, Vol. 8 (2), 2005.
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Fig. 45: Twelve-year opiate use trends as perceived by
experts: Africa
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC's Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Fig. 46: Twelve-year drug use trends as perceived by
experts: opiates
Sources:  UNODC, Annual Reports Questionnaire Data,  Govern-
ment reports, UNODC Field Offices,  UNODC's Drug Abuse Infor-
mation Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Map 6: Abuse of opiates (including heroin) 2003 - 2005 (or latest year available)
Map 7: Ranking of opiates in order of prevalence in 2004
Sources: UNODC Annual Reports Questionnaires data, SAMSHA US National Household Survey on Drug Abuse, Iranian Ministry of Health,
Rapid Assessement Study and UNODC ARQ,Council of Europe, ESPAD.  
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1.4 Coca / Cocaine market
1.4.1 Production
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
CULTIVATION(a) OF COCA BUSH IN HECTARES
Bolivia (b) 50,300 47,900 45,300 47,200 48,100 48,600 48,100 45,800 38,000 21,800 14,600 19,900 21,600 23,600 27,700 25,400
Colombia (c) 40,100 37,500 37,100 39,700 44,700 50,900 67,200 79,400 101,800 160,100 163,300 144,800 102,000 86,000 80,000 86,000
Peru (d) 121,300 120,800 129,100 108,800 108,600 115,300 94,400 68,800 51,000 38,700 43,400 46,200 46,700 44,200 50,300 48,200
Total 211,700 206,200 211,500 195,700 201,400 214,800 209,700 194,000 190,800 220,600 221,300 210,900 170,300 153,800 158,000 159,600
POTENTIAL PRODUCTION OF DRY COCA LEAF IN METRIC TONS (e)
Bolivia 77,000 78,000 80,300 84,400 89,800 85,000 75,100 70,100 52,900 22,800 13,400 20,200 19,800 27,800 38,000 30,900
Colombia 45,300 45,000 44,900 45,300 67,500 80,900 108,900 129,500 165,900 261,000 266,200 236,000 222,100 193,340 170,730 170,730
Peru 196,900 222,700 223,900 155,500 165,300 183,600 174,700 130,600 95,600 69,200 46,200 49,300 52,500 50,790 70,300 67,900
Total 319,200 345,700 349,100 285,200 322,600 349,500 358,700 330,200 314,400 353,000 325,800 305,500 294,400 271,930 279,030 269,530
POTENTIAL MANUFACTURE(f) OF COCAINE IN METRIC TONS
Bolivia 189 220 225 240 255 240 215 200 150 70 43 60 60 79 107 90
Colombia (g) 92 88 91 119 201 230 300 350 435 680 695 617 580 550 640 640
Peru 492 525 550 410 435 460 435 325 240 175 141 150 160 155 190 180
Total 774 833 866 769 891 930 950 875 825 925 879 827 800 784 937 910
GLOBAL ILLICIT CULTIVATION OF COCA BUSH AND PRODUCTION OF COCA LEAF AND COCAINE, 1990-2005
Table 7. GLOBAL ILLICIT CULTIVATION OF COCA BUSH AND PRODUCTION 
(a) Potentially harvestable, after eradication
(b) Sources: 1990-2002: CICAD and US Department of State, International Narcotics Control Strategy Report; 2003-2005: National Illicit Crop
Monitoring System supported by UNODC.
(c) Sources: 1990-1998: CICAD and US Department of State, International Narcotics Control Strategy Report; 1999-2005: National Illicit Crop
Monitoring System supported by UNODC.
(d) Sources: 1990-1999: CICAD and US Department of State, International Narcotics Control Strategy Report; 2000-2005: National Illicit Crop
Monitoring System supported by UNODC.
(e) Refers to the potential dry coca leaf production available for cocaine production, i. e. after deducting the amount, which governments report as
being used for traditional or other purposes allowed under national law. In the absence of a standard definition of "dry coca leaf" and given
considerable differences in the processing of the fresh coca leaf harvested, the figures may not always be comparable across countries.
(f ) Amounts of cocaine that could be manufactured from locally produced coca leaf (due to imports and exports actual amounts of cocaine
manufactured in a country can differ)
(g) Production data for 2004 and 2005 is based on new field research in Colombia.
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Global cultivation of coca remained  essentially stable in
2005
The total area under coca cultivation in Colombia, Peru
and Bolivia amounted to 159,600 hectares in 2005 sug-
gesting that the area under cultivation remained essen-
tially stable (+ 1 per cent as compared to 2004).
However, the area under coca cultivation continues to
be 28 per cent less than the levels recorded in 2000
(221,300 hectares) and lower than in any year of the
1990s. Most coca was cultivated in Colombia (54 per
cent), followed by Peru (30 per cent) and Bolivia (16 per
cent). 
After four consecutive years of decline, over which coca
cultivation decreased in Colombia, the total area under
coca cultivation in that country increased by 6,000
hectares (8 per cent) to 86,000 hectares compared to last
year’s estimate of 80,000 hectares. The increase came
about despite sustained eradication efforts of the Gov-
ernment of Colombia, with fumigation levels which
have constantly remained above 130,000 hectares and
an unprecedented level of manual eradication of 32,000
hectares. 
In Peru, on the other hand, where the area under coca
cultivation increased in 2004 to 50,300 hectares, the
highest level since 1998, coca cultivation appears to
decline slightly,  to 48,100 hectares (-4%). Bolivia, the
smallest producer of coca, has reduced the area under
coca cultivation, from 27,700 hectares in 2004 to
25,400 hectares in 2005. Efforts to eradicate coca con-
tinued in both Bolivia and Peru. 
Longer-term cultivation trends followed different pat-
terns in the three Andean countries. Coca cultivation
declined in both Peru and Bolivia in the second half of
the 1990s but showed again an upward trend in the first
years of the new millenium. In Colombia, in contrast,
cultivation of coca leaf increased in the 1990s and
showed a marked downward trend in subsequent years.  
Overal level of cocaine production remains essentially
stable
The potential production of cocaine reached 910 metric
tons in 2005, about the same as a year earlier. Potential
production in Colombia amounted to 640 metric tons,
in Peru to 180 metric tons and in Bolivia to 90 metric
tons.  The level of overall production is practically
unchanged from the levels of a decade ago.
Alternative livelihood programmes continue to be
implemented
In order to bring about a sustained reduction of coca
cultivation in the region, alternative development pro-
grammes continue to be undertaken in Colombia, Peru
and Bolivia. In Ecuador, a similar project is being car-
ried out, with the intention to prevent certain regions in
the country to turn to illicit drug production. 
Number of seized coca processing laboratories almost
quadrupled between 2000 and 2004
In 2004, Governments reported the destruction of
8,208 coca processing laboratories, an almost four-fold
increase since 2000 when 2,104 laboratories were
reported destroyed. 
The destruction of laboratories and production sites
reflects the fact that most processing of coca leaf into
cocaine takes place close to the cultivating areas in
Bolivia, Colombia and Peru. This is true for both the
intermediate products cocaine paste/base and the final
product, cocaine hydrochloride. Bolivia, Colombia and
Peru reported more than 99 per cent of the global total. 
However, some differences exist between the three main
coca cultivating countries. Whereas in Bolivia and Peru,
destroyed laboratories produce to a large extent coca
paste and coca base, some 13 per cent of all coca pro-
cessing laboratories destroyed in Colombia were manu-
facturing cocaine. Ninety-four per cent of the 256
cocaine processing laboratories destroyed worldwide
were located in Colombia. Outside South America,
Spain, Hong Kong Special Administrative Region of
China, United States and Australia reported the destruc-
tion of cocaine processing laboratories in 2004, which
shows the existence of limited cocaine production out-
side the region. In addition, Argentina and Saint Lucia
reported the destruction of laboratories manufacturing
cocaine paste or base. All of this illustrates that some
production of cocaine  products exists outside the three
main coca cultivating countries. 
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Fig. 47: Global coca bush cultivation (in ha), 1990-2005 
Source: Estimates for Colombia for 1999 and subsequent years come from the national monitoring system established by the Colombian
government with the support of UNODC.   Due to the change of methodology, figures for 1999 and after cannot be directly compared
with data from previous years.
Fig. 48: Potential cocaine production (metric tons), 1990-2005 
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COLOMBIA - COCA BUSH CULTIVATION, 1990 - 2005 (ha) COLOMBIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2005 (mt)
PERU - COCA BUSH CULTIVATION, 1990 - 2005 (ha) PERU - POTENTIAL COCAINE PRODUCTION, 1990 - 2005 (mt)
BOLIVIA - COCA BUSH CULTIVATION, 1990 - 2005 (ha) BOLIVIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2005 (mt)
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Estimates for Colombia for 1999 and subsequent years come from the national monitoring system established by the Colombian government with 
the support of UNODC.  Due to the change of methodology, figures for 1999 and after cannot be directly compared with data from previous years. 
Production data for 2004 and 2005 is based on new field research in Colombia.
Fig. 49. Annual coca bush cultivation and cocaine production in main producing countries, 1990 - 2005
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1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Bolivia 1,100 5,493   7,512   7,000   11,620 15,353 7,653   9,395   11,839   10,089 8,437     6,073     
Colombia 4,904 25,402 22,576 44,123 69,155 44,158 61,568 95,897 153,126 137,033 142,786 170,042 
Peru 1,259   3,462   7,834   14,733 6,208   6,436   7,134     11,312 10,399   12,232   
Table 8. Reported eradication of coca bush, ha 
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20%
Bolivia
11%
Colombia
69%
20052004
20052004
Colombia
50%
Bolivia
18%
Peru
32%
Peru
30%
Bolivia
16%
Colombia
54%
Colombia
70%
Bolivia
10%Peru
20%
Fig. 51: Potential cocaine production (in % of global total)
Fig. 50: Coca bush cultivation (in % of global total)
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1.4.2 Trafficking
Global seizures of cocaine rose to another record high in
2004
Cocaine seizures increased, by 18 per cent, to 588
metric tons in 2004, the highest figure ever recorded.
This followed an increase in global cocaine seizures of
34 per cent in 2003. The increase in cocaine seizures has
been  – to a large extent - the result of better coopera-
tion among law enforcement services and improved
sharing of intelligence information.  
Most of the globally intercepted cocaine is seized in the
Americas (86 per cent). South America accounted for
45 per cent, North America for 33 per cent and Central
America & the Caribbean for 8 per cent of global
seizures. The next largest market after the Americas is
Europe, accounting for 13 per cent of global cocaine
seizures.
For the third year in a row, Colombia topped the rank-
ing of world cocaine seizures, with almost 188 tonnes
cocaine hydrochloride (HCl) and cocaine base seized in
2004, 32 per cent of the world total and an increase of
29 per cent compared to 2003 and the highest such
figure ever reported from any country. This clearly
reflects the strong enforcement efforts undertaken by
the Colombian authorities over the last few years.  The
second largest seizures took place in the United States:
166 tons or 28 per cent of the world total. 
… with the main trafficking route running from the
Andean region to North America
The world’s main cocaine trafficking routes continue to
run from the Andean region, notably Colombia, to the
United States. The trafficking patterns analysis of the
Colombian authorities revealed that more than half of
the country’s seizures took place at the ports; with 60
per cent of the cocaine leaving the country via the
Pacific coast and 40 per cent via the Atlantic coast in
2004. According to the United States Interagency
Assessment of Cocaine Movement, half of the cocaine
trafficked towards the United States in 2004 transited
the Eastern Pacific, whereas 40 per cent were trafficked
through the Western Caribbean. 
The main intermediate target country of cocaine ship-
ments from Colombia is Mexico. Mexico reports that,
about 55 per cent of the cocaine is trafficked to Mexico
by sea, another 30 per cent by land from Central Amer-
ica (Guatemala and Belize) and some 15 per cent comes
by air.  The direction of cocaine trafficking within
Mexico is from the southern parts of the country to the
northern border.  In volume terms, most cocaine ship-
ments are primarily by sea; in terms of trafficking oper-
ations, however, most cocaine deliveries are by land.    
Organized crime groups from Mexico have also started
to target Peru as a source country for cocaine deliveries.
While in the past (until the mid 1990s), coca paste and
coca base exports from Peru used to be in the hands of
the Colombian drug cartels, a significant proportion of
the Peruvian cocaine exports these days is organized by
criminal groups from Mexico and leaves the country by
sea. United States sources estimate that about 70 per
cent of the cocaine hydrochloride (HCl) leaving Peru is
hidden in legitimate maritime cargo. In the past most of
the coca paste and coca base left Peru by air to Colom-
bia, where it was processed into cocaine HCl. 
Criminal organization of ethnic Mexican background,
partly holding US passports, have supplanted Colom-
bian criminal groups as the predominant wholesale
cocaine distributors in several parts of the United States
(notably the southern and mid-western regions) over the
last 15 years. Between 70 and 90 per cent of the cocaine
entering the United States is estimated to transit main-
land Mexico or its waters according to US information.
Colombian organizations still handle cultivation, pro-
duction and initial offshore movement and some direct
shipments to the eastern parts of the United States while
Mexican organizations increasingly coordinate the
remaining transportation and distribution segments
required for the cocaine to reach US streets.
Fig. 52: Global cocaine seizures, regional   
breakdown, 1980-2004
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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Decreasing importance of Caribbean as a transhipment
point to the United States 
In the past, 30-50 per cent of the cocaine entered the
USA directly via the Caribbean. For 2004, however, the
United States Interagency Assessment of Cocaine Move-
ment concluded that this proportion had fallen to below
10 per cent. The main smuggling vectors via the
Caribbean in 2004 concerned Haiti and the Dominican
Rep (2%), Jamaica (2%) and Puerto Rico (1%). 
The United States report that about 12 per cent of all
cocaine entered the country by air in 2004.  In contrast
to the situation in the 1980s, direct shipments by air
from Colombia are no longer very common.
In addition to the countries mentioned above, other
countries in South America, notably Venezuela (Boli-
varian Republic of ) and Ecuador, serve as important
transhipment points. Cocaine seizures in Venezuela
(Bolivarian Republic of ) were the third largest in the
Americas in 2002, 2003 and 2004, amounting to 31
tons in 2004 (after Colombia,USA and ahead of
Mexico). Cocaine seizures in Ecuador increased almost
9-fold, from 5 metric tons in 2004 to more than 44 tons
in 2005, following, inter alia, the implementation of a
joint UNODC/WCO container control project, con-
firming previous suspicions that Ecuador is used by traf-
ficking organisations as a major cocaine outlet.  Further
significant cocaine seizures were reported from Ecuador
in early 2006. 
Strong eradication efforts in the Andean region and
increased interdiction efforts in the main drug transit
countries and in the United States have had an impact
on cocaine availability and prices in the world’s largest
cocaine market. Availability of cocaine, as perceived by
students in the United States, declined between 1999
and 2005. After a downward trend for many years,
cocaine retail prices in the United States increased
slightly in 2004 and increased by 19% over the Febru-
ary to September 2005 period. 
Europe is second most important destination of
cocaine…
The second most important destination of cocaine pro-
duced in the Andean region is Europe. In addition to
Colombia, Peru and Bolivia are  frequently mentioned
among European countries as source countries for
cocaine found on their markets. 
European cocaine seizures amounted to close to 80 tons
in 2004,  the second highest ever reported21  and are
likely to show a new all-time high for the year 2005 at
around 100 metric tons in the European Union accord-
ing to Europol. The proportion of Europe in global
cocaine seizures rose from 2.5 per cent in 1980 to 5.9
per cent in 1990, 8.4 per cent in 2000 and 13.5 per cent
in 2004. Over the 1994-2004 period cocaine seizures in
Europe increased by, on average, 10 per cent per year.
Despite growing seizures, cocaine prices have not risen
in Europe and no significant deterioration in the purity
of cocaine was reported. Thus, the increase in seizures
does not only reflect improved interdiction efforts but –
unfortunately - also increased availability of  cocaine on
the European market.
Shipments to Spain, Europe’s main entry point for
cocaine, were reported to transit primarily Ecuador and
Venezuela. Spain has reported Europe’s largest cocaine
seizures for the last twenty years and accounted for more
than 40 per cent of all cocaine seizures in Europe in
2004. In terms of world cocaine seizures, it ranked third
in 2004, after Colombia and the United States. About
60 per cent of the Spanish seizures were made while the
cocaine was still at sea; 10 per cent were made at airports
and 30 per cent on roads. Traditionally, most cocaine
Fig. 53: Perceived availability of cocaine among
US high school students, 1999-2005 
(unweighted average of 8th, 10th and 12th  
grade students reporting that it is ‘fairly 
easy’ or ‘very easy’ to obtain cocaine  
powder)  
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Source: National Institute on Drug Abuse (United States),
Monitoring the Future- National results on adolescent drug use,
Overview of key findings 2005.  
21  As of 2005, seizure reports from the Netherlands show which seizures have been made in the Netherlands as such and seizures made by the Dutch
authorities in and around the Netherlands Antilles. If seizures made in the Netherlands Antilles are included, overall European seizures would have
remained stable in 2004 as compared to 2003. If seizures made in the Netherlands Antilles are excluded,  European seizures are 10% lower than the
record figure reported for 2003.      
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was seized along the northern Atlantic coast of Spain,
notably in Galicia. Over the last two years, cocaine
entered the country, in addition, increasingly via
Andalusia (southern Spain). In 2005, seizure levels in
Spain increased by about 50 per cent, reaching almost
50 metric tons. Large increases in cocaine seizures have
also been reported from Portugal which has become
another major gateway for cocaine destined for Euro-
pean markets. Portugal reported the third largest
cocaine seizures among the European countries in 2004
after Spain and the Netherlands.   
Cocaine continues to transit Caribbean on its way to
Europe
One of the main cocaine trafficking route to Europe
continues to go via the Caribbean region. The Nether-
lands Antilles are of special importance in this regard.
The Dutch authorities made more than 40 per cent of
their total seizures in the waters around the Netherlands
Antilles in 200422. Like in all years of the past two
decades, seizures made by the Dutch authorities were
the second largest ones in Europe, equivalent to 16 per
cent of European seizures in 2004 or, including seizures
made by the Dutch authorities in the Netherlands
Antilles, equivalent to about a quarter of European
seizures. 
The United Kingdom notes that the Caribbean region,
notably Jamaica,  also continues to play an important
role for cocaine shipments to that country. Important
quantities are also trafficked via Spain and the Nether-
lands into the UK.  
The role of the French departments in the Caribbean
region as transhipment locations is less pronounced as
significant amounts of cocaine enter France via Spain
and the Netherlands. Nonetheless, reports received from
France indicate that there are important cocaine ship-
ments to metropolitan France transiting the Caribbean
region, including the French overseas departments in
the Caribbean. This seems to be particularly true for
Martinique which had the fourth highest drug- related
arrest figures per capita among all 100 French depart-
ments in 2004 exceeding, for instance, the correspon-
ding rates for Paris.  
Other important transit countries from the Andean
region to Europe are Brazil, Suriname and, less fre-
quently mentioned,  Panama and Argentina. The Brazil-
ian authorities estimate that about 70 per cent of the
cocaine originates in Colombia,  20 per cent in Bolivia
and 10 per cent in Peru. Shipments from Brazil go
either directly or – increasingly – via Africa to Europe.
While most cocaine shipments from South America
continue to be directed towards Western Europe (more
than 99 per cent of European cocaine seizures), some
shipments to Eastern Europe and the Balkan countries
have been noticed by the 2005 meeting of Heads of
National Law Enforcement Agency (HONLEA) on
Europe, held in 2005, raising fears of the potential
development of new trafficking routes and/or the incor-
poration of cocaine into the range of products offered
by traditional heroin trafficking groups operating along
the Balkan route.  
Cocaine seizures in West and Central Africa show six-
fold  increase…
The rising importance of Africa, and notably of West
and Central Africa, as a transit points for cocaine ship-
ments destined for European markets is becoming ever
more evident. Seizures made in Africa increased more
than three-fold in 2004 with seizures in West and Cen-
tral Africa increasing more than six-fold. West and Cen-
tral Africa accounted for more than 50 per cent of all
African cocaine seizures in 2004. Cocaine shipments to
Africa are frequent to the countries along the Gulf of
Guinea, from where the cocaine is usually trafficked in
small quantities by body packers by air to various desti-
nations in Europe. In addition, large quantities of
cocaine are shipped to the waters around Cape Verde
and off the coast of Senegal. Most of this cocaine is des-
tined for Spain and Portugal (and for onward shipment
to other European countries). The largest cocaine
seizures over the 2000-2004 period in Africa were made
in Cape Verde, followed by South Africa, Kenya, Ghana
and Nigeria.  More than 1 metric ton of cocaine was
seized in Kenya 2004, indicating that an increasing
number of countries in Africa are affected by large-scale
cocaine trafficking. Out of 32 African countries report-
ing seizure statistics to UNODC in 2004, 23 countries
or 72 per cent reported seizures of cocaine, up from just
34 per cent in 1990. 
The upturn in seizures can be explained by a combina-
tion of increased trafficking and strengthened interdic-
tion efforts. It should be noted, however, that despite
this increase, African seizures still account for less than
1 per cent of global cocaine seizures and only a very
22 These seizures made in the waters around the Netherlands Antilles (13.7 tons) have been subsequently excluded from the total seizures made by the
Netherlands (21.4 tons) in order to gain a more accurate picture of the geographical location of seizures.      
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small proportion of cocaine transiting the African con-
tinent is actually being seized. 
… whereas Asia and Oceania account for less than 0.1
per cent of the global total 
In Asia, cocaine seizures remained essentially stable in
2004 (0.05 per cent of global total). Less than 300 kg of
cocaine were seized in 2004, with the largest seizures
made in Japan (88 kg) and Hong Kong SAR of China
(55 kg) followed by several countries in the Near and
Middle East: Syrian Arab Republic (40 kg), Jordan (32
kg), Israel (31 kg) and Lebanon (12 kg). 
Several clandestine cocaine-manufacturing laboratories
were dismantled, 4 of which were in Hong Kong SAR
of China. In March 2006, authorities in China, in coop-
eration with the US DEA, made their largest ever
cocaine seizure (135 kg), close to Hong Kong SAR of
China.
Seizures in Oceania amounted to 245 kg, below 0.05
per cent of the global total. The market for cocaine in
that region has remained largely stable.
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Fig. 54: Global illicit supply of cocaine 1994 - 2004
* Converted to 100% purity, assuming an actual average purity of 60%. 
 * excluding seizures in liquid form.
** data refer to 2003
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Fig. 55: Global seizures of cocaine, 1994-2004
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Fig. 56: USA: cocaine retail and wholesale prices,
1990-2005 (US$/gram)
Fig. 57: Europe: cocaine retail and wholesale prices,
1990-2005 (US$/gram)
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Fig. 58: Wholesale cocaine prices in Europe and the United States (US$/gram), 1990-2005 
0
20
40
60
80
100
120
90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05
U
S$
/g
ra
m
Europe USA*
* Data for 2005 not available
94
World Drug Report 2006 Volume I. Analysis
M
ap
 1
1:
 C
o
ca
in
e*
 s
ei
zu
re
s 
20
02
 -
 2
00
4:
 e
xt
en
t 
an
d
 t
re
n
d
s 
(c
o
u
n
tr
ie
s 
re
p
o
rt
in
g
 s
ei
zu
re
s 
o
f 
m
o
re
 t
h
an
 0
.0
1 
m
t 
(1
0k
g
.)
)
N
ot
e:
 R
ou
te
s 
sh
ow
n 
ar
e 
no
t 
ne
ce
ss
ar
ily
 d
oc
um
en
te
d 
ac
tu
al
 r
ou
te
s,
 b
ut
 a
re
 r
at
he
r 
ge
ne
ra
l i
nd
ic
at
io
ns
 o
f 
th
e 
di
re
ct
io
ns
 o
f 
ill
ic
it 
dr
ug
 f
lo
w
s.
95
1. Trends in world drug markets Coca / Cocaine market
Most cocaine is used in North America, Western Europe
and South America 
Cocaine use is estimated to affect about 13.4 million
people or 0.3 per cent of the population age 15-64.
Most cocaine continues being used in the Americas,
accounting for close to two thirds of global cocaine use.
With an annual prevalence of 2.3 per cent, cocaine use
is highest in North America, home to almost half of all
cocaine users in the world. The single largest cocaine
market worldwide, which accounts for more than 40 per
cent of all cocaine users worldwide, is still the United
States (2.4 per cent of those aged 12 and above in 2004
or 2.8 per cent of the population age 15-64).    
The next largest markets are those of West and Central
Europe (prevalence rate of 1.1 percent, on average),
accounting with 3.3 million people for about a quarter
of all cocaine users worldwide. Rates above average have
been reported from Spain (2.7 percent), from the
United Kingdom (England & Wales: 2.1 per cent and
Scotland: 1.4 percent) as well as  Italy (1.2 per cent).
Cocaine use seems to be also rather high in the Nether-
lands, the second most important entry point (after
Spain) for cocaine shipped to Europe. A less recent
survey conducted in the Netherlands (2001) found a
cocaine prevalence rate of 1.1 per cent. Cocaine use
levels in the new EU member states are still substantially
lower, typically ranging from 0.1 percent to 0.5 percent.
The average prevalence rate of cocaine use in East
Europe and South-East Europe is around 0.1 per cent,
lower than in Africa (0.2 per cent).  
South America (including Central America and the
Caribbean) ranks third (15 per cent of the global market
with an average prevalence rate of 0.7 percent of the
population age 15-64, the same rate as for Europe as a
whole. Countries in Oceania report slightly higher
prevalence rates (0.9 per cent on average). Given differ-
ences in the part of population admitting drug use, it
could well be that the actual prevalence rates in South
America are higher than those in Oceania. Rates close
to, or above the South American average have been
reported, inter alia, in studies conducted in Bolivia (1.6
per cent for cocaine HCl and 1.9 per cent for cocaine
base in 2005), Chile (1.8 per cent in 2004), Colombia
(0.8 per cent in 2003),  Peru (0.7 per cent in 2002) as
well as in Venezuela, Ecuador and a number of
1.4.3 Abuse
Table 9.  Annual prevalence of cocaine use, 2004-2005
Sources: UNODC, Annual Reports Questionnaire data, various Govt. reports, reports of regional bodies, UNODC estimates.
Number of  users in % of  population
15-64 years
EUROPE 3,524,000 0.7
West and Central Europe 3,333,000 1.1
South-East Europe 64,000 0.1
 Eastern Europe 127,000 0.1
AMERICAS 8,440,000 1.5
North America 6,459,000 2.3
South America 1,981,000 0.7
ASIA 260,000 0.1
OCEANIA 175,000 0.9
AFRICA 959,000 0.2
GLOBAL 13,358,000 0.3
            Cocaine abuse above global average
            Cocaine abuse around global average
            Cocaine abuse below global average      
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Caribbean and Central American countries.   
All other regions have prevalence rates below the global
average. Cocaine use is still very low in most parts of
Asia (average: 0.01 per cent).    
Some decline of cocaine use in North  Americas 
Some moderate declines are found in the general
population drug use data collected as part of the US
National Household Survey on Drug Use and Health.
Annual cocaine prevalence data for cocaine declined
from 2.5 per cent of the population age 12 and above in
2003 to 2.4 per cent in 2004; crack cocaine use figures
fell from 0.6 percent in 2003 to 0.5 percent. As
compared to 1985 (prevalence: 5.1 percent), cocaine use
declined by about 50 per cent and is at about the same
level as at the beginning of the 1990s (2.6 percent in
1991). Given changes in methodology, comparisons of
household survey results are, however, potentially
problematic.
A better trend indicator are the high-school surveys.
They show that after an increase in the first half of the
1990s, cocaine use declined in the United States among
high-school students by more than 20 per cent between
1999 and 2005. Compared to data for 1985, cocaine
use among high-school students is now more than 60
per cent lower.  
Similarly to these trends, data for the province of
Ontario, home to more than a third of Canada’s total
population, showed an upward trend of cocaine use in
the 1990s. This lasted until 2003. Between 2003 and
2005, however, cocaine use among Canadian high
school students fell by almost 18 per cent and is now
slightly below the levels reported 20 years ago.    
… and mixed trend patterns in South America 
Survey data reported from Colombia show that life-time
prevalence of cocaine use increased over the 1996-2004
period (from 1.5 per cent in 1992 and 1.6 per cent in
1996 to 3.7 percent in 2004).  There are indications,
however, that the increase took place in the late 1990s.
Life-time prevalence of cocaine use among youth, aged
10-24, was in 2001 more than 5 times higher than in
1996. A comparison of annual prevalence estimates,
derived from these studies, with actual annual preva-
lence data from the new national survey, suggests that
cocaine use prevalence (including basuco) has actually
declined over the 2001-2004 period.
Following increases in the 1990s, declines in overall
cocaine use have also been reported from Chile. Annual
prevalence of cocaine use among the general population
declined from 1.9 per cent in 2000 to 1.7 per cent in
2004. If only cocaine HCl is considered, the decline was
from 1.5 per cent in 2000 and 2002 to 1.3 per cent in
2004.   
Student surveys conducted in Brazil suggest that cocaine
use, after having grown strongly between 1987 and
1997, remained essentially stable over the 1997-2004
period. 
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Fig. 60: Cocaine use among the general population 
in Chile (age 12 – 64)
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Data  provided by Argentina even shows a massive
decline in cocaine use between 1999-2004. Even
though some of the decline may be due to methodolog-
ical differences in the two surveys, it would be extremely
unlikely that cocaine consumption, in reality, had
increased. The Argentine authorities, however, did not
see the decline in 2004 and based on other indicators
reported an overall stable trend.    
All of these encouraging trends are probably associated
with both intensified prevention efforts in the countries
concerned as well as with the overall stabilization of
cocaine production in the Andean countries over the
past few years.  
Data for Bolivia are not really an exception of these
explanations, even though they show a slightly different
pattern. Following strong increases in the early 1990s
until 1996, cocaine prevalence rates declined and started
increasing again only over the 2000-2005 period. The
abuse trend is largely in line with domestic cocaine pro-
duction.  
The net result of these trends was an increase of cocaine
use over the last decade in the Americas that was below
the global average. In 2004, cocaine use was perceived
by experts as declining.    
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Fig. 61: Life-time prevalence of cocaine use among   
Brazilian students, age 10-18
* unweighted average of results in 10 provincial cities 
Source: CEBRID, Levantamento Nacional Sobre o Uso de Drogas
Psicotrópicas entre Estudantes do Ensino Fundamental e Médio da
Rede Pública de Ensino nas 27 Capitais Brasileiras, 2004
Fig. 62: Cocaine use in Argentina among the general   
population (16-65), 1999-2004
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Fig. 63: Annual prevalence of cocaine use in Bolivia 
(age 12-50), 1992-2005 
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Fig. 64: Cocaine use perception trends: Americas
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Sources:  UNODC, Annual Reports Questionnaire Data,
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Cocaine use in Europe is heading upwards 
Cocaine use levels in Europe have clearly shown
upwards over the last decade, including in England &
Wales and Spain, the countries with the highest cocaine
prevalence rates in Europe. Annual prevalence of
cocaine use in Spain rose from 1.6 per cent of the pop-
ulation age 15-64 in 1997 to 2.7 per cent in 2003. Ger-
many experienced an increase in cocaine use  from 0.2
per cent in 1990 to 1 per cent of the population age 18-
64 in 2003. Data for England and Wales show an
increase in cocaine prevalence from 0.3 per cent in 1992
to 2.4 per cent in 2004. For England and Wales, how-
ever, indications are that a peak may have been reached. 
These increases are also reflected in cocaine use percep-
tion trends which has shown  upwards for Europe over
the last decade, including 2004. No deceleration in the
upward trend was noticed in 2004.    
Fig. 65: Annual prevalence of cocaine use in Spain
among the general population and among
secondary school students, 1994-2004
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Fig. 66: England & Wales: annual prevalence of 
cocaine use among the general population 
(age 16-59),  1991/92 - 2003/04
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Fig. 67: Cocaine use perception trends: Europe
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Cocaine use is increasing in Africa
UNODC’s perception trends suggest that cocaine use
was also growing faster in Africa than at the global level
over the 1992-2004 period, and cocaine use was
apparently increasing again in 2004 following a few
years of stabilization/decline. The reported increases in
cocaine use were mainly from countries in southern
Africa and countries in western Africa, reflecting, inter
alia, the increased use of Africa for the transhipment of
cocaine to Europe. 
Treatment data for South Africa show these trend pat-
terns very clearly. Following very little cocaine related
problems in the early 1990s to the mid 1990s, treat-
ment for cocaine increased from 1.5 per cent of all treat-
ment demand in the second half of 1996 to around 6
per cent over the 1999-2000 period, then falling to less
than 5 per cent over the 2001-2004 period before rising
again strongly to 7.5 per cent in 2004 and 8.5 per cent
in the first two quarters of 2005. The absolute numbers
of people treated for cocaine abuse in South Africa fol-
lowed a similar pattern as shown in the graph below.
Excluding alcohol, the increase in cocaine was from 7
per cent in the second half of 1996 to 16 per cent of
treatment demand in the first two quarters of 2005.      
Cocaine use is largely stable in Asia and declining in
Oceania
Following increases reported over the 1997-2000
period, cocaine use remained stable in the subsequent
years and was reported to have declined in 2004 in
Oceania. The overall increase since 1992 appears to have
been less than at the global level. 
These trends are also reflected in the household surveys
conducted by the Australian authorities. 
Fig. 68: South Africa - cocaine as primary drug in     
treatment demand*
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Fig. 69: Cocaine use perception trends: Africa
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Fig. 70: Cocaine use in Australia, 1993-2004    
(population 14 years and above)
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Source: AIHW, 2004 National Drug Strategy Household Survey,
Canberra, April 2005.
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Stable trend of (very limited) cocaine use in 
Asia – but some early indications that this 
could change 
Cocaine use in Asia has been stable and hardly been
noticeable at all over the last decade. However, there are
some early indications that this might change in the
foreseeable future. In 2005 and 2006 limited but rising
amounts of cocaine were trafficked to some countries
and areas in South-East Asia  including Hong Kong
SAR of China and China, and reports of the disman-
tling of some organized crime networks dealing in
cocaine were received. 
Overall increase of drug use perception indicator mainly
due to rising cocaine use in Europe 
Aggregating the various regional perception trends into
the overall drug use perception indicator by region
shows that Europe primarily fuelled the upward trend of
this indicator over the last decade, followed by the
Americas (mainly countries of South America, the
Caribbean and Central America). In 2004, the percep-
tions of rising levels of cocaine use gave way to reports
of stabilization or decline in a number of American
countries, thus prompting the overall cocaine use per-
ception indicator to decline while the upward trend in
Europe continued unabated.  
Fig. 71: Twelve year cocaine use, as perceived by
experts: Oceania 
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Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
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Fig. 72: Twelve year cocaine use, as perceived by
experts: Asia
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Fig. 73: Twelve year cocaine use, as perceived by
experts: overall trend
99
100
101
102
103
104
105
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
ba
se
lin
e:
 1
99
2 
=
 1
00
Europe Americas Africa Oceania Asia
Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
101
1. Trends in world drug markets Coca / Cocaine market
Map 12: Use of cocaine 2003 - 2005 (or latest year available)
Map 13: Ranking of cocaine in order of prevalence in 2004
Sources: UNODC Annual Reports Questionnaires data, SAMSHA US National Household Survey on Drug Abuse, Iranian Ministry of Health, Rapid
Assessement Study and UNODC ARQ,Council of Europe, ESPAD.  
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Production of cannabis basically comprises three differ-
ent products: cannabis herb, cannabis resin and
cannabis oil.
• Cannabis herb is comprised of the flowering tops
and leaves of the plant, which are smoked like
tobacco using a variety of techniques. While this
drug is consumed throughout the world, the
largest market for cannabis herb is in the Ameri-
cas, accounting more than 60 per cent of global
seizures in 2004. North America alone was
responsible for more than half of all seizures.
Africa accounted for more than 30 per cent of
global cannabis herb seizures. Over the 1994-
2004 period, the proportion of cannabis herb
seizures in global cannabis seizures amounted to
79 per cent (81 per cent in 2004)
• Cannabis resin (hashish) consists of the secretions
of the plant emitted in the flowering phase of its
development. Nineteen per cent of global
cannabis seizures were in the form of cannabis
resin in 2004. Western Europe is the largest
market for cannabis resin, accounting for more
than 70 per cent of global resin seizures in 2004,
and some 80 per cent of the hashish consumed in
Europe is estimated to be produced in Morocco. 
• Cannabis oil (hashish oil) is far less widely used
than cannabis herb or cannabis resin. Although
cannabis oil seizures doubled in 2004, they
accounted still for just 0.01 per cent of global
cannabis seizures in 2004. 
Production estimates for cannabis are collected by
UNODC, but must be regarded with a high degree of
caution. They are highly tentative and should be viewed
as informed guesses established by experts.  As scientif-
ically valid monitoring systems for cannabis cultivation
continue to be the exception and not the rule, even
major producing countries are not in a position to pro-
vide scientifically valid estimates. 
Moreover, the fact that cannabis is a plant that grows in
virtually every inhabited region of the world, that can be
cultivated with little maintenance on small plots, and
that can even be grown indoors, further complicates
matters. Therefore, remote sensing approaches in esti-
mating the areas under cultivation, as used for poppy
and coca, are difficult if not impossible if global culti-
vation had to be estimated. 
In other words, the lack of clear geographical concen-
trations in a few countries (as is the case for opium
poppy or cocaine) has made it difficult to introduce
effective and reliable crop monitoring systems for the
world at large.
Cannabis herb is cultivated in some 176 countries
Over the 1994-2004 period, 82 countries provided
UNODC with cannabis production estimates. For
comparison, only 36 countries provided estimates for
opium poppy cultivation, and only six provided esti-
mates for coca leaf production. 
The fact that a country did not provide an estimate does
not mean that no cultivation exists, as many countries
lack the capacity to establish reliable estimates. Another
possibility to identify cannabis producing countries has
been to analyse reports on the source of the cannabis
trafficked in a country. On this basis, 142 producer
countries could be identified for the 1994-2004 period.  
A third list of producer countries was generated by sin-
gling out those that report the seizure of whole cannabis
plants. It is inefficient and thus unlikely to transport
whole plants internationally, as only certain parts are
1.5 Cannabis market
1.5.1 Production
useable as a drug. Thus, when a whole plant is seized, it
is very likely that it was locally produced. Seizures of
whole cannabis plants were reported in 141 countries
during the 1994-2004 period. 
Combining these three lists results in the identification
of 176 countries and territories where cannabis is pro-
duced. This is equivalent to 90 per cent of the countries
and territories which receive UNODC’s Annual Reports
Questionnaire (195). However, there are no indications
that in the remaining countries cannabis production
does not take place. 
Global production of cannabis is estimated at 45,000
metric tons
Since the publication of the 2005 World Drug Report,
there has been a slight increase in the global cannabis
production estimate, from 42,000 metric tons to
45,000 metric tons. A tentative breakdown of these esti-
mates shows that the bulk of cannabis continues to be
produced in the Americas (54 per cent), notably in
North America (35 per cent), in South America (18 per
cent), Africa (27 per cent) and Asia (15 per cent). Only
4 per cent of global cannabis herb production occurs in
Europe. This may appear low, however, it should be
noted that Europe also accounts for just three per cent
of global cannabis herb seizures. Oceania accounts for 1
per cent of global production. 
Production of herbal cannabis in North America
appears to decline 
A number of indicators suggest that the Americas, and
notably North America, produce more cannabis than
any other region. The cannabis markets in the Americas
are, however, largely self-sufficient, that is, most of the
cannabis produced in the Americas is also consumed in
the region.
According to United States estimates, 10,100 metric
tons of cannabis herb were produced in Mexico in 2005.
This would make Mexico the largest cannabis herb pro-
ducer in North America. In the United States, about
4,455 metric tons of cannabis herb were produced in
2004/5, according to the United States Office of
National Drug Control Policy. An estimated 800 metric
tons of cannabis herb are produced in Canada.
Cannabis herb production in that region appears to
have declined. In Mexico, production of cannabis herb
is said to have decreased from 13,500 metric tons in
2003 to 10,100 metric tons in 2005 (-25 per cent). This
success was largely due to large-scale eradication efforts.
Similarly, in the United States production has been
reduced from some 5,560 metric tons to 4,455 metric
tons. 
Cannabis production significantly increases in Paraguay
The UNODC estimate for cannabis production in
Paraguay was raised from 2,000 to slightly less than
6,000 metric tons23, a three-fold increase. However, the
growth reported from Paraguay was even more dra-
matic, suggesting an annual production of some 15,000
metric tons of cannabis. The upsurge was explained by
an increase in the cultivation area and the introduction
of new species which allow for cannabis cultivation in
the dry winter months, thus leading to higher yields. 
However, the reported estimate did not tally with cre-
dible information that 85 per cent of Paraguayan
cannabis resin (equivalent to 12,750 metric tons) is des-
tined for cannabis markets in Brazil. Given the official
estimates of cannabis users in Brazil (1 per cent of the
population age 15-64 or 1.2 million persons), each user
would have had to consume 10.5 kg of cannabis per
year which is far in excess of the usual figures for annual
use (100-250 grams per user). Absorption capacity in
other South American countries is limited and no infor-
mation has emerged so far from Paraguay conquering
markets outside South America. Therefore, taking all
these factors into consideration, the estimate for
cannabis production in Paraguay was raised more con-
servatively. 
Production also on the rise in Africa and Asia   
Other major producing countries of cannabis herb are –
according to UNODC estimates –  Morocco (3,700
metric tons)24, South Africa (2,200 metric tons),
Colombia (2,000 metric tons) and Nigeria (2,000
metric tons). Further important producer countries are
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23 This would be equivalent to either the new estimate of 3000 hectares and the old yield of 1960 kg/ha or the old area under cultivation estimate
(1,100 ha) and the new yield estimates of more than 5000 kg/ha per year .
24 The estimate of cannabis herb production of Morocco was established on the basis of the cannabis cultivation survey carried out by the Government
of Morocco, in collaboration with UNODC, and seizure data providing an indication of the likely split of cannabis resin and cannabis herb
production. Taking the typical cannabis-to-cannabis-resin transformation ratios into account, seizure data suggest that less than 5 per cent of the
land under cannabis cultivation in Morocco is dedicated to cannabis herb production. Based on these ratios, the total area under cannabis herb
cultivation was estimated at 4,500 hectares in 2004. Using the average yield in Morocco ( 813 kg in 2004) resulted in an estimate of 3,660 metric
tons of cannabis herb production in Morocco.
Kazakhstan, Philippines, Egypt, Lebanon, Canada,
India, Sri Lanka, Kyrgyzstan, Afghanistan, Albania and
Netherlands, with an estimated production ranging
between 300 and 1,600 metric tons per country. 
In Africa, cannabis production shows an upward trend,
except for Morocco where production has declined
sharply. A number of Asian countries also reported
higher production estimates. 
Although the changes at the global level have not been
dramatic over the past two years, current production
estimates are substantially higher than those for the early
1990s. After having fallen in the late 1980s, global
cannabis production seems to be now more than twice
as high as a decade earlier. The trend in production is in
line with seizure data. 
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Fig. 74: Distribution of cannabis herb production in 2004/05 (N = 45,000 metric tons) 
Source: UNODC, Annual Reports Questionnaire Data/DELTA.
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25 The very strong increase between 2001/02 and 2003/04  is due to an expansion of country estimates (applying consumption based production
estimates for countries which did not supply such estimates); without that methodological change, the increase would have only been from 32,000
to 35,000 metric tons. 
Fig. 75: Estimates of global cannabis herb
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Cannabis resin
Morocco continues to be a major source of cannabis
resin 
The world’s largest cannabis resin producer continues to
be Morocco, supplying illicit markets in North Africa
and West Europe.  West Europe is the world’s largest
market for cannabis resin, accounting for more than 70
per cent of global resin seizures in 2004.  
Over the 2002-2004 period, Member States cited
Morocco as source country, followed by Pakistan and
Afghanistan. The proportion of Morocco has, however,
declined slightly, from 31 per cent over 1999-2003vi to
28 per cent over the 2002-2004 period, suggesting that
the source basis for supplying the cannabis resin market
is expanding to a number of other countries. 
Other countries cited as important sources of cannabis
resin are Albania and the Netherlands. In some cases, it
is not always clear whether the cannabis resin was pro-
duced in these countries or whether it was only bought
in these countries, originating from Morocco. Jamaica
and Paraguay are said to be key sources of cannabis resin
in the Americas.
Cannabis resin production plummets in Morocco
Since 2003, the Government of Morocco has conducted
comprehensive cannabis surveys, in cooperation with
UNODC. The 2003 survey placed total resin produc-
tion at about 3,060 metric tons, cultivated on 134,000
hectares of land in the Rif region by some 96,600 fam-
ilies. The 2004 survey showed a 10 per cent decline in
the land dedicated to cannabis cultivation (120,500
hectares), with an estimated production of 2,760 metric
tons.  The 2005 survey found a further 40 per cent
decline to 72,500 hectares and a decline in production
to 1,066 metric tons, clearly reflecting the intensified
efforts of the Moroccan authorities to eliminate
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Fig. 76: Cannabis herb seizures, 1999-2004   
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Source: UNODC, Annual Reports Questionnaire Data. 
Fig. 77: Countries and sub-regions most frequently cited as sources of cannabis resin, 2002-2004 (based on
information from 64 countries)*
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Source: UNODC, Annual Reports Questionnaire Data. 
*   number of times countries were identified as source countries, as a proportion of countries reporting.
** shown together as they lie along the same trafficking route.
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Fig. 78: Morocco - cannabis cultivation and production, 2003-2005
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Table 10: Tentative estimates of global cannabis resin production, 2004
Seizures in 
metric tons 
(2004)
Estimated 
proportion of 
seizures related to 
cannabis resin 
originating in 
Morocco
Potential seizures in 
metric tons related 
to Moroccan 
cannabis resin in 
2004
Cannabis resin 
production estimates
West & Central Europe 1,083.00 80% 866.4
39%094.301acirfA htroN
Seizures related to Moroccan 
cannabis resin
959.4
05.074,1seruzies labolG
Seizures related to Moroccan cannabis resin in % of global seizures 65%
Cannabis resin production in 
Morocco (2004) in metric tons
2,760
1. Estimate of global cannabis resin 
production (based on Moroccan 
cannabis resin production) 
4,230
Cannabis herb Cannabis resin Proportion
Cannabis resin 
production estimates
Seizures in metric tons (2004) 6,189.30 1,470.50 24%
2. Cannabis production estimate 
(based on herb production estimate)
296,01%42000,54
3. Combined estimate
 Average of estimates 1 and 2 7,461
3. UNODC cannabis resin 
production, rounded
7,500
(Range) (4,200-10,700)
2. Estimate based on cannabis herb production estimates and seizures
72,500
cannabis production from their territory.   
The decline of Moroccan cannabis production in 2004
(-10 per cent) was, however, not sufficient to reduce
global cannabis resin production in that year.  Cannabis
resin seizures and consumption estimates suggest that
the long-term upward trend in cannabis resin produc-
tion did not come to a halt in 2004.
Tentative estimates, extrapolating results from Moroc-
can cannabis resin production data and extrapolating
global resin production from herb production estimates
with the help of seizure statistics, suggest that some
7,500 metric tons of cannabis resin were produced in
2004 (range: 4,200-10,700). Previous estimates, based
on the same methodology,  resulted in an estimate of
some 6,300 metric tons (range: 5,100-7,400) for the
year 2002/03.  
No global production estimates for 2005 are, as yet,
available. One can assume, however, that the strong
decline of cannabis resin production  by some 1700
metric tons in Morocco has had an impact on global
cannabis production, leading to some decline  of global
cannabis resin production in 2005.       
A tentative breakdown of global cannabis resin produc-
tion suggests that some 40 per cent of the global
cannabis resin supply is being produced in North Africa
and more than a quarter in the Near and Middle East. 
These two regions account for more than two thirds of
global cannabis resin production. Other cannabis resin
producing regions of importance are Central Asia,
South Asia and, to a lesser extent, South-East Europe
and the Caribbean.
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Fig. 79: Tentative global cannabis resin production
estimates, 2002/3 and 2004
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Sources: UNODC, World Drug Report 2004 and UNODC and
Government of Morocco, Cannabis Survey 2003 and 2004;
UNODC, Annual Reports Questionnaire Data.
Fig. 80: Distribution of global cannabis resin
production (N = 7,500 tons in 2004)
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Source: UNODC, Annual Reports Questionnaire data.
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Trafficking of both cannabis herb and cannabis resin
continues to increase
Cannabis herb and resin remain the most widely traf-
ficked drugs worldwide, accounting for the majority of
all seizures. Almost all countries in the world are
affected by cannabis trafficking. The upward trend in
cannabis seizures, which began in the early 1990s, con-
tinued in 2004.
Cannabis herb seizures surpassed the 6,000 metric ton
mark (+6 percent) in 2004. Most cannabis herb seizures
were reported from Mexico, followed by the United
States, South Africa, Nigeria and Morocco. In 2004,
seizures of cannabis resin also increased by 6 percent to
1,470 metric tons. Most seizures of cannabis resin were
made by Spain, followed by Pakistan, France, Morocco,
Iran.  
Cannabis herb remains, by far, the most widely traf-
ficked drug
In terms of both volume and geographic spread,
cannabis herb is the most intercepted drug in the world.
Cannabis herb seizures rose by 6 per cent in 2004 and
have doubled over the past ten years.    
More than half of the global total of cannabis herb is
seized in North America, notably Mexico and the
United States. With seizures of 2,164 metric tons in
2004, Mexico leads the world's ranking, accounting for
35 per cent of global seizures, followed by the United
States, where 1,118 metric tons of cannabis herb were
seized in 2004. While the overall proportion of seizures
made in North America has largely remained stable, less
seizures are made in South America: whereas in 1990,
South America accounted for 46 per cent of global
cannabis herb seizures, this share has fallen to 7 per cent
in 2004. The share of Africa, on the other hand, has
been increasing continuously: from 16 per cent of global
cannabis herb seizures in 1990 to 20 per cent in 2002
and 31 per cent in 2004. The strong upward trend
recorded in 2004 can be explained by exceptionally high
seizures of cannabis made in South Africa and Nigeria.  
Cannabis seizures increased in Asia, primarily due to a
surge of cannabis seizures in India which increased from
79 tons in 2003 to 144 tons in 2004 (+ 81 per cent).
Europe presents a varied picture: While seizures in West
and Central Europe declined by some 37 per cent (from
101 tons in 2003 to 63 tons in 2004), a strong upward
trend was observed for East Europe where seizures of
cannabis herb more than doubled: from 42 tons in 2003
to 97 tons in 2004 (+ 130 per cent). Almost all of this
increase reflects an upsurge of cannabis herb seizures in
the Russian Federation (from 41 tons in 2003 to 89 tons
in 2004). Cannabis seizures declined in Oceania. 
1.5.2 Trafficking
Fig. 81: Cannabis seizures, 1985-2004
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Source: UNODC, Annual Reports Questionnaire data.
Fig. 82: Regional breakdown of cannabis herb
seizures, 1985-2004
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Year 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Metric tons 2,358   3,209  3,089    3,097    2,998    4,042    4,674    4,857    4,745    5,850   6,189   
* data refer to 2003
2,164,161
1,118,041
818,045
683,101
318,610
155,392
152,317
144,055
89,653
80,249
54,786
33,777
29,520
16,744
16,020
13,824
11,311
20,952
21,349
25,623
23,859
28,200
- 500,000 1,000,000 1,500,000 2,000,000 2,500,000
Mexico
USA
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Nigeria
Morocco
Brazil
Colombia
India
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Egypt
Argentina
Canada
United Kingdom
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Malawi
Kazakhstan
Jamaica
Lesotho
Israel
Zambia
Venezuela
35%
18%
13%
11%
5%
3%
3%
*
2%
878,504
696,022
436,672
398,866
17,289
16,024
8,063
3,748
3,315,979
63,830
42,653
25,184
22,967
19,284
147,079
97,187
-
500,00
0
1,000,
000
1,500,
000
2,000,
000
2,500,
000
3,000,
000
3,500,
000
North America
Southern Africa
West and Central Africa
South America
North Africa
South Asia
East Europe
West & Central Europe
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Central Asia  and Transcaucasian countries
East and South-East Asia
East Africa
Southeast Europe
Near and Middle East /South-West Asia
Central America
Oceania
(54%)
(11%)
(6%)
(7%)
(2%)
(14%)
SEIZURES OF CANNABIS HERB in % of world total and kg- HIGHEST RANKING COUNTRIES - 2004
SEIZURES OF CANNABIS HERB in kg and % - BY REGION - 2004
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Fig. 83: Global seizures of cannabis herb, 1994 -2004
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Fig. 84: Global seizures of cannabis herb, 1994 -2004
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Trafficking in cannabis resin 
Global cannabis seizures increase to all time high in
2004
Global cannabis resin seizures increased by 6 per cent to
1,471 metric tons, reaching a new all time high. The
increases were most significant in West and Central
Europe (+ 13 per cent), the largest market for cannabis
resin in the world. Cannabis resin seizures declined in
Africa, Asia, the Americas and Oceania. 
Most cannabis resin seizures are made in West & Cen-
tral Europe, followed by Near and Middle East / South-
West Asia and North Africa… 
Three subregions account for 99 per cent of global
cannabis resin seizures: West and Central Europe (74
per cent), Near and Middle East/South-West Asia (18
per cent) and North Africa (7 per cent).  The largest
seizures worldwide were reported by Spain (794 metric
tons or 54 per cent of the total), followed by Pakistan
(135 metric tons or 9 per cent), Morocco (86 metric
tons or 6 per cent) and Iran (86 tons or 6 per cent). In
Afghanistan, cannabis resin seizures declined by almost
half, from 81 tons in 2003 to 41 tons in 2004. In Alge-
ria, seizures of some 12 tons of cannabis resin were
reported for 2004, more than double the quantity seized
in 2002. 
Europe continues to be the main destination of cannabis
resin
The main destination of cannabis resin is West & Cen-
tral Europe. About 80 per cent of the cannabis resin des-
tined for the West & Central European market is
estimated to originate in Morocco. Much of the
cannabis resin transits Spain and the Netherlands before
being shipped to other countries. The remainder of the
resin supply originates in Afghanistan/Pakistan, Central
Asia (mostly for the Russian Federation, other CIS states
and some of the Baltic countries)  or from within
Europe (mainly Albania, supplying the markets of vari-
ous Balkan countries and Greece).  
The second largest destination of cannabis resin is the
Near and Middle East / South-West Asia region. This
region is mainly supplied from cannabis resin produced
in Afghanistan and Pakistan and, to a lesser degree, from
cannabis resin originating in Lebanon. Some of the
cannabis resin from Afghanistan/Pakistan is also being
shipped to Canada and to countries in Eastern Africa. 
North Africa makes up the third largest market and is
predominantly supplied by cannabis resin produced in
Morocco. The importance of other markets is limited.
Nepal is a source country for cannabis resin exports to
India and to some other countries and Jamaica is a
source country for cannabis resin exports to some other
countries in the Americas.
Fig. 85: Global cannabis resin seizures, 1985-2004
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Year 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Metric tons 901      1,030   877      818      896      889      1,053   934      1,090   1,386   1,471   
* Data refer to 2003
794,437
135,639
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Fig. 86: Global seizures of cannabis resin, 1993 - 2004
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Cannabis continues to be, by far, the most widely used
drug in the world 
Cannabis remains by far the most commonly used drug
in the world. An estimated 162 million people used
cannabis in 2004, equivalent to 3.9 per cent of the
global population age 15-64. In relative terms, cannabis
use is most prevalent in Oceania, followed by North
America and Africa. While Asia has the lowest preva-
lence expressed as part of the population, in absolute
terms it is the region that is home to some 52 million
cannabis users, more than a third of the estimated total. 
Global cannabis use continues to increase - though
after years of significant increases, it plateaus at cur-
rent levels in some regions
After years of reported increases, cannabis use appears to
have stabilized at current levels in North America, some
countries of East and South-East Asia and in some
countries of Western Europe. Cannabis use continues to
increase in some countries in South, Central and East
Europe and in Africa. 
UNODC’s annual prevalence estimate is only slightly
higher than that published in 2005 World Drug Report.
Stable or declining use rates of cannabis were reported
in Oceania and the Americas. The annual prevalence of
cannabis of secondary school students remained stable
in the United States in 2005. Large increases in the use
of cannabis have been primarily reported in African
countries (eg. Algeria, Nigeria, Zambia). 
The drug use trends, as perceived by experts, continued
pointing upwards at the global level, suggesting a fur-
ther expansion of the cannabis market. Since the late
1990s, cannabis use - as shown by the UNODC annual
prevalence estimates – has increased by more than 10
per cent at the global level.  
Over the last decade, cannabis use has increased in
almost all regions, except Oceania 
UNODC’s drug use trends, as perceived by experts, sug-
gest that there has been an increase in cannabis use in
1.5.3 Abuse
Sources: Sources: UNODC, Annual Reports Questionnaire Data,
Govt. reports, reports of regional bodies, UNODC estimates.
Fig. 88:   Global cannabis market - breakdown by
region 
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Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC's Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 89:   Twelve-year cannabis use trends, as
perceived by experts 
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most regions, with the exception of Oceania where a
downward trend has been observed. However, Oceania
has traditionally had the highest cannabis prevalence
rates in the world.    
Cannabis use in the Americas increased strongly in the
1990s but has stabilized over last few years
UNODC’s drug trends indicator has shown strong
increases of cannabis use in the 1990s, clearly exceeding
the global trend indicator.  Since 2001, cannabis use is
perceived to have been practically stable in the Ameri-
cas. Nonetheless, the Americas showed the highest
increase of all regions after 12 years. 
But these findings have to be qualified. Available trend
data for North America, as reflected in regularly under-
taken school surveys, show indeed strong increases in
cannabis use in the 1990s. But, this was followed by a
stabilization in Canada as of 1999 (and a decline in
2005) and a gradual decline in the United States since
1997 (among 12th grade students). While for each indi-
vidual year the decline was not statistically significant,
over the 1997-2005 period cannabis use among 12th
grade students in the United States declined by almost
13 per cent.  In both Ontario, Canada, and in the
United States prevalence rates in 2005 were lower than
two decades ago. 
in % of 
population age 15-64
EUROPE 30,800,000 5.6
West & Central Europe 23,400,000 7.4
South-East Europe 1,900,000 2.3
East Europe 5,500,000 3.8
AMERICAS 36,700,000 6.4
North America 29,400,000 10.3
South America 7,300,000 2.6
ASIA 52,100,000 2.1
OCEANIA 3,200,000 15.3
AFRICA 39,600,000 8.1
GLOBAL 162,400,000 3.9
               Above global average
               Around global average 
               Below global average
Cannabis use
No. of users
Table 11: Annual prevalence of cannabis use, 2003-2005 
Sources: Annual Reports Questionnaire data, various Government reports, reports of regional bodies, UNODC estimates.
Sources: NIDA, Monitoring the Future, 2005 and CAMH, Ontaria
Drug Use Survey 2005.  
Fig. 90:   Annual prevalence among high-school
students in the USA and in Canada
(Ontario only), 1975-2005
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School surveys carried out in Brazil show a similar
trend. Strong increases were observed in the past. Life-
time prevalence of cannabis use in 10 state capitals of
Brazil among 10-18 year old students increased from
3.4 per cent in 1989, to 4.5 per cent in 1993 and to 7.6
per cent in 1997.26 New school studies conducted in
Brazil across the country in 200427 revealed – using data
from the same 10 capital cities -  a decline to 6.4 per
cent (unweighted average).  The Brazilian data also sug-
gest that cannabis use was in 2004 significantly higher
than a decade ago but lower than in the late 1990s.   
Cannabis use continues to rise in Europe 
UNODC’s cannabis trend indicator for Europe shows
an ongoing upward trend, even though cannabis use has
apparently stabilized in a number of West European
countries, including the Nordic countries, France and
Germany. In much of the rest of Europe, cannabis is
reported to continue growing. UNDOC’s cannabis
trend indicator for Europe shows thus a higher level
than the global indicator, having exceeded the global
average as of 1999.   
Higher cannabis use in Africa 
Cannabis use in Africa is on the rise. Cannabis use was
reported to have grown in all years in Africa since 1992.
It is likely that the drug use trend has been underesti-
mated as many countries in Africa have not regularly
submitted annual reports questionnaires. Strong growth
Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC's Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 91:   Twelve-year cannabis use trends as
perceived by experts: Americas  
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26 IV Levantamento sobre o Uso de Drogas entre Estudantes de 1 e 2 graus em 10 Capitais Brasileiras, 1997.                                                           
27 CEBRID, Levantamento Nacional Sobre o Uso de Drogas Psicotrópicas entre Estudantes do Ensino Fundamental e Médio da Rede Pública de
Ensino nas 27 Capitais Brasileiras, 2004.
Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC's Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 92:   Twelve-year cannabis use trends as
perceived by experts: Europe
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Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC's Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 93:   Twelve-year cannabis use trends as
perceived by experts: Africa
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in recent years has been reported in much of western,
eastern  and northern Africa.  
After some decline in the late 1990s, cannabis use surg-
ing in Asia 
Over the 1992-1995 period, UNODC’s drug trend
indicator for Asia remained below the global average.
However, it  has shown some of the strongest growth
rates since 2000, following some declines in the late
1990s. Exceptions to this general upward trend are a
number of countries in South-East Asia which reported
either stable or declining cannabis use.    
Continuous declines of cannabis use in Oceania
In contrast to most regions, a clear downward trend in
cannabis use has been reported from Oceania. Aus-
tralian Household Survey data suggest that cannabis use
declined by some 37 per cent between 1998 and 2004
and that cannabis use levels are now below the levels in
1993. Similarly, the drug trend indicator – after having
exceeded the global average in the second half of the
1990s - shows for Oceania slightly lower levels than in
1992, twelve years earlier. 
Though no definite answers as to the reasons for the
massive decline exist, there are indications that the wide
spread of cannabis use in Australia (and other countries
in Oceania) in the late 1990s, in combination with
growing levels of THC, meant that problems related to
cannabis use became more apparent, notably to younger
users, so that the substance has lost some of its previous
benign image. There has also been far more media atten-
tion to the adverse effects of cannabis, particularly
cannabis psychosis, prompting potential users to recon-
sider their choices. 
Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC's Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 94:   Twelve-year cannabis use trends as
perceived by experts: Asia
103.2
104.7
98
99
100
101
102
103
104
105
106
107
92 93 94 95 96 97 98 99 00 01 02 03 04
b
as
el
in
e:
 1
99
2 
=
 1
00
Asia Global
Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC's Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 96:   Twelve-year cannabis use trends as
perceived by experts: Oceania
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Fig. 95:   Annual prevalence of cannabis use among
the general population in Australia, 1993-
2004
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1. Trends in world drug markets Cannabis market
Map 17: Use of cannabis 2003-2004 (or latest year available)
Sources: UNODC Annual Reports Questionnaires data, SAMSHA US National Household Survey on Drug Abuse, Iranian Ministry of Health,
Rapid Assessement Study and UNODC ARQ,Council of Europe, ESPAD.  
Map 18: Ranking of cannabis in order of prevalence  in 2004  (or latest year available)      
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Global ATS production estimated at some 480 metric
tons
The group of amphetamine-type stimulants (ATS)
encompasses amphetamines (amphetamine, metham-
phetamine), ecstasy (MDMA and related substances)
and other synthetic stimulants (methcathinone, phen-
termine, fenetylline etc.).
Based on ATS consumption estimates, ATS seizure data
and ATS precursor seizures,  UNODC estimates total
ATS production to have amounted to some 480 tons in
2004 (range: 285 - 1,184 tons).28
Most of the production is ‘amphetamines’ (290 tons of
methamphetamine and 63 tons of amphetamine), fol-
lowed by ecstasy (mainly MDMA, about 126 metric
tons). While these estimates are slightly higher than
those published in the 2005 World Drug Report (445
tons), they are somewhat lower than those for 2000.
Following a continuous increase in ATS production
throughout the 1990s, production peaked in 2000,
before dropping off over the 2001-2003 period and
regaining strength in 2004. The increase in the overall
production estimate was largely due to more production
of ecstasy in 2004.  
Several conflicting indicators cloud the dynamics of the
ATS market. This is particularly true for amphetamines.
Reports of record seizures for precursors used in the pro-
1.6 Amphetamine-type stimulants
1.6.1 Production
Fig. 97: UNODC production estimate of
amphetaminetype stimulants
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Fig. 98: Production estimate of amphetamines
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28    Production of ATS can only be estimated indirectly. The methodology for establishing ATS production estimates was first outlined in Ecstasy and  
Amphetamines - A Global Survey 2003 (United Nations Office on Drugs and Crime, 2004).
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duction of amphetamines and dismantled clandestine
laboratories appear to point to an expansion in produc-
tion. However, declining seizures of amphetamines and
Member States reporting lower abuse levels suggest a
stable market.  As a result of these inconsistencies, the
margin of error for the current amphetamines produc-
tion estimate is higher than it has ever been (between an
estimated 227 and 978 tons). This may also explain why
perceptions of trends regarding the development of the
amphetamines markets diverge, for the time being,
among experts and policy makers across the world.  
Taking drug prices and purities as a point of departure,
two possible scenarios emerge. One scenario suggests a
reduction in amphetamine production due to the large
scale dismantling of laboratories and the record precur-
sor seizures.  The subsequent decline in end-product
seizures would have supported this scenario, as less pro-
duction would also mean less trafficking and thus less
seizures. However, if this had been the case, ampheta-
mines prices should have risen substantially in 2004 and
purity levels should have dropped. The available price
and purity data fail to support this scenario.  
The alternative scenario would have been one of large-
scale increase in amphetamines production in 2004,
reflecting the dramatic rise in precursor seizures and dis-
mantling of laboratories. Under this scenario, ampheta-
mines prices should have dropped substantially and
purity levels should have increased. Again, this did not
happen. A rather stable trend was observed for these
indicators at the global level, showing some moderate
increases in purities and some moderate declines in
prices. 
Thus, the most likely scenario is one of a relatively stable
or just slightly increasing production trend. This seems
to be essentially reflected in UNODC production esti-
mates for amphetamines for 2004, derived from con-
sumption, end-product seizures and precursor seizures.
Improved international cooperation is likely to have
increased the seizure rate of precursors. Although the
number of dismatled latoratories has risen, dismantling
of so-called super-labs has actually declined. Therefore a
large increase in laboratory seizures in 2004 did not nec-
essarily have to indicate any significant increase in pro-
duction levels.
The upward trend for ecstasy is more robust. Though
production may have well declined in the largest ecstasy
producing centre (Netherlands) and consumption defi-
nitely declined in the world’s single largest ecstasy
market (United States), there seem to be, nonetheless,
less discrepancies with regard to the overall upward
trend in global ecstasy production.  UNODC estimates
suggest that ecstasy production increased from between
34 and 141 tons in 2003 to between 81 and 206 tons
in 2004. Though – theoretically – production margins
are still large enough to allow for a decline in produc-
tion, this would seem to be extremely unlikely as all
underlying indicators moved clearly upwards in 2004:
UNODC prevalence estimates rose by 22 per cent,
ecstasy seizures rose by 87 per cent and seizures of
ecstasy precursor chemicals rose by 113 per cent, largely
due to important seizures of 3,4-MDP-2-P (also known
as PMK), the main precursor for ecstasy.  
ATS production occurs mostly in North America, East
and South-East Asia and in Europe  
The  increasing number of countries where clandestine
ATS laboratories are dismantled indicates that ATS pro-
duction is spreading in geographical terms. Nonetheless,
clear concentrations of ATS production can be still
identified. While proportions differ depending on the
specific indicator used and the specific substances
analysed, all available indicators suggest that ATS pro-
duction continues being concentrated in North Amer-
ica, East and South-East Asia and in Europe. Most of
the amphetamine production takes place in Europe;
most of the methamphetamine production occurs in
North America and East and South-East Asia and most
ecstasy is produced in Europe and in North America. 
While seizures decline, the number of dismantled ATS
laboratories rises 
The number of globally dismantled ATS laboratories, as
reported to UNODC, increased from 547 in 1990 to
Sources: UNODC estimates based on UNODC, Annual Reports
Questionnaire Data / DELTA and INCB, 2005 Precursors, March
2006, UNODC, 2005 World Drug Report and UNODC, Ecstasy and
Amphetamines – Global Survey 2003.
Fig. 99: ATS production estimates and potential  
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7,028 in 2000 and to a record high of 18,532 in 2004.
Out of all globally dismantled laboratories, 64 per cent
produced ATS in 2004, up from 60 per cent a year ear-
lier, 50 per cent in 2000 and 19 per cent in 1990.  
Much of the increase in the 1990s was a reflection of the
growth in ATS production. Whether this is, however,
still the case, is less clear as the large-scale dismantling
of laboratories may have helped to reduce, at least, the
expansion of ATS production at the global level. After
having risen strongly in the 1990s, global ATS seizures
declined by 11 per cent in 2004 and by 41 per cent since
2000. Seizures of amphetamines (methamphetamine
and amphetamine) fell by 26 per cent in 2004 and by
53 per cent over the 2000-2004 period.  
The overwhelming majority of dismantled ATS labora-
tories were producing methamphetamine (17,851 or 96
per cent of the total in 2004) and the enormous increase
in 2004 is largely linked to the dismantling of metham-
phetamine laboratories. 
Table 12: Production estimates of amphetamine-type stimulants, 2004
Based on
Estimate Range Estimate Range Estimate Range
Consumption 272 227-318 136 121-151 408 348-469
Drug seizures 247 204-291 98 81-115 346 285-406
Precursor seizures 541 456-978 144 96-206 685 552-1184
Average of all estimates 354 227-978 126 81-206 480 285-1184
‘Amphetamines’ 
(methamphetamine, 
amphetamine)
Ecstasy Total
Sources: UNODC estimates based on UNODC, Annual Reports Questionnaire Data / DELTA and INCB, 2005 Precursors, March 2006. 
Fig. 100: Number of dismantled ATS laboratories and ATS seizures, reported to UNODC, 1985-2004
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However, the number of laboratories where other ATS
were manufactured also increased over the past five
years, from 109 in 1990 to 419 in 2000 and 681 in
2004. The number of amphetamine laboratories seized
more than doubled over the same period, from 115 in
2000 to 319 in 2004. In addition, 86 ‘ecstasy’ laborato-
ries were seized; up from 64 in 2000 and 15 in 1999.   
Most methamphetamine laboratories are dismantled in
North America
The overwhelming majority of methamphetamine lab-
oratories (97 per cent) were dismantled in North Amer-
ica, mainly the United States, and, to a lesser extent,
Mexico. Methamphetamine laboratories were also dis-
mantled in Oceania, in East and South-East Asia, in
Europe (mainly Czech Republic, followed by Slovak
Republic and Republic of Moldova) and in South Africa
(which appears to be emerging as an important local
production centre). 
Despite its substantial proportion of global metham-
phetamine production, the number of methampheta-
mine laboratories dismantled in East & South-East Asia
continues to be low. Just 13 methamphetamine labora-
tories were dismantled and reported to UNODC from
this region in 2004, down from 75 in 2001. Most
methamphetamine laboratories seized in Asia over the
2002-2004 period were reported from China, Philip-
pines, Taiwan Province of China,  Myanmar, Cambodia
(tabletting facilities only), Hong Kong SAR of China
and Malaysia. 
For comparison, according to the International Nar-
cotics Control Board, authorities in South Africa alone,
dismantled 28 illicit ATS laboratories, producing either
methamphetamine or methcathinone in 2004.  
Increasing seizures of ecstasy laboratories in North
America indicate shift in production
Most amphetamine laboratories were seized in Europe
(61 per cent), mainly Russian Federation, Poland,
Netherlands, Bulgaria, Germany, Belgium, Spain, Esto-
nia and Lithuania while 39 per cent were dismantled in
North America, primarily the United States. As for
ecstasy, 48 per cent of all ecstasy laboratories were seized
in North America (United States and Canada), 23 per
cent in Europe (mainly Netherlands, followed by Bel-
gium and Estonia).
The most striking trend has been the decline of Europe
in the proportion of dismantled ecstasy laboratories -
from 75 per cent in 2000 to 39 per cent in 2003 and 23
per cent in 2004. The importance of Europe as the
world’s main ecstasy production centre thus appears to
be declining which can be also seen in ecstasy seizure
statistics: 81 per cent in 1994; 56 per cent in 2000, 53
per cent in 2004. Some of the production has shifted to
North America (mainly United States and Canada).
Fig. 102: Number of dismantled ‘ecstasy’
laboratories, reported to UNODC,
1985-2004
0
20
40
60
80
100
19
85
19
86
19
87
19
88
19
89
19
90
19
91
19
92
19
93
19
94
19
95
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
20
04
N
um
be
r 
of
 la
bo
ra
to
rie
s
Other substances of the 'Ecstasy group' 
MDMA
Source:  UNODC, Annual Reports Questionnaire Data/DELTA.
Fig. 101: Number of dismantled amphetamine
laboratories, reported to UNODC, 
1985-2004
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Increasing ecstasy precursor seizures in North America
also point in this direction. In addition, there is a pro-
liferation of ecstasy production in other parts of the
world. Over the 2002-2004 period, ecstasy laboratories
were dismantled in South-East Asia (Indonesia, China,
Hong Kong SAR of China, Malaysia), in Oceania (Aus-
tralia and New Zealand), in Africa (South Africa and
Egypt) and in some south American countries
(Argentina (2003) and Colombia (2001)).  
ATS precursor seizures reach record levels, exceeding
end-product seizures  
ATS precursor seizures reached an all-time high in
2004, which also reflects major successes in interna-
tional cooperation, notably under Project Prism. Tar-
geting ATS precursors, Project Prism is an initiative of
the International Narcotics Control Board, carried out
by 126 national authorities supported by INCB, Inter-
pol, the World Customs Organization, UNODC and
the European Community. 
The results of increased international cooperation were
reflected in strong increases in precursor seizures, as
reported by INCB:
• The main methamphetamine precursors seized in
2004 were pseudoephedrine (176 tons) and
ephedrine (15 tons).  These are important quanti-
ties, given total licit trade in ephedrine of 526 tons
and of 1207 tons in pseudoephedrine in 2004.
The quantities seized increased from 14 tons of
ephedrine and 18 tons of pseudo-ephedrine a year
earlier;   
• The most important amphetamine precursors
were P-2-P (also known as BMK: 349 tons seized
in 2004 of which at least 33 tons for amphetamine
production) and, to a lesser extent, phenylacetic
acid (232 kg); seizures a year earlier amounted to
5.5 tons of P-2-P and 158 kg of phenylacetic acid;
• The main ecstasy precursors are 3,4-MDP-2P
(also known as PMK: 17 tons seized in 2004),
piperonal (17 tons), safrole (5700 litres) and
isosafrole (no seizures in 2004, 23,400 litres
reported for 2003). Overall seizures of ecstasy pre-
cursors in 2003 had been substantially lower: no
seizures for 3,4-MDP-2P or for piperonal and less
seizures for safrole (515 litres). 
If these seized precursors had been used for production
purposes, they would have been sufficient  to produce29
more than 320 tons of amphetamine-type stimulants in
2004, including some 21 tons of ecstasy (10 tons in
2003), some 16 tons of amphetamine (7 tons in 2003),
some 128 tons of methamphetamine (22 tons in 2003).
Most of the remaining precursors could have produced
either amphetamine or methamphetamine (totalling
some 155 metric tons).
Fig. 103: Seizures of ATS precursors in ATS 
equivalents
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Sources: UNODC, Ecstasy and Amphetamines, Global Survey 2003
and INCB, Precursor and chemicals frequently used in the illicit
manufacture of narcotic drugs and psychotropic substances, New
York 2006. 
29 The following conversion ratios were used: 
Methamphetamine: 150 kg of ephedrine or pseudo-ephedrine for 100 kg of methamphetamine 
Amphetamine: 200 litres of P2P or 150 kg of norephedrine for 100 kg of amphetamine; or 
400 kilograms of phenylacetic acid for 100 kg of amphetamine 
Ecstasy: 125 litres of 3,4-MDP-2-P for 100 kilograms of MDMA
262.5 kg of piperonal for 100 kg of MDMA, or 237.5 kg of isosafrole for 100 kg of MDMA; or 475 kg of safrole for 100 kg of MDMA 
Source: Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International  
Narcotics Control Board for 2005 on the Implementation of Article 12 of the United Nations Convention Against Illicit Traffic in Narcotic Drugs and  
Psychotropic Substances, 1988, (United Nations publication, Sales No. E.06.XI.5), New York 2006.
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Most precursors are seized in North America, Asia and
Europe 
An analysis of precursor seizures for 2004, collected by
the International Narcotics Control Board shows that:
• most of the methamphetamine precursors were
seized in North America (92 per cent), followed
by East & South-East Asia (6 per cent);
• most amphetamine precursors (Phenyl-acetic acid
and P-2-P, excluding the extreme large       P-2-P
seizures reported by the USA (accounting for
more than 90 per cent of global P-2-P seizures in
2004), were seized in Asia (72 per cent) followed
by  Europe (28 per cent); 
• most ecstasy precursors were seized in East and
South-East Asia (49 per cent), followed by Europe
(43 per cent) and North America (6 per cent) and
Oceania (2 per cent)
These data tend to reflect the origin of many of the
chemical precursors in East- and South-East Asia while
large-scale ATS production takes place in North Amer-
ica, East & South-East Asia and Europe. In addition,
countries in South-Asia are sometimes mentioned as
source countries for  ATS precursors.   
Asia: China, Myanmar and Philippines continue to be
main methamphetamine production sites 
Based on information supplied by Member States on
the origin of ATS, 26 source countries for the produc-
tion of methamphetamine could be identified for the
2002/04 period. 
The main countries of origin for methamphetamine
production in Asia continue to be China, Myanmar and
Philippines. 
• Most of the methamphetamine production in
China is located in south-eastern China, in
Guangdong Province (which surrounds Hong
Kong SAR of China) and, to a lesser extent in
neighbouring Fujian province, located off the
coast of Taiwan Province of China. China,
together with India, is also one of the main source
countries of ephedrine and pseudoephedrine, the
main precursor chemicals used to manufacture
methamphetamine. 
• Significant quantities of methamphetamine are
manufactured in Taiwan Province of China. In
2003, 10 laboratories were dismantled there; local
production, however, appears to have declined in
Fig. 104: Seizures of methamphetamine-precursors
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Fig. 105: Seizures of amphetamine and ecstasy
precursors
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recent years. 
• Methamphetamine production in the Philippines
appears to have increased in recent years. Four
methamphetamine laboratories were dismantled
in 2002, 11 in both 2003 and 2004 and 7 in
2005. Production in the Philippines may be oper-
ated by local laboratory owners but seems to be
closely linked to criminal groups from China and
Taiwan Province of China. 
• Myanmar also continues to play an important role
as a production site for methamphetamine, as
reflected in neighbouring countries reports. Illicit
markets in Thailand are basically supplied by
methamphetamine produced in Myanmar and
important parts of the Chinese market (20 per
cent) are also supplied by methamphetamine pro-
duced in Myanmar. The number of dismantled
laboratories, however, has not been particularly
impressive in recent years (4 laboratories disman-
tled in 2002, 1 in 2003, 1 in 2004 and 3 in 2005).
On the other hand, Myanmar authorities have
stepped up efforts against trafficking in ATS, lead-
ing to a number of immense seizures of metham-
phetamine tablets (12 million tablets in January
2006, four times the total seized in 2005 (3.6 mil-
lion)). ATS production in Myanmar is mainly
encountered in the Shan state (notably in the Wa
region), bordering China, though recent reports
suggest that production is also taking place in
areas controlled by the ethnic Chinese Kokang,
the Shan State Army-South and the Kachin
Defense Army (KDA). Production is sometimes
co-located with heroin refineries.
• According to information provided by the Gov-
ernment of Thailand, methamphetamine produc-
tion has largely ceased to exist following the
crackdown on the market in 2003.  
Most South-East Asian methamphetamine is trafficked
towards Oceania, notably Australia and New Zealand,
and North America. The Philippines and China have
been identified as main source countries for South-East
Asian methamphetamine found on North American
markets. South-East Asian methamphetamine, mostly
from Myanmar and the Philippines, transits Thailand
before it is trafficked to European destinations, mainly
the United Kingdom, Netherlands, France and Switzer-
land. 
The United States and Mexico are the main production
sites in the Americas 
The main countries of methamphetamine production
in the Americas are the United States, producing exclu-
sively for the domestic market, followed by Mexico and,
to a lesser extent, Canada. United States authorities con-
tinue to dismantle the largest numbers of methamphet-
amine laboratories worldwide (17,199 laboratories in
2004). Methamphetamine production in the United
States has been traditionally concentrated in California
and several neighbouring states, but it has been spread-
ing towards the rest of the country and has already
reached most states. A large number of laboratories (sev-
eral hundred per state) are now being seized in rural
America, in several states between Texas and Illinois and
along the Mississippi river. Most of the ‘super-labs’, that
is, laboratories capable of manufacturing more than 5
kg of methamphetamine in 24 hours, continue to be
located in California.  The number of ‘super-labs’ seized
in the United States, has, however, shown a downward
trend in recent years, from 245 in 2001 to 55 in 2004
(-77 percent) and a further decline by 34 per cent over
the first half of 2005 as compared to the same period a
year earlier.  Mexico reported the dismantling of 18 lab-
oratories to UNODC in 2004. Most methampheta-
mine production takes place in northern Mexico.
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Fig. 106: Origin* of methamphetamine as reported
by Asian countries,  2002-04
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* Number of times a country was identified by other Asian
countries as a source country for methamphetamine production
over the 2002-04 period,  expressed as a proportion of such
reports (N = 32) ‘Origin’ refers to the countries to which drug
shipments could be traced back.
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
Methamphetamine production in Oceania appears to
have levelled off, and shows signs of slight decrease 
Methamphetamine production in Oceania is concen-
trated in Australia and, at lower levels, in New Zealand.
Reported seizures of methamphetamine laboratories in
New Zealand increased from 1 in 1998 and 9 in 2000
to 201 in 2003, before falling back to 182 in 2004. Si-
milarly, the number of ATS laboratories dismantled in
Australia rose from 10 in 1990  to 150 in 2000 and 314
in 2003 before declining to 245 (including 24 ecstasy
laboratories) in 2004. Rising laboratory seizures in the
1990s did not have much of an impact on prices or
purities, suggesting that production was rising. The si-
tuation was less clear for subsequent years and in 2004,
falling numbers of dismantled laboratories went hand
in hand with slightly falling purity levels, indicating that
production was losing momentum.  In line with
increases in laboratory seizures in the 1990s, there were
also strong increases in the number of methampheta-
mine consumers, suggesting increases in production.
However, over the 1998-2004 period, household survey
results showed some decline and consumption levels
appear to have declined further in 2005 as shown in the
Drug Use Monitoring in Australia (DUMA) data.
Methamphetamine production in Australia takes place
in practically all states though it is particularly concen-
trated in Queensland (35 per cent of all dismantled
amphetamines laboratories in 2004, followed by New
South Wales (20 per cent) and South Australia (20 per
cent)). In addition to locally produced methampheta-
mine, there are increasing imports of methamphetamine
produced in South-East Asia, notably in China and the
Philippines, offsetting some the decline in domestic
production. 
Methamphetamine production in Europe seems to be
rising, though continues to be limited…
Large-scale methamphetamine production and con-
sumption in Europe has – thus far - not occurred. Euro-
pean methamphetamine production continues to be
largely limited to the Czech Republic and, to a lesser
extent, neighbouring Slovak Republic, some of the
Baltic states and Moldova. The number of dismantled
methamphetamine laboratories in the Czech Republic
has increased strongly over the last decade, from 18 in
1995 to 28 in 2000, 188 in 2003 and 248 in 2004.
Large numbers of dismantled laboratories were also
reported from Moldova (136 in 2004), followed by Slo-
vakia (12 in 2004, up from 3 a year earlier). In addition,
limited  imports of methamphetamine from South-East
Asia (Thailand and Philippines) have been reported in
recent years. 
… while amphetamine production continues to be
largely concentrated in Europe – and increasing
Based on information on the origin of seized drugs, 88
per cent of the replies concerned European countries
over the 2002-2004 period, suggesting that ampheta-
mine production continues being concentrated in
Europe. The Netherlands, Poland and Belgium, fol-
lowed by Lithuania and Estonia, Bulgaria and Germany
are frequently cited as main sources of amphetamine. In
terms of amphetamine laboratories seized, Europe
accounted for 77 per cent of all such laboratories over
the 2002-2004 period. The number of amphetamine
laboratories seized in West and Central Europe
increased from 25, on average, over the 1995-99 period
to 35 over the 2000-2004 period (47 in 2004). The
increase has been even stronger in Eastern Europe
(Belarus, Moldova, Russia and Ukraine) where reported
laboratory detections increased from 11, on average,
over the 1995-99 period to 94 over the 2000-2004
period (141 in 2004). Theses data suggest that there is
a gradual shift of amphetamine production towards
Eastern Europe, even though amphetamine production
in West & Central Europe continues expanding. It is,
however, not always clear whether amphetamine or
methamphetamine is produced in Eastern Europe.
Both the Russian Federation and Ukraine have regularly
reported seizures of ephedrine but not of P-2-P. This
would indicate that amphetamines production in these
countries is largely focussed on methamphetamine. The
largest numbers of amphetamine laboratories seized
outside Europe are found in North America. In addi-
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Fig. 107: Origin* of amphetamine in 2002-2004
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tion, significant numbers of amphetamine laboratories
are seized in Oceania and a few in East & South-East
Asia. 
Markets in Africa and South-America mainly supplied
by diverted licit ATS
Overall production of ATS continues to be limited in
South America and in Africa. The main exception here
is South Africa where ATS production, notably produc-
tion of methamphetamine and methcathinone, has
increased substantially in recent years. South Africa used
to report, on average, the dismantling of one laboratory
per year over the 1995-1999 period. This figure
increased to 17 over the 2000-2004 period. Including
methcathinone, 28 illicit laboratories were reported (to
INCB) as having been dismantled in 2004 and this
number is expected to have further increased in 2005.  
Though domestic production of ATS  is very limited in
both Africa (with the exception of South Africa) and
South America, drug use surveys conducted in countries
of South America and Africa suggest, that ATS use is far
from negligible. All of this points to ongoing supply of
these markets with diverted licit ATS. 
While Netherlands and Belgium remain the most
important sources, ecstasy is also produced in regions
other than Europe   
Over the 2002-2004 period a total of 33 ecstasy pro-
ducing countries were identified by UNODC member
states. As in previous years the Netherlands (39 per
cent), followed, by Belgium (10 per cent) have been
cited by Member States as the main countries of origin
for ecstasy imports over the 2002-2004 period.
Together, the Netherlands and Belgium accounted for
about half of all mentions. But their importance as the
main source countries for ecstasy is declining. In 1999
the corresponding proportion of the two countries –
using the same methodology - was still 60 per cent.
There are additional indications that the position of the
Netherlands and Belgium as the world’s main source
countries for ecstasy are waning, reflecting intensified
efforts by the authorities in these countries to address
the problem. While in 2001 99 per cent of all 3,4-
MDP-2-P (PMK, the main ecstasy precursor) seizures
took place in the Netherlands and Belgium, the pro-
portion declined to 60 per cent in 2004 (37 per cent in
the Netherlands and 23 per cent in Belgium in 2004).
The number of ecstasy laboratories dismantled in the
Netherlands and Belgium declined from 29 (41 per cent
of the world total) in 2001 to 17 (20 per cent of the
world total) in 2004, including 14 laboratories in the
Netherlands and 3 in Belgium. In addition, the US
authorities (the USA constitutes one of the biggest
ecstasy markets worldwide) reported that the proportion
of ecstasy found in the USA, originating in the Nether-
lands, has declined substantially in recent years. 
The decline of ecstasy production in Western Europe,
however, appears to have been offset by increasing levels
of ecstasy produced in other countries, including other
European countries, countries in North America
(United States and Canada), in the Oceania region and
in East and South-East Asia. The number of dismantled
ecstasy laboratories in North America rose from 11 per
year over the 1995-1999 period to  24 per year over the
2000-2004 period (41 in 2004); in South-East Asia as
well as in the Oceania region the corresponding num-
bers rose from practically zero to 9 per year over the
2000-2004 period (24 in the Oceania region in 2004),
also indicating that a shift towards ecstasy production
outside the ‘traditional’ production centres in Europe is
gaining momentum. 
Most of the precursors for the manufacture of MDMA,
notably 3,4-MDP-2-P (PMK) originate in Asia. The
Chinese authorities were, however, successful in seizing
substantial amounts of PMK (5,300 litres or 31 per cent
of global PMK seizures). In addition, piperonal (a pre-
cursor for PMK) has gained in importance. 78 per cent:
of global piperonal seizures took place in China in 2004.
Moreover, safrole, another precursor for PMK, is
increasingly used as a pre-precursor for MDMA; accord-
ing to INCB, 97 per cent of all safrole seizures also took
place in China in 2004. 
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Fig. 108: Origin* of ecstasy in 2002-2004
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1.6.2. Trafficking      
After huge increases in the 1990s, ATS seizures continue
to decline in 2004... 
Seizures of ATS declined by 11 per cent in 2004 to 28
tons (in kilogram equivalents), mainly reflecting lower
seizures made in East and South-East Asia. The decline
is even more marked over the period 2000-2004 over
which seizures decreased by 80 per cent. Nonetheless,
even now ATS seizures are almost 4 times higher than  a
decade earlier and 6 times as high as in 1990. 
...due to lower seizures across East and South-East Asia 
The proportion of seizures made in East and South-East
declined from 73 per cent in 2000 to 25 per cent in
2004. Strong declines in ATS seizures over the 2000-
2004 period were reported from China (-86 per cent),
Singapore (-86 per cent), Brunei Darussalam (-73 per
cent), Thailand (-79 per cent), Hong Kong Special
Administrative Region of China (-76 per cent), Myan-
mar (-69 per cent), Malaysia (-48 per cent), Japan  (-46
per cent), Philippines (-26 per cent) and Indonesia (-16
per cent). Seizures in the Lao PDR remained stable and
increased in Cambodia, Viet Nam and Republic of
Korea. The overall decline of seizures in that subregion
suggests a sizeable reduction in production and traffick-
ing, possibly as a consequence of improvements in law
enforcement cooperation. 
Seizures of some 20 tons of amphetamines (metham-
phetamine, amphetamine and other synthetic stimu-
lants) were reported for 2004 of which most were made
in the United States (15 per cent of total), followed by
China (14 per cent), Belgium (13 per cent), Thailand
(10 per cent), United Kingdom (8 per cent)30, Bulgaria
(7 per cent), Mexico (5 per cent), Philippines (4 per
cent) and Netherlands (3 per cent).  
Some 8 tons of ecstasy were reported seized in 2004.
Canada and Belgium both account for 19 per cent of
the seizures made, followed by Australia (17 per cent),
the Netherlands (13 per cent) and United Kingdom (8
per cent)31.  
Methamphetamine continues to most widely seized ATS,
followed by ecstasy
Over the 2000-2004 period, methamphetamine
accounted for 62 per cent of all ATS seizures, ampheta-
mine for 14 per cent and non-specified stimulants
(including amphetamine, methamphetamine, meth-
cathinone and other synthetic stimulants) 7 per cent.
Substances of the ecstasy group accounted for the
remaining 17 per cent. In 2004, the proportion of
ecstasy as part of overall ATS seizures increased to 28 per
cent and the proportion of amphetamine to 21 per cent. 
While methamphetamine and amphetamine are, by far,
the two most important substances in the ampheta-
mines group, trafficking in methcathinone is signficant
in a number of CIS countries (where it is known as
ephedrone), in some parts of the United States, and, as
a rather recent phenomenon, in South Africa. Meth-
cathinone is usually domestically produced and traf-
ficked. 
Trafficking in fenetylline (captagon) continues to be
considerable in the Near and Middle East. Fenetylline is
often produced in clandestine laboratories in South-
Eastern Europe (mainly Bulgaria) and trafficked via
Turkey to Syrian Arab Republic, Jordan and Saudi
Arabia.     
In contrast to the ATS precursor trade which is interna-
tional, trafficking in amphetamine and in methamphet-
amine continues to be largely intra-regional, although
there are some exceptions (notably trafficking of
methamphetamine from South-East Asia to Oceania). 
Most ecstasy continues to be trafficked in Europe but
with the development of illicit markets for the substance
in other regions, trafficking of ecstasy to other regions
has increased. However, of late production of ecstasy has
been reported from North America, Oceania and
South-East Asia. If ecstasy production in regions outside
Europe rises, it is likely that, like for other ATS, ecstasy
trafficking will become (again) increasingly intra-
regional in nature.   
Trafficking in methamphetamine
Despite decline in seizures, most methamphetamine
continues to be trafficked in East and South-East Asia 
Global seizures of methamphetamine fell by 70 per cent
between 2000 and 2004 to 11 tons. This decline was
entirely due to lower methamphetamine seizures made
in East and South-East Asia (-82 per cent). This decline
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30 UK data refer to 2003.                                                                                                                                                                                  
31 UK data refer to 2003.
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appears to have been a reflection of an underlying
decrease in trafficking following the crack-down of sev-
eral ATS markets (notably Thailand in 2003), some
improvements in international precursor control, and
better cooperation among law enforcement agencies
across the region. A number of regional initiatives may
have also contributed to stem the upward tide experi-
enced in East and South-East Asia in the 1990s. Though
the proportion of methamphetamine seizures made in
East and South-East Asia declined from 89 per cent in
2002 to 76 per cent in 2003 and 58 per cent in 2004,
global trafficking in methamphetamine remains con-
centrated in this area. 
Most methamphetamine in South-East Asia is trafficked
within the region and some to Oceania and North
America. Methamphetamine from outside the region is
only rarely seized. Authorities  in the Republic of Korea
identified the United States as a source country, in 2003
and 2004. The important trafficking routes are: 
• from Myanmar to Thailand and to China, or from
Myanmar to Lao PDR, for transport to Thailand
or Cambodia or Viet Nam; smaller amounts also
appear to leave Myanmar for India for local use in
the north-eastern provinces;  
• from China to Hong Kong SAR of China, Philip-
pines, Malaysia, Republic of Korea, Japan;
• from Hong Kong SAR of China, to Japan, Aus-
tralia and Guam (United States); 
• from the Philippines to Republic of Korea,
Malaysia, Brunei Darussalam, Taiwan Province of
China, Japan, Australia,  United States (including
Guam) and Canada; 
• from Thailand to Malaysia, to Taiwan Province of
China, Republic of Korea, and to markets outside
the region. 
The most financially lucrative methamphetamine
market in the region remains Japan.  There are indica-
tions that methamphetamine continues being smuggled
into Japan from China, Philippines, Taiwan Province of
China as well as from Indonesia. US sources indicate
that there  have also been methamphetamine shipments
from the United States as well as several shipments from
Canada to Japan. While there are still suspicions that
some of the methamphetamine found on the Japanese
market emanated or was trafficked via the Democratic
People’s Republic of Korea (reported to UNODC in
2002/03), no new evidence emerged in 2004 or 2005.
Methamphetamine trafficking is rising in North
America
The proportion of North America in global metham-
phetamine trafficking has been rising in recent years,
from 10 per cent in 2002 and 21 per cent in 2003 to 38
per cent in 2004. Methamphetamine seizures increased
Fig. 109: Seizures of amphetamine-type stimulants, 
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Fig. 110: Breakdown of ATS seizures,  by substance, 
2000-2004 (N = 34 tons p.a.)
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from 1.6 tons in 2002 to 4.6 tons in 2003 before falling
slightly to 4.1 tons in 2004. 
Trafficking in North America is mostly targeting the
United States methamphetamine market. The bulk of
the methamphetamine used in the United States is
domestically produced and authorities in the United
States sees a decline in the domestic supply. However, it
appears that large laboratories have emerged in Mexico
which are essentially supplying the United States
market. The increase of methamphetamine seizures
along the along the US Mexican border (1.1 tons in
2002, 1.7 tons in 2003 and 2 tons in 2004) would con-
firm this trend. Mexico reported to UNODC that 99
percent of local production in 2004 were destined for
the US market. To a lesser extent, the United States
market is also supplied from Canada. 
Increasing seizures are reported – though from lower
levels – in other regions 
Methamphetamine seizures in Oceania, in Europe, in
the Near and Middle East and in Africa have shown an
upward trend over the last few years – albeit from low
levels. In Oceania, on the other hand, methampheta-
mine seizures declined in 2004, which appears to be
associated with some reductions of methamphetamine
trafficking in Australia. Though methamphetamine
seizures in Europe are still very small - Europe
accounted for just 2 per cent of global methampheta-
mine seizures in 2004 -  20 European countries reported
such seizures in 2004, up from 11 countries in 2000. 
Trafficking in amphetamine
Most amphetamine continues to be seized in Europe 
Amphetamine seizures increased to 6 tons in 2004, up
from 5.7 tons a year earlier and 3.1 tons in 2000.
Throughout the 2000-2004 period amphetamine
seizures made in Europe accounted for more than 90
per cent of the world’s total (96 per cent in 2004). How-
ever, this proportion for Europe may not be realistic as
a number of countries outside Europe classified their
amphetamine seizures under the broader category of
‘amphetamine-type stimulants’. 
Europe’s amphetamine seizures increased between 1980
and 1997, then declined until 2000 before rising again
and exceeding by 2004 the previous record high of
1997.  This pattern seems to reflect underlying traffick-
ing activities as seen in a number of additional indica-
tors, suggesting that amphetamine trafficking is, once
again, increasing in Europe. 
Though amphetamine seizures increased in West and
Central Europe in recent years, the proportion of these
seizures as part of global reported amphetamine seizures
declined, from 86 per cent in 2000 to 67 per cent in
2004. Most of the increase took place in South-East
Europe, with seizures rising from 7 per cent of the
world’s total to 26 per cent in 2004. This increase was
mainly due to rising seizures reported by Bulgaria. There
have also been increases in seizures reported by Poland
while seizures in the Netherlands declined from their
peak levels in 1998 and have been fluctuating at lower
levels over the 2001-2004 period. 
The Netherlands and Poland remained the most fre-
quently mentioned source countries for seized amphet-
amine in 2004. This was, in particular, the case in West
and Central Europe. In South-East Europe, in contrast,
this position is held by Bulgaria although Bosnia and
Herzegovina as well as Serbia and Montenegro appear to
have emerged as source countries in this subregion as
well. Most neighbouring countries of the Netherlands
and Belgium identified the two as the main source
countries. The same is true for Poland which is named
as a primary source by most of its neighbours. All of this
indicates that there are currently several production cen-
tres in Europe - producing for the local market and sup-
plying amphetamine, primarily, to neighbouring
countries.   
Fig. 111: Breakdown of methamphetamine seizures
in 2004 (N = 10.9 tons) 
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The United Kingdom continues to be Europe’s largest
amphetamine market. It has the largest number of
amphetamine users in Europe (as a rate and in absolute
terms) and for the past twenty years, most amphetamine
seizures have been reported from the United Kingdom.
Over the 2000-2004 period, important quantities were
also seized by the Netherlands and Bulgaria (11 per cent
each of the world total), Germany (8 per cent), Sweden
(6 per cent), Poland (4 per cent) and Belgium (4 per
cent). Seizures for 2004 have not yet been reported by
the United Kingdom. Assuming similar levels as a year
earlier, the United Kingdom is likely to have topped the
list again (some 26 per cent of the total) followed by
Bulgaria (24 per cent), the Netherlands (10 per cent),
Germany (9 per cent), Sweden (7 per cent), Poland (4
per cent), Norway (4 per cent) and the Russian Federa-
tion (3 per cent). 
Fig. 112: Breakdown of amphetamine seizures* by sub-region in 2004 (N = 6 tons)
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Fig. 113: Amphetamine seizures in Europe, 1980-2004
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Fig. 114: Global seizures of amphetamines*, 1994 - 2004
Year 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Metric tons 6          7          10        15        14        33        44        26        21        28        20         
* data refer to 2003
** total seizures reported by national as well as State & Territory law enforcement agencies which may result in double counting.
 * metric ton equivalents. 1 unit assumed to be equivalent to 30mg. 
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Trafficking in Ecstasy 
Ecstasy seizures rise to record high in 2004
Reported seizures of ecstasy increased by 87 per cent in
2004 and reached a new record of 8 tons (expressed in
kilogram equivalents), topping even peak levels
recorded in 2002 by 20 per cent.
Seizures of ecstasy rose across all sub-regions, with the
strongest increases reported from Southern Africa (+385
per cent) and the lowest in South America (+12 per
cent). Over the last decade, ecstasy seizures rose almost
7-fold or 21 per cent per year, a far higher growth rate
than for most other drugs.  
Most ecstasy continues to be trafficked in Europe,
followed by North America 
Out of total seizures of 8 tons, 51 per cent were made
place in Europe (mostly West and Central Europe), 22
per cent in North America, 17 per cent in Oceania and
5 per cent in East and South-East Asia. In addition,
ecstasy seizures were reported – in order of importance
- from Southern Africa, South-East Europe, the Near
and Middle East, South America, the Caribbean, East
Europe, North Africa, Central America, and South Asia.
Only three regions have not yet filed reports of ecstasy
seizures with UNODC: Central Asia, West & Central
Africa and East Africa.  
European share in global ecstasy seizures continues to
fall as production starts in other regions
The proportion of Europe in global ecstasy seizures
declined over the last decade, from 81 per cent in 1994
to 51 per cent in 2004; in 2003, Europe still accounted
for 58 per cent of global seizures. Together with other
information, this suggests that, over the last decade, the
expansion of ecstasy has been stronger in markets out-
side Europe. The proportion of ecstasy seizures rose
between 1994 and 2004:
• From 17 per cent to 22 per cent in North Amer-
ica;
• From 0.3 per cent to 17 per cent in Oceania; 
• From 0.2 per cent to 5 per cent in East and South-
East Asia; and 
• From 0.01 per cent to 2 per cent in southern
Africa.
However, there was no linear upward trend in these
regions. Notably in North America, the proportion of
ecstasy seizures, after having increased from 17 per cent
of global ecstasy seizures in 1994 to 33 per cent in 2000,
fell to 22 per cent by 2004 reflecting an overall declin-
ing ecstasy market in North America in recent years. 
The importance of the Netherlands and Belgium, tradi-
tional source countries for ecstasy appears to be declin-
ing, as production in other European countries grows.
Outside Europe, ecstasy production has been reported
from, inter alia, the United States, Canada, Australia,
China, Indonesia, Hong Kong SAR of China, and
South Africa. 
The intra-regional distribution of ecstasy within Europe
- like trafficking in amphetamine - seems to be carried
out by a large number of relatively small drug traffick-
ing groups that purchase the substance in the Nether-
lands and  Belgium and traffic the drugs to local
re-distribution centres across Europe.  
Trafficking of ecstasy from Europe to North America
and some other regions has been – for years - controlled
by criminal groups of Israeli origin, sometimes with
links to Russia, other European countries and the USA.
Israeli citizens have been part of international ecstasy
trafficking networks in source, transit, and distribution
countries and were found in several European countries
to serve as brokers and transporters of ecstasy to the
United States. These trafficking groups operate mainly
outside Israel, though in some instances, they have been
also involved in trafficking ecstasy from the Netherlands
Fig. 116: Breakdown of ecstasy seizures* by sub-  
region in 2004 (N = 8.1 tons)
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Source: UNODC, Annual Report Questionnaire Data / DELTA
and Belgium to Israel. 
Criminal groups from the Dominican Republic con-
tinue to be involved in shipping ecstasy in significant
quantities from Europe, often via the Caribbean to the
United States as indicated by recent reports from
Europol. 
The strongest expansion in recent years, however, has
been among Asian criminal groups, shipping precursors
from China to Belgium and the Netherlands for manu-
facture into ecstasy, and then trafficking the end-prod-
uct to Canada for further shipment to the United States;
more recently such Asian groups, have started traffick-
ing precursor chemicals from China and produce the
ecstasy in Canada, to supply major markets in the
United States. These groups are now also in the process
of building nation-wide distribution channels in the
United States, and are attempting to crowd out the
Israeli/Russian groups who controlled much of the
ecstasy business so far.  The emergence of these traffick-
ing networks may also explain why Canada, for the first
time ever, reported most ecstasy seizures worldwide in
2004, accounting for 19 per cent of global ecstasy
seizures, marginally ahead of Belgium.  Most of these
seizures were made in the process of detecting such clan-
destine laboratories.   
The third largest ecstasy seizures worldwide  were
reported from Australia in 2004, accounting for 17 per
cent of the total. Most of the ecstasy found on the Aus-
tralian market used to come from Europe. However, of
late, production of ecstasy in Australia appears to have
increased, as reflected in the dismantling of several large-
scale laboratories, with precursors imported from Asia,
mostly China. In addition, some ecstasy seized in Aus-
tralia also appears to originate from Asia. In 2004, Aus-
tralian seizures of ecstasy exceeded those of the
Netherlands (13 per cent of global seizures in 2004). 
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Fig. 117: Seizures of ecstasy in % of world total and 
kg - highest ranking countries – 2004
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 * total seizures reported by national as well as State & Territory law enforcement agencies which may result in double counting.
 ** data refer to 2003.
 * total seizures reported by national as well as State & Territory law enforcement agencies which may result in double counting.
 ** data refer to 2003.
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this group.
** 1 unit is assumed to be equivalent to 100mg of MDMA.
Fig. 118: Global seizures of ecstasy*, 1994 - 2004
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1.6.3. Abuse
The group of amphetamine-type stimulants (ATS)
encompasses amphetamines (amphetamine, metham-
phetamine), other synthetic stimulants (methcathinone,
phentermine, fenetylline etc.)  and substances of the
ecstasy group (MDMA and related substances such as
MDA). 
Amphetamines and other synthetic
stimulants 
Most methamphetamine  is used in South-East Asia and
North America  
Some 15 million people or more than 60 per cent of the
world’s amphetamines users live in Asia, most of whom
are methamphetamine users in East and South-East
Asia. The highest methamphetamine prevalence rates
worldwide have been reported from the Philippines. For
many years, Thailand reported the highest prevalence
figures for methamphetamine use, but this has changed
following the market crack-down in 2003.   
Highest annual prevalence rates of amphetamines use at
a the subregional level are reported from Oceania, fol-
lowed by East and South-East Asia and North America.
The Americas, notably North America, are the second
largest market for amphetamines, with more than 4 mil-
lion users. 
Amphetamine use widespread in Europe;
methamphetamine use limited
Europe is home to an estimated 2.7 million of amphet-
amines users. Although declines have been reported, the
United Kingdom continues to be the largest ampheta-
mine market in Europe. Methamphetamine use contin-
ues to be largely limited to the Czech Republic,
Slovakia, Estonia and Latvia.  Some reports suggest the
emergence of methamphetamine use in the United
Kingdom, albeit at very low levels. 
South Africa emerging as ATS market
The main emergent ATS market in recent years, has
been South Africa, where both methamphetamine and
methcathinone are produced and used. Otherwise,
amphetamines in Africa, like in South America, origi-
nate mainly from the diversion of various central nerv-
ous stimulants from licit sources.  
Fenetylline, locally known as ‘Captagon’, smuggled into
the region from South-East Europe,  continues to play
an important role in several countries of the Middle
East. 
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Table 13: Annual prevalence of amphetamines use, 2003-2005 
No. of users 
in % of population              
15-64 years
EUROPE 2,700,000 0.5
West & Central Europe 2,185,000 0.7
South-East Europe 180,000 0.2
Eastern Europe 335,000 0.2
AMERICAS 4,320,000 0.8
North America 3,190,000 1.1
South America 1,130,000 0.4
ASIA 15,250,000 0.6
OCEANIA 610,000 3.0
AFRICA 2,000,000 0.4
GLOBAL 24,880,000 0.6
Sources: Annual Reports Questionnaire data, various Government reports, reports of regional Bodies, UNODC estimates
Above global average Below global average Around global average
Global ATS market driven by Asia 
Expert perceptions of drug use trends, suggest that most
of the increase of ATS use - at the global level -  was
linked to higher use in Asia. The increase was particu-
larly pronounced over the 1992-2002 period, but has
since lost momentum.  Nonetheless, the perceived drug
use trend suggests that ATS use in Asia is still rising at
higher rates than in any other region.
However, Japan appears to be an exception, as declines
in methamphetamine use have been reported. The
ongoing fall in reported violations against the Japanese
Stimulants Law seem to confirm this view.   
Further declines were also reported by the Government
of Thailand. After a concerted effort against drug traf-
ficking in 2003, significantly lower rates of metham-
phetamine use were reported. Even if official household
survey data of 2005 reflect some under-reporting as a
result of the severity of crack-down on methampheta-
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Fig. 121: Twelve-year drug use trends, as perceived
by expert: ATS 
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Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 119 : Breakdown of amphetamines users by  
region
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Fig. 120: Reported violations against the Stimulants Law in Japan, 1950-2005
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mine, all other available indicators (including treatment
data and arrest data) point to sizeable drop in the
number of ATS users in the country.  
Use of ATS in the Americas reported stable but treat-
ment demand has grown
In 2004, expert perceptions of ATS use indicated a fairly
stable trend for the Americas. In the United States,
school surveys, an important indicator of emerging drug
use problems, have shown declines and general popula-
tion survey indicate a stable market. However, treatment
demand for methamphetamine abuse has increased dra-
matically. 
Against the background of such diverging indicators, it
is difficult to gauge the direction in which the metham-
phetamine market in the United States is actually
moving. What is, however, evident is that there is an
ongoing geographical spread of methamphetamine
across the country. While this used to be a localized
problem in the West of the United States (California,
Nevada and Oregon), abuse has gradually spread east-
wards over the last decade. 
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Fig. 122: Twelve-year ATS use trends as perceived by  
experts: Asia
Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Source: Treatment Episode Data Set (TEDS), 1993-2003.
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ATS drug use in Europe perceived to be growing   
ATS use in Europe is mostly amphetamine use. After
strong increases in the 1990s, the overall use level has
been relatively stable and below the global average. This
may, however, change soon, as increases in ampheta-
mine use have been reported since 2002.  This reflects
ATS use in Germany, Italy and a large number of Cen-
tral and East European countries, while a number of
other West European countries, including the United
Kingdom, France, the Nordic Countries as well as Spain
and Portugal reported stable or declining levels. 
ATS use in Africa remains constant – except for South
Africa 
ATS use does not seem to be a growing problem in
Africa. It grew in the 1990s, up until 1996, but seems
to have been rather stable in subsequent years, possibly
a reflection of some improvements in the control
regimes of a number of countries to prevent diversion of
licit ATS on to the market.  The main exception here is
South Africa which reported growing levels of both
methamphetamine and methcathinone abuse in recent
years, coming mainly from local clandestine manufac-
ture. 
Fig. 123: Twelve-year ATS use trends as perceived by
experts: Americas
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Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
Fig. 124: Twelve-year drug use trends as perceived
by experts: Europe 
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Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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Fig. 125: ATS use trends as perceived by experts:
Africa  
Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
Information Network for Asia and the Pacific (DAINAP), EMCDDA,
CICAD, HONLEA reports and local studies.
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In Oceania, ATS use is perceived to be declining
significantly 
Although Oceania continues to have the highest ATS
prevalence rate of any region, use of amphetamines have
shown significant declines over the past four years. Data
based on the testing of arrested persons across Australia
(Drug Use Monitoring in Australia) show a fairly stable
trend for 2005.   
Ecstasy use is still concentrated in Europe, though
gaining in importance in other regions   
There are more than 3 million ecstasy users in Europe,
accounting for almost 40 per cent of all ecstasy users
worldwide. The annual prevalence rate of ecstasy use is
highest in West & Central Europe (0.9 per cent of the
population age 15-64), exceeding that of North Amer-
ica (0.8 per cent), reflecting the decline of ecstasy use in
North America over the last few years. While drug use
trends in most of Western Europe are largely stable,
ecstasy use continues to rise in several East and South-
East European countries as well as Italy.  
Prevalence rates for ecstasy are still highest in Oceania
(3 percent) and increases have been reported from that
region. While prevalence of ecstasy continues to be low
in the whole of Asia (0.1%), East and South-East Asia
has been the main emerging ecstasy market over the last
few years. In addition, some countries in South Amer-
ica have reported rising levels of ecstasy use.  
Ecstasy use declines strongly in North America 
The most impressive decline in ecstasy use has been
reported from countries in North America. Following
strong increases in the late 1990s, school surveys in both
Fig. 126: Twelve-year ATS use trends as perceived by
experts: Oceania 
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Sources:  UNODC, Annual Reports Questionnaire Data,
Government reports, UNODC Field Offices,  UNODC’s Drug Abuse
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Table 14: Annual prevalence of ecstasy use, 2003-2005
Sources: Annual Reports Questionnaire data, various Government reports, reports of regional Bodies, UNODC estimates
No. of users 
in % of population              
15-64 years
EUROPE 3,177,000 0.6
West & Central Europe 2,815,000 0.9
South-East Europe 196,000 0.2
Eastern Europe 167,000 0.1
AMERICAS 2,686,000 0.5
North America 2,165,000 0.8
South America 522,000 0.2
ASIA 2,990,000 0.1
OCEANIA 616,000 3.0
AFRICA 191,000 0.04
GLOBAL 9,660,000 0.2
Above global average Below global average Around global average
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Ontario, Canada, and in the United States showed sig-
nificant declines in the levels of ecstasy use since 2000.
The decline seems to have been associated with a lower
availability of the drug, due to lower levels of ecstasy
trafficking from Europe, as well as with the perception
of an increased risk of potential users of the health haz-
ards related to ecstasy use.  
Fig. 127: Ecstasy use among high-school students in
the USA and in Canada (Ontario)
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2005 and CAMH,  Drug Use among Ontario Students, Toronto
2005  
149
1. Trends in world drug markets Amphetamine-type stimulants
Map 22: Use of amphetamines in 2004 (or latest year available)
> 1% of  population
Level of Abuse (Annual prevalence)
0.3 - 0.5% of  population
0.1 - 0.3% of  population
0.5 - 1%  of  population
Main manufacturing  areas
< 0.1%  of  population
Data not available
Map 23: Ranking of amphetamine-type stimulants in order of prevalence in 2004 (or latest year available)
Sources: UNODC Annual Reports Questionnaires data,  National Household Surveys on Drug Abuse, UNODC Rapid Assessement Studies, Council
of Europe, ESPAD.
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Map 24: Use of ecstasy in 2004 (or latest year available)
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2. CANNABIS: WHY WE SHOULD CARE
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The global community is confused about cannabis.  On
the one hand, cannabis is controlled with the same
degree of severity as heroin and cocaine under the Single
Convention on Narcotic Drugs, 1961. Virtually every
country in the world is a party to that Convention. On
the other hand, however, cannabis offences are treated
far more leniently than those related to other narcotic
drugs in many countries. A conflicting message is thus
sent to the population and it is no wonder that public
opinion becomes confused. 
Rather than confronting this schism head-on, cannabis
has been allowed to fall into a grey area. Technically ille-
gal but widely de-prioritized, the drug has grown in
popularity at a rate outpacing all others while simulta-
neously enriching those willing to break the law. A
global blind-spot has developed around cannabis, and in
this murk the plant itself has been transformed into
something far more potent than in the past. Suddenly,
the mental health impact of cannabis use has been
thrown into sharp relief, and the drug with which the
world has felt so familiar seems strange once again.
Coming to terms with cannabis is important because it
is, by quite a wide margin, the world’s most popular
illicit drug. An estimated 4 per cent of the world’s adult
population consumes it each year, more than all the
other illicit drugs combined. In some countries, more
than half of the young people polled have tried it.
Mankind has cultivated the plant for a variety of reasons
for centuries, and it has been the subject of reams of aca-
demic research in the last 50 years alone, including
recent studies of its therapeutic applications.
Given this wealth of knowledge and experience, it is
rather surprising that many basic facts about the drug
remain unknown. Concerned with the situation,
Member States requested UNODC, in General Assem-
bly resolution 59/160, to prepare a global market survey
on cannabis. However, when it comes to the mechanics
of the market, the world’s biggest illicit drug is actually
the least understood. In contrast to drug crops like coca
and opium poppy, very little is known about the extent
of cannabis cultivation around the world. In fact, few
Governments can confidently give an estimate of the
scale of cultivation in their own countries. In the United
States, for example, a country with both resources and a
strong infrastructure for drug control, official estimates
of the extent of domestic cultivation vary by more than
a factor of six. Even if the number of hectares under
cannabis were documented, there has been little study of
how much drug product these fields would yield. As a
result, global production estimates remain highly tenta-
tive.
There are several reasons why these questions are so dif-
ficult to answer. Unlike other drug crops, cannabis can
be grown virtually anywhere, including indoors, and
there are very few countries where it can be definitively
said that cannabis is not cultivated. Moreover, cannabis
is both easy to grow and highly productive, yielding a
large quantity of ready-to-use drug per plant. As a result,
many users can, and do, produce their own supply. Cur-
rent illicit crop monitoring techniques, such as satellite
surveillance, are of little use in assessing cultivation
taking place in private homes and small plots in com-
munities spread across the globe. In addition, there
remain unanswered questions about basic aspects of
cannabis use, such as the precise amounts bought and
consumed by users.
Many of these issues could be cleared up with appro-
priate targeted research. The fact that this research has
not been done reflects the global ambiguity on cannabis.
These political attitudes reflect popular perceptions that
cannabis is different from other controlled substances.
Indeed, many of the risks associated with other illicit
drugs are not an issue with cannabis. It is nearly impos-
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2.1. Introduction
sible to die of an overdose of cannabis. Because it is rel-
atively cheap in most markets, crimes associated with
acquiring money for cannabis dependency are limited.
In many parts of the developed world, cannabis is
regarded as a soporific, and the behaviour of the intox-
icated as humorous, not dangerous. For many, it is a
point of faith that cannabis is harmless, the victim of
relentless disinformation.
It is true that much of the early material on cannabis is
now considered inaccurate, and that a series of studies
in a range of countries have exonerated cannabis of
many of the charges levelled against it. But the latest
research indicates that the pendulum may have swung
too far in the opposite direction. There are serious
mental health consequences associated with cannabis,
including a significant risk of dependency, precipitation
and aggravation of psychosis, and acute dysphoric
episodes. These risks appear to be higher for people who
start consuming cannabis during adolescence. Each
year, thousands of people seek medical attention for
problems related to their cannabis use, and this number
appears to be growing. Cannabis is not the harmless
herb often portrayed, but a psychoactive drug that
deserves to be taken seriously.
One reason these serious effects are only being appreci-
ated now is that they appear to be related to the growth
of high-potency cannabis in many countries where such
research is commonly done. For the last several decades,
cannabis breeders and cultivation experts have laboured
to transform the plant, creating a much more potent
and productive version of the drug previously reviewed.
These developments were reviewed, along with other
aspects of the cannabis market, in a double issue of the
Bulletin on Narcotics (Volume XLIX, Nos.1 and 2, 1997;
Volume L, Nos.1 and 2, 1998). The situation has
advanced considerably since that time. High-potency
cannabis may be responsible for the growing number of
people seeking help for cannabis problems in developed
countries around the world. Although most of the
cannabis consumed globally is grown the traditional
way, the problems associated with the ‘new’ cannabis
may simply be large-print versions of issues not recog-
nized before.
2.2. The world’s biggest drug market is
growing and uncharted
All available indicators suggest that global cannabis pro-
duction, after having fallen in the late 1980s (mainly
due to large-scale eradications in Latin America), rose
again in the 1990s and continues rising in the new mil-
lennium. The volumes of cannabis seized by the police
internationally have been increasing since the early
1990s, and surveys show that global demand has also
increased. An estimated 162 million people used
cannabis in 2004, over 10 per cent more than in the late
1990s.  According to expert opinions solicited from
Member States in 2004, far more countries felt that
cannabis use was increasing (59 per cent of 97 countries
responding) than declining (13 per cent) in 2004. In the
last decade, the consensus is that cannabis use has been
growing faster than the use of cocaine or opiates.
Exactly how widespread is cannabis cultivation?  One
way to find out is to ask the law enforcement authori-
ties in every country in the world whether cannabis is
grown in their country, and this is precisely what the
UNODC does. Each year, UNODC receives responses
from Member States to its Annual Reports Question-
naire (ARQ), a survey of national Governments on their
local drug situations. The ARQ contains questions
about the extent of cannabis cultivation and use.  Most
are unable to give estimates on the extent of cannabis
cultivation in their countries, and those that do often
give questionable responses. But quite a few admit that
cannabis is produced in their countries, and their other
responses are revealing as well.
Over the 1994-2004 period, 82 countries provided
UNODC with cannabis production estimates. For
comparison, only six provided estimates for coca-leaf
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Fig. 1: Global cannabis seizures
production. But the fact that a country did not provide
an estimate does not mean that no cultivation exists, as
some countries simply lack the capacity to come up with
accurate estimates. Luckily, there are other ways of iden-
tifying cannabis producing countries. 
In the ARQ, Member States are also asked to identify
the national source of the cannabis consumed in their
countries. This evidence is often based on considerable
experience in the field, and its value should not be
underestimated. On this basis, 142 producer countries
can be identified. 
A third list of producer countries can be generated by
singling out those that report the seizure of whole
cannabis plants. It is extremely inefficient to transport
whole plants internationally, as only certain parts are
useable as a drug. Thus, when a whole plant is seized, it
is very likely that it was locally produced. Seizures of
whole cannabis plants were reported in 141 countries
during the 1993-2004 period. Combining these three
lists results in the identification of some 176 countries
and territories where cannabis is produced, out of 195
countries reporting (90 per cent).
Of course, evidence of some cultivation does not mean
the practice is large in scale. Many of these 176 coun-
tries produce primarily to satisfy local demand, but
there are a number of countries that produce for mass
export. For example, Paraguay produces much of the
herbal cannabis consumed in its neighboring countries,
and European production hubs include Albania and the
Netherlands.  Much of the world’s resin supply comes
from Morocco and Afghanistan. Other significant
exporters include:
• in Africa: Nigeria, South Africa, Malawi, Lesotho,
Swaziland
• in the Americas: Mexico, Canada, Jamaica,
Colombia 
• in Central Asia: Kazakhstan, Kyrgyzstan 
• in the Middle East: Egypt, Lebanon
• in South Asia: India, Pakistan
• in Southeast Asia: Cambodia, Thailand, Philip-
pines
More cannabis herb is seized, and it is seized in a wider
range of locations, than any other drug in the world,
although 90 per cent of global seizures by weight occur
in just eight countries. Global cannabis herb seizures
were over 6,000 metric tons in 2004, and 135 countries
reported seizures of cannabis herb, more than for
cocaine (119), heroin (114), cannabis resin (83), ecstasy
(69), and amphetamines (47). Cannabis herb seizures
have been rising continuously over the past decade, and
were 162 per cent higher in 2004 than in 1994.
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Types of cannabis
Several drug products can be produced from
cannabis, falling into three main categories: 
• 'herbal cannabis', the leaves and flowers
of the plant, also known as 'marijuana',
'ganja', and a host of other names;
• 'cannabis resin', the pressed secretions of
the plant, commonly referred to as
'hashish' in the Western countries or
'charas' in India. 
• 'cannabis oil'. 
Herbal cannabis is most popular in North
America and most of the rest of the world,
while cannabis resin is most popular in much
of Europe and a few traditional  resin-produc-
ing regions.
India
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Fig. 2: Country shares of global herbal cannabis
seizures in 2004
In recent years, most of global cannabis herb seizures
have occurred in North America (with Mexico, United
States, and Canada accounting for 52 per cent in 2004),
usually followed by Africa, Latin America, and Europe.
This has not always been the case: North America was
only responsible for 32 per cent of global seizures in
1990. As the chief supplier to the North American
market, Mexico is the perennial world leader in
cannabis seizures, seizing 2,164 tons or 35 per cent of
the global total in 2004. Africa’s share has been increas-
ing and Latin America’s declining over the last 15 years.
But seizure figures also depend on the attention given by
national law enforcement authorities to drug interdic-
tion.  While seizures give an idea of the minimum of the
amount of the drug present in a society, the lack thereof
does not discount the possibility of substantial markets,
and it is never clear how much the tip constitutes of the
iceberg. Global seizure figures do show that cannabis is
everywhere, though the specifics of any given market
remain rather obscure. The following quick tour of
cannabis throughout the world underscores the diversity
and the ubiquity of this drug. 
Cannabis is everywhere
North America: the world’s biggest cannabis market
In financial terms, there can be little doubt that North
America constitutes the world’s largest cannabis market.
With high prices and a large user base, the North Amer-
ican market alone has been valued at US$ 10 billion to
60 billion, depending on the underlying production
estimates. Most of this demand is satisfied by North
American production.1 It is also one of the best under-
stood markets, due the attention paid to the issue by the
United States government in particular. Estimates made
available to UNODC suggest that North America
accounts for about one third of global production, or
14,000 metric tons. 
Judged simply on the basis of seizures, Mexico would
appear to be the largest herbal cannabis producer in the
world, responsible for a reported 36 per cent of the
cannabis seized globally in 2004, over 2,000 metric
tons. Cannabis production was estimated at 13,500 tons
in 2003, declining to 10,400 tons in 2004, with a cor-
responding decline in cultivation area from 7,500
hectares to 5,800 hectares.2
Such wide-scale production calls to mind images of
sprawling cannabis plantations, but, remarkably, most
Mexican cannabis production occurs in small concealed
plots averaging less than 1,000 square metres.3 This is
due to the country’s intensive eradication programme,
which destroyed an estimated 31,000 hectares in 2004.
If these estimates are correct, upwards of 80 per cent of
all the cannabis cultivated in Mexico is destroyed each
year, and the large United States market is primarily
supplied by the residual 20 per cent. 
The Mexican authorities divide cannabis production
into two major zones: the Pacific region, responsible for
52 per cent of production, and the Central-North area,
responsible for 47 per cent. In recent years, the share
cultivated in the Pacific has declined, and that in the
Central-North area has increased. The Mexican govern-
ment says they have eradicated almost all of the crops
located in the top 10 producer provinces since 1994,
but that residual areas remain in the Sierra Madre
mountains.4 Cultivation micro-regions occur in a long
arc through the Sierra Madre Occidental to the Sierra
Madre del Sur, roughly coincident with the opium pro-
ducing areas. The Government of Mexico estimates that
70 per cent of its cannabis is destined for the United
States and 30 per cent for local markets.5
This would suggest that about 3,000 tons of cannabis
are reserved for domestic use. Current estimates of
cannabis consumption among the adult population,
based on a 2002 survey, indicate that only 1.6 per cent
of the population uses cannabis annually.  This allows
nearly 2 kilograms of cannabis per user per year, or 5
grams per user per day, equivalent to about 10 Ameri-
can-sized joints, which appears to be much too high.
Either the production figures are exaggerated, the esti-
mate on the share of production remaining in the coun-
try excessive, or the number of users is greater than the
survey data would indicate. Given the volume of drugs
in the country, the latter explanation is the most likely.
The United States ranks second in seizures of herbal
cannabis, seizing some 1,118 metric tons in 2004, an
estimated 18 per cent of the world’s total. While culti-
vation has been discovered in every one of the country’s
50 states, most of the large-scale cannabis production
seems to be concentrated in just a few areas. Eradication
reached a new high in 2005 to over 4 million plants
seized, with counts highest in California, Kentucky,
Tennessee, Hawaii, and Washington.6 This is a different
profile from previous decades, where the Midwest
played a more prominent role. 
In recent years, much of the outdoor production in the
United States has been found in so called ‘guerrilla
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grows’ on public lands, such as the national forests and
parks of California and Kentucky. As enforcement
strengthens in California, outdoor cultivation has
moved to public lands in Oregon and Washington.7
Rangers eradicating crops on public lands in California
are frequently met with violent resistance from the
organized crime groups controlling the trade, and booby
traps on guerrilla grows are not uncommon. 
US authorities claim that domestic cannabis production
is increasingly controlled by Mexican organized crime
groups. While polls conducted in the United States sug-
gest that much of cannabis cultivation and distribution
takes place via social networks, a more than US$10 bil-
lion market attracts organized crime elements. A recent
assessment of gang activity in the United States found
that 65 per cent of law enforcement agencies polled said
that gangs were involved in the distribution of cannabis
in their areas, a much higher share than for any other
drug.8
The lack of consensus on the amount of cannabis pro-
duced in the United States highlights the fact that even
countries with sophisticated monitoring systems strug-
gle to come up with credible estimates of the extent of
domestic cannabis cultivation. One government esti-
mate placed production at between 3,100 and 7,100
metric tons in 2004,9 but other figures have placed it as
high as 19,000 tons.10 The high end of these estimates
is very difficult to reconcile with what is known about
global production. The International Narcotics Control
Board, in its annual report for 2005, suggests that
10,000 tons of cannabis are produced each year in the
United States, a significant share of the global total.11
Some 11 per cent of the US population over the age of
12 uses cannabis annually, including 28 per cent of
people aged 18-2512 and over a third of children in their
final year of high school.13 The United States Office of
National Drug Control Policy has estimated that these
users consumed, on average, a remarkable 19 joints a
month containing 0.4 grams of cannabis in 2000, for a
total consumption of over 1,000 metric tons of
cannabis. While the amount of cannabis consumed per
user seems remarkably high, given that a large share of
these are casual users, the total consumed is rather low,
about a third of the lowest estimates of domestic pro-
duction alone, let alone imports. 
In the past, both Jamaica and Colombia were major
suppliers of cannabis to the United States, but it would
appear that both have been displaced by the rise of Mex-
ican organized crime to its current position of domi-
nance, and the growth of Canadian production. Jamaica
is still a major supplier to the rest of the Caribbean,
along with St Vincent and the Grenadines.
In Canada, an estimated 960 to 2,400 metric tons of
cannabis are produced annually.14 Canada has also
stepped up enforcement, seizing 1.1 million plants per
year between 1998 and 2002, a six-fold increase over
1993.15 Cannabis of Canadian origin is trafficked
mostly to the United States but reportedly also to Asia,
including Taiwan Province of China and Japan.
Formerly, most of Canadian production had been con-
centrated in British Columbia, but this is no longer the
case. Seizure and eradication figures suggest that
Ontario and Quebec have recently caught up, and,
more recently, major operations have been detected in
other provinces.16 At present, about 40 per cent of
Canada’s cannabis is produced in British Colombia,
with 25 per cent coming from Ontario, 25 per cent
from Quebec, and 10 per cent from other provinces.17
In Canada, most of the medium and large cannabis pro-
duction operations are controlled by organized crime.
Outlaw Motorcycle Gangs, such as the Hell’s Angels,
control outdoor and hydroponic (plants grown indoors
in a nutrient bath, rather than soil) grows, while Viet-
namese groups control indoor organic (soil-based) pro-
duction.18 Previously, cross-border trafficking was
conducted by small-scale traffickers, and the growth of
organized crime involvement is reflected in the growing
size of shipments across the border.19 Money derived
from cannabis operations may be allowing minor organ-
ized crime groups to graduate to weapons and explosives
trafficking, cocaine smuggling, and stock-market fraud. 
The Americas as whole are estimated to have a cannabis
production of around 24,000 metric tons.
Africa: Massive seizures, uncertain origins
With an estimated production of 11,000 metric tons,
Africa is the second largest producer of herbal cannabis
in the world. After North America, Africa leads the
world in herbal cannabis seizures and is growing in
importance: in 1990, only 16 per cent of world
cannabis seizures were made in Africa, but by 2004, it
was more than 30 per cent. In 2004, 818 metric tons of
herbal cannabis were seized in South Africa alone, rank-
ing third in the world, after Mexico and the United
States. 
Production takes place in all sub-regions in Africa, with
major seizures being made in North Africa (Morocco
and Egypt), West Africa (Nigeria and Ghana), East
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Africa (Tanzania and Kenya), and Southern Africa
(South Africa, Swaziland, Lesotho, Malawi, and
Zambia).  Much of this product is consumed on the
continent, as an estimated 8 per cent of African adults
consume the drug each year, but there are also substan-
tial exports to Europe, and, to a lesser extent, to Asia. 
Morocco is the world’s largest producer of cannabis
resin, and possesses the largest documented cannabis
cultivation area. Morocco produces about 80 per cent of
the resin consumed in Europe,20 and Western Europe
was responsible for about 74 per cent of global seizures
in 2004.
The Government of Morocco, in cooperation with
UNODC, has conducted comprehensive cannabis resin
surveys of the country for the last three years. The 2003
survey placed total resin production at about 3,070
tons, cultivated on 134,000 hectares of land in the Rif
region by some 96,600 families, providing income for
about 800,000 people. The 2004 survey showed a 10
per cent decline in the land dedicated to cannabis culti-
vation (120,500 ha), with production falling to 2,760
tons. Drought, combined with eradication efforts,
resulted in a strong decline in production in 2005.
In 2004, the total gross farmers income from cannabis
cultivation is estimated at about US$325 million. Based
on an estimate of some 804,000 persons benefiting
from cannabis cultivation in the Rif region, this repre-
sents a gross per capita income of US$400, well below
the country’s overall 2003 GDP per capita of US$
1,478. Clearly, cannabis production in Morocco is the
recourse of poor farmers, who do not make a great deal
off the trade.
Aside from Morocco, credible estimates of the number
of hectares under cannabis cultivation are difficult to
find in Africa. In South Africa, the best developed coun-
try in sub-Saharan Africa, estimates vary, but are gener-
ally between 1,000 and 2,000 hectares, located mostly
along the east coast of the country. Most plots are small,
averaging about 300 square metres.21 South Africa is a
significant source of cannabis exports to Europe. For
example, in 2004, the Republic of Ireland reported that
99 per cent of the cannabis consumed in their country
comes from South Africa.
It is estimated that 70 per cent of the cannabis entering
South Africa was grown in Lesotho, and cannabis is esti-
mated to be Lesotho’s third largest source of income.
Fields are rarely larger than one hectare, and the plant is
grown alongside corn. As in South Africa, small farmers
sell their produce to wholesalers, who consolidate the
many small inputs for trafficking, and multiple harvests
are claimed. All but the main harvest are rather unim-
pressive, however, with plants remaining rather small.
Swaziland is known for producing high-quality
cannabis. The seed stock has been marketed interna-
tionally. In 2001, the Swazi police noted cannabis traf-
ficking to the United Kingdom, the United States, the
Netherlands, and Japan,22 and this situation does not
appear to have changed much more recently. The Swazi
authorities eradicated between 400 and 500 hectares
annually between 2001 and 2003.
Malawi is also world renowned for the quality of its
cannabis. About three to nine tons are seized annually
in this small, under-policed country of about 13 million
people, suggesting a substantial export market.
Cannabis is also grown for export in West Africa,
notably in Nigeria, Ghana, and Senegal. Cannabis is
presently cultivated in all 36 states of Nigeria,23though
the plant was only introduced to the area following
World War Two24 “Operation Burn the Weeds” was
launched in 1994, and has become the title of Nigeria’s
ongoing eradication program.25 After a peak in the late
1990s, relatively little area was eradicated in the first
years of the 21st Century, contrary to some interna-
tional reports. Preliminary figures from the 2005 eradi-
cation effort suggest that renewed attention is being
given to the matter. Cannabis of Nigerian origin is
known to be trafficked to other West African countries. 
Nigeria reported the second largest cannabis herb
seizures in Africa (after South Africa) in 2004. 
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Fig. 3: Hectares of cannabis eradicated in Nigeria
Ghana has one of the highest known rates of annual
cannabis use, with an estimated annual prevalence of 22
per cent in 1998. Ghana’s cannabis production has
expanded greatly since the 1960s,26 and it has been
named as the source of a number of recent major
seizures (in excess of one metric ton) of herbal cannabis
destined for Belgium and the United Kingdom. The
Belgian authorities estimate that 25 per cent of the
cannabis trafficked into their country comes from
Ghana, and Ghana is listed as a major supplier to Italy,
after Albania. 
In Senegal, the distribution of cannabis is mostly
regional, with Dakar, other urban centres in Senegal,
and Gambia being significant outlets.27 Cannabis traf-
ficking has reportedly been a source of funding for the
insurgents of the Movement of the Democratic Forces
of Casamance (MFDC), though its relative importance
has been debated among experts.28 It has been claimed
that the Liberian National Patriotic Front for Liberia
traded guns for MFDC cannabis.29
There is also documented production of cannabis resin
in Senegal, although the extent to which this product is
trafficked internationally remains unclear. In 2003, the
German police seized 2.7 tons of cannabis resin in a
motor home in Hamburg, which they say originated in
Senegal and transited Mauritania and Morocco. Its ulti-
mate destination was said to be the Netherlands.30 The
country has also been the source of a number of signif-
icant seizures of resin of unknown origin destined for
Belgium, typically concealed in vehicles such as campers
and trucks. Resin has been seized coming into Senegal
from both Morocco and Afghanistan, so it is unclear
how much of this is locally produced.
In East Africa, fairly large-scale cannabis cultivation
occurs in Kenya, primarily in the Lake Victoria basin, in
the central highlands around Mt. Kenya and along the
coast. As much as 1,500 hectares of cultivation have
been estimated in this area, some in the lower farmlands
concealed among traditional crops and smaller cultiva-
tion in the higher reaches in areas regarded as national
wildlife reserve.31 Despite two successful, highly publi-
cized targeted raids of 14 farms along Mt. Kenya in
2001 and 2002 that collectively destroyed 461 tons of
cannabis, police saw an increase in this crop during tar-
geted raids in 2004. 
Cannabis is cultivated in ten of the 20 regions of main-
land Tanzania, especially in those near the international
borders, and police believe that as many as half of the
families in these ten regions of the country are involved
in the cultivation of cannabis.32 Seizures have been
impressive, though erratic, with an unbelievable haul of
733,222 kilograms in 2003. From January through June
2004 the Tanzanian government destroyed over
230,000 kilograms of cannabis, nearly as much as the
annual total in the previous record year, in 2001.33
According to official reports, 80 per cent of the cannabis
in Tanzania is grown domestically, with 20 per cent
being imported from Malawi, and 90 per cent of locally
produced cannabis is consumed locally.34 This is
remarkable because estimates on the prevalence of
cannabis use in Tanzania, based on 1999 survey data, are
very low (0.2 per cent). It is likely that the user popula-
tion has grown in the last seven years, since over 5,000
people were arrested for cannabis-related matters in
2003 and over 2,000 people were arrested for dealing
cannabis in the first half of 2004 alone.35 Still, the
extent of transhipment is probably being underesti-
mated, although the destination of this traffic is
unknown.
South and Central America: Too much production, too few
users?
South America contains two major exporting countries,
one that exports beyond the region (Colombia) and one
that exports primarily for regional consumption
(Paraguay). South America is unusual in having high
levels of seizures and, according to surveys, low levels of
domestic use. Only one South American country has
reported an annual adult cannabis use level above the
global average: Chile (5.3 per cent in 2004). 36 Chile is
one of the most developed countries with the lowest
crime levels in the region, and has one of the lowest
levels of seizures. But Brazil (with 1 per cent of the pop-
ulation 12-64 reporting cannabis use in 2001), Colom-
bia (1.9 per cent estimated), Paraguay (0.5 per cent
estimated), Argentina (1.9 per cent estimated), and
Bolivia (2.2 per cent estimated) all made it to the top 20
nations in terms of the weight of cannabis seized in
2004. If the survey figures are correct, either interdic-
tion rates are extremely high, or much of the cannabis
cultivated in the region is exported. With the exception
of Colombia, however, none of the nations is known to
export cannabis in any great quantity outside the region.
High regional levels of production with low levels of use
pose something of a puzzle. For example, only 1 per
cent of the population age 12 to 65 in Brazil reported
using cannabis in 2001, a total of just over 1 million
annual users. But looking just at the amounts seized,
nearly 200 metric tons of herbal cannabis were found in
the country in 2002, for an average of about 200 grams
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seized per user for the year. In addition, almost 2.5 mil-
lion plants were eradicated that year. If these had been
missed, they could have produced another 250 tons,
raising the per user production to almost half a kilo
apiece. This is more than a joint a day apiece, which is
probably more than was actually consumed by these
annual users, many of whom use only occasionally. And
this is just the amount destroyed, likely a fraction of the
total present in the country. Unless interdiction rates are
above 50 per cent, these figures suggest an export
market, but Brazil is not known to be a major exporter
of cannabis. In fact, it is a major importer; officials argue
that most of the cannabis consumed in the country
comes from Paraguay, with only 20 per cent being pro-
duced locally.37
Most Brazilian cannabis is grown in the Northeast of
the country, although estimates of the land under culti-
vation vary widely, from 3,500 hectares to 118,000
hectares. Production is said to involve plantation style
operations, utilizing forced labour, with connections to
urban organized crime.38 Cannabis grown in Brazil sup-
posedly has a 90-day production cycle, allowing three to
four annual harvests in the irrigated areas of the North-
east and three harvests in the rain-fed areas of the North.
Farmers are estimated to make as much as US$ 150 per
month (average) by growing cannabis. The price of 1 kg
of cannabis at the producer level is less than US$ 30.
This can be sold for approximately US$ 220 on the
streets.39
In a school survey of seven Latin American countries,
Paraguay had the second lowest levels of annual
cannabis use (1.7 per cent), and cannabis was only the
second most popular drug, after jarra loca (a mix of wine
and tranquilizers)40 and its estimated adult use levels are
the lowest in Latin America. Yet only Brazil and Colom-
bia claim higher seizures that Paraguay, with about 80
tons seized per year, or about 1.3 kilograms for each of
about 60 thousand annual users. Aside from being the
primary supplier of Brazil, law enforcement officials in
Argentina, Chile and Uruguay all claim that nearly all
their cannabis comes from Paraguay. So a lot of the
cannabis grown in Paraguay goes out of the country, but
it is still surprising that a country with so much pro-
duction per capita would have so little local consump-
tion.
Paraguay contains an estimated cultivation area about
the same as that in Colombia – around 5,500 hectares.
In 2004, the Paraguayan government eradicated 753
hectares of this area.41 In 2005, authorities estimated
total land area under cultivation to be 6,000 hectares,
producing 15,000 tons of cannabis in two harvests of
3,000 hectares each.42 If these estimates are accurate,
Paraguay is producing about a third more cannabis than
Mexico, and is likely the world’s largest producer of
herbal cannabis, responsible for a good share of global
production.  The destination of this massive supply is a
mystery, as estimates indicate very small user popula-
tions, and Paraguay is not known to export beyond the
continent. According to Paraguayan law enforcement
162
World Drug Report 2006 Volume I. Analysis
0.5
1.0 1.3
1.5 1.6 1.8
1.9 1.9 2.0 2.2 2.2
2.6
3.0 3.3
4.0 4.0
5.0
5.6
9.1
0
2
4
6
8
10
Pa
ra
g
u
ay
Br
az
il
C
os
ta
 R
ic
a
U
ru
gu
ay
H
on
du
ra
s
Pe
ru
A
rg
en
tin
a
C
ol
om
bi
a
Su
rin
am
e
N
ic
ar
ag
ua
Bo
liv
ia
 
G
uy
an
a
Ec
ua
do
r
V
en
ez
ue
la
Pa
n
am
a
G
lo
ba
l a
ve
ra
ge
El
 S
al
va
do
r
C
hi
le
G
ua
te
m
al
a
Source: UNODC DELTA Database Estimations
Fig. 4: Share of the adult (15-64) population using cannabis annually in South and Central America
authorities, 85 per cent is destined for the Brazilian
market, 10 per cent-15 per cent for other Southern
Cone countries, and 2 per cent-3 per cent for local con-
sumption.43 Paraguayan authorities estimate the yield of
cannabis crops at an incredible three metric tons per
hectare,44 attributable in part to the development of a
strain of cannabis that can be grown in the dry months
of the winter.45 Paraguay also produces a form of
cannabis resin – cera Paraguaya – for export to
Argentina and Brazil.
Colombia has long been the region’s primary exporter of
cannabis. In the 1970s, when Colombian exports to the
United States were at their peak, some 30,000 hectares
were estimated to be under cannabis. More recently, the
United States has estimated that 5,000 hectares have
been under cannabis cultivation every year since 1996,
with a potential yield of about 4,000 metric tons, of
which less than 6 per cent has ever been seized in
Colombia.46 In 2003, Colombia reported eradicating
20 hectares, and estimated that 2,000 remained for pro-
duction. Colombia also eradicated some 11,000
cannabis plants in three major cases in 2003.
Chile, the country with the highest per capita use levels
in the region, destroyed nearly 80,000 plants in 2003
(about 8 tons of potential cannabis), showing sizeable
domestic production, mostly in the centre of the coun-
try. The Chilean government estimates local production
capacity at about 80 tons, suggesting a 10 per cent erad-
ication rate. Despite this, it estimates that 78 per cent of
its supply comes from Paraguay, some 20 per cent of the
cannabis consumed locally is of unknown origin, and
about 2 per cent is from Peru. Some four tons were
seized in 2003, and since Chile is not an obvious traf-
ficking route to anywhere, they were probably intended
to be consumed in the country.
While cannabis is cultivated and used in most Central
American countries, exports are small and interdiction
capacity is limited. In 1995 and 2000, the Inter-Amer-
ican Observatory on Drugs described Central American
seizures as ‘insignificant.’47 But Costa Rica, a country
with just over four million citizens, claims to have erad-
icated about two million plants in 1999, 2000, and
2001, and about one million in 2002 and 2003, enough
for 100 to 200 tons of production.48
Oceania: The world’s highest use levels?
Cannabis grows wild on many of the region’s countries
and territories, including Australia, Fiji, Federated States
of Micronesia, New Zealand, Papua New Guinea, and
Samoa, as well as in American Samoa.49 Most countries
are self-sufficient in terms of their cannabis supply, and
there is little evidence of widespread cross-island traf-
ficking in Oceania today.
In Australia, an estimated 5,000 hectares of cannabis are
cultivated in the outdoors,50 often on public lands, but
the most commonly detected method of cultivation is
actually indoors.51 Almost all cannabis used in the coun-
try is locally produced. Cannabis trafficking to Australia
has declined greatly in recent years, due in part to law
enforcement efforts and in part to growing domestic
production, particularly indoor production. In 1996/7,
over 24 tons of cannabis were seized at Australia’s bor-
ders52. In contrast, in 2003/4 total seizures of cannabis
entering the country amounted to only 15.3 kg, with an
average weight of less than 25 grams per detection.53
Most of the cannabis produced in New Zealand is used
domestically. Crops are regularly eradicated, destroying
about a half a million plants annually.54 Most plots are
situated in the more remote areas of the North Island.
There appears to be a relationship between cannabis cul-
tivation operations and the manufacture of metham-
phetamine – the New Zealand authorities report
locating seven clandestine methamphetamine laborato-
ries during the course of a two-month spraying opera-
tion.55
In Papua New Guinea, cannabis and annual use levels
are believed to be among the highest in the world (30
per cent of those aged 15-64 in 1995, the latest survey
available). The country produces Nuigini Gold, a dis-
tinct cultivar characterised by its red stem. Nuigini Gold
was formerly exported to Australia, but is no longer
widely available in that country.  In 2002, it was
reported that firearms were being traded for the drug,
fuelling high level of violence among local communities,
but these accounts have more recently been discred-
ited.56 In 1998/1999, Papua-New Guinea was the
embarkation point for 30 kg of cannabis intercepted by
Australian Customs, but by 2003/4, this figure was less
than one kilogram.57 Cannabis is produced in remote
areas of the Highlands where it has to be transported by
foot, and much of this cultivation appears to be small
scale. Seizure figures have not been provided to
UNODC, but reports from other sources also suggest
the amounts trafficked are also relatively small.58 In the
cities, the drug is dealt by ‘raskols’, urban street gang-
sters. 
In Indonesia, over 200,000 cannabis ‘trees’ were
uprooted by the government in 2004, and 24 tons of
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the drug were seized in 2003. Seizures more than tripled
in 2004, with almost 85 metric tons.  The Indonesian
authorities claim that half the local production is con-
sumed domestically, while the other half is exported to
Australia, although this conflicts with the Australian
claim that most of their cannabis is produced domesti-
cally.  It has been alleged that the Free Aceh Movement
(GAM), an insurgent group, was funding itself in part
through cannabis trafficking. The Indonesian police
report recently seizing over 40 tons of cannabis and
arresting a number of GAM members guarding the pro-
duction areas. As in other areas where insurgencies are
allegedly involved in cannabis, the GAM allegedly levies
a tax on rural production, which is controlled by
Jakarta-based trafficking organizations.59
Cannabis cultivation in the Philippines appears to have
grown dramatically in the last three decades, from just
nine identified plantations to 107 in 2005.60 In the
Philippines in 2004, using manual eradication, the gov-
ernment destroyed 2.4 million cannabis plants and
seedlings.61 The Communist New People’s Army is said
to provide protection to growers in the northern areas
exchange for a ‘revolutionary tax’. The Abu Sayyaf
Group (ASG) also collects protection money and con-
trols a thriving cannabis production site in Basilan.
Most of the cannabis produced in the Philippines is for
local use, with the remainder supposedly smuggled to
Australia, Japan, Malaysia, Taiwan Province of China,
and Europe.62
Europe: A changing market
Cannabis use has increased substantially in almost every
country in Europe over the last 10 years, and Europe
currently accounts for about 20 per cent of global
cannabis use. While Europe cannabis use is often asso-
ciated with cannabis resin, it does possess a substantial
and growing herbal market. Indeed, in Austria, Bel-
gium, Czech Republic, Estonia, and Netherlands, the
market for herbal cannabis is estimated to exceed that of
cannabis resin.63 If estimates about the growing market
share commanded by home grown product in the
United Kingdom are accurate, then its herbal market
may also be larger. And while it is believed that cannabis
resin is still most popular in Germany, the margin is
small and may be growing smaller. In countries where
herbal cannabis represents a cheaper source of THC
than resin, resin may be facing a declining market share.
Over half the cannabis resin seized in the world in 2004
was seized in Spain (794 tons out of 1,470 tons seized)
and 100 per cent of the cannabis resin seized in Spain is
believed to originate in Morocco. Adding in the rest of
West and Central Europe accounts for 74 per cent of the
global total, and another 86 tons were seized at source
in Morocco. Thus, the Western Europe/Morocco resin
market is responsible for about 80 per cent of global
resin seizures.
Morocco is said to be the source of all the resin con-
sumed in Spain and Portugal, and most of that con-
sumed in France (82 per cent), Belgium (80 per cent),
Sweden (85 per cent), and the Czech Republic (70 per
cent). Much of the cannabis resin transits Spain and the
Netherlands before being shipped to other countries.
The remainder of the resin supply originates in
Afghanistan/Pakistan, Central Asia or from within
Europe (mainly Albania). 
In Germany, the bulk of seized cannabis products enter-
ing the country in 2003 came from two sources (both
about 3.5 tons, out of 8.6 tons imported): relatively
small shipments (of an average weight of about 2 kg)
from the Netherlands and massive shipments (averaging
about 1 ton) directly from Morocco. Spain was also a
significant supplier (just under a ton) of medium sized
shipments (averaging 15 kg). In 2004, the size of the
Moroccan shipments dropped drastically (to an average
of 64 kg), and the Netherlands became clearly the lead-
ing source, responsible for half of the volume and 78 per
cent of the cases.64
The Netherlands has long been an epicentre of cannabis
cultivation in Europe and beyond. Many countries or
areas indicate that the Netherlands is a significant source
of the herbal cannabis entering their counties, either as
an origin or a transit country, including Austria,
Belarus, Belgium (25 per cent of all cannabis in the
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Source: Annual Reports Questionnaire data.
Fig. 5: Countries and regions identified as source of
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country is estimated to be Dutch), Czech Republic (50
per cent), Estonia (20 per cent), France, Germany,
Hong Kong Special Administrative Region of China,
Hungary (50 per cent), Iceland, Ireland, Italy (17 per
cent), Latvia (50 per cent), Lithuania (75 per cent) Lux-
embourg, Poland, Spain, Sweden, Switzerland, and the
United States. In addition, several other countries iden-
tify the Netherlands as a transit zone for resin entering
their countries. The role of the Netherlands in the
global production of high-potency cannabis is discussed
below.
Belgian authorities report 90 per cent of the cannabis
produced in their country is for export, and that culti-
vation areas are found mostly along the border with the
Netherlands. Despite this, small-scale production for
personal use appears to be on the increase. Some 70 per
cent of the cultivation operations detected in 2003
involved less than six plants.65 Belgian and Dutch
groups are said to “control’’ indoor production in
France.
In Eastern Europe, Albania remains a major exporter of
herbal cannabis, where mass production began in the
southern parts of the country in the early 1990s.66
Herbal cannabis is said to be trafficked by road from
Albania through the former Yugoslav Republic of Mace-
donia and Bulgaria to Turkey.67 Albanian cannabis also
feeds the markets of Austria, Bosnia and Herzegovina,
Bulgaria (45 per cent), Croatia (30 per cent), Greece,
Italy (77.4 per cent), Serbia and Montenegro (50 per
cent), Slovenia, the Former Yugoslav Republic of Mace-
donia and Sweden.68 Cannabis production in the south-
ern areas of Albania is believed to be destined almost
exclusively for export to Italy.69
In addition to receiving imports from Albania, cannabis
is also cultivated domestically in Greece and Italy. Some
200,000 cannabis plants were eradicated by the Italian
authorities in 2003. Greek authorities uprooted 21,000
plants in 2003, about 40 per cent of which were found
on Crete. The growth in Albanian cannabis production
is believed to be linked in part to the Greek crackdown
on cannabis cultivation in some areas of the country.70
In Bulgaria, cannabis is grown in the Southwest and in
the North/ Northwest. Many of the growers are elderly,
paid by people linked to organized crime. Production
on public lands is also reported.71 About half the herbal
cannabis trafficked in Bulgaria is domestic, while most
of the balance is Albanian, and this produce may be traf-
ficked on to Turkey and Greece. Some 12 tons of
cannabis plants were destroyed in eradication operations
in 2003 in a relatively small number of operations (31),
suggesting large-scale cultivation.
About 20 per cent of herbal cannabis trafficked in Croa-
tia is domestic, with the balance being imported from
Bosnia (about half ), Serbia, Montenegro, and other
areas. About half of this remains in the country, while
the rest is trafficked to Western Europe. All domestically
produced cannabis is consumed in the country, how-
ever.
Polish authorities report cultivation of cannabis in Cen-
tral, Southeastern, and Western Poland, in cereal fields,
by forest roads, in gardens, and in greenhouses. In 2003,
they eradicated over six hectares of cultivated area, and
seized 32 indoor operations. They estimate about 45 per
cent of local produce is destined for export, mainly to
the Netherlands and Germany.
As discussed further below, the United Kingdom seems
to be undergoing a transition from reliance on imported
herbal cannabis and resin to locally produced herbal
cannabis. Despite this, large amounts of cannabis are
still imported into the UK. A recent example is the
seizure of five tons of cannabis from Mexico hidden in
a containerised shipment in October 2005.72
Asia: Home to a third of global cannabis users
Asia as a whole has the lowest per capita rate of cannabis
use of any major region in the world (2.2 per cent) but
sheer population size means that it is home to the largest
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Sources: UNODC, Annual Reports Questionnaire Data, Govt.
reports, reports of regional bodies, UNODC estimates.
Fig. 6: Regional shares of global cannabis users
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number of users, some 34 per cent of the estimated
global total.
Central Asia, in particular the countries of Kazakhstan
and Kyrgyzstan, contain what appears to be the largest
cannabis fields in the world. In Kazakhstan’s Chui valley
alone, as much as 400,000 hectares of cannabis grow
wild, with a potential output of 6,000 tons, but an esti-
mated harvest of only 500 tons.73 This wild cannabis
has an unusually high THC content, up to 4 per cent,74
making it viable for low-end international sale, and
good stock for cannabis resin production. The consen-
sus is, however, that most of this cannabis is consumed
in the region, and that its value does not merit long-
range trafficking across multiple borders.75 Thus, while
the productive potential of this area remains immense,
it is likely to remain unrealised unless circumstances
change. 
The Kyrgyz authorities have estimated cultivation at
about 6,000 hectares since 2001. In the Kyrgyzstan dis-
tricts surveyed by UNODC, approximately 3,005
hectares of cannabis were identified. More than 70 per
cent of the cannabis found was either on abandoned
farmland or on land being used for agricultural pur-
poses.76
Russian authorities say 70 per cent of the herbal
cannabis consumed in their country is locally produced,
with another 15 per cent coming from Kazakhstan and
Ukraine, and 15 per cent from Kyrgyzstan and
Moldova.77 In some areas, such as South-East Asia and
the Caucasus region, the demand for cannabis products
is still almost entirely satisfied by local production.78
Authorities estimate 63 per cent of domestic cannabis
cultivation occurs in the oblast of Kursk, with 13 per
cent occurring in the Moscow region.79
The second largest market for cannabis resin is the Near
and Middle East/Southwest Asia region. This region is
mainly supplied from cannabis resin produced in
Afghanistan and Pakistan and, to a lesser degree, from
cannabis resin originating in Lebanon. Some of the
cannabis resin from Afghanistan/Pakistan is also being
shipped to Canada and to countries in Eastern Africa. 
Afghanistan has long been a centre of cannabis resin
production, both for regional use and for being traf-
ficked to Europe. While today Afghanistan commands
only a minority share of Europe’s resin market, produc-
tion remains considerable. Cannabis is grown like a
hedge around opium poppy plots, with the same farm-
ers cultivating both drugs. 
The Afghan authorities report the area under cannabis
cultivation in 2003 to be 52,000 hectares, compared to
80,000 hectares of opium poppy in that year. Each
hectare is said to produce 85 kg of resin a year. Esti-
mated total resin production was thus 4420 tons
according to the Afghan authorities. In contrast,
research by UNODC in connection with the annual
opium survey suggested a cultivation area of about
30,000 hectares. Cannabis production was reported to
take place in most provinces of Afghanistan. 
In 2003, there were more people arrested for cannabis
trafficking (62) than for heroin trafficking (41) in
Afghanistan. Cannabis seizures were exclusively in the
form of cannabis resin (81.2 tons). Cannabis resin traf-
ficking was reported to have increased, mainly going to
central Pakistan as well as to the Islamic Republic of
Iran, Tajikistan and Turkmenistan. The Afghan govern-
ment reports that 5 per cent of the cannabis is locally
used, and the rest is for export. 
Most of cannabis processing is reported to take place in
the border regions with Pakistan.80 It is thus difficult to
disentangle Afghan and Pakistani cannabis products,
and while it is widely believed that cannabis is produced
throughout Pakistan, it would appear that the bulk of
the cultivation occurs on the Afghan side of the border.
Turkey reports about half of the resin trafficked into the
country comes from Lebanon, with 27 per cent coming
from Syria, and 18 per cent coming from Iran. Lesser
amounts are also said to come from Jordan.  But, in
2003, the Syrian and Jordanian authorities said that all
the cannabis resin in their countries came from
Lebanon.
Lebanon was once the world’s leading producer of
cannabis resin. In the late 1980s, cannabis cultivation
was estimated to be as high as 11,000 to 16,000
hectares, yielding up to 1,000 tons of cannabis resin.
From 1991 to 1993, Lebanese and Syrian forces eradi-
cated illicit cultivation in the Bekaa Valley. Despite this,
40 tons were still seized in 1994.81 In 2002, it was again
estimated that over 11,000 hectares were under cultiva-
tion, dropping to 727 hectares in 2003.  In 2004, a
reported 16,000 hectares were eradicated. The Lebanese
authorities assert that 98.8 per cent of the cannabis resin
produced in the country is also used there, with a small
share being exported to Bulgaria and Dubai, United
Arab Emirates. Most production today occurs in the
Bekaa Valley, in the areas of Baalbek and Hermel. 
The Syrian authorities say 100 per cent of the cannabis
resin trafficked in their country comes from Lebanon,
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and 95 per cent of it is headed for the Gulf States, with
5 per cent being destined for Turkey. They assert there
is no drug production in Syria. 
In South Asia, cannabis is also cultivated in India, espe-
cially in the Kullu Valley in Himachal Pradesh. In addi-
tion, cannabis is grown in Andhra Pradesh, Uttar
Pradesh, Tamil Nadu, Kerala, and Manipur states, as
well as in remote areas of Jammu and Kashmir. In 2004,
the Indian government eradicated 214 hectares of
cannabis. Seizures of 144 metric tons were reported in
2004. In addition to local production, cannabis resin
(‘charas’) is imported from Afghanistan, Pakistan, and
Nepal. It is smuggled into India from Nepal across the
land border in the states of Bihar and Uttar Pradesh,
from where it finds its way to Delhi and Mumbai.82
India is a major cannabis consumer country. In 2004,
UNODC and the Indian Ministry of Social Justice and
Empowerment, jointly released the National Survey on
the Extent, Pattern and Trends of Drug Abuse in India,
the first of its kind. It showed that 2.3 million Indians
were dependent on cannabis.83
In Nepal, cannabis is cultivated in the southern parts of
the country and grows wild through much of the north.
Nepalese cannabis resin is trafficked around the world,
with seizures made in the United Kingdom, Denmark,
New Zealand, Hong Kong Special Administrative
Region of China, and Canada. There have been claims
that Maoist revolutionary groups are using cannabis to
fund their insurgency. Maoists are known to have called
upon locals in the Birgunj area to increase cannabis pro-
duction. The Nepalese authorities report that the
Maoists levy a 40 per cent tax on cannabis production
in certain areas.84 There is evidence that the Maoist
insurgents both charge a levy on cannabis resin passing
through territory they control and operate a system
whereby growers are authorized to cultivate a certain
hectarage per year for the payment of a fee.85
In Southeast Asia, herbal cannabis also continues to be
cultivated in and smuggled out of Cambodia, Indone-
sia, Lao People’s Democratic Republic, Myanmar and
Thailand. Some 14 hectares of cannabis were eradicated
in Cambodia in 2004, and production is said to be as
much as 1,000 tons. Much of the production occurs in
Cambodia’s northwest provinces and is reputed to be
“contract cultivation” with Cambodians operating with
the financial help, and under the control or influence of
foreign (especially Thai) criminal syndicates. 
A similar phenomenon is seen in Lao People’s Democ-
ratic Republic (PDR), where low-grade cannabis pro-
duction is largely in the lowlands, in the southern Lao
PDR and in particular in areas near to the Mekong
River. Most of this is for export to Thailand, undertaken
on contract for Thai organized crime groups, who
advance money and consolidate production in Thai-
land, Cambodia, and Lao PDR.86
Some of this produce is transhipped through Viet Nam,
confusing its source of origin, while cultivation in Viet
Nam is said to be ‘insignificant’.87 Viet Nam, however,
had a long tradition of cannabis cultivation and was
once the source of potent cannabis for export to the US
market.
The 2005 drug abuse surveillance data has shown that
cannabis use has been increasing across China, with
high levels of use in Xinjiang, Hubei and Guangdong
provinces.88 Eradication campaigns have been carried
out in the Yunnan province and the autonomous
Uighur region. In Hong Kong Special Administrative
Region of China, herbal cannabis is imported from the
Golden Triangle, Cambodia, and the Netherlands, often
via South Africa, Dubai, or Thailand, whereas resin is
imported from South Asia.
As the discussion above indicates, the state of our
knowledge on the extent of global cannabis production
is far from perfect. In many regions, it is difficult to rec-
oncile production estimates with what is known about
local consumption and trafficking. For example, in both
Latin America and Africa, large seizures are made in
countries with low reported use levels that are not
known to export cannabis.  It is unclear where this drug
is coming from and where it is going.  Even in the
United States, a country with a regular household
survey on drug use, a large eradication programme, and
well-developed criminal intelligence, recent official esti-
mates of the extent of domestic cultivation vary by more
than a factor of six. These difficulties are necessarily
reflected in any attempt to estimate of the scope of
global production.
A global market that defies efforts to size it up
The above makes clear that cannabis is widespread, but
determining how much is produced is another matter
entirely.  There are two broad approaches that could be
taken. One is to start with information on extent of pro-
duction (supply-side), such as estimates of the extent of
cultivation and crop yields, or seizure figures.  The
second is to estimate how much is consumed (demand-
side), though user survey data and research on how
much of the drug is typically consumed to produce the
desired effect. The problem is that these two approaches
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typically produce very different results, as highlighted in
the discussion that follows.
How much is produced?
The Annual Reports Questionnaire (ARQ) sent every
year by UNODC requires Member States to provide
estimates of the number of hectares under cultivation in
their respective countries, but most do not fill out this
section. In fairness, most states would have little knowl-
edge of how to make such an estimate. This leaves one
with little information on which to base a supply-side
calculation of total global production.
Combining the information available about the biggest
markets with seizure data may help to come up with
some idea of the number of hectares under cannabis cul-
tivation, at least for those markets for which reliable esti-
mates exist. The table below lays out the top producers
about which information is available. Together, these
nations are responsible for at least 78 per cent of global
cannabis seizures.89
This approach suggests that the bulk of global cannabis
production could occur in an area of about 231,000
hectares, of which more than half are in Morocco. This
is a small area, about the size of the Comoros. Of this,
about 10 per cent gets eradicated. The estimated seizure
rate for these big producers is about 17 per cent, includ-
ing seizures made by destination countries. In other
words, after eradication, four-fifths of the remaining
cannabis gets past law enforcement.
This rate of interdiction refers to some of the most
developed markets in the world, and it is likely that the
corresponding figure in places like Africa is much less.
Application of this rate should therefore be considered
a low-end estimate. Global cannabis seizures in 2004
were 6,264 tons of herbal and 1,470 tons of resin (about
37,000 tons of herbal equivalent) for some 43,000 tons
of global cannabis production seized. If this is about a
fifth of true production, about 215,000 tons were pro-
duced in 2004. However, most of this (85 per cent) was
reduced to resin. Total cannabis product output should
thus be over 30,000 tons of cannabis herb and more
than 7,000 tons of resin.
How much is consumed? 
Another way of estimating global production is to look
at global consumption. To come up with demand-side
estimates of total cannabis production, three things
need to be known:
1. What share of the global population consumes
cannabis annually? 
2. How many days a year do they consume it?
3. How much do they consume on the days when
they use the drug?
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Estimated hectares 
under cultivation Hectares eradicated 
Estimated 
production in 
herbal 
equivalents90  
(tons)
Total seizures in 
herbal equivalents 
(tons)a
Morocco 134,000 --- 98,000 21,000b
Afghanistan 52,000 --- 50,000 6432c
Mexico 29,500 22,000 10,400 2160
United States -4500 365d 4455 1224
Paraguay 5,500 753 15,000 257e
Colombia 5,000 0 4,000 134
TOTAL 231,000 23,118 181,885 31,207
Table 1: 2003 Cannabis production estimates for major producers 
Figures in parenthesis are estimates based on other data; resin data are converted into "herbal equivalent" by multiplying by 25
a  Assumes a 4 per cent yield. 
b  Assumes Morocco is responsible for 80 per cent of resin seizures in Spain, France, UK, Portugal, Italy, Germany, Belgium, Ireland,
Denmark, Norway, and Sweden.
c  Assumes Afghanistan is responsible for 100 per cent of resin seizures in Pakistan (as per ARQ) and Iran - the Afghan contribution to
European resin is not included.
d Total plants converted to 1 plant per square metre outdoor equivalents.
e  Assumes Paraguay is responsible for 80 per cent of herbal seizures in Brazil and Argentina.
One key issue in trying to determine the amount of
cannabis required to meet global demand (in metric
tons) is that not all cannabis is created equal. Cannabis
resin and sinsemilla (the potent flowering tops of the
unfertilised female plant – see Annex 1) are concen-
trated forms of the drug, and users use less of these
drugs (in terms of weight) than they would of low-grade
product. In order to relate demand to production, the
markets for these products would ideally be calculated
separately. 
What share of the global population consumes cannabis
annually? Answering this question requires some extrap-
olation, as there are massive gaps in the survey data. The
traditional approach is to use sub-regional averages to
calculate use levels for those countries for which data are
lacking. It is also possible to extend data from a limited
sub-sample of the population (the most obvious exam-
ple being school surveys) to the population as a whole
on the basis of ratios determined from countries where
both sets of data exist. 
All this is hinged on the survey data. There has been
considerable debate about the veracity of self-reporting
on matters involving criminal activity,91 and the level of
inaccuracy may vary considerably– in areas where drug
use is highly stigmatized, subjects may be unwilling to
report use, even if confidentiality is assured. 
An additional complication lies in the fact that surveys
on cannabis use generally do not distinguish between
herbal and resin use.  From the prospective of reconcil-
ing use data with figures on cultivation, this is a major
problem, since production of cannabis resin requires a
much greater land area. However, since resin potency
and herbal potency are approaching parity in Europe,
the largest market for resin, it is probably fair to assume
the rate at which users consume resin is about the same
as the rate at which they consume herbal cannabis, and
this is all that matters for a demand side estimate.
The UNODC estimate of global annual adult preva-
lence for cannabis use is 4 per cent, or about 162 mil-
lion people. Use rates vary substantially by region, but
for the rough estimate made here, regional differences in
consumption patterns are not taken into account.
Of course, these 162 million people did not all use
cannabis at the same rate. Some of them may have
experimented with the drug once or twice, while others
consume the drug on a daily basis. It is estimated that
10 per cent of people who try cannabis will progress to
daily use for some period of their lives, with a further 20
per cent to 30 per cent using on a weekly basis.92 This
leaves, however, a large share of people whose use is less
frequent. The prevalence of use tends to vary depending
on the life-stage of the user. For example, about 60 per
cent of French 19-year-old boys have tried cannabis,
and, of these, more than one in three uses 20 times a
month or more. This share drops greatly in later life
stages.93
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Sources: UNODC, Annual Reports Questionnaire Data, Government reports, reports of regional bodies, UNODC estimates.
Fig. 7: Regional annual prevalence rates
2.1 2.3 2.6
3.8
6.4
7.4
8.1
10.3
15.3
0
4
8
12
16
20
Asia South-East
Europe
South
America
East
Europe
Americas West and
Central
Europe
Africa North
America
Oceania
Sources from a wide range of countries suggest that
about 14 per cent of annual cannabis users are daily
users, a higher figure than many would expect. If these
figures could be generalized to the total global popula-
tion, this suggests that about 22.5 million people use
cannabis daily or near-daily, with the other 138.5 mil-
lion using it less often. This figure is important because
only at the level of daily or near-daily use does tolerance
develop, and this has an impact on the amount of
cannabis used. Of daily users, about a third are chroni-
cally intoxicated. For more details on this breakdown,
see Annex 3.
One can estimate that of the 162 million people who
use cannabis each year, about 75 million could be
classed ‘casual’ (using less than once a month), 66 mil-
lion could be classed ‘regular’ (more than monthly but
less than daily), 15 million ‘daily’, and 7 million
‘chronic’ (continually intoxicated) users. These groups
can be expected to consume at different rates. 
Casual users are unlikely to finish a joint by themselves
in any of the one to 11 sessions of use in the year (for
more on cannabis dosage, see Annex 3). More likely,
these users had two to three hits off a 0.5 gram joint
shared by three or four people, representing about 0.15
grams of cannabis consumption per usage session. The
distribution curve for less than 12 time per year users is
heavily skewed towards one to three sessions of use
according to the US data, and a weighted average of this
category is about four sessions per year. Thus 75 million
people would smoke an average of 0.15 grams of
cannabis an average of four times a year, for a total of 45
tons of total consumption.
While regular users, who do not consume cannabis on
a near-daily basis, are not likely to build up much of a
tolerance, they are more likely to consume the drug
alone, or more than once in a single day of use. On the
other hand, they are also more likely to prefer premium
cannabis (which may be up to 10 times stronger) and to
have better inhalation technique (which can increase
THC absorption four fold), both of which would mean
that they would require less cannabis to get high than
casual users. If it is assumed that these factors cancel
each other out somewhat, the average use level of about
0.15 grams per day of use can be maintained. The dis-
tribution of responses in the US is also skewed toward
the lower end in this group, with a weighted average of
about 100 days of use. These 66 million people would
thus smoke an average of 0.15 grams an average of 100
times a year, for a total of 990 metric tons of consump-
tion.
Daily users, according to most sources, consume
between one and four joints a day. The weighted aver-
age in this category, based on the American data, is
about 320 days of use. Thus, 15 million people smoked
an average of one gram of cannabis a day for 320 days a
year, for a total of 4,800 metric tons of consumption in
2004.
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Sources: UNODC, Annual Reports Questionnaire Data,
Government reports, reports of regional bodies, UNODC
estimates.
Fig. 8: Breakdown of annual cannabis users by
frequency of use
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estimates.
Fig. 9: Shares of total cannabis consumption by
frequency of use
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Chronic users can consume huge amounts of the drug.
Use patterns vary so widely that it is impossible to come
up with an average, but using medical cannabis guide-
lines and field reports, it appears that about ten joints,
or five grams, of cannabis is a reasonable level for fairly
constant intoxication. These seven million users con-
sume every day, so their total consumption should be
about 12,775 metric tons.
This estimate supports the oft-made assumption that a
core of ‘heavy’ users consume the bulk of the cannabis
produced. The 22 million people (13.5  per cent of all
users) who use the drug every day consume 95 per cent
of the drug and of those, 7 million (4 per cent) who
smoke it constantly consume 69 per cent.
Can supply and demand-side estimates be reconciled? 
Supply and demand side estimates have proven difficult
to reconcile for a range of analysts. The 2006 World
Drug Report estimates global cannabis production at
about 45,000 tons, and the global consumer base at 162
million people annually. Dividing the one quantity by
the other results in about 277 grams per user, or over a
quarter of a kilo apiece. If we use a figure of 0.5 g of
cannabis per joint (see Annex 1), 277 grams therefore
equals 554 joints per year, or more than one and a half
per day per user. Taking the example of the US market,
with a price of $10 a gram, each user would spend
$2,770 on cannabis in one year. With a US national
average per capita income of about $35,750, this expen-
diture would represent 8 per cent of pre-tax income of
every American who smoked cannabis last year.
Although the bulk of this is consumed by a highly ded-
icated cadre of daily and chronic users, many of whom
must have access to a free supply of cannabis, this still
seems impossibly high.
Two possibilities may be considered:
• The amount of production is being overestimated,
or
• The number of users is being underestimated.
Just over 6,000 tons of cannabis were seized in 2004,
which would mean that about 15 per cent of total esti-
mated global production is seized. A seizure rate of more
than 15 per cent seems unlikely, given that the ratio of
estimated Mexican production to seizures is just over 20
per cent (2,000 of 10,000 tons), and it is unlikely that
less well resourced regions (such as much of Africa)
would perform better. This is particularly true given
recent trends towards smaller-scale indoor production
within developed countries and production for personal
use. Thus, it is unlikely that production is being signif-
icantly overestimated.
The estimated number of annual users – at nearly 4 per
cent of the global population 15-64 – is already very
high. Even doubling this rate would only halve the aver-
age consumption per annual user to 110 g, which is still
over $1,000 a year per user in the US. Doubling US
annual use estimates would also mean more than a quar-
ter (26 per cent) of all Americans 15-64 spent this
amount of money on an illegal drug last year.
The problem may lie with the seizure figures, rather
than the production figures. Since it is unlikely that all
seizures are weighed, and it is likely that eradicated crops
are added into the total in some cases, an element of
estimation exists in generating seizure figures. In theory,
the entire cannabis plant could be used for psychoactive
purposes – in practice, increasing demand for quality in
today’s market means that user-ready sales are often of
the flowering tops only. Thus, seizure estimates may be
dealing with a lot of bulk that would never translate into
saleable street product. If seizure amounts were scaled
down, production figures could also be adjusted with-
out exaggerating the interception rate.
Turning to the figures generated for this chapter,
demand side estimates place global production at
19,000 tons per year. But this is 19,000 tons of cleaned
product, not 19,000 tons of the product as it is gener-
ally sold.  On the supply side, an estimated 231,000
hectares are under cultivation, but the majority of these
are dedicated to cannabis resin. An estimated 30,000
tons of cannabis herb and just under 7,000 tons of resin
are produced, of which 6,264 tons of herbal and 1,470
tons of resin were seized in 2004, leaving about 24,000
tons of herbal and 5,500 tons of resin for consumers.
The difference of 5,000 tons between the two estimates
on cannabis herb (24,000 tons for the production side
estimate and 19,000 tons for the demand side estimate)
may be attributable to the distinction between cannabis
as sold and cannabis as used.
Unfortunately, given the paucity of the data, the argu-
ments above cannot move beyond the hypothetical. Too
little is known about how and where cannabis is being
grown. Each year a growing number of people consume
the drug, but the source of their supply and the extent
of their use remain obscure. This state of ignorance is
particularly unsatisfactory given emerging information
about the dangers of cannabis use. Cannabis is chang-
ing in alarming ways, and, at present, the international
community lacks the capacity to apply more than rough
estimates to the scope of the problem.
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The health consequences of cannabis are a matter of
longstanding debate. A range of official national com-
missions have reviewed the topic, and exonerated
cannabis of many of the charges laid against it.94 But in
just the last decade, sinsemilla cannabis  has doubled in
potency in a number of key markets, and a range of
recent studies have highlighted the negative impact the
drug has on mental health in particular. 
The re-engineering of cannabis
Improved breeding and the rediscovery of sinsemilla
Cannabis consumption in the Western world really took
off in the second half of the 20th century, and since
those early days, consumer tastes have evolved consider-
ably. Most of the cannabis smoked in the 1960s would
be considered to be of low quality today. In addition to
seeds, it comprised a great deal of the large leaf, twigs,
and other material that would be currently regarded as
waste. Improvement in the ‘manicure’ (the portions of
the plant offered for sale) may be seen as an inevitable
consequence of the maturation of the market.
But law enforcement action in the second half of the
1970s to the early 1980s appears to have inadvertently
prompted other improvements in the product. First, it
reduced the availability and the quality of imported
cannabis in many of the most important consumer mar-
kets, particularly the United States. Second, it seems to
have pushed some domestic production indoors,95 and
stimulated growers to focus on producing greater qual-
ity rather than quantity in order to evade detection.
These developments prompted a revolution in produc-
tion technology in the United States, which was later
spread to Europe and beyond.
Until the mid 1970s, nearly all the cannabis consumed
in North America was a landrace96 strain of the so-called
sativa variety (see Annex 1 for more on the varieties of
cannabis). The subjective effects of sativas are preferred
by those who are looking for a more cerebral effect, pos-
sibly due to high levels of THC relative to CBD levels
(see Annex 1). But sativas are both late maturing
(making them difficult to grow in northerly latitudes)
and very tall (making them difficult to conceal outside
and problematic to grow inside). It was not until seed
stock from central Asia and the Middle East was intro-
duced to the gene pool that these problems were over-
come. These ‘indica’ genes accelerated the life cycle,
boosted yields, and produced plants that were both
more cold resistant and more manageably sized. 
Experiments crossing sativa and indica strains led to the
development of “skunk”, a hybrid said to be 75 per cent
sativa and 25 per cent indica, which was among the first
to capture the THC high of the sativas with the rapid
growth cycle and yield of the indicas.97 It remains one
of the cornerstone cultivars used in contemporary
breeding, and in countries such as Australia, France,
New Zealand and the United Kingdom, cannabis with
a high THC content is often referred to as ‘skunk’
today.98
At the same time, an ancient cultivation technique was
being reinvigorated. The term ‘sinsemilla’ refers to the
product of a growing technique, not a genetic strain or
special preparation of the plant. The most potent
cannabis is comprised exclusively of the female flower-
ing heads (‘buds’) that have remained unfertilised
throughout maturity and which, consequently, contain
no seeds (i.e. are sin semilla, ‘without seeds’ in Spanish).
The production of sinsemilla requires identifying the
females and ensuring that they are not exposed to male
pollen, and then marketing only the buds and small
leaves. Cannabis cultivators in India have long known
that the best cannabis comes from the unfertilised buds
of the female plant, and have employed ‘paddars’ (ganja
doctors) to remove male plants from cultivation areas
before they are mature enough to cause any damage.99
The technique was also apparently understood in Cen-
tral America, though it appears to have fallen into
disuse. It is very difficult to grow unfertilised plants out-
doors in areas of intense cultivation, because a single
rogue male can ruin an entire crop. Thus, the law-
enforcement prompted move towards more indoor cul-
tivation may have supported the expansion of the
production of seedless cannabis. 
Most commentators place the emergence of sinsemilla
in the United States around the early to mid-1970s,100
and in Europe to about 1980.101 Today, nearly all high-
grade cannabis is grown sinsemilla. Indeed, while West-
ern cannabis markets may exhibit many shadings, most
contain a stark distinction between seedless product
grown of good genetic stock (usually produced domes-
tically or in another developed country) and more
mundane product, field-grown domestically or in a
developing country.
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2.3. The emergence of ‘new cannabis’ and the reassessment of health risks
The potency of sinsemilla is much higher than the
seeded product, with a 2004 average of about 10.5 per
cent THC in the US (as compared to 2.5 per cent for
low-grade cannabis)102 and close to 18 per cent in the
Netherlands103 (as compared to about 6 per cent for
imported cannabis).104 Individual samples have exhib-
ited THC levels in excess of 30 per cent, although this
is extremely rare. Sinsemilla is distinct enough in
appearance and potency to be considered a separate
drug. There has even been discussion of scheduling sin-
semilla as a ‘hard drug’ in countries that that have lib-
eralised their cannabis policies.105
The application of greenhouse technology
In addition to improved breeding and the rediscovery of
sinsemilla, the movement towards indoor cultivation
has also allowed the application of greenhouse technol-
ogy to what had traditionally been a field crop.106
Around 1985, some cannabis breeders from the United
States fled for a country with more amenable drug poli-
cies – the Netherlands. At the time, indoor cultivation
of cannabis was just starting to take off in the Nether-
lands,107 and the fusion of American breeding stock and
Dutch agricultural practice sparked a revolution in
cannabis breeding and production.108 Today, Dutch
‘seed banks’ sell the product of this breeding over the
Internet, in competition with a growing number of
rivals, notably those based in Canada.
The first and most obvious boost to sinsemilla produc-
tion was the use of clones. ‘Cloning’ simply means
taking a cutting from a successful ‘mother’ plant, a tech-
nique known to anyone who grows houseplants but not
generally used in field agriculture. This cutting is rooted
and planted. It is a genetic duplicate of its mother and
can be used to generate still more cuttings. Eventually,
a grower can work with entire crops of genetically iden-
tical plants. A square meter of mother plants can pro-
duce 100 clones a week.109
There are several advantages of working with clones.
First, the cuttings are guaranteed to be exclusively
females. Growing from seed means that half the crop
will be waste (male) plants, and overlooking a male can
ruin an entire sinsemilla crop. Second, the clones will be
duplicates of a mother proven to be a successful pro-
ducer, and whose lifecycle and weaknesses are known.
Finally, the clone assumes the life-stage of the mother,
and so needs less time to reach flowering than would a
similarly sized plant grown from seed. Used in combi-
nation with the forced flowering technique, clones dra-
matically accelerate the rate of cannabis production.
In addition to selective breeding for fast maturity, the
rate at which cannabis plants come to flower can be
increased by manipulation of the light cycle. Outdoors,
the success of cannabis grown for drug purposes is
highly dependent on latitude. This is because most types
of cannabis only flower when the days grow shorter. At
high latitudes, this happens before the plant has had a
chance to fully develop, or is coincident with lethal
frosts. This makes outdoor cultivation in much of
Europe, for example, very difficult, especially for sativa
strains that evolved at lower latitudes. Indoors, these
restrictions clearly do not apply, and, in addition, the
photoperiod (the amount of light received by the plants
during the day) can be manipulated to force flowering
whenever it suits the grower. 
Forced flowering results in smaller yields per plant than
if each plant had been allowed to mature further, but
this is more than offset by the faster overall production
time and in the greater number of small plants that can
be fit into a given growth area. Whereas traditional out-
door growers are limited to one or two harvests a year,
indoor growers can stagger production to produce
almost continual harvests. The turnaround time from
clone to harvest is generally on the order of eight to ten
weeks, allowing between four to six harvests off the
same square meter of floor space. The best-known
example of this is the Dutch “Sea of Green” (SOG)
technique, of which there are many variations.
The SOG technique involves cultivating a large amount
of plants in a given area for a short period of time before
flowering. This results in a smaller yield per plant, but
more plants in a harvest, with shorter cultivation peri-
ods, which allows for more harvests per year. Different
parts of the growing area are used for plants in different
stages of their life cycle, staggering production. The
total process, from seeds to sales, can take about 16 to
18 weeks, but this can be shortened by the use of clones.
From clone to harvest can take as little as two months,
allowing up to six harvests a year from the same floor
space.
The ‘new cannabis’ has doubled in potency in the last
decade.
From the above, it becomes clear that a large number of
people in several countries have worked very hard over
the course of decades to produce more potent cannabis.
But it is still being debated whether their work has had
any impact on the potency of the global cannabis
supply. As early as 1980, claims were made that cannabis
potency had increased by a factor of 10 (from 0.2 to 2
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per cent) over five years.110 There have been subsequent
claims that cannabis potency has increased by a factor of
30 or even 60 since the 1970s. These claims have been
criticised as exaggerated as they rely on the very low
THC levels found in some early tests, which may been
inaccurate due to storage issues and other methodolog-
ical difficulties.
Claims of extreme increases in potency and the reaction
they have garnered have cast doubt on the general argu-
ment that cannabis today is different from cannabis in
the past. This is unfortunate, because there can be little
doubt that cannabis has changed, and that high potency
cannabis represents an important and growing sector of
the market in a number of major consumer countries.
The potency debate has generally hinged on measure-
ments from police forensic testing. This information is
collected for other purposes, not to create international
comparable, time-series data. There is really no system-
atic programme monitoring cannabis potency levels
anywhere in the world. Probably the closest is the
United States Marijuana Potency Monitoring Project
(MPMP), but this programme does not involve a
random sampling of the cannabis available in the coun-
try.111 From this core problem are derived several others,
relating to terminology, sampling and more technical
aspects of testing.
There are also complications related to the nature of
cannabis itself. THC degrades over time, so the age of
the sample and the conditions under which it was stored
are highly relevant. The moisture content also varies
greatly, and for this reason, samples seized on the street
cannot be compared to samples taken during field erad-
ication, unless the moisture levels are standardised. 
Traditionally, potency has been framed in terms of
either delta-9 THC content or total THC content,112
without regard to other psychoactive cannabinoids.
THC, however, is only one of a number of psychoactive
chemicals in cannabis, and one, cannabidiol (CBD) in
particular is believed to ‘moderate’ the effects of THC,
promoting relaxation and possibly even having an anti-
psychotic effect. Accordingly, the growth of sinsemilla,
which typically shows low levels of CBD, could be
changing the nature of the cannabis experience. Where
possible, it would be advisable to track both THC and
CBD levels in future evaluations of ‘potency’. 
Since different laboratories do THC testing for different
purposes, comparing findings is difficult. Differing
techniques are evident in the fact that some Western
European countries that source most of their cannabis
resin from the same area (in Morocco), such as Portugal
and Italy, report dramatically different THC levels. Even
within a given jurisdiction, techniques have improved
over time. This makes comparing figures between coun-
tries or over time difficult.
Combining the forensic data with other information
sources, however, gives good reason to believe that high-
end cannabis is more potent than in the past and that
this product is commanding a growing share of the
market in many important consumer markets. 
First, there can be little doubt that knowledge about the
cultivation and use of cannabis as a drug has improved
since the 1960s. The ‘medical marihuana’ providers in
Canada are able to mass-produce 14 per cent THC
herbal cannabis. While individual samples of similar or
greater potency may have been found in the past, it is
highly unlikely that anyone operating thirty years ago
would have been able to approximate this performance.
The sinsemilla technique, selective breeding for potency,
more selective manicuring, a greater understanding of
ripeness, curing, and storage techniques, and other
improvements in cultivation technology have made it
possible to produce far more potent product than was
possible in the past.
But just because the technology is there does not mean
that all cultivators use it. The vast bulk of cannabis
grown throughout the world is still cultivated the tradi-
tional way. In many countries, growers lack the knowl-
edge, the resources, and the incentive to produce better
quality cannabis. The market for low potency product
remains strong, and producing higher quality requires
both more work and more input costs. Even if a
cannabis farmer in a developing country wanted to
improve potency, he would have to find a market for
this product. Local consumers may not be able to afford
his produce, and his international connections would be
linked to established low-potency markets.
Thus, a higher potential potency does not necessarily
mean an increase in the average potency consumed by
users. In order to understand the real impact of the new
cannabis technology in specific markets, the relative
market shares of the high-end and low-end markets
need to be observed across time. 
The 2004 European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA) study on cannabis
potency in Europe is the best recent cross-national study
of forensic information.113 The study cites estimates on
the market share of four product types in Europe:
imported herbal cannabis, cannabis resin, sinsemilla,
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and domestic resin. Most cannabis consumers prefer
one product or the other, so the herbal and resin mar-
kets should be seen as distinct, not agglomerated.
Within the herbal market, data distinguishing between
sinsemilla and imported cannabis were available for only
three countries: the Netherlands, the United Kingdom,
and Ireland. 
• In the Netherlands, 67 per cent of the cannabis
consumed is sinsemilla, 29 per cent imported
resin, 3 per cent imported herbal, and 1 per cent
domestic resin. 
• In the UK, in contrast, sinsemilla holds only 15
per cent of the total market, but it holds 50 per
cent of the herbal market. In other words,
imported herbal also holds 15 per cent of the
market, and imported resin 70 per cent. Other
analysts suggest that as much as half the cannabis
consumed in the UK might be produced domes-
tically, most of which would be sinsemilla.114
• In Ireland, herbal cannabis is also evenly split
between local sinsemilla and imports, with most
of the market (90 per cent) being imported resin.
Thus, for the three European countries for which sin-
semilla information was available, the sinsemilla market
either equalled or exceeded the herbal import market. 
The share of detected cannabis cultivation operations
that are located indoors in the US has also increased in
recent years, from 2 per cent indoor in 1985 to 7 per
cent indoor in 2003, with the greatest change being seen
between 1989 and 1992.115 Law enforcement sources
confirm that indoor cultivation is as widespread as out-
door cultivation, and that the sinsemilla market is grow-
ing.116
In addition, Canada is playing an increasingly impor-
tant role in cannabis imports to the US, contributing 20
per cent of the cannabis imported into the US in
2003.117 Between 1997 and 2000, some 78 per cent of
cannabis production operations detected in British
Columbia, the province that produces over 40 per cent
of the detected cultivation operations in the country
and a major supplier to the US, were indoors. The
number of detected indoor operations tripled during the
same time period.118 A slightly lower share of all opera-
tions detected in the country were indoors.119 Canadian
authorities consider all the cannabis they test to be sin-
semilla, and average potency levels were 9.6 per cent in
2003, compared to 7.4 per cent for US sinsemilla.120
The trend has been towards larger and larger indoor
operations, due in part to the growing involvement of
organized crime groups in production.121 US sources
estimate that Canada produces about 12 per cent of the
cannabis consumed in the US (about 1,000 metric tons
per annum).122 This would suggest Canadian sinsemilla
imports alone should comprise at least 8 per cent of the
American market. 
Other countries have also shown a growing market for
indoor, sinsemilla, high potency cannabis. In New
Zealand, for example, the number of national survey
respondents who had ever used ‘skunk’ increased from
10 per cent in 1998 to 14 per cent in 2001.123 In the
United Kingdom, survey research concludes that ‘skunk’
was the only type of herbal cannabis to improve its
market share among regular users between 1994 and
1997, up just under 10 per cent during this time
period.124 In Australia, after many years of winning
market share from both imports and a remarkable out-
door industry,125 hydroponic (plants produced indoors
in a nutrient bath rather than soil) production is now
the most commonly detected method of cultivating
cannabis.126 In 2003, Hong Kong authorities noted for
the first time the importation of ‘buds’ from the Nether-
lands.127
Internationally, there appears to be a trend toward
developed countries relying more on internal produc-
tion and less on imports. In the United States, for
example, the estimated share of cannabis that is grown
domestically has increased dramatically in recent years.
In 1986, it was estimated that one-sixth of cannabis
consumed in the United States was produced within the
country,128 whereas more recent estimates place this at
one third,129 and the most recent assessment suggests
that this trend is continuing.130 Similarly, in Canada in
1985, only 10 per cent of the cannabis consumed was
produced domestically,131 but by 2002, it was estimated
that “well over half ” was Canadian grown.132  In the
United Kingdom, as noted above, an estimated 30 per
cent of the cannabis used by regular users was home
grown in 1997,133 increasing to 66 per cent in 2005,
and imports from Morocco, Netherlands, and India
appear to have decreased.134 In the Netherlands, the
trend has been away from imported cannabis resin and
towards domestically produced sinsemilla and cannabis
resin. Even in Iceland, “Domestically cultivated mari-
juana has become increasingly competitive with
imported marijuana, and current estimates indicate it
makes up anywhere from 10 per cent to 50 per cent  of
the total cannabis market.”135
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Part of this move toward domestic product is due to an
increase in small-scale production for personal con-
sumption. Belgian authorities report that production
for personal consumption is on the increase in their
country, and that some 70 per cent of the cultivation
operations detected (258 in 2003) involved less than six
plants.136 While survey respondents may be willing to
admit use of cannabis, they may be hesitant to admit
cultivation, since this is generally regarded as a more
serious (and ongoing) offence. Nonetheless, in New
Zealand, a household survey found that 10 per cent of
all current users grew at least some of their own
supply.137 The corresponding survey in Australia found
just over 5 per cent grew their own supply.138
The share of people cultivating for personal use is much
higher among those who use the drug frequently. A
survey of regular users in Australia found that two-thirds
of respondents grew some cannabis for their own use,
and nearly half grew all or most of the cannabis they
used.139 This tendency is not limited to areas with good
conditions for growing cannabis, like Australia. In the
United Kingdom, 63 per cent of a sample of regular
users reported having grown the drug at some point in
their lives, growing an average of 24 plants. They esti-
mate that while only 30 per cent of the cannabis used
by regular users in the United Kingdom was home-
grown in 1997,14066 per cent was home grown in
2005.141 If this is correct, a significant share of the
cannabis used is produced and distributed free within
the country. A study concurs, “…domestic production
is on the increase and as much as half of the cannabis
consumed in England and Wales may be grown here.
Some cultivation is on a commercial basis, but much is
on a small scale, for personal use or use by friends.”142
Research suggests that what these small growers do not
use or give away, they often sell within their social circle.
According to US national survey data, most (78 per
cent) of those who say they bought the drug in the last
year say they bought it from ‘a friend’. In Australia, the
figure is also over 70 per cent, with only 14 per cent
buying from a dealer.143 Even higher figures were found
in an international comparative study of cannabis users
in Bremen (80 per cent) and San Francisco (95 per
cent).144 Only 1 per cent of annual users polled bought
from a stranger in Ireland.145 While social networks may
also deal in imported product, the job of transporting
drugs across borders is more likely to be dominated by
professionals. In contrast, those producing indoors on a
small scale would very likely market their product
through friends.
Thus, it would appear that the supply of high potency
cannabis is growing in developed countries as produc-
tion becomes increasingly domestic and indoor,
although demand remains for low potency products as
well.
Within this growing share of the market, potent prod-
ucts appear to have been made much more potent in the
last decade. The EMCDDA study and subsequent liter-
ature show quite dramatic increases in the sinsemilla
potency in the United Kingdom (up from about 6 per
cent in 1995 to over 12 per cent in 2002) and the
Netherlands (up from about 9 per cent in 1999/2000 to
about 16 per cent in 2001/2002).146 More recent figures
from the Netherlands drawn from about 60 annual sam-
ples of the most popular strains of nederwiet (sin-
semilla) purchased from coffee shops show a doubling
in potency between 1999 and 2003, with levels stabiliz-
ing at about 18 per cent since that time (Figure).
In Germany, the European country with the largest
sample base, no distinction is made between sinsemilla
and low-grade cannabis. Despite this, aggregate herbal
potency has been clearly going up very recently. In
1996, samples averaged about 5 per cent; in 2004, they
were about 11 per cent.147 This is very significant, as the
EMCDDA estimates herbal cannabis commands 40 per
cent of the growing cannabis market in Germany. 
In the United States, virtually all cannabis seized by the
agencies of the national government is tested by the
Marijuana Potency Monitoring Project (MPMP) at the
University of Mississippi, which has been in place for
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Sources:  Niesink, RJM, Rigter, S, & Hoek, J., THC-concentraties
in wiet, nederwiet en hasj in Nederlandse coffeeshops (2004-
2005). Utrecht: Trimbos Institute, 2005.
Fig. 10: Sinsemilla THC levels in the Netherlands
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over 20 years. The trend generally reported is an aggre-
gated one, including both sinsemilla and low potency
products, but it has been unmistakably upward for some
time. This trend strongly suggests an increased avail-
ability of high potency product since the mid-1990s. As
in the Netherlands, the increase has been particularly
pronounced since 1999.
In Canada, before the early 1980s, THC levels seldom
reached above 1 per cent, but by the late 1990s they
were over 6 per cent.148 Declining shares of tested sam-
ples have less than 5 per cent THC and a growing share
register above 10 per cent. Very high potency samples
(above 20 per cent) remain relatively rare, but have cer-
tainly increased in share since 1999. These changes are
partly attributed to changes in the make-up of samples
admitted for analysis. 
Thus, for every country where reliable data are available,
it appears that sinsemilla is commanding a greater share
of the herbal cannabis market, and that this sinsemilla
has become dramatically more potent in the last decade.
In summary, it would appear that the technological
capacity to produce large amounts of high-potency
cannabis has emerged in recent decades. This has seri-
ous implications for the developed countries where such
product is consumed. 
Impact on public health: Three reasons to worry
The growth of acute health episodes
The existence of higher THC products and the growth
of the high potency market do not necessarily mean that
more THC is being ingested. In theory, users could
simply consume less. The onset of psychoactive effect
for smoked cannabis is very rapid, so users should
receive quick feedback on their levels of intoxication.
However, the existence of a more concentrated form of
any drug does pose a risk, especially for novice users. A
single ‘hit’ or two of extremely potent product may even
catch experienced users off guard, since tolerance devel-
ops only with near daily use, and those accustomed to a
particular consumption pattern may not adapt it suffi-
ciently to take into account highly variable product
strength. Cannabis is often consumed in groups, and
social pressure may be a key factor in the amount con-
sumed. 
Measuring these effects is extremely difficult, but there
are several indicators that the emergence of high-
potency sinsemilla has resulted in more THC con-
sumption. First, it would be expected that higher
potency would result in smaller units of consumption,
but evidence from several countries show that, if any-
thing, the size of consumption units has increased.
Second, there have been unexplained increases in the
number of emergency room episodes associated with
cannabis in the United States, and in the share of total
treatment berths occupied by people seeking help with
cannabis in both the US and in Europe.
One of the best data sets for evaluating the extent to
which cannabis use contributes to acute medical prob-
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Source: Marijuana Potency Monitoring Project (MPMP)
Fig. 11: Share of MPMP samples testing above 9 per
cent THC
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Source: Adapted from Viau, R., L. Marro, M. Walker, Retrospective
Examination of the THC Levels of Marihuana Seized in Canada,
Second Technical Conference on Drug Control Research Vienna,
July 19-21, 2004.
Fig. 12: Canadian cannabis sample THC breakdown 
0%
20%
40%
60%
80%
100%
89 90 91 92 93 94 95 96 97 98 99 00 01 02 03
%THC < 5 5  %THC <10
10  %THC < 15 15  %THC < 20
20  %THC 
lems comes from the United States. The Department of
Health and Human Services’ Substance Abuse and
Mental Health Services Administration (SAMHSA) is
responsible for collecting a range of important indica-
tors about the state of substance abuse in the United
States. These include the Drug Abuse Warning Network
(DAWN), which records the number of cases in which
medical staff from a representative sample of emergency
room departments determined that presenting trauma
was related to the use of legal or illegal drugs (referred
to as ‘mentions’), as well as deaths that coroners deter-
mine to be drug-related.149 While there are very few
deaths attributable to cannabis use, the number of
cannabis-related emergency room episodes is substan-
tial, and has risen over the years.
According to the medical professionals participating in
the DAWN system150, 'marijuana' (which includes
cannabis resin) was a feature in 45,259 emergency room
episodes in 1995. The number of mentions increased to
119,472 in 2003, a 164 per cent increase. Looking at
these figures as rates, which would take into account the
increase in population during this period, there were 47
mentions per 100,000 in 2002, an increase of 139 per
cent over 1995. This increase is less than was seen for
MDMA (767 per cent) but more than for cocaine (33
per cent) or heroin (22 per cent).
These figures would support the argument that
cannabis emergency room admissions for cannabis have
increased, and have increased at a rate disproportionate
to most other drugs of abuse. But other SAMHSA data
indicates that overall cannabis use levels also increased
during this period. According to the National Survey on
Drug Use and Health (NSDUH), the number of annual
users of cannabis in the United States was 17,755,000
in 1995. This figure increased to 25,755,000 in 2002,
an increase of 31 per cent. 
Using these figures, it is possible to calculate the number
of drug users per emergency room cannabis mention. In
1995, there was one visit for every 392 people who used
the drug that year. In 2002, there was one visit for every
216 users, an increase of 55 per cent. This suggests that
the share of total cannabis users who find themselves in
an emergency room has increased.
However, when cannabis was mentioned, it was usually
mentioned in combination with other drugs. In 72 per
cent of the cases when cannabis was mentioned, other
drugs were also mentioned. Thus, in only a minority of
cases could it be clearly argued that cannabis was the
only drug that might be involved in precipitating the
emergency room visit. But the share of “cannabis only”
mentions has increased since 1995, when 78 per cent of
the episodes where cannabis was mentioned also fea-
tured other drugs, which supports the notion that the
drug on its own is becoming more problematic.
Those seeking emergency attention with a drug situa-
tion are further classified as to the exact cause of the
emergency. In recent years, the most common reason for
seeking emergency room attention for cannabis is an
unexpected reaction to the drug. This is consistent with
the kind of effect that would be expected with the
increasing circulation of high potency cannabis. 
The growth of rehabilitation demand
In addition to acute episodes, high potency cannabis
could contribute to chronic problems in a variety of
ways. It has been argued that increased potency repre-
sents increased addiction potential.151
Once again, the best data on treatment presentations
comes from the largest cannabis market, the United
States, in the form of the Treatment Episode Data Set
(TEDS), which tracks some 1.5 million admissions to
drug treatment in facilities that report to state adminis-
trative data systems.152 Unfortunately, using these fig-
ures to determine the extent to which drug users are
finding their consumption to be problematic is compli-
cated by the fact that large shares of people entering
treatment do not do so voluntarily. Those apprehended
in possession of cannabis (especially young people) are
often given a choice in court: enter treatment via a
diversion programme or go to jail. 
According to TEDS, 111,418 people were admitted to
treatment in 1993 with cannabis as their primary sub-
stance of abuse, comprising 7 per cent of the overall
treatment population. In 1999, this number was
232,105, comprising 13 per cent of the treatment pop-
ulation. In other words, the number of cannabis admis-
sions more than doubled in six years and, in addition,
cannabis users nearly doubled their share of the treat-
ment population.  However, this increase took place at
a time of renewed law enforcement focus on cannabis
use: the number of cannabis arrests increased from
380,700 in 1993 to 704,800 in 1999, an increase of 85
per cent. During this same period of time, non-cannabis
drug arrests increased by just 11 per cent.153 Partly as a
result, the share of cannabis users in treatment who were
there due to a criminal justice referral increased during
this period.  It appears that changes in criminal justice
policy were responsible for the bulk of the dramatic
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increase between 1993 and 1999, but they do not
account for all of it. With regard to the treatment data,
therefore, the American case is inconclusive.
However, the United States is not alone in seeing an
increase in the number and share of cannabis admissions
to treatment. A similar trend is seen in Europe, where
most countries have been liberalizing their cannabis
policies, rather than emphasizing enforcement, in recent
years. Treatment data within Europe are not uniform, so
it is difficult to compare between countries. But it
would appear that cannabis has increased its share of the
treatment population in all European countries for
which records are available in recent years. The increase
is lowest in Greece and Italy, two countries that receive
most of their herbal cannabis from Albania. Some of the
countries where the market share of sinsemilla has
increased, such as Germany and the Netherlands, have
also seen dramatic increases in the treatment share for
cannabis. Exceptions include the United Kingdom
(believed to be using more sinsemilla but with modest
increases in treatment share) on the one hand and
Sweden (still largely consuming cannabis resin but
tripling admission share) on the other. 
These figures refer to the share cannabis holds of the
treatment population, and thus documents that
cannabis is becoming more problematic relative to other
drugs. In most cases, this would also suggest an increase
in absolute numbers of cannabis users seeking treat-
ment. 
Monitoring efforts in Australia are too new for time
series data, but cannabis commanded 43 per cent of the
non-alcohol treatment admissions (some 27,000 indi-
viduals), ahead of heroin and amphetamines, in 2002-
2003.155 Criminal justice referrals made up at least 37
per cent of this treatment population, however.156 Inde-
pendent of this data, it has been argued that an increas-
ing number of people are seeking treatment for cannabis
problems in centres used to treating alcohol and opiate
dependence.157 The reasons for this increase remain
unclear.
In South Africa, cannabis has also grown in its share of
admissions to treatment in the major urban centres,
including Cape Town (4 per cent in 1996 to 11 per cent
in 2004), Durban (10 per cent in 1996 to 25 per cent
in 2004), and Gauteng (which includes Johannesburg
and Pretoria, 11 per cent in 1998 to 19 per cent in
2004), as well as the rural province of Mpumulanga (14
per cent in 1999 to 24 per cent at the end of 2004).158
Whether the treatment increase is possibly due to
increased potency is unknown – South African cannabis
is rarely tested for THC levels, and other factors, such
as the declining age of the treatment population, may be
responsible.
Thus although there simply is not enough data to prove
that high potency cannabis is behind these trends, there
is certainly a basis for a focused study of the association.
As border controls stiffen, it is likely that a growing
share of cannabis will be produced domestically, and in
many countries this means indoors.  But for most of the
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1996 1997 1998 1999 2000 2001 2002 Increase
Denmark 11 27 145%
Germany 18 30 66%
Greece 6 7 17%
Spain 4 11 175%
France 11 14 27%154
Ireland 11 21 91%
Italy 8 9 12%
Luxembourg 4 11 175%
Netherlands 11 17 55%
Finland 18 23 28%
Sweden 7 30 329%
UK 8 10 25%
Source: EMCDDA Annual Reports 1999 and 2002
Table 2: Share of primary cannabis users in the treatment populations of European countries
world, cannabis remains what it has been for years.
What is changing is our understanding of the risks asso-
ciated with the drug.   
Our understanding of the impact on health is changing
The widespread use of cannabis is clearly related to the
public perception that smoking herbal cannabis is vir-
tually harmless.159 It is widely understood that, unlike
other drugs, death by cannabis overdose is extremely
unlikely and few people develop cannabis habits that
force them into street crime or prostitution. Cannabis is
not associated with violent behaviour in many coun-
tries, and its role in accidents is vague in the public
mind. The stereotypical ‘stoner’ character has become
celebrated in popular media as harmless and somewhat
endearing. Moreover, claims of purported medical ben-
efits of cannabis have created the impression that
cannabis may actually be beneficial to health. 
Despite the good press, cannabis remains a powerful
drug. Cannabis use affects virtually every organ system
of the body, from the central nervous system to the car-
diovascular, endocrine, respiratory, and immune sys-
tems.160 Its impact on the psyche and behaviour of users
can be considerable. Few casual users of cannabis know
that cannabis dependence is a major issue when they
first start experimenting with the drug. 
There have been many recent reviews of the literature
on the health impacts of cannabis. This discussion uses
the one published by World Health Organization in
1997161 as a point of departure, focusing on the major
new findings since this review was conducted. The
health effects of cannabis were also examined in a spe-
cial double edition of UNODC’s Bulletin on Narcotics in
1998. 
Impact on the brain and behaviour
People smoke cannabis because it significantly changes
their state of mind. The acute effects of cannabis use are
an altered state of consciousness characterized by eupho-
ria and relaxation, perceptual alterations, time distor-
tion, and the intensification of ordinary sensory
experiences. 
But altered consciousness comes at a cost. Short-term
memory and attention, motor skills, reaction time, and
skilled activities are impaired while a person is intoxi-
cated.162 This has a potential impact on driving skills
and involvement in accidents. Moreover, cannabis has
the ability to produce dysphoric reactions, including
severe anxiety and panic, and paranoia.163
In addition to its acute effects, cannabis use can produce
long-term psychological problems. There is growing
evidence that it can trigger latent psychosis and promote
personality decompensation in diagnosed schizophren-
ics. Finally, some regular cannabis users find it difficult
to stop using the drug, even when it is having adverse
consequences for their lives. 
Altered brain function can affect driving
The debate around cannabis and driving has been pro-
tracted. The World Health Organization states that
there is sufficient consistency in the experimental evi-
dence and studies among accident victims to conclude
that there is an increased risk of accidents in people who
drive when intoxicated with cannabis.164 Subsequent
research has pointed in both directions.165
The short-term impact of cannabis on cognitive and
psychomotor performance has been recognized for
many years. The effects include the slowing of reaction
time, motor incoordination, impairment in short-term
memory, difficulty in concentration, and slower prob-
lem solving. The effects are dose-related but can be
demonstrated after relatively small doses (5-10 mg
THC), even in experienced users.166 But studies have
conflicted on whether this impairment affects driving
performance, with some suggesting that those intoxi-
cated on cannabis recognise their condition and drive
more carefully in compensation.
Research in this area has been complicated by the way
the drug is metabolised. THC is fat-soluble, and quickly
passes out of the blood into the brain and other organs,
where it and its metabolites can remain for extended
periods of time before slowly being excreted. Thus, the
detection of cannabis metabolites in urine only serves to
prove that the subject has used cannabis at some time in
the recent past, not that intoxication was indicated at
the time of the testing. And, unlike alcohol, even blood
tests are not always reliable measures of the level of
intoxication, particularly if they measure metabolites
instead of THC. Perhaps partly as a result, the more
recent studies in this area reach conflicting conclusions.
On the other hand, surveys that established recent use
of cannabis by directly measuring THC in blood
showed that THC positives, particularly at higher doses,
are about three to seven times more likely to be respon-
sible for accidents in which they were involved as com-
pared to drivers that had not used drugs or alcohol.167
And laboratory studies of driving by subjects given
known quantities of THC have repeatedly found a con-
nection between cannabis intoxication and bad driving,
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as THC impairs cognition, psychomotor function and
actual driving performance in a dose related manner.
The degree of performance impairment observed in
experimental studies after doses up to 300 mcg/kg THC
were equivalent to the impairing effect of an alcohol
dose producing a blood alcohol concentration of 0.05
g/dl, the legal limit for driving under the influence in
most European countries.168
Progress in this debate might be assisted by standardis-
ing methodologies and finding more accurate ways of
documenting current cannabis intoxication. One way of
sidestepping the scientific problems is to ask the users
themselves if they feel the perceptual distortions associ-
ated with cannabis consumption affect their driving.
For example, one survey of regular cannabis users in
Australia reported a quarter (25 per cent) of respondents
felt their driving performance was impaired, reflexes and
reaction times slowed, and their concentration affected
when attempting to drive under the influence of
cannabis.169 The fact that over half of those polled in the
national surveys on drug use in New Zealand say they
never drive when under the influence of cannabis also
demonstrates that cannabis users themselves feels that
cannabis impairs their driving performance.170
Adverse psychological effects
The ‘reefer madness’ discourse of the early anti-drug
campaigns in the United States appears to have under-
mined the credibility given to official pronouncements
on the mental health risks of cannabis. This is unfortu-
nate, because it is becoming increasingly clear that
cannabis use can have serious psychological conse-
quences. In the last eight years, several major reviews of
the psychiatric problems associated with cannabis use
have been conducted.171
With regard to the acute effects of the drug it is clear
that cannabis can cause some dysphoric effects when
used in high doses, including panic and delusions and
‘cannabis psychosis’. In 1997, the World Health Orga-
nization found that the existence of such a disorder
would require further research evidence. However, a
recent review found that very high doses of cannabis can
induce a brief psychosis, but this condition is extremely
rare.172 In contrast, another report found that an appre-
ciable proportion of cannabis users report short-lived
adverse effects, including psychotic states, following
heavy consumption.173
With regard to long-term effects, several impacts have
been hypothesised. One of the early attempts to describe
the negative impact of cannabis on the mental state of
users is the so-called ‘amotivational syndrome’, a per-
sonality deterioration with loss of energy and drive to
work.174 Again, the World Health Organization was
unable to confirm the existence of such a syndrome
based on the research in 1997. The state of evidence on
amotivational syndrome largely comprises uncontrolled
studies of long-term cannabis users in various cul-
tures.175 Evidence to the contrary is seen in cultures
where cannabis is traditionally consumed to increase
work output, such as South Africa and Jamaica. Due to
the lack of a strong evidence base, the validity of this
diagnosis remains uncertain.176 It is probable that it rep-
resents nothing more than ongoing intoxication in fre-
quent users.177
More worrying is the conflicting evidence around the
claim that cannabis can either cause psychosis in vul-
nerable individuals or precipitate latent psychosis. The
World Health Organization argues that there is clear
evidence of an association between cannabis use and
schizophrenia. One recent review of the literature deter-
mined that cannabis exposure is associated with an
increased risk of psychosis, possibly by interacting with
a pre-existing vulnerability for these disorders. A dose-
response relationship was found between cannabis expo-
sure and risk of psychosis, and this association was
independent from potential confounding factors such as
exposure to other drugs and pre-existence of psychotic
symptoms.178 Increased rates of psychotic symptoms
were found to be associated with the development of
cannabis dependence in young people (ages 18 and 21)
in a longitudinal study of a birth cohort of 1,265 indi-
viduals in New Zealand, even when pre-existing symp-
toms and other background factors were taken into
account.179
Since some schizophrenics ‘self-medicate’ with cannabis,
it can be difficult to determine the lines of causation. An
association between use of cannabis in adolescence and
subsequent risk of schizophrenia was reported in a
follow-up study of Swedish conscripts. The authors later
extended the follow-up period and identified additional
cases. Between the two studies, 50,087 subjects partici-
pated. Cannabis was associated with an increased risk of
developing schizophrenia, consistent with a causal rela-
tion.180
Studies have also indicated that early use of cannabis is
associated with the later development of psychosis. The
Dunedin longitudinal study of adolescent cannabis use
found that using cannabis in adolescence increases the
likelihood of experiencing symptoms of schizophrenia
in adulthood among psychologically vulnerable individ-
uals. Moreover, the authors added that early cannabis
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use (by age 15) confers greater risk for schizophrenia
outcomes than later cannabis use (by age 18). This risk
was specific to cannabis use, as opposed to use of other
drugs.181
Aside from full-blown psychosis, cannabis is associated
with other forms of mental illness. One study found
that the prevalence of co-morbid psychiatric disorders
and the severity of depressive and anxious symptoms
increased progressively with the degree of involvement
with cannabis.182
A link between cannabis and major depression was
found in an epidemiological study of 6,792 young
adults in the USA. The risk of major depression was
moderately associated with the number of occasions of
cannabis use and with more advanced stages of cannabis
use.183 These data were later confirmed in a review of
cohort studies and well-designed cross-sectional studies
in the general population. A modest but significant
association was found between early-onset, regular
cannabis use and later depression. On the other hand,
some evidence was also found of an increased risk of
later cannabis use among people with depression. This
would support the hypothesis that people dealing with
mental illness may turn to cannabis or other drugs in an
attempt at self-medication. Little evidence was found
for an association between depression and infrequent
cannabis use. 184
Furthermore, research based on the Christchurch cohort
study (a 21-year longitudinal study of a birth cohort of
1265 New Zealand children) concluded that a signifi-
cant link exists between the frequency of cannabis use
and negative psychosocial outcomes, including prop-
erty/violent crime, depression, suicidal behaviours and
other illicit drug use. Especially, for the measures of
crime, suicidal behaviours and other illicit drug use
there was evidence of age-related variation in the
strength of association with cannabis use, with younger
users (14-15 years old) being more affected by regular
cannabis use than older regular users (20-21 years old).
The association between cannabis use and depression
did not vary with age.185
A significant association between cannabis use and poor
mental health was found in adolescents and young
adults during the Dunedin long-term prospective study.
Cannabis use and poor mental health were linked to low
socio-economic status, a history of behaviour problems
in childhood, and low parental attachment in adoles-
cence. Mental disorder at age 15 led to a small but sig-
nificantly elevated risk of cannabis use at age 18; by
contrast, cannabis use at age 18 elevated the risk of
mental disorder at age 21. The authors conclude that
the primary causal direction leads from mental disorder
to cannabis use among adolescents and the reverse in
early adulthood. In contrast, alcohol use and cigarette
smoking had independent associations with later mental
health disorders.186
Current heavy cannabis use appears to have a negative
impact on intelligence. In one study, IQ scores were
examined before, during and after cessation of regular
cannabis use to determine any impact of the drug on
this measure of cognitive function. It was found that
current cannabis use was significantly correlated in a
dose-related fashion with a decline in IQ over the ages
studied. Current cannabis use had a negative effect on
global IQ score only in subjects who smoked five or
more joints per week (heavy users). A negative effect was
not observed among subjects who had previously been
heavy users but were no longer using the substance.
Smoking at least five joints weekly should not be inter-
preted as a definitive threshold, as subjects were at low
risk for other factors that could have a negative syner-
getic effect on IQ score. Authors conclude that cannabis
does not have a long-term negative impact on global
intelligence, however they also identified the need for
further investigation of the cognitive consequences of
both current and previous cannabis use, especially a
residual cannabis effect in more specific cognitive
domains such as memory and attention.187
Cannabis use in early adolescence appears to have the
ability to interfere with the normal development
process. For example, one study pointed out that long-
term cannabis users with early age of onset of their drug
consumption (age 14 to 16) showed a specific deficit in
visual scanning. A group of cannabis users (17 partici-
pants) compared to control group (20 participants)
showed less effective search behaviour, including longer
response times and more fixations at about the same
error level. In sum, the results point to two loci of
adverse effects: impairment in visual short-term
memory, and less effective visual processing at a more
strategic, top down controlled level.188
Furthermore, an early age of onset, rather than other
potential predictors of test performance like present age,
degree of acute intoxication or cumulative toxicity, was
found to be the only factor predicting enduring effects
on specific attentional functions in adulthood. Visual
scanning undergoes a major maturation process around
age 12-15 years and it is known to react specifically and
sensitively to cannabinoids. A comparison of a group of
young adult regular users of cannabis only with a group
of non-users on a battery of tests of selective attention,
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one of which is a test of visual scanning attention,
showed that performance of cannabis users was selec-
tively worse on this test, and the only feature that cor-
related with this impairment was the age at which
adolescents began to use cannabis. Apparently vulnera-
ble periods during brain development exist that are sub-
ject to persistent alterations by interfering exogenous
cannabinoids.189
Cannabis and aggression
The argument is made by many that cannabis is a “sop-
orific” and therefore the historical associations the drug
has with violence are unfounded. However, this position
seems to underestimate the importance of ‘set and set-
ting’ in understanding the impact of any drug. Research
has illustrated that the effects of a drug are not simply a
product of its chemistry, but rather the interaction of
this chemistry with the user’s situation, mindset and his
immediate environment when taking the drugs. So,
while in the Western paradigm, cannabis is seen as drug
inducing levity and sloth, this may not be the only
interpretation that could be given to its physiological
effects.
Depending on the dose, cannabis is generally classed as
an ‘hallucinogen’, not a sedative or depressant. In many
species the behavioural actions of low doses of delta-9
THC are characterized by a unique mixture of depres-
sant and stimulant effects in the central nervous system.
Heart rate is raised, body temperature drops, and
thought processes are disturbed, for better or worse.190
Some users refer to cannabis as a ‘mood enhancer’.
There may also be a chemical basis for differing views of
the subjective effects of cannabis on aggression. In
South Africa to this day, African people see cannabis as
a stimulant, which eases labour, fuels creativity, and can
fuel violence.191 One study notes that South African
cannabis smokers seem to be particularly prone to psy-
chosis with hypomanic features.192 The cannabis native
to this area is considered a pure sativa, with very little
CBD (see Annex 1 for more on this cannabinoid),193
which is believed to moderate the stimulant effects of
the drug,194 and which may possess anti-psychotic prop-
erties.195 It may be that more attention needs to be paid
the variability of the cannabis plant before generalizing
about its subjective effects. 
There is little in the Western scientific literature to sup-
port the contention that cannabis is strongly associated
with violence, however. There is some research that does
find a link between cannabis and violent crime. While
these studies fall far from demonstrating that cannabis
and violence are deeply linked, they do contradict the
view that cannabis intoxication makes violence
unthinkable.
New evidence for the gateway hypothesis?
One of the perennial debates surrounding the impact of
cannabis is the so-called ‘gateway’ hypothesis: cannabis
opens the door to the subsequent use of other drugs.
Much of the early work in this area suffered from the
post hoc ergo propter hoc logical fallacy. The fact that
many users of other drugs report first using cannabis
does not demonstrate a causal link between the two
behaviours, and even a cursory look at the survey data
illustrates the fact that most people who try cannabis do
not go on to use other drugs. 
More sophisticated recent studies indicate there may be
more to this argument than its early incarnations sug-
gested, however. One remarkable twin study was con-
ducted in Australia. A national volunteer sample of 311
young adult identical and fraternal same-sex twin pairs
was assembled. In each case, one twin had used cannabis
before 17 years, while the other had not. Individuals
who used cannabis by age 17 years were 2.1 to 5.2 times
more likely than their co-twin to have experienced other
drug use, alcohol dependence, and drug abuse/depend-
ence. Controlling for known risk factors had only neg-
ligible effects on these results. The authors conclude that
associations between early cannabis use and later drug
use and abuse/dependence cannot solely be explained by
common predisposing genetic or shared environmental
factors. They argue that association may arise from the
effects of the peer and social context within which
cannabis is used and obtained. In particular, early access
to and use of cannabis may reduce perceived barriers
against the use of other illegal drugs and provide access
to these drugs.196
A good share of cannabis users find that they 
cannot stop
Cannabis is not popularly associated with addiction.
Traditionally, cannabis was regarded as a non-addictive
drug because of the lack of observed physiological with-
drawal symptoms. But the terminology around addic-
tion changed with the publication in 1994 of the
American Psychiatric Association’s version four of its
Diagnostic and Statistical Manual (DSM-IV). Rather
than “addiction” the DSM-IV refers to “substance
dependence,” a condition that requires no physical
withdrawal symptoms. The emphasis is now on the
inability to end use despite the desire to do so and the
problems that use causes in the lives of the dependent
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person.197 At the same time, new research indicated that
heavy cannabis users do experience a clinically signifi-
cant withdrawal syndrome, although its effects appear
to be relatively mild. 
The World Health Organization (WHO) cites research
indicating that about half of those who use cannabis
daily will develop dependence, which is roughly consis-
tent with these findings. WHO also notes that the low
number of users presenting for treatment relative to the
size of the user population suggests that there is a high
rate of remission even in the absence of treatment.198
A 2002 review of clinical and research experience con-
cluded there is strong evidence demonstrating that
cannabis can and does produce dependence. Clinical
and epidemiological studies indicate that cannabis
dependence is a relatively common phenomenon asso-
ciated with significant psychosocial impairment.199
One comparative review of drug dependence risk found
an estimated 9 per cent of lifetime users will develop
cannabis dependence at some point. This risk, however,
is less than many other drugs, including legal drugs. It
is estimated that 15 per cent of alcohol users, 23 per
cent of opiate users, and 32 per cent of tobacco users
will develop dependence on the drug.200
Of the 9 per cent of those who try cannabis and go on
to develop dependence, it is estimated that 80 per cent
of these people will not seek treatment.201 Despite this,
globally, more people receive treatment for cannabis
than for any other illicit drug group besides heroin.  Just
under a million people participate in rehabilitation pro-
grammes every year for help with their cannabis prob-
lems in the United States alone. As discussed above, the
exact numbers may be misleading, because often con-
victed users may be given a choice between jail time and
treatment. But even in countries where this policy does
not hold, large shares of the total treatment population
say their primary drug is cannabis.202 In a number of
African countries, cannabis exceeds even alcohol in
demand for treatment. 
Impact on the unborn
The World Health Organization points out that
research in this area is complicated by sampling issues
and questionable self-report data. Despite these, they
conclude that there is reasonable evidence that cannabis
use during pregnancy leads to reduced birth weight,
possibly due to the same mechanism as tobacco smok-
ing, foetal hypoxia. They conclude that there is little evi-
dence to support the idea that cannabis smoking causes
chromosomal or genetic abnormalities or birth defects.
Most studies have confirmed the WHO conclusion by
finding no relationship with either minor or major mor-
phologic abnormalities.203 However, the Atlanta Birth
Defects Case-Control Study was used to identify 122
isolated simple ventricular septal defects (VSD) cases
and 3029 control infants born during the period 1968
through 1980 in the metropolitan Atlanta area. Data on
alcohol, cigarette, and illicit drug use were obtained
through standardized interviews with mothers and
fathers. A two-fold increase in risk of isolated simple
VSD was identified for maternal self- and paternal
proxy-reported cannabis use. Risk of isolated simple
VSD increased with regular (three or more days per
week) cannabis use. This is the first study to identify an
association between maternal cannabis use and VSD in
offspring.204
Three case-control studies have found associations
between cannabis use during pregnancy and increased
risk of cancer in children. The mothers of children with
acute non-lymphoblastic leukaemia were 11 times more
likely to have used cannabis before and during preg-
nancy then were mothers of controls.205
Mild but significant cognitive impairment in the off-
spring of mothers who smoked cannabis during preg-
nancy were found in the Ottawa Prospective Prenatal
Study.206 These data were confirmed through other
studies. Prenatal cannabis use was significantly related to
increased hyperactivity, impulsivity, and inattention
symptoms at age 6207 and age 10.208 Furthermore it had
a significant effect on academic performance: learning
and memory of 10-year olds209 and deficits in reading,
reading comprehension, spelling, and overall lower
rating on the teachers’ evaluations of the children’s per-
formance.210
A follow-up study by of the same group between the
ages of 13 and 16 indicated that those who had been
exposed to cannabis in utero had poorer performance on
tasks involving visual memory, analysis and integra-
tion.211
Cannabis smoking is not good for the lungs
As the World Health Organization concluded, smoking
cannabis is not good for the lungs. Moreover, as
cannabis smokers inhale more deeply, smoking a joint
results in exposure to significantly greater amounts of
combusted material per inhalation than smoking a
tobacco cigarette. Of course, most cannabis users con-
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sume fewer cigarettes than most tobacco smokers, but
this may not be the case with those classified as ‘chronic’
consumers above. 
Daily cannabis smoking has been clearly shown to have
adverse effects on pulmonary function and produce res-
piratory symptomatology (cough, wheeze, and sputum
production) similar to that of tobacco smokers.212 Sev-
eral studies have demonstrated that, even after limited
exposure to cannabis smoke, airway inflammation
develops. Examination of the lungs of cannabis smokers
who smoked an average of only a few joints per day
showed the same degree of airway injury as that detected
in tobacco smokers who smoked 20 to 30 cigarettes per
day. This underscores the importance of deep inhalation
in enhancing the relative injury caused by cannabis
smoke.213
Cannabis smoke is also a potential cause of cancer
because it contains many of the same carcinogenic sub-
stances as cigarette smoke. A review of the basic science
work concluded that the evidence clearly demonstrated
the ability of cannabis smoke to produce mutations and
cancerous changes.214 In a recent review of all of the cur-
rent evidence, one study concludes that there are good
grounds for believing that chronic smoking of cannabis
carries a significant risk of cancer in aerodigestive tract
and lung.215
Cannabis is not good for people with heart prob
lems
Acute cardiovascular effects of cannabis are dose-
dependent tachycardia, which can lead to increased car-
diac output and is generally associated with a mild
increase in blood pressure. At high doses, sympathetic
activity is inhibited and parasympathetic activity
increased, leading to bradycardia and hypotension.216
The cardiovascular effects of cannabis are not associated
with serious health problems for most young, healthy
users, although occasional myocardial infarction, stroke,
and other adverse cardiovascular events are reported.217
Cannabis is not good for health
As noted above, the fact that the therapeutic effects of
cannabis are being researched and legal changes are
being made to accommodate this work may have
obscured one simple fact: cannabis use is not good for
health.
• According to a number of studies and many users,
cannabis smoking impairs one’s ability to drive a
car and perform complex operations requiring
motor skills. 
• A significant share of cannabis users (about a fifth,
according to one study) have experienced
unwanted psychic effects during cannabis intoxi-
cation, including panic attacks, paranoia, and
‘psychotic symptoms’, and this risk of this hap-
pening may be increased by the growing availabil-
ity of high potency cannabis.
• Numerous studies find an association between
cannabis use and psychosis, and this effect is also
likely to be influenced by the potency of the
cannabis consumed.
• Despite early claims to the contrary, cannabis
dependence is a reality: many people who use
cannabis (several studies indicate just under 10 per
cent) find it difficult to stop, even when it inter-
feres with other aspects of their lives, and more
than a million people from all over the world enter
treatment for cannabis dependence each year.
• Research indicates that younger users, whose
brains are still developing, may be especially vul-
nerable to the negative effects of cannabis.
• Cannabis smoking is bad for the lungs for all the
same reasons that tobacco smoking is.
• There appear to be significant risks associated with
prenatal exposure to cannabis and the effects of
cannabis on the cardiovascular system.
Whether these negative effects are greater or lesser than
other substances, including legally available substances,
is of little relevance to the users whose lives are impacted
by them. Despite its normalization in some countries
and its occasional celebration in popular culture, it
should be noted that cannabis is a powerful drug that
has recently become more powerful in many parts of the
world. 
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2.4. CONCLUSION
The world has failed to come to terms with cannabis as a drug. In some countries, cannabis use and trafficking are
taken very seriously, while in others, they are virtually ignored. This incongruity undermines the credibility of the
international system, and the time for resolving global ambivalence on the issue is long overdue. Either the gap
between the letter and spirit of the Single Convention, so manifest with cannabis, needs to be bridged, or parties to
the Convention need to discuss re-defining the status of cannabis.
The ability to make evidence-based decisions is undermined by our lack of knowledge about the nature of cannabis
markets. Despite an academic bibliography that could run into several volumes, there remain large gaps in our
understanding of where and how the plant is cultivated and consumed. This ignorance is particularly dangerous
because many assume that cannabis is understood quite well, and base their decisions on shaky foundations.
At the same time, the drug itself is changing. High-potency sinsemilla produced in indoor cannabis factories repre-
sents genuine innovation in a substance that has been around for centuries. Its emergence highlights the fact that
global illicit drugs markets are a moving target, and policies must be dynamic in order to address continual shifts
and unexpected turns. There must be constant feedback between research and intervention if our approach to drugs
issues is to be sound.
In several respects, cannabis is unique among illicit drugs. It is not dependent on transnational trafficking or organ-
ized crime to move from cultivator to user. Often, they are the same person, or at least socially related. There exist
international advocacy groups promoting legal reform concerning the drug, a phenomenon not seen for cocaine or
heroin. Medical use of the active ingredients, if not the plant itself, is championed by respected professionals. It is
not surprising that national opinions on this issue have begun to diverge. It is essential, however, that consensus be
regained, and that what is truly a global issue is again approached with consistency on a global level. After all, it is
for precisely this that the multilateral drug control system was designed.
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Mankind has cultivated cannabis for so long that the
origin of the plant remains unclear. Most experts suggest
Central Asia, where vast fields of wild cannabis can be
found today, as its likely birthplace. But the plant has
proven as adaptable as humanity itself, and it has spread,
both by design and opportunistically, to all corners of
the globe.
There is evidence for early recognition of its intoxicat-
ing effects, but historically it has been most widely cul-
tivated as a fibre crop. Hemp, the fibre derived from the
long stalks of the cannabis plant, was especially useful
for the production of rope and sailcloth due to its
strength and water-resistant qualities. The potency of
feral cannabis is generally quite low, so it was probably
first consumed in its concentrated form, as cannabis
resin. But all this is speculative, and it is entirely possi-
ble that the drug qualities of cannabis have been re-dis-
covered several times in different locations. Like so
much about cannabis, its history is obscure and diffuse.
Cannabis: Many plants in one
Cannabis is an annual plant, completing its lifecycle in
a single season and dying after reproduction.218 It grows
well under similar conditions as corn does. It prefers
temperatures between 14 and 27 degrees Celsius, but
can withstand freezing temperatures for brief periods of
time. In latitudes from about 30 to 60 degrees in the
Northern hemisphere, seeds are traditionally planted
between March and May, and the plant flowers between
September and November – about a six-month growth
cycle, with only one crop possible.219 Closer to the equa-
tor, however, it is possible to manage two annual crops
off the same plot220 and it has been claimed that some
tropical varieties will experience three or four growth
seasons a year.221 It prefers direct sunlight, as much as it
can get. After the first six weeks, it can grow with little
water as it possesses a powerful taproot, but it only
flourishes with regular moisture. It requires well-drained
soil or its roots will rot, however, so it does not grow
well in clay.222 While it can grow in difficult soil types,
such as sand, it prefers loams rich in nitrogen, with a
fairly neutral PH of between 6 and 7. Thus, while
cannabis grows wild in a wide range of areas, rather spe-
cific conditions are required for optimal growth.
When intentionally cultivated, cannabis can be grown
in most inhabited areas of the world, and cannabis sur-
vives in diverse climates by radically changing its shape,
ranging in appearance from a weedy shrub to a six metre
tall ‘tree’. The plant’s extreme adaptive morphology has
led to much debate around the taxonomic classification
of cannabis, and it was reclassified several times before
being given its own family, the cannabaceae, shared only
with the hops plant. 
It is still being debated whether there is only one species
of cannabis or several. The scientific debate has had
little influence on illicit cultivators who agree that
cannabis has two or three distinct varieties, based on
clear differences in the way the plants taken from spe-
cific regions appear and grow, as well as their divergent
subjective effects.223
• ‘Cannabis sativa’ is the term applied to both the
genus as well as to the most widespread variety, a
tall, conical plant typically found in warmer, low-
land climates (Thailand, Mexico and South
Africa, for example). 
• ‘Cannabis indica’ is a squat, bushy, highland plant,
putatively originating in northern India. 
• ‘Cannabis ruderalis’ is a more recently (and less
widely) recognized variety,224 found growing wild
in Central Asia. It is a small (less than 1 metre at
full maturity), tough plant, able to withstand the
harsh climate of the region. In some taxonomies,
industrial hemp is also seen as a distinct species. 
So different are these three that most casual observers
would regard them as distinct plants. In addition to
being different in appearance, strains of cannabis differ
in their chemical composition. Cannabis contains over
400 chemicals, of which about 70 are chemically unique
and are collectively referred to as cannabinoids. Delta-9
tetrahydrocannabinol (generally referred to simply as
THC) is believed to be responsible for the most of the
psychoactive effects of cannabis, although related chem-
icals are believed to also play a role. The precise way the
various components of cannabis interact and influence
the physiological and subjective effects of cannabis is a
topic of ongoing research.
One of the most important secondary chemicals is
cannabidiol (CBD), the biosynthetic precursor to THC,
which converts to THC as the plant matures. This
chemical is believed to ‘moderate’ the effects of THC,
having a more sedative effect, as well as muscle relaxant
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and anti-psychotic properties.225 In general, it is
believed that sativa varieties exhibit high levels of THC
relative to CBD, while for indicas, the opposite is true.
Users report pure sativas to produce a greater ‘high’ with
less of a ‘stoned’ feeling: i.e., they have more of a cere-
bral and less of a somatic effect, which is in keeping with
what is understood about the nature of their chemical
compositions.
Aside from shape shifting, cannabis is unusual in several
other ways, which are important to appreciate in order
to understand cultivation practices. Cannabis is ‘dioe-
cious’, which means each individual plant is either male
or female. Male plants fertilise females by means of
wind-borne pollen. This is of great importance to culti-
vators, as the most potent cannabis comes from the
flowers of the unfertilised female plant. Early in life,
male plants have as much or more THC as females, but
at the peak of ripeness, females far surpass males, par-
ticularly if unfertilised. As will be discussed below,
unfertilised female flowers are referred to as ‘sinsemilla’
(Spanish: without seeds), and today they constitute a
distinct drug product. 
The plant flowers over time or when it detects the
coming of autumn, as evidenced in the shortening of
days. This photosensitivity allows plants that germi-
nated late to complete their life cycle in an accelerated
manner. The exact photoperiod required to induce flow-
ering depends on the genetics of the plant, but a 12-
hour night period is enough to induce flowering in
most, if not all, varieties. This allows indoor cultivators
to decide when their plants will blossom.
In fact, all of the above unusual characteristics (variabil-
ity, adaptability, dioeciousness, wind-borne pollination,
photo-period linked fertility) have implications for
illicit cannabis production, and it is only recently that
these qualities have been exploited to their greatest
potential. These developments, and the impact they are
having on both the market and public health, will be
discussed in the final sections of this chapter.
Cannabis: Many drugs in one
Several drug products can be produced from cannabis,
falling into three main categories: 
• ‘herbal cannabis’, the leaves and flowers of the
plant, also known as ‘marijuana’,  ‘ganja’, and a
host of other names;
• ‘cannabis resin’, the pressed secretions of the plant,
commonly referred to as ‘hashish’ in the Western
countries or ‘charas’ in India. 
• ‘cannabis oil’. 
Herbal cannabis is most popular in North America and
most of the rest of the world, while cannabis resin is
most popular in much of Europe and a few traditional
hashish-producing regions.
Herbal cannabis
As is discussed further below, the nature of herbal
cannabis in the developed world has changed in recent
years.  This is the product of three distinct processes:
• In the past, most users were content to smoke var-
ious parts of the cannabis plant, including the
large leaves, but growing consumer consciousness
has led to demand for cannabis comprised of just
the flowering heads and small leaves, or ‘buds’,
which are the strongest part of the plant. 
• In addition, cannabis breeders from the United
States, the Netherlands, and Canada have worked
tirelessly to produce more potent cannabis. The
strains they have developed are known by their
brand names (e.g., ‘White Widow’, ‘Afghan Haze’,
‘AK-47’) or generically as ‘skunk’ in countries such
as Australia, France, New Zealand, and the United
Kingdom.
• The method for cultivating cannabis crops con-
sisting exclusively of unfertilised female plants
(‘sinsemilla’), which are the most potent, has been
re-discovered.
Today, the most potent forms of cannabis come from
the unfertilised female (sinsemilla) flowers (buds) of
plants bred for their high THC levels (skunk), and most
premium products on the market today partake of all
three of these characteristics.  Of course, in most of the
world, less refined products are the norm, but the tech-
nology is spreading through the mails and the Internet,
and, as discussed below, premium products appear to be
commanding increasing market share in the developed
world.
Today, most, but by no means all, high-potency
cannabis is produced indoors in developed countries, to
service local markets or those in neighbouring states.
Some of this indoor product is produced in soil and
some is produced hydroponically (in a non-soil
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medium, nourished through a nutrient bath). While
premium cannabis can be produced more efficiently
indoors and hydroponically, equally potent cannabis
can be grown in soil. 
Terms like ‘buds’, ‘sinsemilla’, ‘skunk’, and ‘hydroponic’
are often used as though they were interchangeable, and
there are large areas of overlap. But each represents a dis-
tinct aspect of the ways high-end cannabis has changed
in recent decades. Most high-end cannabis today con-
sists only of buds. Most of this is sinsemilla, and, in
developed countries,  it is likely the beneficiary of breed-
ing for high potency. Most high-potency sinsemilla is
grown indoors, some of which is grown hydroponically.
But even buyers of low-potency cannabis prefer buds
today, there is some outdoor sinsemilla cultivation, and
a good deal of indoor product is grown in soil. 
In short, there are many herbal cannabis products today,
though they are often discussed as though they are one
and the same. This further adds to the confusion around
the drug, and makes cross-cultural comparisons diffi-
cult.
Cannabis resin
In addition to the varieties of herbal cannabis, the drug
can also be consumed in the form of a resin.226 As the
plant flowers, glands called ‘trichomes’ produce a sappy,
resinous substance in which much of the cannabinoid
content of the plant is concentrated. The resin may be
collected while wet (by hand) or once the plant has
dried (by sieving), and is generally formed into balls,
sticks, or bricks. Dried resin must be heated or pressed
to make it malleable. Sale-ready hashish differs in colour
from sandy to reddish to black. It differs in consistency
from putty-like to brittle and dusty. It can also be found
in solution, as ‘hash oil’, but the market for this drug is
not widespread.
In hand rubbing, workers remove the gummy resin
from the living plants by running their hands over the
flowering tops. The resin adheres to the skin and has to
be removed by forcefully peeling it away and rubbing it
into little balls, which are combined and moulded into
shapes for marketing. Hand-rubbed hashish may have
been the first way cannabis was consumed, and it repre-
sents a rather inefficient and labour-intensive means of
gathering the drug. Hand rubbing today is concentrated
in India and Nepal.
Hand rubbing is not to be confused with hand pressing.
The dust-like product produced by sieving becomes
malleable when heat and pressure are applied, and this
can be done by hand or by machine in order to prepare
it for storage and shipping. Sieving requires the plants
to be dried first, which means an arid climate is essen-
tial. The resin and trichomes become powdery and brit-
tle, and can be removed from the bulk of the plant
matter by use of a screen and some percussive force. Tra-
ditionally, fabric is used as a screen and a basin or pot as
a collection device. Light tapping produces the purest
hashish, but greater quantities (including quite a lot of
relatively inert plant matter) can be gathered by the
application of more force. Thus, like olive oil, hashish is
often “graded” depending on whether it is the first or
subsequent “pressing”. The powdery resin that precipi-
tates is either gently heated or manually or mechanically
pressed to make it malleable. Lower grades may be adul-
terated with a range of oils and inert or active bulking
agents, although the European Monitoring Centre for
Drugs and Drug Addiction says such additives are ‘rare’
in European samples.227
Both of these processes are highly labour intensive and
somewhat wasteful, so it is not surprising that some
cannabis resin users have devised more efficient tech-
nologies. Many of these were piloted in the Nether-
lands. The potency of the hashish they produce
(nederhasj) is much higher than through traditional
methods. A third sort of hash – “jelly hash” – has also
emerged in recent years. This appears to be a combina-
tion of nederhasj and cannabis oil, with a soft consis-
tency and very high THC levels.
Smoked, baked, or vaporised?
As there are many forms of cannabis, there are also
many ways of consuming the drug. The amount of
THC delivered to the user depends a lot on the method
of ingestion, so trying to get a sense of how much is
consumed requires knowing exactly how it was con-
sumed. And each technique is subject to local variations.
Most herbal cannabis is smoked, but there are many
ways of doing this, and each culture where the drug is
introduced comes up with its own techniques and ter-
minology. Perhaps the most popular technique is to
make a kind of cigarette (‘joint’) using specialty rolling
paper or other material (such as scrap paper or the leaves
of local plants). In Ireland, for example, 98 per cent of
people who used cannabis (herbal or resin) in the last
month said smoking joints was one of the ways they
consumed cannabis, with the second most popular
response being pipes (7 per cent).228 In Europe, a filter
is often used, sometimes taken from a tobacco cigarette.
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Cannabis is generally smoked with tobacco (in part to
facilitate smooth burning) in Europe, parts of Asia,
North Africa, Australia, and New Zealand, but this is
unusual in most of sub-Saharan Africa and in the West-
ern Hemisphere.
Other popular consumption techniques include:
• Pipes, including both specially made and tobacco
pipes, often with a foil screen;
• Water pipes, hookahs, ‘hubble bubbles’ or bongs,
in which the smoke is cooled by passing through
a water chamber;
• Cigars, which have been emptied of their tobacco
contents and refilled with cannabis (referred to as
‘blunts’ in the United States after Philly Blunts, a
popular cigar brand);
• Vaporizers, modern machines that heat, but do
not burn, the cannabis, releasing the THC into a
plastic bag for inhalation;
• Makeshift devices, such as hollowed out apples,
beer-can bongs, etc.
• More exotic techniques, such as the chillum (a
large, horn-like, clay pipe used in India and
Jamaica) and others.
Cannabis (typically resin) can also be eaten. THC is fat-
soluble, and so cannabis can be included in a range of
food products, and is typically consumed in baked
goods. The subjective effects of eating cannabis are dif-
ferent from the experience of smoking, due to different
metabolic processes involved in absorbing the drug. It is
clear that the onset is slower and the duration longer
when cannabis is eaten.
The amount consumed is related to the method of con-
sumption. Vaporization is estimated to require twice as
much cannabis, and eating four times as much, to pro-
duce the same effect.229 Bongs are actually a more effi-
cient way to consume cannabis than joints, as less
material is lost in side-stream smoke. In Australia, sur-
veys indicate that bongs are more popular with younger
users (who were also more likely to prefer buds), while
joints were more popular with older users. This suggests
that younger users prefer to ingest more THC, or at
least to ingest their THC more quickly, as they choose
the best parts of the plant and the most efficient means
of consumption.230
Though there is considerable variation, the typical bowl
on a bong is large enough to accommodate about 1/20th
of a gram of cannabis, and most bong smokers will
reload their bowls several times in a consumption ses-
sion. Purpose-made cannabis pipes tend to have much
smaller bowls than tobacco pipes. A good example is the
‘sebsi’ used in Morocco to smoke ‘kif ’, a
cannabis/tobacco mixture. The bowl of a sebsi is typi-
cally very small. In contrast, the chillum used in India
and Jamaica can hold vast amounts of cannabis, but
these are commonly used by people who consume the
drug religiously, not casual users. 
The amount of cannabis found in a joint is dependant
on whether tobacco is included,231 whether a single or
multiple rolling papers are used, and the strength of the
cannabis concerned. Studies of cannabis joint size in the
United Kingdom in the 1970s suggested between a sev-
enth and a third of a gram per joint,232 and more recent
research in the UK233 and Ireland234 has found that this
has changed little over the years. This may be due to the
local consumption culture: British and Irish joints are
typically mixed with tobacco and a single rolling paper
is used, so there is little room for more cannabis. 
Joints in the Netherlands are typically comprised of the
tobacco of one cigarette with a small amount of high
potency cannabis. Dutch coffee houses offer pre-rolled
joints with a filter containing about 0.1g of cannabis
and 0.9 g of tobacco, and Dutch street joints average
around 0.25 g cannabis.235 A study in the Netherlands
showed life-sized pictures of joints to 400 frequent users
and asked them to indicate which represented what they
typically consumed. On this basis, 0.16 grams of
cannabis per joint was found to be an average, or over 6
joints to the gram. This was much less than what users
estimated they used when asked directly how many
joints they thought they got from a gram – four, or 0.25
grams per joint.236 This tendency to overestimate con-
sumption should be kept in mind in evaluating other
self-reported use data.
Figures from the United States are much higher, because
tobacco is rarely used, low-potency Mexican cannabis
dominates the market, and ‘multi-skin’ (using several
rolling papers) joints are common. Estimates range from
0.4 g,237 to 0.5 g238 to 0.8 g239 to an entire gram or more
in a single joint.240 Blunts can contain up to 3 g of
cannabis,241 but the product used is typically low-grade.
Jamaican ‘spliffs’ (joints) are about 10 centimetres long,
and were once said to contain as much as two or three
grams of cannabis.242
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Cheap enough to share
For most users, a joint should not be seen as a unit of
consumption because joints are usually consumed com-
munally. In France, 82 per cent of occasional users
(between one and nine incidents of use in the survey
year) never consume the drug alone. Even among regu-
lar users (between 10 and 19 incidents of use per
month), 20 per cent never consume alone, and only 20
per cent report they ‘often’ do so.243 In New Zealand in
2001, only 4 per cent of users polled said they smoked
alone during a ‘typical’ consumption session.244 In the
United States, a majority (57 per cent) of users said they
got the cannabis they used most recently for free or that
they shared someone else’s cannabis.245 In Ireland, the
figure is 64 per cent.246 And this phenomenon is not
unique to casual users: surveys among regular users in
the UK show almost all of them (96 per cent) share
joints at least some of the time. 247 The tendency to
share is related to the fact that an entire joint is too
much for most casual users, a subject that is explored
further below.
One of the reasons cannabis users can afford to be so
generous is that, in most countries, cannabis is relatively
cheap. In producer countries in the developing world, it
is sometimes cheaper to get high on cannabis than to get
drunk on beer. In South Africa, for example, the price
of a matchbox full of cannabis buds is about four rand
(just over 50 US cents), less than a bottle of beer in a
bar. In Singapore, cannabis has been used in the past by
worker communities as an inexpensive substitute for
alcohol.249 As might be expected, prices are cheapest in
various poor producer countries (India, Lao People’s
Democratic Republic, Colombia, various African coun-
tries) and highest in the developed countries, especially
where law enforcement is strong (Japan, Singapore,
Sweden, United States,). The United States is one of the
more expensive places in the world to buy cannabis, and
an average United States price of US$300 an ounce (28
grams) sounds substantial, until it is pointed out that a
dose sufficient to get a casual user high costs less than
US$5. And despite enforcement efforts, the price of
cannabis in the US has been relatively stable, between
US$10 and US$20 per gram for small buyers through-
out most of the 1980s and 1990s.250
Cannabis is also used together in cocktails with other
drugs. In South Africa, the ‘white pipe’ combination of
methaqualone, tobacco, and low-grade cannabis is the
primary way methaqualone is consumed. In Guyana,
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Country Cannabis per joint
Tobacco 
added?
Mostly 
sinsemilla?
Joints per gram
Netherlands 0.1 g - 0.25 g Yes Yes 4 – 10
United Kingdom/Ireland 0.15 g – 0.33 Yes Yes 3 – 7
USA 0.4 g – 0.5 g No No 2
Canada 0.2 g – 0.33 g Sometimes Yes 3 – 5
Jamaica 2 g – 3 g No No 0.5 – 0.33
Table 3: Variation in sizes of joints
Source: National Advisory Committee on Drugs (2005) 248
Fig. 13: Where cannabis was obtained on the last
occasion of use in Ireland
Given by stranger
3%
Bought from a contact 
not known personally
16%
Bought from a friend
20%
Shared among friends
27%
Given by family friend
30%
Bought from a stranger
1%
Given by a contact not 
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3%
Suriname, Haiti, Jamaica, Martinique, Dominica, Saint
Kitts and Nevis as well as Guatemala – cannabis joints
are occasionally spiked with cocaine base, with each
country having its own name for this combination.
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Source: Annual Reports Questionnaire Data.
Fig. 14: Selected herbal cannabis prices
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Various figures are used by law enforcement to estimate
the amount of cannabis that could be produced on a
given area of land, but the scientific basis of these esti-
mates is often unclear. A number of factors need to be
taken into consideration:
• Land dedicated to cannabis resin production will
only yield about 4 per cent as much drug product
by weight as will a similar sized field dedicated to
herbal cannabis. 
• Sinsemilla yields may differ from commercial
yields, which allow for a lot more bulk material to
be included in the product. 
• For commercial yields, it is important to distin-
guish between the product as sold and the prod-
uct used, the weights of which may be very
different.  
• Cultivation conditions, particularly the availabil-
ity of water, can play a major role.
• The experience of the grower and the style of cul-
tivation are key.
• If the climate is such that multiple crops are pos-
sible, this must be tallied, taking possible variation
between seasonal outputs into consideration.
• If the land is situated indoors, a different set of
rules applies.
Processing herbal cannabis from a whole plant in the
field to saleable product requires drying the material and
cutting away the parts not deemed suitable for sale.
Drying results in a substantial loss of weight, with the
dry plant weighing about 70 per cent less than the wet
plant. After trimming, the wet plant to dry product
ratio is said to be about 14 per cent.251
Empirically-based yield figures for sinsemilla can be
drawn from the medical cannabis industry, where a sci-
entific approach is taken to produce maximal yields of
good quality under controlled indoor conditions with
minimised input costs. The Bureau voor Medicinale
Cannabis in the Netherlands is one such facility. Analy-
sis of a recent crop would suggest that saleable material
represents about 30 per cent of dried plant weight and
about 8 per cent-10 per cent of wet plant weight. This
is easily summarized in the ratio 10-3-1.
Given the expertise of the medical producers, these fig-
ures should thus be regarded as optimal sinsemilla
yields. However, street product will likely contain more
plant bulk – this is obvious in the case of non-sinsemilla
products, because seeds are the densest part of the plant.
Medical cannabis producers, concerned about fungal
and mould growth, also tend to dry their product more
than illicit producers, typically to about 10 per cent
moisture content. Street samples generally contain more
moisture, ranging from 12 per cent-16 per cent, but the
impact on total bulk is minimal.252 In the end, the 10-
3-1 ratio (wet weight of plant – dry weight of plant –
dry weight of product) is probably reasonable for sin-
semilla. 
For low-grade cannabis, most of the seeds (and perhaps
more stems and leaves) are included. Inert, or relatively
inert, portions are generally removed before smoking.253
Seeds make up 23 per cent of the dry weight of the
entire plant, and stems 43 per cent.254 Most of the stem
weight is not included in the street product, but most of
the seeds are. Even if all of the stem were removed, seeds
would still make up about 40 per cent of the dry prod-
uct by weight. Allowing for some stem, it is possible that
about half the weight of low-grade cannabis, as sold on
the streets, is unusable. 
Yields per plant and unit area are dependent on the
degree of care given to the crop and the style of cultiva-
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Annex 2 -  Estimating yield
Source: Bureau voor Medicinale Cannabis, Netherlands.
Fig. 15: Ratio of wet plant to dry plant to yield in a
test crop of medical cannabis
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tion. Today, there are a wide variety of cultivation styles
in evidence around the world. In many developing
countries, people simply drop seeds and return months
later to collect whatever develops, a practice that is vir-
tually cost-free and thus very difficult to deter. In others,
huge plantations of cannabis are cultivated. The threat
of asset forfeiture has led cultivators in developed coun-
tries to plant on public lands (‘guerrilla grows’). In still
others, law enforcement pressures or an unsuitable cli-
mate have pushed production indoors, where inputs are
higher but so are returns.
Within these styles, there is further variation. Some cul-
tivation techniques emphasise dense plantings, while
others focus on a smaller number of highly productive
plants. It has been argued that, for the average home
garden plot, cultivating a large number of small plants
or a small number of large plants results in roughly the
same yield.255 Many indoor growers discuss their yields
in terms of wattage – one pound per 600-watt high-
pressure sodium bulb being a common rule of thumb.
But this is not much help in comparing indoor and out-
door yields. The following discussion concludes that
yields should be expressed per unit area (square metre or
hectare) rather than per plant.
A single cannabis plant, given individual attention and
wide room to grow, can be far more productive than the
average plant cultivated in the dense conditions that
typically accompany clandestine grows. Further, low
planting densities quickly reach the point of diminish-
ing returns for growers.256 Using low-density, per-plant
yields as a rule of thumb is likely to produce inflated
estimates, and that laws that seek to regulate the number
of plants grown, rather than the land area under culti-
vation, may be misplaced.
In practice, many traditional growers use much greater
planting densities, especially on prime lands. In
Morocco, to cite an extreme case, about 30 plants are
cultivated per square metre in irrigated areas.257 Similar
densities are used in ‘sea of green’ indoor operations,
where per-plant yields are in the neighbourhood of 10
g apiece,258 far from the ‘pound a plant’ rule sometimes
cited.259
In addition to plant density, cultivation style is clearly
relevant in determining yield. Dense, indoor, high-tech
plantings are more productive than dense, outdoor, tra-
ditional ones. Looking at some 35 yield estimates given
by a wide range of different sources, a degree of con-
sensus is discernable on the yields per square metre of
the various cultivation strategies. Looking first at the
outdoor situation, yields vary from as low as 47 grams
per square metre for varieties grown without irrigation
in difficult climates, to as high as 500 grams per square
metre in well-tended gardens. An average of about 200
g per square metre outdoors has been said to be consis-
tent with figures gathered in US court cases,260 but con-
ditions in the United States are generally better than
those encountered in much of the developing world. For
the purposes of the present analysis, a figure of 100
grams per square metre (or one metric ton per hectare)
will be used for outdoor crops when cultivation style is
unspecified.
All this highlights that cannabis is an extremely pro-
ductive drug crop. One square metre of outdoor culti-
vation space is sufficient to supply a user with one 0.27
g joint a day (a reasonable size for a European user) for
a year. A hectare could produce enough cannabis to
supply 10,000 daily users. If all 162 million annual
users smoked this amount (which is clearly not the
case), global demand could be met by a production area
of 162 square kilometres, an area about the size of
Liechtenstein. 
There is one important complicating factor, however.
Some parts of the world appear to harvest multiple
cannabis crops, and there is considerable confusion
about this matter. In latitudes where there is variation in
the seasons, there is usually one prime season (corre-
sponding to the summer months) and up to three sub-
sidiary seasons. In Lesotho, for example, it is often
claimed that there are two or three harvests, but one of
these may simply be the weeding of the male plants.
Yield figures for off-season crops would be lower in all
but the most generous climates, and some farmers may
only deem the summer crop to be worth the effort.
Thus, figures on the area under cultivation may vary
seasonally for each area under consideration, and the
yields per unit area would also vary by season. This con-
siderably complicates yield estimates based on cultiva-
tion area.
In addition, it is nearly impossible to say how much
cannabis is produced indoors in developed countries.
According to a wide range of sources, indoor yields vary
from a low of just over 300 grams to a high of just under
800 grams a square metre. These yields are produced by
a number of different strategies, with considerable
debate as to which is most productive. Individual plants
can be freakishly productive, and this can be perpetu-
ated, to some extent, by cloning. Overall, an average of
about 500 grams per square metre per harvest seems to
be confirmed by several sources. Some medical
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providers cite much lower figures, however. Of course,
the real productivity of indoor ‘plots’ is determined by
the number of crops than can be produced in a year. As
discussed above, a four-stage cultivation system allows
three to six crops per unit of floor area per year. Thus,
indoor crops are between 15 and 30 times as productive
per square metre of cultivation space than are outdoor
crops. 
But indoor-grown cannabis, generally being sinsemilla
of good seed stock, is also more potent than most out-
door-grown product. In the Netherlands, a strong cor-
relation has been found between potency and price.261
Data from the United States suggest that sinsemilla is
worth three to 12 times as much as commercial grade
cannabis per ounce.262 This suggests that, in addition to
producing greater bulk, indoor production is likely to
produce much greater value. While input costs are also
greater, there would appear to be a great deal of incen-
tive to produce indoors in consumer countries, avoiding
the hazard of cross-border trafficking, particularly in a
climate of enhanced law enforcement.
The share of the market commanded by indoor, high-
potency production is the subject of ongoing investiga-
tion. This is a key area of research, as it has implications
for both enforcement and public health.  But since the
bulk of the global market seems to be supplied by tra-
ditional outdoor grows, a global production estimate
can ignore this variable without hazarding too much
error.
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Light tokers and chain-smokers
The estimated 162 million people who use cannabis do
not all use it at the same rate. Some of them may have
experimented with the drug once or twice, while others
consume the drug on a daily basis. It is estimated that
10 per cent of people who try cannabis will progress to
daily use for some period of their lives, with a further 20
per cent to 30 per cent using on a weekly basis.263 This
leaves, however, a large share of people whose use is less
frequent. The prevalence of use tends to vary depending
on the life-stage of the user. For example, about 60 per
cent of French 19-year-old boys have tried cannabis,
and, of these, more than one in three uses 20 times a
month or more. This share drops greatly in later life
stages.264
Understanding global cannabis demand requires the
creation of a typology of users, and the obvious source
for the data on which to base this typology is household
and school survey data. Unfortunately, while the
number of ‘last-month’ users is often a feature of the
standard surveys, more precise questions about the
number of days the drug was used are often lacking.
In the United States, the National Survey on Drug Use
and Health (NSDUH) has been conducted regularly
since 1972. According to NSDUH data, of the 25 mil-
lion US citizens over 12 who used cannabis in 2003,
14.5 million of them said they had used it in the past
month, or about 58 per cent. This is almost exactly what
has been found in Australia, where 60 per cent of annual
users consumed the drug in the last month.265 A similar
share is seen in the Netherlands (61 per cent), with
slightly lower levels seen in France (52 per cent), Greece
(53 per cent), Ireland (51 per cent), and Latvia (47 per
cent).266 A slightly higher level is seen in the United
Kingdom (63 per cent).267
For a small share of these respondents, their use in the
past month may have been the only time the drug was
used in the past year. In other words, use in the past
month does not mean that the drug was used every
month of the previous year: ‘past month use’ does not
mean ‘monthly use’. This would suggest that the share
of annual users that are also monthly users would be
slightly lower than the figures discussed above. On the
other hand, some heavier users might, for whatever
reason, have missed out in the previous month. Data
from the United States (discussed below) shows that 68
per cent of the annual respondents said they used the
drug 12 or more times (i.e. on average, once a month).
In Australia, National Drug Strategy Household Surveys
have been held regularly since 1998. According to the
2001 data, 16 per cent of annual users over 14 con-
sumed the drug every day, 23 per cent once a week or
more, 12 per cent about once a month, and 49 per cent
less often.268 Thus it would appear, if anything, that the
number of those who say they used in the last month
may be slightly less than the number that used ‘monthly’
(12 or more times in the past year.). For the purposes of
this discussion, 55 per cent of the annual users will be
196
World Drug Report 2006 Volume I. Analysis
Annex 3 -  Estimating individual consumption
Country Year
Annual 
Prevalence
 per cent used 
in 30 days 
1 to 3 
days
4 to 9 
days
10 to 19 
days
20+ days
France 2000 8.4 4.4 42.5 15.5 15.5 26.4
Greece 1998 4.4 2.3 37.7 27.3 15.6 19.5
Ireland 2002/03 5.1 2.6 40.9 22.3 14.3 22.5
Italy 2001 6.2 4.7 38 30.4 12.3 19.3
Latvia 2003 3.8 1.8 57.1 24.2 13.3 5.4
Netherlands 2000/01 6.1 3.7 41.5 21.1 13.8 23.6
Portugal 2001 3.3 3.3 33.7 23.8 19.2 23.2
Spain 2001 9.7 6.8 29.5 24.8 12.1 33.6
Source: EMCDDA, Statistical Bulletin 2004.
Table 4: Breakdown of European cannabis users by frequency of use
designated ‘regular’ (about once a month or more) and
45 per cent ‘casual’ (less than 12 times in the previous
year).
Comparing the US and Australian figures shows a dif-
ferent breakdown in levels of use between the two areas.
Only a third (32 per cent) of US users said they con-
sumed the drug less than once a month, whereas nearly
half (49 per cent) of the Australian users fall in this cat-
egory. On the other hand, 16 per cent of the Australian
users were daily consumers, compared to just 7 per cent
of the US respondents. Taken at face value, Australian
users seem to be taken to the extremes, with US users
more likely to fall somewhere in the middle. If the cat-
egories were softened a bit, however, the fit is better. For
example, if ‘daily’ use is considered five times or more
per week, 18 per cent of the US respondents qualify,
close to the Australian 16 per cent. New Zealand uses a
softer standard for ‘heavy’ use: 10 or more times in the
past month, but 20 per cent of the annual users fall into
this category.269
Statistics from European household surveys as compiled
by the European Monitoring Centre for Drugs and
Drug Addiction show rates of cannabis use among those
who used in the past 30 days. These figures show that
between 1 per cent (Finland) and 7 per cent (Spain) of
those who had used cannabis also consumed the drug in
the last 30 days. Among past month users, between 5
per cent (Latvia) and 34 per cent (Spain) consumed the
drug more than 20 days out of the last 20, and are des-
ignated by EMCDDA as “daily or almost daily users”.
This figure would correspond to more than 240 days
use in the past year, close to five times a week or more
(260 days a year). Thus, we would expect the European
figures for 20+ day last month users to be close to the
16 per cent to 18 per cent seen in Australia and the US,
and, as the Table below shows, they are in several cases.
This analysis shows that survey data from a number of
countries (the US, Australia, France, Greece, Ireland,
Italy, and the Netherlands) indicate that past month
users comprise about half of annual users, and that ‘daily
or almost daily’ users comprise between 10 per cent and
20 per cent of the annual user pool, with a mean,
median, and mode of 14 per cent. 
Sources from a wide range of countries suggest that
about 14 per cent of annual cannabis users are daily
users, a higher figure than many would expect. If these
figures could be generalized to the total global popula-
tion, this suggests that about 22.5 million people use
cannabis daily or near-daily, with the other 138.5 mil-
lion using it less often. This figure is important because
only at the level of daily or near-daily use does tolerance
develop, and this has an impact on the amount of
cannabis used.
How much cannabis in a dose?
Like all drugs, cannabis dosage is highly dependant on
factors such as body weight, individual metabolism, and
tolerance, and there is limited material on what consti-
tutes a ‘dose’ among recreational users. There are two
ways of approaching this problem, both of which are
pursued below. One is to determine, on the basis of sci-
entific testing, how much cannabis a user needs to con-
sume to receive the desired effects. Due to the extreme
variability in potency, however, cannabis dosages would
need to be expressed in the amount of THC absorbed
by the system, rather than the weight of the product
consumed. The second approach would be to look at
actual use patterns based on survey or other data.
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Country
Share of 
respondents users 
who are annual 
users 
Share of 
respondents who 
are past month 
users
Share of annual 
users that are 
monthly users
Share of monthly 
users who are 
daily users
Share of annual 
users that are 
daily users
France 8.40% 4.40% 52% 26% 14%
Greece 4.40% 2.30% 53% 20% 11%
Ireland 5.10% 2.60% 51% 23% 12%
Italy 6.20% 4.70% 76% 19% 14%
Netherlands 6.10% 3.70% 61% 24% 15%
Source: Calculations based on EMCDDA data.
Table 5: Ratios of annual to more frequent users
The question of what an ‘average’ user consumes is com-
plicated by the issue of tolerance. While the extent of
tolerance has not been precisely quantified, it appears to
build within a few days of chronic use and dissipate just
as fast.270 In other words, tolerance is not an issue for
anyone but daily or near-daily users, but there are likely
to be stark differences in the dosage levels, and conse-
quently the consumption levels, between these two
groups.
Determining dosage levels in a laboratory setting is
complicated by a number of factors. For example, test-
ing of blood THC levels of those known to have con-
sumed a set quantity of cannabis demonstrates that
smoking technique makes a considerable difference in
the amount of THC absorbed. When smoked, only
between 15 per cent and 50 per cent of the THC in a
joint is absorbed into the blood stream, but experienced
users are able to access about twice as much THC as
casual users, due to superior inhalation technique.271
Using this absorption range, smoking an average joint in
the United States (0.5g of 10 per cent THC272) would
result in the ingestion of 7.5mg to 25mg of THC.
When smoked, the World Health Organization
(WHO) says that only 2mg to 3mg are sufficient to pro-
duce the desired effect in most people.273 Using the
WHO standards, this would mean consumption of per-
haps 10 per cent to at most 40 per cent of an average
joint in the United States should be sufficient to pro-
duce the desired effect. This represents a ‘dose’ level of
between 0.05g and 0.2g.274 Of course, threshold levels
are often exceeded,275 but these guidelines are meant to
capture the experience of the average user. 
In other words, one average joint represents enough
cannabis to serve between two and ten people, accord-
ing to WHO standards. This may be one reason why
cannabis is frequently consumed in groups, or a joint is
smoked in more than one consumption session. Higher
quality cannabis would obviously require less of a joint
to be smoked. Thus, however convenient the unit, a
joint should not be considered a ‘dose’. Consumption of
an entire joint in a single setting by a casual user would
be rare, rather like a casual drinker consuming an entire
bottle of wine. Cannabis of reasonable potency is actu-
ally more like spirits: just a few ‘shots’ are enough to
produce the desired level of inebriation.
As cannabis is usually consumed communally, with a
single joint being passed around, there is almost no
lower limit to the amount consumed by casual users. In
other words, survey respondents who say they have con-
sumed cannabis in the last year (especially novice users)
may have only had a toke or three on one or more occa-
sions.  The quantity consumed by these individuals in
terms of the weight of the drug product is minimal.
This level of use is reflected in the New Zealand survey
data, which is unique in asking users how much they
consumed on each occasion they used the drug, and
allowing for specification of amounts lower than one
joint. In 2001, the average annual user reported smok-
ing six-tenths of a joint. This average includes the 20 per
cent of the annual users who were classed as ‘heavy’
smokers (using 10 or more times in the last month), so
modal values for occasional users would be much less.
The New Zealand surveys also ask about sharing joints,
the results show that nearly all use takes place in groups
of two or more. In 2001, only 4 per cent smoked alone
during a ‘typical’ consumption session, while 14 per
cent shared with one other, 29 per cent with two others,
24 per cent with three others, 17 per cent with four
others, 6 per cent with five others, 3 per cent with six
others, and 2 per cent with seven others. A large share
(45 per cent in 2001) never bought the cannabis they
consumed, and another significant part (26 per cent)
received at least some of their cannabis for free.276 This
is consistent with figures from France, the US, and Ire-
land.
While there is virtually no floor on the amount of
cannabis that might have been used by an annual user,
it also seems that the ceiling on use is very high. Unlike
other drugs, it is impossible to die of an ‘overdose’ of
cannabis. Experienced smokers can use the drug con-
tinuously if there are no social barriers to their use.
Those who grow their own supply may also circumvent
financial constraints. For these users, the only ceiling on
their use is the time it takes to prepare and consume the
drug. 
Many daily users have rules around when and where
they will consume, generally restraining their use to
leisure time. Surveys of users in New Zealand show 95
per cent of annual smokers polled said they never used
the substance at the workplace, so employment may
form a major impediment to constant consumption.277
A study of users in Amsterdam, where the drug is widely
tolerated, found that declining to consume at work was
the single most commonly followed ‘rule’ around con-
sumption, and that 27 per cent of their sample of expe-
rienced users adhered to this rule, while a further 20 per
cent abstained from smoking during the day, and 15 per
cent abstained during the morning.278 In France, just
under a quarter (24 per cent) of ‘heavy’ (20 times a
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month or more) users only ‘sometimes’ or ‘never’ con-
sumed in the morning or afternoon.279 Thus, a reason-
able division could be hypothesized between daily users
who have a joint or two in the morning and/or evening
and those whose lifestyles allowed them to be continu-
ously intoxicated. These ‘chronic’ users need to be dis-
tinguished from other daily users, as amount of
cannabis they consume is much greater.
One source of information on dose levels for heavy users
is the literature on medical use of cannabis. There is a
great deal of contradictory information on what consti-
tutes a ‘normal’ use pattern among medical cannabis
recipients. Using the prescription guidelines for syn-
thetic THC as a guideline, users required to be con-
stantly under the influence of cannabis would need to
smoke the equivalent of between two and ten standard
0.5 g joints of good potency daily.280 Some reports have
suggested higher amounts, however. One study of four
long-term medical cannabis patients found consump-
tion levels of between seven and nine grams a day,
although this dosage was the product of years of con-
stant use, and lower consumption levels had been ade-
quate at earlier stages.281
Unfortunately, the ability to generalize actual medical
use patterns to the public at large is limited because
medical users tend to have access to better quality
cannabis than the general public.282 It seems likely that
heavy users without access to medical cannabis would
use more potent product as well, and would be more
likely to grow their own, but the extent to which this is
true is unclear. 
Another source of information on user habits is the reg-
ulated industry of the Dutch coffee shops. According to
the Dutch Ministry of Health, Welfare, and Sports, the
600,000 users of cannabis products in the Netherlands
consume an average of two grams per week per cus-
tomer.283 Of course, this average consumption level
obscures great variation in individual use levels, and,
like medical cannabis, the quality of this product is
likely to be much better than that available to users in
other parts of the world.
Field accounts of use levels among non-medical regular
users vary in quality, and the question of sampling is
always an issue. The Independent Drug Monitoring
Unit (IDMU) in the United Kingdom makes use of a
sample of ‘regular’ users gathered at “pop-festivals and
pro-cannabis rallies… subcultural magazines, snow-
balling, via direct mailings to pressure groups, and at
other events.” This sample is clearly not representative
of annual cannabis users, but does give information on
the upper end of the use scale. 
The IDMU notes that even within this pool, the major-
ity of the regular users consume relatively small amounts
of the drug, with a mean consumption of 1 g per day.
But among daily users, the average was over six joints a
day, with some examples of much heavier use.284 Other
research in the United Kingdom also suggests that daily
users may consume as much as five joints a day.285 Infor-
mal interviews conducted in connection with this study
with a number of employed daily users suggest a
monthly consumption level of about 28g, enough
cannabis for about two joints a day.286
One qualitative study of drug users in Milan found that
while most users consume only occasionally, daily users
smoke between two and five joints, or one to two grams
of cannabis, a day. One dealer interviewed in connec-
tion with the study, however, claimed that at one point
in his life he consumed up to 20 grams in a day.287 In
Costa Rica, a study of 41 long term users found that 10
joints a day were smoked, but the total weight of the
cannabis was only 2 g with an average THC level of 2.2
per cent.288 One study of long-term, regular289 users in
Australia found a median use pattern of two ‘standard’
joints a day (50 per cent smoked between one and four
joints a day), but there were some stark outliers. Over-
all, one-third smoked cannabis throughout the day,
while the rest restricted themselves to evenings or other
times.290 There are some studies that suggest much
higher levels of use, but the credibility of these accounts
has been questioned.291
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